 EXHIBIT 2.1     

EXHIBIT 2.1

  

  

 

EXECUTION VERSION

 

  

  

 

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION

  

  

This Agreement and Plan of Merger and Reorganization ("Agreement") is made and
entered into as of January 11, 2015, by and among Tekmira Pharmaceuticals
Corporation, a British Columbia corporation ("Parent"); TKM Acquisition
Corporation, a Delaware corporation and a wholly-owned direct subsidiary of
Parent ("Merger Sub"); and OnCore Biopharma, Inc., a Delaware corporation (the
"Company"). Certain capitalized terms used in this Agreement are defined in
Exhibit A.

  

  

Recitals

  

  

A. Parent, Merger Sub and the Company intend to engage in a business
combination to advance their long-term strategies to be effected by a merger
of Merger Sub into the Company in accordance with this Agreement and the DGCL
(the "Merger"). Upon consummation of the Merger, Merger Sub will cease to
exist, and the Company will become a wholly-owned direct subsidiary of Parent.

  

  

B. It is intended that the Merger qualifies as a "reorganization" within the
meaning of Section 368(a) of the Code and that this Agreement qualifies as a
"plan of reorganization" within the meaning of Sections 1.368-2(g) and
1.368-3(a) of the United States Treasury Regulations.

  

  

C. The respective boards of directors of Parent, Merger Sub and the Company
have approved this Agreement and the Merger.

  

  

D. In order to induce Parent to enter into this Agreement and cause the Merger
to be consummated, certain stockholders of the Company are executing
stockholder consents to be delivered to Parent concurrently with the execution
of this Agreement (the "Company Stockholder Consents").

  

  

E. In order to induce the Company to enter into this Agreement and consummate
the Merger, certain stockholders of Parent are executing and delivering to
Company and Parent, concurrently with the execution of this Agreement, voting
agreements in favour of the Company and Parent (the "Parent Stockholder Voting
Agreements"), in the form attached hereto as Exhibit B.

  

  

F. Certain stockholders of the Company and certain stockholders of Parent are
entering into lock-up agreements (collectively, the "Lock-up Agreements"), in
the forms attached hereto as Exhibit C, concurrently with the execution of
this Agreement.

  

  

G. In order to induce the Company to enter into this Agreement and consummate
the Merger, Parent is entering into a registration rights agreement (the
"Registration Rights Agreement") with certain stockholders of the Company
concurrently with the execution of this Agreement, to be effective upon the
consummation of the Merger (the "Closing"), in the form attached hereto as
Exhibit D.

  

  

H. In order to induce the Parent to enter into this Agreement and cause the
Merger to be consummated, the largest stockholder of the Company is entering
into a governance agreement (the "Governance Agreement") and a standstill
agreement (the "Standstill Agreement") with the Parent concurrently with the
execution of this Agreement, each to be effective upon the Closing, in the
forms attached hereto as Exhibits E and F, respectively.

  

  

Agreement

  

  

The parties to this Agreement, intending to be legally bound, agree as
follows:

  

  

 

 

 

  

   

  

 

 

 

  

Section 1. Description of Transaction

  

  

1.1 Merger of Merger Sub into the Company. Upon the terms and subject to the
conditions set forth in this Agreement and the applicable provisions of the
DGCL, at the Effective Time, Merger Sub shall be merged with and into the
Company. By virtue of the Merger, at the Effective Time, the separate
existence of Merger Sub shall cease and the Company shall continue as the
surviving corporation in the Merger (the "Surviving Corporation").

  

  

1.2 Effects of the Merger. The Merger shall have the effects set forth in this
Agreement and in the applicable provisions of the DGCL.

  

  

1.3 Closing; Effective Time. The Closing shall take place at the offices of
Cooley llp, 3175 Hanover Street, Palo Alto, California, or as otherwise agreed
by the parties hereto, on a date to be designated jointly by Parent and the
Company, which shall be no later than the second Business Day after the
satisfaction or waiver of the last to be satisfied or waived of the conditions
set forth in Section 6 and Section 7 (other than the conditions, which by
their nature are to be satisfied at the Closing, but subject to the
satisfaction or waiver of each of such conditions). The date on which the
Closing actually takes place is referred to as the "Closing Date." Subject to
the provisions of this Agreement, a certificate of merger satisfying the
applicable requirements of the DGCL (the "Certificate of Merger") shall be
duly executed by the Company and concurrently with or as soon as practicable
following the Closing shall be filed with the Secretary of State of the State
of Delaware. The Merger shall become effective at the time of the filing of
such certificate of merger with the Secretary of State of the State of
Delaware or at such later time as may be designated jointly by Parent and the
Company and specified in such certificate of merger (the time as of which the
Merger becomes effective being referred to as the "Effective Time").

  

  

1.4 Certificate of Incorporation and Bylaws; Directors and Officers.

  

  

(a) At the Effective Time, the Certificate of Incorporation of the Company
shall be amended and restated in its entirety to contain the provisions of the
Certificate of Incorporation of Merger Sub as in effect immediately prior to
the Effective Time, except for Article One of the Certificate of Incorporation
of the Company, which shall not be amended unless otherwise agreed to by the
parties hereto, and, as so amended and restated, shall be the Certificate of
Incorporation of the Surviving Corporation, until amended in accordance with
applicable law;

  

  

(b) The Bylaws of the Surviving Corporation shall be the Bylaws of the Merger
Sub as in effect immediately prior to the Effective Time, until amended in
accordance with applicable law; and

  

  

(c) The directors and officers of the Surviving Corporation immediately after
the Effective Time shall be the officers and directors of Merger Sub as of
immediately prior to the Effective Time.

  

  

1.5 Conversion of Shares.

  

  

(a) Subject to the terms and conditions of this Agreement, at the Effective
Time, by virtue of the Merger and without any further action on the part of
Parent, Merger Sub, the Company or any stockholder of the Company:

  

  

(i) any shares of Company Capital Stock owned by any wholly-owned Subsidiary
of the Company immediately prior to the Effective Time (or held in the
Company's treasury) shall be canceled and retired and shall cease to exist,
and no consideration shall be delivered in exchange therefor;

  

  

 

 

 

  

 

2  

  

 

 

 

  

(ii) except as provided in clause "(i)" above and subject to Sections 1.5(c)
and 1.5(d), each share of Company Capital Stock outstanding immediately prior
to the Effective Time shall be converted into the right to receive, on an as-
converted basis, the number of shares of Parent Common Stock equal to the
Exchange Ratio (such number as may be adjusted in accordance with Section
1.5(b)); and

  

  

(iii) each share of common stock, $0.001 par value per share, of Merger Sub
outstanding immediately prior to the Effective Time shall be converted into
one share of common stock of the Surviving Corporation.

  

  

(b) If, during the period from the date of this Agreement through the
Effective Time, the outstanding shares of Company Common Stock or shares of
Company Common Stock issuable upon conversion of outstanding shares of Company
Preferred Stock or the outstanding shares of Parent Common Stock or shares of
Parent Common Stock issuable upon conversion of outstanding shares of Parent
Preferred Stock are changed into a different number or class of shares by
reason of any stock split, division or subdivision of shares, stock dividend,
reverse stock split, combination of shares, reclassification, recapitalization
or other similar transaction, or if a stock dividend is declared by the
Company or Parent during such period, then the Exchange Ratio shall be
adjusted to the extent appropriate to provide the same economic effect as
contemplated by this Agreement prior to such action.

  

  

(c) If any shares of Company Capital Stock outstanding immediately prior to
the Effective Time are unvested or are subject to a repurchase option, risk of
forfeiture or other condition under any applicable restricted stock purchase
agreement or other Contract with the Company or under which the Company has
any rights, then (except to the extent provided in any binding agreement
between the Company and the holder thereof): (i) the shares of Parent Common
Stock issued in exchange for such shares of Company Capital Stock will also be
unvested and subject to the same repurchase option, risk of forfeiture or
other condition; and (ii) the certificates representing such shares of Parent
Common Stock may accordingly be marked with appropriate legends. Prior to the
Effective Time, the Company shall ensure that, from and after the Effective
Time, Parent or the Surviving Corporation is entitled to exercise any such
repurchase option or other right set forth in any such restricted stock
purchase agreement or other Contract.

  

  

(d) No fractional shares of Parent Common Stock shall be issued in connection
with the Merger, and no certificates or scrip for any such fractional shares
shall be issued. Any holder of Company Capital Stock who would otherwise be
entitled to receive a fraction of a share of Parent Common Stock (after
aggregating all fractional shares of Parent Common Stock issuable to such
holder) shall, in lieu of such fraction of a share and upon surrender of such
holder's Company Stock Certificate(s), or delivery of non-certificated shares
of Company Capital Stock represented by book entry ("Book Entry Shares"),
subject to Section 1.7(b), be paid in cash the dollar amount (rounded down to
the nearest whole cent), without interest, determined by multiplying such
fraction by the 10 trading day average closing price, of a share of Parent
Common Stock traded on the NASDAQ (instead of the daily volume-weighted
average prices), ending on the last Business Day prior to the date on which
the Merger becomes effective (the "Parent Common Stock Price").

  

  

1.6 Closing of the Company's Transfer Books. At the Effective Time: (a) all
shares of Company Capital Stock outstanding immediately prior to the Effective
Time shall automatically be canceled and retired and shall cease to exist, and
all holders of Book Entry Shares or of certificates representing shares of
Company Capital Stock that were outstanding immediately prior to the Effective
Time shall cease to have any rights as stockholders of the Company, except the
right to receive shares of Parent Common Stock as contemplated by Section 1.5,
cash in lieu of any fractional share of Parent Common Stock pursuant to
Section 1.5(d) and any dividends or other distributions pursuant to
Section1.7(c); and (b) the stock transfer books of the Company shall be closed
with respect to all shares of Company Capital Stock outstanding immediately
prior to the Effective Time. No further transfer of any such shares of Company
Capital Stock shall be made on such stock transfer books after the Effective
Time. If, after the Effective Time, a valid certificate previously
representing any shares of Company Capital Stock outstanding immediately prior
to the Effective Time (a "Company Stock Certificate") or a Book Entry Share is
presented to the Exchange Agent or to the Surviving Corporation or Parent,
such Company Stock Certificate or Book Entry Share shall be canceled and shall
be exchanged as provided in Section 1.7.

  

  

 

 

 

  

 

3  

  

 

 

 

  

1.7 Exchange of Certificates.

  

  

(a) Prior to the Closing Date, Parent shall arrange for its transfer agent to
act as exchange agent in the Merger (the "Exchange Agent"). Prior to the
Effective Time, Parent shall issue and cause to be deposited with the Exchange
Agent: (i) non-certificated shares of Parent Common Stock represented by book
entry issuable pursuant to Section 1.5; and (ii) cash sufficient to make
payments in lieu of fractional shares in accordance with Section 1.5(d). The
shares of Parent Common Stock and cash amounts so deposited with the Exchange
Agent, together with any dividends or distributions received by the Exchange
Agent with respect to such shares of Parent Common Stock, are referred to
collectively as the "Exchange Fund."

  

  

(b) Promptly after the Effective Time, the Exchange Agent will mail to the
Persons who were record holders of Company Stock Certificates or Book Entry
Shares immediately prior to the Effective Time: (i) a letter of transmittal in
customary form and containing such provisions as Parent may reasonably specify
and the Company shall reasonably approve prior to the Effective Time
(including a provision confirming that delivery of Company Stock Certificates
or Book Entry Shares shall be effected, and risk of loss and title to Company
Stock Certificates or Book Entry Shares shall pass, only upon delivery of such
Company Stock Certificates or Book Entry Shares to the Exchange Agent); and
(ii) instructions for use in effecting the surrender of Company Stock
Certificates or Book Entry Shares in exchange for non-certificated shares of
Parent Common Stock in book entry form. Upon surrender of a Company Stock
Certificate or Book Entry Shares to the Exchange Agent for exchange, together
with a duly executed letter of transmittal and such other customary documents
as may be reasonably required by the Exchange Agent or Parent: (A) the holder
of such Company Stock Certificate or Book Entry Shares shall be entitled to
receive, and the Exchange Agent shall (and Parent shall cause the Exchange
Agent to) in exchange therefor transfer from the Exchange Fund to such holder
the number of whole shares of Parent Common Stock (which shares shall be
certificated and bear an appropriate legend to the effect that such shares
have not been registered under the Securities Act and are therefore subject to
restrictions on transfer) that such holder has the right to receive pursuant
to the provisions of Section 1.5 (and cash in lieu of any fractional share of
Parent Common Stock pursuant to Section 1.5(d) and any dividends or other
distributions pursuant to Section 1.7(c)); and (B) the Company Stock
Certificate or Book Entry Shares so surrendered shall be canceled. Until
surrendered as contemplated by this Section 1.7(b), each Company Stock
Certificate and Book Entry Share shall be deemed, from and after the Effective
Time, to represent only the right to receive shares of Parent Common Stock
(and cash in lieu of any fractional share of Parent Common Stock) as
contemplated by Section 1.5 and any dividends or other distributions pursuant
to Section 1.7(c). If any Company Stock Certificate shall have been lost,
stolen or destroyed, Parent may, in its discretion and as a condition to the
issuance of any non-certificated shares of Parent Common Stock in book entry
form, require the owner of such lost, stolen or destroyed Company Stock
Certificate to provide an appropriate affidavit and indemnification obligation
and/or post a bond, in such reasonable and customary amount as Parent may
direct, as indemnity against any claim that may be made against Exchange
Agent, Parent or the Surviving Corporation with respect to such Company Stock
Certificate.

  

  

 

 

 

  

 

4  

  

 

 

 

  

(c) No dividends or other distributions declared or made with respect to
Parent Common Stock with a record date after the Effective Time shall be paid
or otherwise delivered to the holder of any unsurrendered Company Stock
Certificate or Book Entry Share with respect to the shares of Parent Common
Stock that such holder has the right to receive in the Merger until such
holder surrenders such Company Stock Certificate or Book Entry Share in
accordance with this Section 1.7 (at which time such holder shall be entitled,
subject to the effect of applicable abandoned property, escheat or similar
laws, to receive all such dividends and distributions, without interest).

  

  

(d) Any portion of the Exchange Fund that remains undistributed to holders of
Company Stock Certificates and Book Entry Shares as of the date that is one
year after the date on which the Merger becomes effective shall be delivered
to Parent upon demand, and any holders of Company Stock Certificates or Book
Entry Shares who have not theretofore surrendered their Company Stock
Certificates or Book Entry Shares in accordance with this Section 1.7 shall
thereafter look only to Parent for satisfaction of their claims for Parent
Common Stock, cash in lieu of fractional shares of Parent Common Stock and any
dividends or distributions with respect to shares of Parent Common Stock.

  

  

(e) Each of the Exchange Agent, Parent and the Surviving Corporation shall be
entitled to deduct and withhold from any consideration payable or otherwise
deliverable pursuant to this Agreement to any holder or former holder of
Company Capital Stock such amounts as may be required to be deducted or
withheld from such consideration under the Code or any provision of state,
local or foreign tax law or under any other applicable Legal Requirement. To
the extent such amounts are so deducted or withheld and paid to the
appropriate Governmental Body, such amounts shall be treated for all purposes
under this Agreement as having been paid to the Person to whom such amounts
would otherwise have been paid. The Exchange Agent, Parent and the Surviving
Corporation shall use commercially reasonable efforts to reduce or eliminate
any such withholding.

  

  

(f) All transfer, documentary, registration and other such Taxes (including,
without limitation, charges for or in connection with the recording of any
instrument or document as provided in this Agreement) payable in connection
with the Merger and the other transactions contemplated by this Agreement
shall be timely paid by Parent.

  

  

(g) Neither Parent nor the Surviving Corporation shall be liable to any holder
or former holder of Company Capital Stock or to any other Person with respect
to any shares of Parent Common Stock (or dividends or distributions with
respect thereto), or for any cash amounts required to be delivered to any
public official pursuant to any applicable abandoned property law, escheat law
or other Legal Requirement.

  

  

1.8 Issuance of Shares of Surviving Corporation. On the Effective Date, the
Surviving Corporation will issue ninety nine shares of common stock of the
Surviving Corporation to Parent in consideration for Parent issuing Parent
Common Stock to the stockholders of the Company in satisfaction of the right
granted pursuant to Section 1.5(a)(ii).

  

  

1.9 Tax Consequences. For U.S. federal income tax purposes, the Merger is
intended to constitute a reorganization within the meaning of Section 368(a)
of the Code that is not subject to the application of Section 367(a)(1) of the
Code. The parties to this Agreement adopt this Agreement as a "plan of
reorganization" within the meaning of Sections 1.368-2(g) and 1.368-3(a) of
the United States Treasury Regulations.

  

  

 

 

 

  

 

5  

  

 

 

 

  

1.10 Further Action. If, at any time after the Effective Time, any further
action is determined by Parent or the Surviving Corporation to be necessary or
desirable to carry out the purposes of this Agreement or to vest the Surviving
Corporation with full right, title and possession of and to all rights and
property of Merger Sub and the Company, the officers and directors of the
Surviving Corporation and Parent shall be fully authorized (in the name of
Merger Sub, in the name of the Company and otherwise) to take such action.

  

  

1.11 Dissenting Shares. Notwithstanding any provision of this Agreement to the
contrary, shares of Company Capital Stock issued and outstanding immediately
prior to the Effective Time of the Merger and held by a holder who has not
voted in favor of adoption of this Agreement or consented thereto in writing
and who has properly exercised appraisal rights of such shares of Company
Capital Stock in accordance with Section 262 of the DGCL (such Shares being
referred to collectively as the "Dissenting Shares" until such time as such
holder fails to perfect or otherwise loses such holder's appraisal rights
under the DGCL with respect to such shares) shall not be converted into a
right to receive the applicable amount of Parent Common Stock contemplated by
Section 1.5(a)(ii), but instead shall be entitled to only such rights as are
granted by Section 262 of the DGCL; provided, however, that if, after the
Effective Time of the Merger, such holder fails to perfect, withdraws or loses
such holder's right to appraisal pursuant to Section 262 of the DGCL or if a
court of competent jurisdiction shall determine that such holder is not
entitled to the relief provided by Section 262 of the DGCL, such shares of
Company Capital Stock shall be treated as if they had been converted as of the
Effective Time into the right to receive the applicable amount of Parent
Common Stock contemplated by Section 1.5(a)(ii), if any, to which such holder
is entitled. The Company shall provide Parent prompt written notice of any
demands received by the Company for appraisal of shares of Company Capital
Stock, any withdrawal of any such demand and any other demand, notice or
instrument delivered to the Company pursuant to the DGCL that relates to such
demand, and Parent shall have the opportunity and right to direct all
negotiations and proceedings with respect to such demands. Except with the
prior written consent of Parent, the Company shall not, and shall not permit
the Company to, make any payment with respect to, or settle or offer to
settle, any such demands.

  

  

Section 2. Representations and Warranties of the Company

  

  

The Company represents and warrants to Parent and Merger Sub as follows (it
being understood that each representation and warranty contained in this
Section 2 is subject to: (a) the exceptions and disclosures set forth in the
part or subpart of the Company Disclosure Schedule corresponding to the
particular Section or subsection in this Section 2 in which such
representation and warranty appears; and (b) any exception or disclosure set
forth in any other part or subpart of the Company Disclosure Schedule to the
extent it is reasonably apparent that such exception or disclosure is relevant
to such representation and warranty):

  

  

2.1 Subsidiaries; Due Organization; Etc.

  

  

(a) Part 2.1(a) of the Company Disclosure Schedule identifies each Subsidiary
of the Company and indicates its jurisdiction of organization. Neither the
Company nor the Company's Subsidiary owns any capital stock of, or any equity
interest of any nature in, any other Entity, other than the Company's
Subsidiary. No Owl Corporation has agreed or is obligated to make, or is bound
by any Contract under which it may become obligated to make, any future
investment in or capital contribution to any other Entity.

  

  

(b) Each of the Owl Corporations is a corporation or other business
organization duly organized, validly existing and in good standing (to the
extent that the laws of the jurisdiction of its formation recognize the
concept of good standing) under the laws of the jurisdiction of its
organization and has all necessary organizational power and authority: (i) to
conduct its business in the manner in which its business is currently being
conducted; (ii) to own and use its assets in the manner in which its assets
are currently owned and used; and (iii) to perform its obligations under all
Contracts by which it is bound.

  

  

 

 

 

  

 

6  

  

 

 

 

  

(c) Each of the Owl Corporations is qualified to do business as a foreign
corporation, and is in good standing, under the laws of all jurisdictions
where the nature of its business requires such qualification, except for
jurisdictions in which the failure to be so qualified or in good standing,
individually or in the aggregate, would not have a Company Material Adverse
Effect.

  

  

2.2 Certificate of Incorporation and Bylaws. The Company has delivered or Made
Available to Parent accurate and complete copies of the certificate of
incorporation, bylaws, memorandum of association and articles of association
or equivalent governing documents of each of the Owl Corporations, including
all amendments thereto. The Company has delivered or Made Available to Parent
accurate and complete copies of: (a) the charters of all committees of the
Company Board; and (b) any code of conduct, corporate governance policies or
principles, related party transaction policy, stock ownership guidelines,
whistleblower policy, disclosure committee charter or similar codes policies,
or guidelines adopted by any of the Owl Corporations or by the board of
directors, or any committee of the board of directors, of any of the Owl
Corporations.

  

  

2.3 Capitalization; Ownership of Subsidiary.

  

  

(a) The authorized capital stock of the Company consists of: (i) 25,000,000
shares of Company Common Stock, $0.001 par value per share, of which 6,839,672
shares have been issued and are outstanding as of the last Business Day ending
immediately prior to date of this Agreement, of which 4,809,060 are Company
Restricted Shares; and (ii) 15,000,000 shares of Company Preferred Stock, all
of which are designated as Series R Preferred Stock, $0.001 par value per
share, of which 13,061,224 shares are issued and are outstanding and
convertible into 13,061,224 shares of Company Common Stock. All of the
outstanding shares of Company Capital Stock have been duly authorized and
validly issued, and are fully paid and nonassessable. None of the Owl
Corporations (other than the Company) holds any shares of Company Capital
Stock or any rights to acquire shares of Company Capital Stock.

  

  

(b) Except as set forth in Part 2.3(b) of the Company Disclosure Schedule: (i)
none of the outstanding shares of Company Capital Stock is entitled or subject
to any preemptive right, right of repurchase or forfeiture (other than Company
Restricted Shares), right of participation, right of maintenance or any
similar right; (ii) none of the outstanding shares of Company Capital Stock is
subject to any right of first refusal in favor of the Company; (iii) there is
no Company Contract relating to the voting or registration of, or restricting
any Person from purchasing, selling, pledging or otherwise disposing of (or
from granting any option or similar right with respect to), any shares of
Company Capital Stock; and (iv) none of the Owl Corporations is under any
obligation, or is bound by any Contract pursuant to which it may become
obligated, to repurchase, redeem or otherwise acquire any outstanding shares
of Company Capital Stock or other securities, except for the Company's right
to repurchase or reacquire Company Restricted Shares held by an employee of
the Company upon termination of such employee's employment or upon any other
forfeiture of a vesting condition.

  

  

(c) As of the date of this Agreement: (i) 237,570 shares of Company Common
Stock are subject to issuance pursuant to Company Options; (ii) 4,809,060
Company Restricted Shares are subject to repurchase after the date of this
Agreement; and (iii) 653,370 shares of Company Common Stock are reserved for
future issuance pursuant to equity awards not yet granted under the Company
Option Plan.

  

  

 

 

 

  

 

7  

  

 

 

 

  

(d) The Company has delivered or Made Available to Parent a complete and
accurate list that sets forth with respect to each Company Equity Award
outstanding as of the date of this Agreement the following information: (i)
the particular plan (if any) pursuant to which such Company Equity Award was
granted; (ii) the name of the holder of such Company Equity Award; (iii) the
type of Company Equity Award (whether a Company Option, Company Restricted
Share, or another type of Company Equity Award); (iv) the number of shares of
Company Common Stock subject to such Company Equity Award; (v) the per share
exercise or purchase price of such Company Equity Award; (vi) the applicable
vesting schedule, and the extent to which such Company Equity Award is vested
and/or exercisable; (vii) the date on which such Company Equity Award was
granted; (viii) the date on which such Company Equity Award expires (if
applicable); (ix) if such Company Equity Award is a Company Option, whether
such Company Option is intended to be an "incentive stock option" (as defined
in the Code) or a non-qualified stock option; and (x) if such Company Equity
Award is a Company Restricted Share, the dates on which shares of Company
Common Stock with respect to such Company Restricted Share are scheduled to
vest. The Company has delivered or Made Available to Parent accurate and
complete copies of all equity plans pursuant to which any outstanding Company
Equity Awards were granted by the Company, and the forms of all agreements
evidencing such Company Equity Awards. The exercise price of each Company
Option is not less than the fair market value of a share of Company Common
Stock as determined on the date of grant of such Company Option. All grants of
Company Equity Awards were made at fair market value on the date of the award
and, recorded on the Company's financial statements (including, any related
notes thereto) in accordance with GAAP, and no such grants involved any "back
dating" or similar practices with respect to the effective date of grant
(whether intentional or otherwise). Except as otherwise set forth in this
Section 2.3, there are no outstanding stock appreciation, restricted stock
unit, phantom stock, profit participation or similar rights with respect to
any of the Owl Corporations.

  

  

(e) Except as set forth in Sections 2.3(a), 2.3(b) and 2.3(c), or as permitted
from and after the date of this Agreement pursuant to Section 4.2, there is
no: (i) outstanding subscription, option, call, warrant or right (whether or
not currently exercisable) to acquire any shares of the capital stock or other
securities of any of the Owl Corporations; (ii) outstanding security,
instrument or obligation that is or may become convertible into or
exchangeable for any shares of the capital stock or other securities of any of
the Owl Corporations or that has the right to vote on any matter on which the
stockholders of the Company have the right to vote; (iii) Contract under which
any of the Owl Corporations is or may become obligated to sell or otherwise
issue any shares of its capital stock or any other securities; or (iv)
condition or circumstance that would reasonably be expected to give rise to or
provide a basis for the assertion of a claim by any Person to the effect that
such Person is entitled to acquire or receive any shares of capital stock or
other securities of any of the Owl Corporations.

  

  

(f) All outstanding shares of Company Capital Stock, and all Company Equity
Awards and other securities of the Owl Corporations, have been issued and
granted in compliance in all respects with: (i) all applicable securities laws
and other applicable Legal Requirements; and (ii) all requirements set forth
in applicable Contracts.

  

  

(g) All of the outstanding shares of capital stock of each of the Company's
Subsidiaries have been duly authorized and validly issued, are fully paid and
nonassessable and free of preemptive rights, with no personal liability
attaching to the ownership thereof, and are owned beneficially and of record
by the Company, free and clear of any Encumbrances, other than restrictions
under applicable securities laws.

  

  

(h) The only Subsidiary of the Company is Enantigen Therapeutics, Inc.
("Enantigen"). The authorized capital stock of Enantigen consists of: (i)
1,197 shares of common stock, $0.001 par value per share, of which 1,197
shares have been issued and are outstanding as of the last Business Day ending
immediately prior to date of this Agreement. All of the outstanding shares of
capital stock of Enantigen have been duly authorized and validly issued, and
are fully paid and nonassessable. Except as disclosed on Part 2.3(h) of the
Company Disclosure Schedule, (a) the Company is the beneficial and record
holder of all of the outstanding shares of capital stock of Enantigen and (b)
no Person (other than the Company) holds any shares of capital stock of
Enantigen, any rights to acquire capital stock of Enantigen, or any claim of
ownership of any capital stock of Enantigen.

  

  

 

 

 

  

 

8  

  

 

 

 

  

2.4 Financial Statements.

  

  

(a) The Company has delivered or Made Available the following financial
statements: (i) the audited statements of operations and statements of cash
flows for the period from May 10, 2012 (the Company's date of inception)
through December 31, 2012 and the year ended December 31, 2013 and the audited
balance sheets as of December 31, 2012 and 2013 (together with an unqualified
opinion of Grant Thornton LLP, the "Company Audited Financial Statements");
and (ii) the unaudited statements of operations and statements of cash flows
for the nine months ended September 30, 2014 and the unaudited balance sheet
as of September 30, 2014 ((i) and (ii) collectively, the "Company Financial
Statements"). The Company Audited Financial Statements (including any related
notes) complied as to form in all material respects with the published rules
and regulations of the SEC applicable to audited financial statements for
companies filing a registration statement under the Securities Act. The
Company Financial Statements: (i) were prepared in accordance with GAAP
applied on a consistent basis throughout the periods covered (except as may be
indicated in the notes to such financial statements or, in the case of
unaudited financial statements, as permitted by GAAP, and except that the
unaudited financial statements may not contain footnotes and are subject to
normal and recurring year-end adjustments, none of which will be material);
and (ii) fairly present, in all material respects, the financial position of
the Company as of the respective dates thereof and the results of operations
and cash flows of the Company for the periods covered thereby. No financial
statements of any Person other than the Owl Corporations are required by GAAP
to be included in the Company Financial Statements.

  

  

(b) The Company's auditor has at all times since the date of enactment of the
Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined
in Section 2(a)(12) of the Sarbanes-Oxley Act); (ii) "independent" with
respect to the Company within the meaning of Regulation S-X under the Exchange
Act; and (iii) to the Knowledge of the Company, in compliance with subsections
(g) through (l) of Section 10A of the Exchange Act and the rules and
regulations promulgated by the SEC and the Public Company Accounting Oversight
Board thereunder.

  

  

(c) The Company maintains a system of internal control over financial
reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
which is designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, and includes those policies and procedures
that: (i) pertain to the maintenance of records that in reasonable detail
accurately and fairly reflect the transactions and dispositions of the assets
of the Owl Corporations; (ii) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in
conformity with GAAP and that receipts and expenditures are being made only in
accordance with authorizations of management and directors of the Company; and
(iii) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the assets of the Owl
Corporations that could have a material effect on the Company's consolidated
financial statements. To the Knowledge of the Company, neither the Company nor
any of its Subsidiaries nor the Company's independent registered accountant
has identified or been made aware of: (A) any significant deficiency or
material weakness in the design or operation of internal control over
financial reporting utilized by the Owl Corporations; (B) any material illegal
act or fraud related to the business of the Owl Corporations that involves the
Company's management or other employees; or (C) any material claim or
allegation regarding any of the foregoing.

  

  

 

 

 

  

 

9  

  

 

 

 

  

(d) Part 2.4(d) of the Company Disclosure Schedule lists, and the Company has
delivered or Made Available to Parent accurate and complete copies of the
documentation creating or governing, all securitization transactions and "off-
balance sheet arrangements" (as defined in Item 303(c) of Regulation S-K under
the Exchange Act) currently in effect or effected by any of the Owl
Corporations. None of the Owl Corporations has any obligation or other
commitment to become a party to any such "off-balance sheet arrangements" in
the future.

  

  

(e) None of the information supplied or to be supplied by or on behalf of the
Company for inclusion or incorporation by reference in the Proxy Statement or
Circular will, at the time the Proxy Statement and Circular are mailed to the
stockholders of Parent or at the time of the Parent Stockholders' Meeting (or
any adjournment or postponement thereof), contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the
circumstances under which they are made, not misleading.

  

  

2.5 Absence of Changes. Except as set forth in Part 2.5 of the Company
Disclosure Schedule, since September 30, 2014 through the date of this
Agreement:

  

  

(a) there has not been any Company Material Adverse Effect, and no event has
occurred or circumstance has arisen that, in combination with any other events
or circumstances, would reasonably be expected to have or result in a Company
Material Adverse Effect;

  

  

(b) there has not been any material loss, damage or destruction to, or any
material interruption in the use of, any of the material assets of any of the
Owl Corporations (whether or not covered by insurance);

  

  

(c) none of the Owl Corporations has: (i) declared, accrued, set aside or paid
any dividend or made any other distribution in respect of any shares of
capital stock; or (ii) repurchased, redeemed or otherwise reacquired any
shares of capital stock or other securities of the Owl Corporations (other
than repurchase of restricted Company Common Stock in connection with
termination of employment of the previous holder of such Company Common Stock
that were made in the ordinary course of business and consistent with past
practices, or upon the cashless or net exercise of outstanding Company
Options);

  

  

(d) none of the Owl Corporations has sold, issued or granted, or authorized
the issuance of: (i) any capital stock or other security (except for Company
Common Stock issued upon the valid exercise of outstanding Company Options);
(ii) any option, warrant or right to acquire any capital stock or any other
security (except for Company Options identified in Part 2.3(d) of the Company
Disclosure Schedule); or (iii) any instrument convertible into or exchangeable
for any capital stock or other security;

  

  

(e) the Company has not amended or waived any of its rights under, or
permitted the acceleration of vesting under: (i) any provision of the Company
Option Plan; (ii) any provision of any Contract evidencing any outstanding
Company Option; (iii) any restricted stock unit agreement; or (iv) any other
Contract evidencing or relating to any equity award (whether payable in cash
or stock);

  

  

(f) (i) there has been no amendment to the certificate of incorporation or
bylaws of the Company, (ii) none of the Owl Corporations has effected or been
a party to any merger, consolidation, share exchange, business combination,
recapitalization, reclassification of shares, stock split, reverse stock split
or similar transaction and (iii) none of the Owl Corporations has acquired or
disposed of any business or a material amount of assets;

  

  

 

 

 

  

 

10  

  

 

 

 

  

(g) the Owl Corporations have not made any capital expenditures that in the
aggregate exceed $100,000;

  

  

(h) none of the Owl Corporations has written off as uncollectible, or
established any extraordinary reserve with respect to, any material account
receivable or other material indebtedness;

  

  

(i) none of the Owl Corporations has: (i) lent money to any Person (other than
routine travel advances made to employees in the ordinary course of business);
or (ii) incurred or guaranteed any indebtedness for borrowed money;

  

  

(j) none of the Owl Corporations has: (i) adopted, established or entered into
any Company Employee Plan or Company Employee Agreement; (ii) caused or
permitted any Company Employee Plan or Company Employee Agreement to be
amended in any material respect; or (iii) increased the amount of the wages,
salary, commissions, fringe benefits or other compensation or remuneration
payable to any of its directors, officers or other employees by in excess of
$100,000 in any individual case;

  

  

(k) none of the Owl Corporations has changed any of its methods of accounting
or accounting practices in any material respect except as required by
concurrent changes in GAAP or SEC rules and regulations;

  

  

(l) none of the Owl Corporations has made any material Tax election, made any
material amendments to Tax Returns previously filed or settled or compromised
any material Tax liability or refund;

  

  

(m) none of the Owl Corporations has commenced or settled any Legal
Proceeding;

  

  

(n) none of the Owl Corporations has entered into any material transaction or
taken any other material action outside the ordinary course of business or
inconsistent with past practices; and

  

  

(o) none of the Owl Corporations has agreed or committed to take any of the
actions referred to in clauses "(c)" through "(n)" above.

  

  

2.6 Title to Tangible Assets. The Owl Corporations own, and have good and
valid title to, all material tangible assets purported to be owned by them,
including: (a) all material assets reflected on the Company Unaudited Balance
Sheet (except for inventory sold or otherwise disposed of in the ordinary
course of business since the date of the Company Unaudited Balance Sheet); and
(b) all other material assets reflected in the books and records of the Owl
Corporations as being owned by the Owl Corporations. All of said assets are
owned by the Owl Corporations free and clear of any Encumbrances, except for:
(i) any lien for current Taxes not yet due and payable or for Taxes that are
being contested in good faith and for which appropriate reserves have been
established; (ii) minor liens that have arisen in the ordinary course of
business and that do not (in any case or in the aggregate) materially detract
from the value of the assets subject thereto or materially impair the
operations of any of the Owl Corporations; and (iii) liens described in Part
2.6 of the Company Disclosure Schedule. The Owl Corporations are the lessees
of, and hold valid leasehold interests in, all material tangible assets
purported to have been leased by them, including: (A) all material assets
reflected as leased on the Company Unaudited Balance Sheet; and (B) all other
material assets reflected in the books and records of the Owl Corporations as
being leased to the Owl Corporations, and the Owl Corporations enjoy
undisturbed possession of such leased assets.

  

  

 

 

 

  

 

11  

  

 

 

 

  

2.7 Equipment; Real Property; Leasehold.

  

  

(a) All material items of equipment and other tangible assets owned by or
leased to the Owl Corporations are adequate for the uses to which they are
being put, are in good condition and repair (ordinary wear and tear excepted)
and are adequate for the conduct of the businesses of the Owl Corporations in
the manner in which such businesses are currently being conducted.

  

  

(b) No Owl Corporation owns any real property.

  

  

(c) Part 2.7(c) of the Company Disclosure Schedule sets forth an accurate and
complete list of each lease pursuant to which any of the Owl Corporations
leases real property from any other Person for annual rent payments in excess
of $100,000. (All real property leased to the Owl Corporations pursuant to the
real property leases identified or required to be identified in Part 2.7(c) of
the Company Disclosure Schedule, including all buildings, structures, fixtures
and other improvements leased to the Owl Corporations, is referred to as the
"Company Leased Real Property.") To the Knowledge of the Company, there is no
existing plan or study by any Governmental Body or by any other Person that
challenges or otherwise adversely affects the continuation of the use or
operation of any Company Leased Real Property. Part 2.7(c) of the Company
Disclosure Schedule contains an accurate and complete list of all subleases,
occupancy agreements and other Company Contracts granting to any Person (other
than any Owl Corporation) a right of use or occupancy of any of the Company
Leased Real Property. Except as set forth in the leases or subleases
identified in Part 2.7(c) of the Company Disclosure Schedule, there is no
Person in possession of any Company Leased Real Property other than an Owl
Corporation. None of the Owl Corporations has received any written notice (or,
to the Knowledge of the Company, any other communication, whether written or
otherwise) of a default, alleged failure to perform, or any offset or
counterclaim with respect to any occupancy agreement with respect to any
Company Leased Real Property which has not been fully remedied and withdrawn.

  

  

2.8 Intellectual Property.

  

  

(a) Part 2.8(a) of the Company Disclosure Schedule accurately identifies:

  

  

(i) in Part 2.8(a)(i) of the Company Disclosure Schedule: (A) each material
item of Registered IP in which any of the Owl Corporations has or purports to
have an ownership interest of any nature (whether solely or jointly with
another Person) and that either: (1) relates to any Company Product; (2)
relates to the manufacture, development, use, administration, delivery,
promotion, or testing of any Company Product or the provision of any service
or test using the Company Product; or (3) is used or held for use in
connection with any Company Product (the "Company Material Registered IP");
(B) the jurisdiction in which such Company Material Registered IP has been
registered or filed and the applicable registration or serial number; and (C)
any other Person that has an ownership interest in such item of Company
Material Registered IP and the nature of such ownership interest; and

  

  

(ii) in Part 2.8(a)(ii) of the Company Disclosure Schedule: (A) each material
item of Registered IP licensed with respect to any field to any of the Owl
Corporations; (B) each Contract pursuant to which any license or other right
is granted under, to or in any Intellectual Property (x) to any of the Owl
Corporations (other than commercially available third party software) or (y)
from any of the Owl Corporations, which Contract is material to the Owl
Corporations, including any development, collaboration, manufacture, services,
distribution or commercialization agreements relating to any Company Product;
and (C) whether these licenses or other grant of rights are exclusive or
nonexclusive (for purposes of this Agreement, a covenant not to sue or not to
assert infringement claims shall be deemed to be equivalent to a nonexclusive
license).

  

  

 

 

 

  

 

12  

  

 

 

 

  

(b) The Company has delivered or Made Available to Parent an accurate and
complete copy of each standard form of the following documents and Contracts
used by any Owl Corporation at any time: (i) terms and conditions with respect
to the clinical testing, distribution, sale, or provisioning of any Company
Product; (ii) employee agreement or similar Contract containing any assignment
or license of Intellectual Property or any confidentiality provision; or (iii)
consulting or independent contractor agreement or similar Contract containing
any assignment or license of Intellectual Property or any confidentiality
provision. Part 2.8(b) of the Company Disclosure Schedule accurately
identifies each Company Contract concerning the subject matter of (i), (ii) or
(iii) that is material to the Company and that deviates in any material
respect from the corresponding standard form described above.

  

  

(c) The Owl Corporations exclusively own all right, title and interest to and
in the Company IP (other than Intellectual Property licensed to the Company,
as identified in Part 2.8(a)(ii) of the Company Disclosure Schedule or
pursuant to commercially available third party software and material transfer
agreements entered into in the ordinary course of business) free and clear of
any Encumbrances. Without limiting the generality of the foregoing:

  

  

(i) to the Knowledge of the Company, all documents and instruments necessary
to perfect the rights of the Owl Corporations in the Company IP that is
Company Material Registered IP have been validly executed, delivered and filed
in a timely manner with the appropriate Governmental Body;

  

  

(ii) no Company Associate, to the Knowledge of the Company, has any claim,
right (whether or not currently exercisable) or interest to or in any Company
IP and each Company Associate who is or was involved in the creation or
development of any Intellectual Property for or on behalf of any Owl
Corporation has signed a valid, enforceable agreement containing an assignment
of all rights in and to such Intellectual Property to the Owl Corporations and
confidentiality provisions protecting the Company IP;

  

  

(iii) each Owl Corporation has taken all reasonable steps to maintain the
confidentiality of and otherwise protect and enforce its rights in all
proprietary information held by any of the Owl Corporations, or purported to
be held by any of the Owl Corporations, as a trade secret;

  

  

(iv) none of the Owl Corporations is now or has ever been a member or promoter
of, or a contributor to, any industry standards body or any similar
organization that would reasonably be expected to require or obligate any of
the Owl Corporations to grant or offer to any other Person any license or
right to any Company IP; and

  

  

(v) the Owl Corporations own or otherwise have, and after the Closing the
Surviving Corporation will continue to have, the right, through ownership,
license or otherwise, to all Intellectual Property reasonably necessary to
conduct the business of the Owl Corporations as conducted as of the date of
this Agreement or as currently proposed to be conducted.

  

  

(d) To the Knowledge of the Company, all Company IP that is material to the
business of any of the Owl Corporations is valid, subsisting and enforceable.

  

  

 

 

 

  

 

13  

  

 

 

 

  

(e) Neither the execution, delivery or performance of this Agreement nor the
consummation of any of the Contemplated Transactions will, or would reasonably
be expected to, with or without notice or the lapse of time, result in or give
any other Person the right or option to cause, create, impose or declare: (i)
a loss of, or Encumbrance on, any Company IP; (ii) the release, disclosure or
delivery of any Company IP by or to any escrow agent or other Person; or (iii)
the grant, assignment or transfer to any other Person of any license or other
right or interest under, to or in any of the Company IP.

  

  

(f) To the Knowledge of the Company, no Person has infringed, misappropriated
or otherwise violated, and no Person is infringing, misappropriating or
otherwise violating, any Company IP. Part 2.8(f) of the Company Disclosure
Schedule: (i) accurately identifies (and the Company has Made Available to
Parent an accurate and complete copy of) each letter or other written or
electronic communication or correspondence that has been sent or otherwise
delivered by or to any of the Owl Corporations or any Representative of any of
the Owl Corporations regarding any alleged or suspected infringement or
misappropriation of any Company IP, as of the date of this Agreement; and (ii)
provides a brief description of the current status of the matter referred to
in such letter, communication or correspondence.

  

  

(g) To the Knowledge of the Company, the conduct of the business of any of the
Owl Corporations as previously conducted, currently conducted or as currently
proposed to be conducted, including, without limitation, the development,
manufacture, use, import, export, offer for sale, sale or other
commercialization of any of the Company Products, does not and has not
infringed (directly, contributorily, by inducement or otherwise),
misappropriated or otherwise violated any Intellectual Property of any other
Person. Part 2.8(g) of the Company Disclosure Schedule: (i) accurately
identifies (and the Company has Made Available to Parent an accurate and
complete copy of) each letter or other written or electronic communication or
correspondence that has been sent or otherwise delivered by or to any of the
Owl Corporations or, to the Knowledge of the Company, any Representative of
any of the Owl Corporations, as of the date of this Agreement regarding any
alleged or suspected infringement or misappropriation of any Intellectual
Property of any other Person by any of the Owl Corporations or any of the
Company Products; and (ii) provides a brief description of the current status
of the matter referred to in such letter, communication or correspondence.

  

  

(h) No infringement, misappropriation or similar claim or Legal Proceeding
involving infringement or misappropriation of any Intellectual Property of any
other Person is or has been pending and served or, to the Knowledge of the
Company, pending and not served or threatened against any Owl Corporation or
against any other Person who is, or has asserted or would reasonably be
expected to assert that it is, entitled to be indemnified, defended, held
harmless or reimbursed by any Owl Corporation with respect to such claim or
Legal Proceeding (including any claim or Legal Proceeding that has been
settled, dismissed or otherwise concluded).

  

  

(i) Except as set forth in Part 2.8(i) of the Company Disclosure Schedule,
none of the Owl Corporations has transferred title to, or granted any
exclusive license, or granted an option to acquire title or an exclusive
license, with respect to, any material Company IP.

  

  

(j) Part 2.8(j) of the Company Disclosure Schedule lists all inter partes
proceedings or actions known to the Company before any court or tribunal
(including the United States Patent and Trademark Office or equivalent
authority anywhere in the world) related to any Company IP. No Company IP is
the subject of any outstanding decree, order, judgment, settlement agreement,
or stipulation restricting in any manner the use, transfer, or licensing
thereof by any of the Owl Corporations, or that may affect the validity, use
or enforceability of such Company IP.

  

  

 

 

 

  

 

14  

  

 

 

 

  

(k) To the Knowledge of the Company, the Owl Corporations have not taken any
action or failed to take any action that reasonably could be expected to
result in the abandonment, cancellation, forfeiture, relinquishment,
invalidation or unenforceability of any Company Material Registered IP
(including failure to pay required fees associated with registrations of any
Company Material Registered IP; failure to disclose any known material prior
art in connection with the prosecution of patent applications included in the
Company Material Registered IP) nor to the Knowledge of the Company, has the
owner of any material items of Registered IP licensed to any of the Owl
Corporations taken or failed to take any such action in respect to such
material items of Registered IP.

  

  

(l) None of the Owl Corporations has entered into any services agreements
relating to development, testing, manufacture or formulation of any Company
Product under which the party performing such services has obtained rights to
Intellectual Property covering such Company Products or their manufacture,
formulation or use.

  

  

2.9 Contracts.

  

  

(a) Part 2.9(a) of the Company Disclosure Schedule identifies each Company
Contract that constitutes a Company Material Contract as of the date of this
Agreement. For purposes of this Agreement, "Company Material Contract" shall
mean:

  

  

(i) any Contract which is in effect and which has been filed (or would be
required to be filed) by the Company as an exhibit pursuant to Item 601(b)(10)
of Regulation S-K under the Securities Act or that the Company would be
required to disclose under Item 404 of Regulation S-K if the Company were to
file a registration statement on Form S-1 under the Securities Act;

  

  

(ii) any Contract: (A) constituting a Company Employee Agreement; (B) pursuant
to which any of the Owl Corporations is or may become obligated to make any
severance, termination or similar payment to any Company Associate or any
spouse, heir or Representative of any Company Associate except for severance,
termination or similar payments required by applicable Legal Requirements that
does not exceed $100,000 per employee; (C) pursuant to which any of the Owl
Corporations is or may become obligated to make any bonus or similar payment
(other than payments constituting base salary, incentive bonuses or
commissions paid in the ordinary course of business) in excess of $100,000 to
any Company Associate; or (D) pursuant to which any of the Owl Corporations is
or may become obligated to grant or accelerate the vesting of, or otherwise
modify, any stock option, restricted stock, stock appreciation right or other
equity interest in any of the Owl Corporations;

  

  

(iii) any Contract identified or required to be identified in Part 2.8 of the
Company Disclosure Schedule;

  

  

(iv) any Contract with any distributor and any contract with any other
reseller or sales representative, in each case that provides exclusivity
rights to any third party;

  

  

(v) any Contract that is with a supplier of equipment, consumables, products,
reagents, raw materials or any component, or any services used in or with
respect to the Company Products, which supplier is the only source in the
market place or only supplier to the Owl Corporations or that imposes a
minimum purchase order;

  

  

(vi) any Contract pursuant to which an Owl Corporation (A) is obligated to pay
to any other Person royalties, milestone or other payments with respect to any
Company Product, (B) is obligated to provide to any other Person a percentage
interest in the sales or revenues of any Company Product, (C) is obligated to
pay to any Person any royalties, fees, commissions or other amounts for the
use or enforcement of any Company IP, (D) is obligated to research, develop,
distribute, promote or sell any drug, compound, product or service, or (E) is
required to have an exclusive relationship with any other Person;

  

  

 

 

 

  

 

15  

  

 

 

 

  

(vii) each joint venture or partnership agreement or any similar Contract
involving a sharing of profits, losses, costs or liabilities with any other
Person other than another Owl Corporation (excluding indemnification
obligations entered into in the ordinary course of business, commission, bonus
or similar arrangements with employees and independent contractors);

  

  

(viii) any Contract that provides for: (A) reimbursement of any current
director or officer of an Owl Corporation for, or advancement to any current
director or officer of an Owl Corporation of, legal fees or other expenses
associated with any Legal Proceeding or the defense thereof; or (B)
indemnification of any current director or officer of an Owl Corporation;

  

  

(ix) any Contract imposing any restriction on the right or ability of any Owl
Corporation: (A) to engage in any line of business, geography or therapeutic
area or compete with any other Person; (B) to acquire any product or other
asset or any services from any other Person; (C) to develop, sell, supply,
distribute, offer, support or service any product or any technology or other
asset to or for any other Person anywhere in the world; (D) to perform
services for any other Person; or (E) to use, exploit, assert or enforce any
Company IP anywhere in the world; or (F) to transact business with any other
Person, in each case which restriction would or would reasonably be expected
to materially and adversely affect: (x) the conduct of the business of the Owl
Corporations as currently conducted or as currently is proposed to be
conducted; or (y) the design, development, manufacturing, reproduction,
marketing, licensing, sale, offer for sale, importation, distribution,
performance, display, creation of derivative works with respect to and/or use
of any Company Product or provision of any service using any Company Product;

  

  

(x) any Contract granting to any Person a right of first negotiation, right of
first refusal or option to purchase or acquire any material assets;

  

  

(xi) any Contract incorporating or relating to any material guaranty,
warranty, sharing of liabilities or indemnity (including any indemnity with
respect to Intellectual Property or Intellectual Property Rights) or similar
obligation, other than Contracts entered into in the ordinary course of
business;

  

  

(xii) any Contract relating to any currency hedging;

  

  

(xiii) any Contract requiring that any of the Owl Corporations give any notice
or provide any information to any Person prior to responding to or prior to
accepting any Acquisition Proposal or similar proposal, or prior to entering
into any discussions, agreement, arrangement or understanding relating to any
Acquisition Transaction;

  

  

(xiv) any Contract relating to the lease or sublease of Company Leased Real
Property or of any real property owned by any Owl Corporation;

  

  

(xv) any Contract that: (A) involved the payment or delivery of cash or other
consideration in an amount or having a value in excess of $250,000 in the
fiscal year ending December 31, 2014 or the following fiscal years; (B)
requires by its terms the payment or delivery of cash or other consideration
in an amount or having a value in excess of $250,000 in the fiscal year ending
December 31, 2014 or the following fiscal years; (C) involved the performance
of services having a value in excess of $250,000 in the fiscal year ended
December 31, 2014; (D) requires by its terms the performance of services
having a value in excess of $250,000 in the fiscal year ending December 31,
2014 or the following fiscal years; (E) in which the Company or any Owl
Corporation has agreed to supply any Company Product at a specified price or
on specified terms or has granted development rights, "most favored nation"
pricing provisions or marketing or distribution rights relating to any Company
Product; (F) in which the Company or any Owl Corporation has agreed to
purchase a minimum quantity of goods or has agreed to purchase goods
exclusively from a certain party; (G) is material to the Owl Corporations and
relates to any Company Product (including any raw materials) or any ongoing
clinical trial; or (H) relates to the lease by an Owl Corporation of material
tangible personal property;

  

  

 

 

 

  

 

16  

  

 

 

 

  

(xvi) any other Contract not required to be listed pursuant to subclauses (i)
through (xv) above, the termination of which would reasonably be expected to
have a Company Material Adverse Effect.

  

  

The Company has delivered or Made Available to Parent an accurate and complete
copy of each Company Contract that constitutes a Company Material Contract.

  

  

(b) Each Company Contract that constitutes a Company Material Contract is
valid and in full force and effect, and is enforceable in accordance with its
terms, subject to: (i) laws of general application relating to bankruptcy,
insolvency and the relief of debtors; and (ii) rules of law governing specific
performance, injunctive relief and other equitable remedies.

  

  

(c) Except as set forth in Part 2.9(c) of the Company Disclosure Schedule: (i)
none of the Owl Corporations has violated or breached in any material respect,
or committed any default in any material respect under, any Company Material
Contract; (ii) to the Knowledge of the Company, no other Person has violated
or breached in any material respect, or committed any default in any material
respect under, any Company Material Contract; (iii) to the Knowledge of the
Company, no event has occurred, and no circumstance or condition exists, that
(with or without notice or lapse of time) would reasonably be expected to: (A)
result in a violation or breach in any material respect of any of the
provisions of any Company Material Contract; (B) give any Person the right to
declare a default in any material respect under any Company Material Contract;
(C) give any Person the right to accelerate the maturity or performance of any
Company Material Contract; or (D) give any Person the right to cancel,
terminate or modify any Company Material Contract; (iv) none of the Owl
Corporations has received any notice or other communication regarding any
actual or possible violation or breach of, or default under, any Company
Material Contract; (v) none of the Owl Corporations has received any notice or
other communication that any of their material suppliers or service providers
intends to cancel, not renew or otherwise terminate their relationship with
any of the Owl Corporations; (vi) none of the Owl Corporations is
participating in any active discussions to amend the terms of any Company
Material Contract other than in the ordinary course of business; and (vii)
none of the Owl Corporations has received any notice or other communications
from any parties to the Company Material Contracts set forth in Part
4.2(b)(viii) of the Company Disclosure Schedule regarding any actual or
possible termination of any such Company Material Contract or transition of
any exclusive arrangement in any such Company Material Contract to a non-
exclusive arrangement.

  

  

(d) Neither the execution, delivery or performance of this Agreement nor the
consummation of any of the Contemplated Transactions will, or would reasonably
be expected to, with or without notice or the lapse of time, (i) result in a
breach of, default under or termination of any Company Material Contract; (ii)
by the terms of any Company Material Contract, result in a loss of any
material rights of any Owl Corporation under any Company Material Contract,
including a reduction of any royalties or other payments any Owl Corporation
would otherwise be entitled to receive; or (iii) by the terms of any Company
Material Contract, result in a material increase in any obligations of any Owl
Corporation pursuant to any Company Material Contract, including causing any
payment by any Owl Corporation to become due or causing an increase in any
royalty or other payments any Owl Corporation would otherwise be required to
make under such Company Material Contract.

  

  

 

 

 

  

 

17  

  

 

 

 

  

2.10 Liabilities. None of the Owl Corporations has any accrued, contingent or
other liabilities of the type required to be disclosed, accrued or reserved in
the liabilities column of a balance sheet prepared in accordance with GAAP,
except for: (a) liabilities identified as such, or specifically reserved
against, in the Company Unaudited Balance Sheet; (b) liabilities that have
been incurred by the Owl Corporations since the date of the Company Unaudited
Balance Sheet in the ordinary course of business and consistent with past
practices; (c) liabilities for performance of obligations of the Owl
Corporations pursuant to the express terms of Company Contracts; (d)
liabilities under this Agreement or incurred in connection with the
Contemplated Transactions; and (e) liabilities that are not, individually or
in the aggregate, material to the Owl Corporations, or that are described in
Part 2.10 of the Company Disclosure Schedule.

  

  

2.11 Compliance with Legal Requirements; Regulatory Matters.

  

  

(a) Each of the Owl Corporations is, and at all times has been in compliance
in all material respects with all Legal Requirements (including Health Care
Laws), each to the extent that the same are applicable to the Owl
Corporations' businesses as they are currently conducted and proposed to be
conducted. None of the Owl Corporations has received any notice or other
written communication from any Governmental Body or other Person (i) regarding
any violation of, or failure to comply with, any Legal Requirement, (ii) that
it is or has been the subject of any inspection, investigation, survey, audit,
monitoring or other form of review by any Governmental Body, accrediting
organization or certifying agency for the purpose of any alleged improper
activity related to Health Care Laws on the part of such Entity, other than
routine inspections, surveys, audits, monitoring or other forms of review in
the ordinary course of business, or (iii) of any claim, requirement or demand
of any licensing or certifying agency to rework or redesign any Owl
Corporation's operations or any part thereof, other than rework or design
changes arising from the results of audits or reviews in the ordinary course
of business that are not material to the Owl Corporation's operations.

  

  

(b) To the Knowledge of the Company, none of the Owl Corporations nor any of
their employees, officers or directors have been: (i) debarred, disqualified,
suspended or excluded from participation in any state or Federal Health Care
Program, (ii) listed on the U.S. System for Award Management list of excluded
parties, or (iii) debarred under the FDA Act or any similar state or foreign
Law. In addition, to the Knowledge of the Company, no Owl Corporation has: (A)
engaged in any activity: (1) which is cause for the imposition of mandatory or
permissive exclusion from a state or Federal Health Care Program, or (2) for
which debarment is authorized or mandated by the FDA Act or any similar state
or foreign law; nor (B) been made a party to any other action by any
Governmental Body that may prohibit the Company or Parent from developing or
selling products or providing services to any governmental or other purchaser
pursuant to any Health Care Laws. To the Knowledge of the Company, there is no
civil, criminal, administrative or other legal proceeding, notice or demand
pending, received or, to the Knowledge of the Company, threatened against any
Owl Corporation, its employees, officers or directors, which would reasonably
be expected to result in such debarment, disqualification, suspension or
exclusion.

  

  

(c) None of the Owl Corporations or, to the Knowledge of the Company, any
director, officer or employee of any of the Owl Corporations:

  

  

 

 

 

  

 

18  

  

 

 

 

  

(i) has been convicted of or has been charged by any Governmental Body or by
any third party on behalf of any Governmental Body with any violation of any
Legal Requirement related to any Federal Health Care Program; or

  

  

(ii) has been convicted of or has been charged by any Governmental Body with
any violation of any Legal Requirement related to fraud, theft, embezzlement,
breach of fiduciary responsibility, financial misconduct, obstruction of an
investigation or controlled substances.

  

  

2.12 Certain Business Practices. Neither the Company nor, to the Knowledge of
the Company, any of its directors, employees or officers, and to the Knowledge
of the Company, none of the agents or consultants engaged by the Company (a)
has used or is using any corporate funds for any illegal contributions, gifts,
entertainment or other unlawful expenses relating to political activity, (b)
has used or is using any corporate funds for any direct or indirect unlawful
payments to any official or employee of a foreign or domestic Governmental
Body, (c) has violated or is violating any provision of the US Foreign Corrupt
Practices Act of 1977, the Corruption of Foreign Public Officials Act SC 1998,
c. 34, in each case as amended (including the rules and regulations issued
thereunder) or any other law, rule, regulation, or other legally binding
measure of any jurisdiction including the Organization for Economic
Cooperation and Development, that relates to bribery or corruption
(collectively, "Anti-Bribery Laws"), (d) has established or maintained, or is
maintaining, any unlawful fund of corporate monies or other properties, (e)
has made any bribe, unlawful rebate, unlawful payoff, influence payment,
kickback or other unlawful payment of any nature in furtherance of an offer,
payment, promise to pay, authorization, or ratification of the payment,
directly or indirectly, of any gift, money or anything of value to any
official or employee of a foreign or domestic Governmental Body to secure any
improper advantage (within the meaning of such term under any applicable Anti-
Bribery Law) or to obtain or retain business, or (f) has otherwise taken any
action that has caused, or would reasonably be expected to cause the Company
to be in violation of any applicable Anti-Bribery Law.

  

  

2.13 Governmental Authorizations.

  

  

(a) The Owl Corporations hold all material Governmental Authorizations
necessary to enable the Owl Corporations to conduct their respective
businesses in the manner in which such businesses are currently being
conducted, including all Governmental Authorizations required under
Environmental Laws. All such Governmental Authorizations are valid and in full
force and effect. Each Owl Corporation is, and has at all times been, in
compliance in all material respects with the terms and requirements of such
Governmental Authorizations. None of the Owl Corporations has received any
notice or other communication from any Governmental Body regarding: (i) any
actual or possible violation of or failure to comply with any term or
requirement of any material Governmental Authorization; or (ii) any actual or
possible revocation, withdrawal, suspension, cancellation, termination or
modification of any material Governmental Authorization.

  

  

(b) Part 2.13(b) of the Company Disclosure Schedule describes the terms of
each material grant, incentive or subsidy provided or Made Available to or for
the benefit of any of the Owl Corporations by any U.S. federal, state or local
Governmental Body or any foreign Governmental Body. Each of the Owl
Corporations is in full compliance with all of the material terms and
requirements of each grant, incentive and subsidy identified or required to be
identified in Part 2.13(b) of the Company Disclosure Schedule. Neither the
execution, delivery or performance of this Agreement, nor the consummation of
the Merger or any of the other Contemplated Transactions, does, will or would
reasonably be expected to (with or without notice or lapse of time) give any
Person the right to revoke, withdraw, suspend, cancel, terminate or modify any
grant, incentive or subsidy identified or required to be identified in Part
2.13(b) of the Company Disclosure Schedule.

  

  

 

 

 

  

 

19  

  

 

 

 

  

2.14 Tax Matters.

  

  

(a) Each of the material Tax Returns required to be filed by or on behalf of
the respective Owl Corporations with any Governmental Body with respect to any
taxable period ending on or before the Closing Date that are required to be
filed on or before the Closing Date (taking into account any applicable
extensions of such due date) (the "Owl Corporation Returns"): (i) has been or
will be filed on or before the Closing Date; and (ii) has been, or will be
when filed, prepared in all material respects in compliance with all
applicable Legal Requirements. All amounts shown on the Owl Corporation
Returns to be due on or before the Closing Date have been or will be paid on
or before the Closing Date, except with respect to matters contested in good
faith in appropriate proceedings and for which adequate reserves have been
established in accordance with GAAP.

  

  

(b) To the Knowledge of the Company, the Company Unaudited Balance Sheet fully
accrues all actual and contingent liabilities for material Taxes with respect
to all periods through the date of the Company Unaudited Balance Sheet in
accordance with GAAP.

  

  

(c) To the Knowledge of the Company, no Owl Corporation and no Owl Corporation
Return is subject to (or has been subject to) an audit with respect to Taxes
by any Governmental Body. No extension or waiver of the limitation period
applicable to any of the Owl Corporation Returns has been granted (by the
Company or any other Person), and no such extension or waiver has been
requested from any Owl Corporation.

  

  

(d) No claim or Legal Proceeding is pending or, to the Knowledge of the
Company, has been threatened in writing against or with respect to any Owl
Corporation in respect of any material Tax. There are no unsatisfied
liabilities for material Taxes with respect to any notice of deficiency or
similar document received by any Owl Corporation with respect to any material
Tax (other than liabilities for Taxes asserted under any such notice of
deficiency or similar document which are being contested in good faith by or
on behalf of such Owl Corporation and with respect to which adequate reserves
for payment have been established in accordance with GAAP on the Company
Unaudited Balance Sheet). There are no liens for material Taxes upon any of
the assets of any of the Owl Corporations except liens for current Taxes not
yet due and payable or for Taxes which are being contested in good faith by
the Owl Corporations and with respect to which adequate reserves for payment
have been established in accordance with GAAP on the Company Unaudited Balance
Sheet. None of the Owl Corporations has been, and none of the Owl Corporations
will be, required to include any material adjustment in taxable income for
U.S. federal income Tax purposes for any Tax period (or portion thereof)
pursuant to Section 481 or 263A of the Code as a result of transactions or
events occurring, or accounting methods employed, prior to the Closing.

  

  

(e) To the Knowledge of the Company, no written claim has ever been made by
any Governmental Body in a jurisdiction where an Owl Corporation does not file
a Tax Return that it is or may be subject to taxation by that jurisdiction
which has resulted or would reasonably be expected to result in an obligation
to pay material Taxes.

  

  

(f) There are no Contracts relating to the allocating, sharing or
indemnification of Taxes to which any Owl Corporation is a party, other than
Contracts containing customary gross-up or indemnification provisions in
credit agreements, derivatives, leases, and similar agreements entered into in
the ordinary course of business.

  

  

(g) No Owl Corporation has constituted either a "distributing corporation" or
a "controlled corporation" within the meaning of Section 355(a)(1)(A) of the
Code.

  

  

 

 

 

  

 

20  

  

 

 

 

  

(h) No Owl Corporation is or has been a United States real property holding
corporation within the meaning of Section 897(c)(2) of the Code during the
applicable period specified in Section 897(c)(1)(A)(ii) of the Code.

  

  

(i) No Owl Corporation has been a member of an affiliated group of
corporations within the meaning of Section 1504 of the Code or within the
meaning of any similar Legal Requirement to which an Owl Corporation may be
subject, other than an affiliated group of Persons within the meaning of the
Income Tax Act (Canada) or the affiliated group of which the Company is the
common parent. No Owl Corporation has any liability for Taxes of a predecessor
or transferor that became a liability of the successor or transferee by
operation of law.

  

  

(j) The Company has disclosed on its federal income Tax Returns all positions
that could give rise to a material understatement penalty within the meaning
of Section 6662 of the Code or any similar Legal Requirement.

  

  

(k) No Owl Corporation has participated in, or is currently participating in,
a "listed transaction" within the meaning of Treasury Regulation Section
1.6011-4(b)(1).

  

  

(l) Each Owl Corporation has withheld and paid all material Taxes required to
have been withheld and paid in connection with amounts paid or owning by such
Owl Corporation to any employee, independent contractor, creditor, shareholder
or other Person.

  

  

(m) No Owl Corporation has taken any action or knows of any fact that would
reasonably be expected to prevent the Merger from qualifying as a
reorganization within the meaning of Section 368(a) of the Code. No Owl
Corporation has taken any action or knows of any fact that would reasonably be
expected to cause the Merger to be subject to Section 367(a)(1) of the Code.

  

  

2.15 Employee and Labor Matters; Benefit Plans.

  

  

(a) Except as set forth in Part 2.15(a) of the Company Disclosure Schedule or
as required by applicable Legal Requirements, the employment of each of the
Owl Corporations' employees is terminable by the applicable Owl Corporation at
will, without severance or payment of compensation other than wages earned and
paid time off benefits earned but not taken through the date of termination.
No current or former independent contractor of the Owl Corporations could
reasonably be deemed to be a misclassified employee. No independent contractor
(i) has provided services to any of the Owl Corporations for a period of six
consecutive months or longer or (ii) is eligible to participate in any Company
Employee Plan. No Owl Corporation could be considered a joint or co-employer
of any temporary or leased employees from a third party that worked at any of
the Owl Corporations.

  

  

(b) Except as set forth in Part 2.15(b) of the Company Disclosure Schedule,
none of the Owl Corporations is a party to, or has a duty to bargain for, any
collective bargaining agreement or other Contract with a labor organization or
works council representing any of its employees and there are no labor
organizations or works councils representing, purporting to represent or, to
the Knowledge of the Company, seeking to represent any employees of any of the
Owl Corporations. There has not been any strike, slowdown, work stoppage,
lockout, job action, picketing, labor dispute, question concerning
representation, union organizing activity, or any threat thereof, or any
similar activity or dispute, affecting any of the Owl Corporations or any of
their employees. There is not now pending, and, to the Knowledge of the
Company, no Person has threatened to commence, any such strike, slowdown, work
stoppage, lockout, job action, picketing, labor dispute, question regarding
representation or union organizing activity or any similar activity or
dispute. The Owl Corporations are not and have not engaged in any unfair labor
practices as defined in the National Labor Relations Act of 1947, as amended
"the "NLRA"), and there is no claim or grievance pending or, to the Knowledge
of the Company, threatened against any Owl Corporation relating to any
employment Contract, wages and hours, leave of absence, plant closing
notification, employment statute or regulation, privacy right, labor dispute,
workers' compensation policy or long-term disability policy, safety,
retaliation, immigration or discrimination matters involving any Company
Associate, including charges of unfair labor practices or harassment
complaints.

  

  

 

 

 

  

 

21  

  

 

 

 

  

(c) The Company has delivered or Made Available to Parent an accurate and
complete list, as of the date of this Agreement, of each Company Employee Plan
and each Company Employee Agreement. None of the Owl Corporations intends, and
none of the Owl Corporations has committed, to establish or enter into any new
Company Employee Plan or Company Employee Agreement, or to modify any Company
Employee Plan or Company Employee Agreement (except to conform any such
Company Employee Plan or Company Employee Agreement to the requirements of any
applicable Legal Requirements, in each case as previously disclosed to Parent
in writing or as required by this Agreement).

  

  

(d) The Company has delivered or Made Available to Parent accurate and
complete copies of: (i) all documents setting forth the terms of each Company
Employee Plan and each Company Employee Agreement, including all amendments
thereto and all related trust documents; (ii) the three most recent annual
reports (Form Series 5500 and all schedules and financial statements attached
thereto), if any, required under applicable Legal Requirements in connection
with each Company Employee Plan; (iii) if the Company Employee Plan is subject
to the minimum funding standards of Section 302 of ERISA, the most recent
annual and periodic accounting of Company Employee Plan assets, if any; (iv)
the most recent summary plan description together with the summaries of
material modifications thereto, if any, required under ERISA or any similar
Legal Requirement with respect to each Company Employee Plan; (v) all material
written Contracts relating to each Company Employee Plan, including
administrative service agreements and group insurance contracts; and (vi) all
material correspondence in its possession regarding any Company Employee Plan
regarding any audit, investigation or proceeding regarding such Company
Employee Plan or any fiduciary thereof.

  

  

(e) Each of the Owl Corporations and Company Affiliates has performed in all
material respects all obligations required to be performed by it under each
Company Employee Plan and Company Employee Agreement, and each Company
Employee Plan and Company Employee Agreement has been established and
maintained in all material respects in accordance with its terms and
applicable Legal Requirements. No "prohibited transaction," within the meaning
of Section 4975 of the Code or Sections 406 and 407 of ERISA, and not
otherwise exempt under Section 408 of ERISA, has occurred with respect to any
Company Employee Plan. Each Company Employee Plan (other than any Company
Employee Plan to be terminated prior to the Effective Time in accordance with
this Agreement) can be amended, terminated or otherwise discontinued after the
Closing in accordance with its terms, without liability to Parent, any of the
Owl Corporations or any Company Affiliate (other than any liability for
ordinary administration expenses). There are no audits or inquiries pending
or, to the Knowledge of the Company, threatened by the IRS, the DOL or any
other Governmental Body with respect to any Company Employee Plan or any
fiduciary thereof. There are no actions, suits or claims pending or, to the
Knowledge of the Company, threatened or reasonably anticipated (other than
routine claims for benefits) against any Company Employee Plan or against the
assets of any Company Employee Plan. None of the Owl Corporations, and no
Company Affiliate, has ever incurred: (i) any material penalty or tax with
respect to any Company Employee Plan under Section 502(i) of ERISA or Sections
4975 through 4980 of the Code; or (ii) any material penalty or Tax under
applicable Legal Requirements. Each of the Owl Corporations and Company
Affiliates has made all contributions and other payments required by and due
under the terms of each Company Employee Plan and each Company Employee
Agreement. Neither the terms nor the performance of any Company Employee
Agreement or Company Employee Plan would reasonably be expected to result in
gross income inclusion after the Effective Time pursuant to Section
409A(a)(1)(A) of the Code.

  

  

 

 

 

  

 

22  

  

 

 

 

  

(f) None of the Owl Corporations, and no Company Affiliate, has ever
maintained, established, sponsored, participated in or contributed to any: (i)
Company Pension Plan subject to Title IV of ERISA; (ii) "multiemployer plan"
within the meaning of Section (3)(37) of ERISA; (iii) plan described in
Section 413 of the Code; (iv) Company Employee Plan intended to be qualified
under Section 401(a) of the Code; or (v) Company Foreign Plan. No Company
Employee Plan is or has been funded by, associated with or related to a
"voluntary employees' beneficiary association" within the meaning of Section
501(c)(9) of the Code. None of the Owl Corporations, and no Company Affiliate,
has ever maintained, established, sponsored, participated in or contributed to
any Company Pension Plan in which stock of any of the Owl Corporations or any
Company Affiliate is or was held as a plan asset. There are no material
liabilities of the Owl Corporations with respect to any Company Employee Plan
that are not properly accrued and reflected in the financial statements of the
Company in accordance with GAAP.

  

  

(g) None of the Owl Corporations, and no Company Affiliate, maintains,
sponsors or contributes to any Company Employee Plan that is an employee
welfare benefit plan (as such term is defined in Section 3(1) of ERISA) and
that is, in whole or in part, self-funded or self-insured. No Company Employee
Plan provides (except at no cost to the Owl Corporations or any Company
Affiliate), or reflects or represents any liability of any of the Owl
Corporations or any Company Affiliate to provide, post-termination or retiree
life insurance, post-termination or retiree health benefits or other post-
termination or retiree employee welfare benefits to any Person for any reason,
except as may be required by COBRA or other applicable Legal Requirements.
None of the Owl Corporations nor any Company Affiliate has ever represented,
promised or contracted (whether in oral or written form) to any Company
Associate (either individually or to Company Associates as a group) or any
other Person that such Company Associate(s) or other Person would be provided
with post-termination or retiree life insurance, post-termination or retiree
health benefits or other post-termination or retiree employee welfare
benefits, except to the extent required by applicable Legal Requirements.

  

  

(h) Except as set forth in Part 2.15(h) of the Company Disclosure Schedule,
and except as expressly required or provided by this Agreement, neither the
execution of this Agreement nor the consummation of the Contemplated
Transactions will or would reasonably be expected to (either alone or in
connection with any other circumstance or event) constitute an event under any
Company Employee Plan, Company Employee Agreement, trust or loan that will or
may result (either alone or in connection with any other circumstance or
event) in any payment (whether of severance pay or otherwise), acceleration,
forgiveness of indebtedness, vesting, distribution, increase in benefits or
obligation to fund benefits with respect to any Company Associate.

  

  

(i) Except as set forth in Part 2.15(i) of the Company Disclosure Schedule,
each of the Owl Corporations and Company Affiliates: (i) is, and has at all
times been, in compliance in all material respects with any Order or
arbitration award of any court, arbitrator or any Governmental Body,
respecting employment, employment practices, terms and conditions of
employment, wages, hours, worker classification (including the proper
classification of workers as independent contractors and consultants),
occupational safety and health and employment practices, including the
Immigration Reform and Control Act, or other labor related matters; (ii) has,
to the Knowledge of the Company, withheld and reported all amounts required by
applicable Legal Requirements or by Contract to be withheld and reported with
respect to wages, salaries and other payments to Company Associates; (iii) is
not, to the Knowledge of the Company, liable for any arrears of wages or any
taxes or any interest or penalty for failure to comply with the Legal
Requirements applicable to the foregoing; (iv) is not liable for any payment
to any trust or other fund governed by or maintained by or on behalf of any
Governmental Body with respect to unemployment compensation benefits, social
security, social charges or other benefits or obligations for Company
Associates (other than routine payments to be made in the normal course of
business and consistent with past practice); and (v) is not liable for any
unpaid wages, compensation, wage-related penalties, or other sums for failure
to comply with any of the foregoing. There are no controversies pending, or to
the Knowledge of the Company, threatened between any of the Owl Corporations
and any current or former employee, which controversies would reasonably be
expected to result in an action, suit, proceeding, claim, arbitration or
investigation before any Governmental Body.

  

  

 

 

 

  

 

23  

  

 

 

 

  

(j) There is no agreement, plan, arrangement or other Contract covering any
Company Associate, and no payments have been made or will be made in
connection with the Merger to any Company Associate, that, considered
individually or considered collectively with any other such Contracts or
payments, will, or would reasonably be expected to, be characterized as a
"parachute payment" within the meaning of Section 280G(b)(2) of the Code. No
Owl Corporation is a party to or has any obligation under any Contract to
compensate any Person for excise taxes payable pursuant to Section 4999 of the
Code or for taxes payable pursuant to Section 409A of the Code.

  

  

(k) None of the Owl Corporations has effectuated a "plant closing," partial
"plant closing," "relocation," "mass layoff" or "termination" (as defined in
the Worker Adjustment and Retraining Notification Act (the "WARN Act") or any
similar Legal Requirement) affecting any site of employment or one or more
facilities or operating units within any site of employment or facility of any
of the Owl Corporations.

  

  

(l) Each Company Employee Plan and Company Employee Agreement that is a
"nonqualified deferred compensation plan" (as defined under Section 409A of
the Code) has been operated in compliance in all material respects with
Section 409A of the Code and has complied in all material respects with
applicable documentary requirements of Section 409A of the Code. No stock
right or other equity option or appreciation right granted under any benefit
plan has an exercise price that is less than the fair market value of the
underlying stock or equity units (as the case may be) as of the date such
option or right was granted, or has any feature for the deferral of
compensation other than the deferral of recognition of income until the later
of exercise or disposition of such option or right.

  

  

2.16 Environmental Matters.

  

  

(a) None of the Owl Corporations has received any notice or other
communication, whether from a Governmental Body, citizens group, or otherwise,
that alleges that any of the Owl Corporations is not or might not be in
compliance with any Environmental Law, and, to the Knowledge of the Company,
there are no circumstances that may prevent or interfere with the compliance
by any of the Owl Corporations with any Environmental Law in the future.

  

  

(b) To the Knowledge of the Company: (i) all Company Leased Real Property and
any other property that is or was leased to or owned, controlled or used by
any of the Owl Corporations, and all surface water, groundwater and soil
associated with or adjacent to such property, is free of any Materials of
Environmental Concern or material environmental contamination of any nature;
(ii) none of the Company Leased Real Property or any other property that is or
was leased to or owned, controlled or used by any of the Owl Corporations
contains any underground storage tanks, asbestos, equipment using PCBs or
underground injection wells; and (iii) none of the Company Leased Real
Property or any other property that is or was leased to or owned, controlled
or used by any of the Owl Corporations contains any septic tanks in which
process wastewater or any Materials of Environmental Concern have been
Released.

  

  

 

 

 

  

 

24  

  

 

 

 

  

(c) No Owl Corporation has ever sent or transported, or arranged to send or
transport, any Materials of Environmental Concern to a site that, pursuant to
any applicable Environmental Law: (i) has been placed on the "National
Priorities List" of hazardous waste sites or any similar state list; (ii) is
otherwise designated or identified as a potential site for remediation,
cleanup, closure or other environmental remedial activity; or (iii) is subject
to a Legal Requirement to take "removal" or "remedial" action as detailed in
any applicable Environmental Law or to make payment for the cost of cleaning
up any site.

  

  

(d) Except with respect to Contracts relating to Company Leased Real Property,
none of the Owl Corporations has entered into any Company Contract that may
require any of them to guarantee, reimburse, defend, hold harmless or
indemnify any other party with respect to liabilities arising out of
Environmental Laws, or the activities of the Owl Corporations or any other
Person relating to Materials of Environmental Concern.

  

  

2.17 Insurance. Each material insurance policy and self-insurance program and
arrangement relating to the business, assets and operations of the Owl
Corporations is in full force and effect. None of the Owl Corporations has
received any notice or other communication regarding any actual or possible:
(a) cancellation or invalidation of any material insurance policy; (b) refusal
of any coverage or rejection of any material claim under any insurance policy;
or (c) material adjustment in the amount of the premiums payable with respect
to any insurance policy. There is no pending workers' compensation or other
claim under or based upon any insurance policy of any of the Owl Corporations
involving an amount in excess of $100,000 in any individual case or $500,000
in the aggregate.

  

  

2.18 Transactions with Affiliates. As of the date of this Agreement, no event
has occurred that would be required to be reported by the Company pursuant to
Item 404 of Regulation S-K promulgated by the SEC if the Company were to file
a registration statement on Form S-1 or become subject to the periodic
reporting requirements under the Exchange Act.

  

  

2.19 Legal Proceedings; Orders.

  

  

(a) Except as set forth in Part 2.19(a) of the Company Disclosure Schedule,
there is not as of the date of this Agreement, and there has not at any time
been, any pending and served Legal Proceeding, or (to the Knowledge of the
Company) any pending but not served Legal Proceeding and during such period no
Person has threatened to commence any material Legal Proceeding: (i) that
involves any of the Owl Corporations, any business of any of the Owl
Corporations, any of the assets owned, leased or used by any of the Owl
Corporations; or (ii) that challenges, or that may have the effect of
preventing, delaying, making illegal or otherwise interfering with, the Merger
or any of the other Contemplated Transactions. To the Knowledge of the
Company, no event has occurred, and no claim, dispute or other condition or
circumstance exists, that would reasonably be expected to give rise to or
serve as a reasonable basis for the commencement of any Legal Proceeding of
the type described in clause "(i)" or clause "(ii)" of the first sentence of
this Section 2.19(a).

  

  

(b) There is no Order to which any of the Owl Corporations, or any of the
material assets owned or used by any of the Owl Corporations, is subject. To
the Knowledge of the Company, no officer or other key employee of any of the
Owl Corporations is subject to any Order that prohibits such officer or other
employee from engaging in or continuing any conduct, activity or practice
relating to the business of any of the Owl Corporations.

  

  

2.20 Authority; Binding Nature of Agreement. The Company has the corporate
right, power and authority to enter into and perform its obligations under
this Agreement and, subject to obtaining the Required Company Stockholder
Vote, consummate the transactions contemplated hereby. The Company Board (at a
meeting duly called and held at which a quorum of directors was present) has:
(a) determined that this Agreement and the Merger are advisable and fair to,
and in the best interests of, the Company and its stockholders; (b) authorized
and approved the execution, delivery and performance of this Agreement by the
Company and approved the Merger; and (c) recommended that this Agreement be
adopted and the Merger be approved by the holders of Company Capital Stock.
Assuming the due authorization, execution and delivery of this Agreement by
Parent and Merger Sub, this Agreement constitutes the legal, valid and binding
obligation of the Company, enforceable against the Company in accordance with
its terms, subject to: (i) laws of general application relating to bankruptcy,
insolvency, the relief of debtors and creditors' rights generally; and (ii)
rules of law governing specific performance, injunctive relief and other
equitable remedies.

  

  

 

 

 

  

 

25  

  

 

 

 

  

2.21 Inapplicability of Section 203 of the DGCL and other Anti-takeover
Statute. The Company Board has taken, and during the Pre-Closing Period the
Company Board will take, all actions necessary to ensure that the restrictions
applicable to business combinations contained in Section 203 of the DGCL are
not, and will not be, applicable to the execution, delivery or performance of
this Agreement, or to the consummation of the Merger or any of the other
Contemplated Transactions. The Company Board (at a meeting duly called and
held at which a quorum of directors was present) has, to the extent necessary,
adopted a resolution having the effect of causing the Company not to be
subject to any state takeover law or similar Legal Requirement that might
otherwise apply to the Merger or any of the other Contemplated Transactions.
No state takeover statute or similar Legal Requirement (other than Section 203
of the DGCL) applies or purports to apply to the Merger, this Agreement, or
any of the Contemplated Transactions. None of the Company or, to the Knowledge
of the Company, any of its respective "affiliates" or "associates" is or has
been an "interested stockholder" (as defined in Section 203 of the DGCL) with
respect to Parent.

  

  

2.22 Vote Required. The affirmative vote of the holders of a majority of the
voting power of the shares of Company Capital Stock, voting as a single class
and outstanding as of the date of this Agreement and the affirmative vote of a
majority of the voting power of all shares of Company Preferred Stock, voting
as a single class and outstanding as of the date of this Agreement (the
"Required Company Stockholder Vote") are the only votes of the holders of any
class or series of the Company Capital Stock necessary to adopt this Agreement
or consummate the transactions contemplated hereby.

  

  

2.23 Non-Contravention; Consents. Assuming compliance with the applicable
provisions of the DGCL, Investment Canada Act and the HSR Act, except as set
forth in Part 2.23 of the Company Disclosure Schedule, neither (1) the
execution, delivery or performance of this Agreement, nor (2) the consummation
of the Merger or any of the other Contemplated Transactions, will, directly or
indirectly (with or without notice or lapse of time):

  

  

(a) contravene, conflict with or result in a material violation of: (i) any of
the provisions of the certificate of incorporation, bylaws or other charter or
organizational documents of any of the Owl Corporations; or (ii) any
resolution adopted by the stockholders, the board of directors or any
committee of the board of directors of any of the Owl Corporations;

  

  

(b) contravene, conflict with or result in a material violation of, any Legal
Requirement or any Order to which any of the Owl Corporations, or any of the
assets owned or used by any of the Owl Corporations, is subject;

  

  

(c) contravene, conflict with or result in a material violation of any of the
terms or requirements of, or give any Governmental Body the right to revoke,
withdraw, suspend, cancel, terminate or modify, any Governmental Authorization
that is held by any of the Owl Corporations or that otherwise relates to the
business of any of the Owl Corporations or to any of the assets owned or used
by any of the Owl Corporations;

  

  

 

 

 

  

 

26  

  

 

 

 

  

(d) except as already disclosed in Part 2.9(c) of the Company Disclosure
Schedule, contravene, conflict with or result in a material violation or
breach of, or result in a default under, any provision of any Company Material
Contract, or give any Person the right to: (i) declare a default or exercise
any remedy under any such Company Material Contract; (ii) accelerate the
maturity or performance of any such Company Material Contract; or (iii)
cancel, terminate or modify any right, benefit, obligation or other term of
such Company Material Contract; or

  

  

(e) result in the imposition or creation of any Encumbrance upon or with
respect to any asset owned or used by any of the Owl Corporations (except for
minor liens that will not, in any case or in the aggregate, materially detract
from the value of the assets subject thereto or materially impair the
operations of any of the Owl Corporations).

  

  

Except as may be required by the DGCL, Investment Canada Act and the HSR Act,
none of the Owl Corporations is or will be required to make any filing with or
give any notice to, or to obtain any Consent from, any Governmental Body in
connection with: (x) the execution, delivery or performance of this Agreement;
or (y) the consummation of the Merger or any of the other Contemplated
Transactions, except where the failure to make any such filing or give any
such notice or to obtain any such Consent would not, individually or in the
aggregate, be material to the Owl Corporations.

  

  

2.24 No Broker Fee. No broker, finder or investment banker is entitled to any
brokerage, finder's or other fee or commission in connection with the Merger
or any of the other Contemplated Transactions based upon arrangements made by
or on behalf of any of the Owl Corporations.

  

  

2.25 Acknowledgement by the Company. The Company is not relying and has not
relied on any representations or warranties whatsoever regarding the subject
matter of this Agreement, express or implied, except for the representations
and warranties in Section 3 or contained in the Parent Stockholder Voting
Agreements. The representations and warranties by Parent and Merger Sub
contained in Section 3 constitute the sole and exclusive representations and
warranties of Parent, the other Tiger Corporations and their respective
Representatives in connection with the Contemplated Transactions and the
Company understands, acknowledges and agrees that all other representations
and warranties of any kind or nature whether express, implied or statutory are
specifically disclaimed by Parent.

  

  

2.26 Private Placement. The Company understands and acknowledges that the
Parent Common Stock issuable pursuant to the Merger has not been and will not
be registered or otherwise qualified under the Securities Act, any applicable
state securities laws, or any Canadian Securities Laws; will be issued in
transactions exempt from such registration and qualification requirements; and
that therefore, such Parent Common Stock will be "restricted securities" (as
defined in Rule 144 under the Securities Act) and subject to restrictions on
resale under the Securities Act and a seasoning period under Section 2.6(3) of
National Instrument 45-102. The Company further understands and acknowledges
that certificates representing such Parent Common Stock will bear a legend to
such effect.

  

  

Section 3. Representations and Warranties of Parent and Merger Sub

  

  

Parent and Merger Sub represent and warrant to the Company as follows (it
being understood that each representation and warranty contained in this
Section 3 is subject to: (a) the exceptions and disclosures set forth in the
part or subpart of the Parent Disclosure Schedule corresponding to the
particular Section or subsection in this Section 3 in which such
representation and warranty appears; and (b) any exception or disclosure set
forth in any other part or subpart of the Parent Disclosure Schedule to the
extent it is reasonably apparent that such exception or disclosure is relevant
to such representation and warranty; and (c) any information set forth in
Parent SEC Documents filed on the SEC's EDGAR database and any information set
forth in the Parent Canadian Disclosure Documents filed on SEDAR, in each case
that were filed on or after January 1, 2013 and publicly available prior to
the date of this Agreement, other than information set forth therein under the
headings "Risk Factors" or "Forward-Looking Statements" or similar captions
and any other information set forth therein that is predictive, cautionary or
forward-looking in nature):

  

  

 

 

 

  

 

27  

  

 

 

 

  

3.1 Subsidiaries; Due Organization; Etc.

  

  

(a) Part 3.1(a) of the Parent Disclosure Schedule identifies each Subsidiary
of the Parent and indicates its jurisdiction of organization. Neither the
Parent nor any of Parent's Subsidiaries owns any capital stock of, or any
equity interest of any nature in, any other Entity, other than the Parent's
Subsidiaries. No Tiger Corporation has agreed or is obligated to make, or is
bound by any Contract under which it may become obligated to make, any future
investment in or capital contribution to any other Entity.

  

  

(b) Each of the Tiger Corporations is a corporation or other business
organization duly organized, validly existing and in good standing (to the
extent that the laws of the jurisdiction of its formation recognize the
concept of good standing) under the laws of the jurisdiction of its
incorporation and has all necessary organizational power and authority: (i) to
conduct its business in the manner in which its business is currently being
conducted; (ii) to own and use its assets in the manner in which its assets
are currently owned and used; and (iii) to perform its obligations under all
Contracts by which it is bound.

  

  

(c) Each of the Tiger Corporations is qualified to do business as a foreign
corporation, and is in good standing, under the laws of all jurisdictions
where the nature of its business requires such qualification, except for
jurisdictions in which the failure to be so qualified or in good standing,
individually or in the aggregate, would not have a Parent Material Adverse
Effect.

  

  

(d) The corporate records and minute books of each of the Tiger Corporations
have been maintained in accordance with all applicable Legal Requirements in
all material respects, and such corporate records and minute books are
complete and accurate in all material respects, including, but not limited to
the fact that, the minute books contain the minutes of all meetings of the
boards of directors, committees of the board and shareholders and all
resolutions passed by the boards of directors, committees of the boards and
the shareholders. The financial books, records and accounts of each of the
Tiger Corporations (i) have in all material respects been maintained in
accordance with good business practices and in accordance with GAAP and with
the accounting principles generally accepted in the country of domicile of
each such entity on a basis consistent with prior years, and (ii) accurately
and fairly reflect the basis for the consolidated financial statements of
Parent.

  

  

3.2 Certificate of Incorporation and Articles. Parent has delivered or Made
Available to the Company accurate and complete copies of the certificate of
incorporation, notice of articles and articles, bylaws or equivalent governing
documents of each of the Tiger Corporations, including all amendments thereto.
The Parent has delivered or Made Available to the Company accurate and
complete copies of: (a) the charters of all committees of the Parent Board;
and (b) any code of conduct, corporate governance policies or principles,
related party transaction policy, stock ownership guidelines, whistleblower
policy, disclosure committee charter or similar codes policies, or guidelines
adopted by any of the Tiger Corporations or by the board of directors, or any
committee of the board of directors, of any of the Tiger Corporations.

  

  

 

 

 

  

 

28  

  

 

 

 

  

3.3 Capitalization, Etc.

  

  

(a) The authorized capital stock of the Parent consists of: (i) an unlimited
number of shares of Parent Common Stock, no par value, of which 22,438,176
shares have been issued and are outstanding as of December 31, 2014; and (ii)
an unlimited number of shares of Parent Preferred Stock, no par value, of
which none are issued or outstanding as of the last Business Day ending
immediately prior to the date of this Agreement. All of the outstanding shares
of Parent Common Stock have been duly authorized and validly issued, and are
fully paid and nonassessable. None of the Tiger Corporations (other than the
Parent) holds any shares of Parent Common Stock or any rights to acquire
shares of Parent Common Stock.

  

  

(b) Except as set forth in Part 3.3(b) of the Parent Disclosure Schedule: (i)
none of the outstanding shares of Parent Common Stock is entitled or subject
to any preemptive right, right of repurchase or forfeiture, right of
participation, right of maintenance or any similar right; (ii) none of the
outstanding shares of Parent Common Stock is subject to any right of first
refusal in favor of the Parent; and (iii) there is no Parent Contract relating
to the voting or registration of, or restricting any Person from purchasing,
selling, pledging or otherwise disposing of (or from granting any option or
similar right with respect to), any shares of Parent Common Stock. None of the
Tiger Corporations is under any obligation, or is bound by any Contract
pursuant to which it may become obligated, to repurchase, redeem or otherwise
acquire any outstanding shares of Parent Common Stock or other securities,
except for the Parent's right to repurchase or reacquire restricted shares of
Parent Common Stock held by an employee of the Parent upon termination of such
employee's employment or upon any other forfeiture of a vesting condition.

  

  

(c) As of the date of this Agreement: (i) 1,822,983 shares of Parent Common
Stock are subject to issuance pursuant to Parent Options; (ii) 785,398 shares
of Parent Common Stock are reserved for future issuance pursuant to equity
awards not yet granted under the Parent Option Plans, and (iii) 398,250 shares
of Parent Common Stock are reserved for future issuance pursuant to Parent
Warrants.

  

  

(d) The Parent has delivered or Made Available to Company a complete and
accurate list that sets forth with respect to each Parent Equity Award
outstanding as of the date of this Agreement the following information: (i)
the particular plan (if any) pursuant to which such Parent Equity Award was
granted; (ii) the name of the holder of such Parent Equity Award; (iii) the
type of Parent Equity Award (whether a Parent Option or another type of Parent
Equity Award); (iv) the number of shares of Parent Common Stock subject to
such Parent Equity Award; (v) the per share exercise price (if any) of such
Parent Equity Award; (vi) the applicable vesting schedule, and the extent to
which such Parent Equity Award is vested and exercisable, if applicable; (vii)
the date on which such Parent Equity Award was granted; (viii) the date on
which such Parent Equity Award expires (if applicable); and (ix) if such
Parent Equity Award is a Parent Option, whether such Parent Option is intended
to be an "incentive stock option" (as defined in the Code) or a non-qualified
stock option. The Parent has delivered or Made Available to the Company
accurate and complete copies of all equity plans pursuant to which any
outstanding Parent Equity Awards were granted by the Parent, and the forms of
all agreements evidencing such Parent Equity Awards. The exercise price of
each Parent Option is not less than the fair market value of a share of Parent
Common Stock as determined on the date of grant of such Parent Option. All
grants of Parent Equity Awards were recorded on the Parent's financial
statements (including, any related notes thereto) contained in the Parent SEC
Documents in accordance with GAAP, and were recorded on the Parent's financial
statements (including, any related notes thereto) contained in the Parent
Canadian Securities Documents (as defined below in Section 3.4(a)) in
accordance with Canadian Securities Laws, and no such grants involved any
"back dating" or similar practices with respect to the effective date of grant
(whether intentional or otherwise). There are no outstanding stock
appreciation, phantom stock, profit participation or similar rights or equity-
based awards with respect to any of the Tiger Corporations.

  

  

 

 

 

  

 

29  

  

 

 

 

  

(e) Except as set forth in Sections 3.3(a), 3.3(b) and 3.3(c), or as permitted
from and after the date of this Agreement pursuant to Section 4.3, there is
no: (i) outstanding subscription, option, call, warrant or right (whether or
not currently exercisable) to acquire any shares of the capital stock or other
securities of any of the Tiger Corporations; (ii) outstanding security,
instrument or obligation that is or may become convertible into or
exchangeable for any shares of the capital stock or other securities of any of
the Tiger Corporations or that has the right to vote on any matter on which
the stockholders of Parent have the right to vote; (iii) Contract under which
any of the Tiger Corporations is or may become obligated to sell or otherwise
issue any shares of its capital stock or any other securities; or (iv)
condition or circumstance that would reasonably be expected to give rise to or
provide a basis for the assertion of a claim by any Person to the effect that
such Person is entitled to acquire or receive any shares of capital stock or
other securities of any of the Tiger Corporations.

  

  

(f) All outstanding shares of Parent Common Stock, and all options and other
Parent Equity Awards and other securities of the Tiger Corporations, have been
issued and granted in compliance in all material respects with: (i) all
applicable corporate and securities laws and other applicable Legal
Requirements; and (ii) all requirements set forth in applicable Contracts.

  

  

(g) All of the outstanding shares of capital stock of each of the Parent's
Subsidiaries have been duly authorized and validly issued, are fully paid and
nonassessable and free of preemptive rights, with no personal liability
attaching to the ownership thereof, and are owned beneficially and of record
by the Parent, free and clear of any Encumbrances, other than restrictions
under applicable securities laws.

  

  

3.4 SEC Filings; Canadian Securities Regulatory Filings; Financial Statements.

  

  

(a) The Parent has delivered or Made Available to the Company accurate and
complete copies of all registration statements, proxy statements, Parent
Certifications and other statements, reports, schedules, forms and other
documents filed by the Parent with the SEC, including all amendments thereto,
since January 1, 2012 (collectively, the "Parent SEC Documents") and all
documents filed by Parent under Canadian Securities Laws, including without
limitation all documents filed by the Parent on SEDAR, since January 1, 2012
(the "Parent Canadian Securities Documents") All statements, reports,
schedules, forms and other documents required to have been filed by the Parent
or its officers with the SEC or under Canadian Securities Laws since January
1, 2012 have been so filed on a timely basis. None of the Parent's
Subsidiaries is required to file any documents with the SEC or under Canadian
Securities Laws. As of the time it was filed with the SEC or under Canadian
Securities Laws, as applicable, (or, if amended or superseded by a filing
prior to the date of this Agreement, then on the date of such filing): (i)
each of the Parent SEC Documents and Parent Canadian Securities Documents
complied as to form in all material respects with the applicable requirements
of the Securities Act or the Exchange Act and Canadian Securities Laws (as the
case may be) and the applicable rules of the TSX; and (ii) none of the Parent
SEC Documents or Parent Canadian Securities Documents contained any untrue
statement of a material fact or omitted to state a material fact required to
be stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading and
Parent has not filed any confidential material change report under Canadian
Securities Laws that at the date hereof remains confidential. Each of the
certifications and statements relating to the Parent SEC Documents required
by: (A) Rule 13a-14 or Rule 15d-14 under the Exchange Act; (B) 18 U.S.C. 1350
(Section 906 of the Sarbanes-Oxley Act); or (C) any other rule or regulation
promulgated by the SEC or applicable to the Parent SEC Documents or relating
to the Parent Canadian Securities Documents required under Canadian Securities
Laws (collectively, the "Parent Certifications") is accurate and complete, and
complies as to form in all material respects with all applicable Legal
Requirements. As used in the introduction to this Section 3 and in this
Section 3.4, the term "file" and variations thereof shall be broadly construed
to include any manner in which a document or information is filed, furnished,
submitted, supplied or otherwise Made Available to the SEC or Canadian
securities regulatory authorities or any member of their respective staff or
filed on SEDAR.

  

  

 

 

 

  

 

30  

  

 

 

 

  

(b) Parent is a "reporting issuer" in each Province of Canada within the
meaning of applicable Canadian Securities Laws and not on the list of
reporting issuers in default under applicable Canadian Securities Laws, and no
securities commission or similar regulatory authority has issued any order
preventing or suspending trading of any securities of Parent, and Parent is in
compliance in all material respects with applicable Canadian Securities Laws.

  

  

(c) The Parent Common Stock is listed on the TSX and NASDAQ and, except for
such listings, no securities of any of the Tiger Corporations are listed on
any other stock or securities exchange or market or registered under any
securities laws. Trading in Parent Common Stock on the TSX and NASDAQ is not
currently halted or suspended. No delisting, suspension of trading or cease
trading order with respect to any securities of Parent is pending or, to the
Knowledge of Parent, threatened in writing. To the Knowledge of Parent, as of
the date of this Agreement, no inquiry, review or investigation (formal or
informal) of Parent by any securities commission or similar regulatory
authority under applicable Canadian Securities Laws, the TSX or NASDAQ is in
effect or ongoing or reasonably expected to be implemented or undertaken.

  

  

(d) Parent maintains disclosure controls and procedures as defined by Rule
13a-15 or 15d-15 under the Exchange Act and under Canadian Securities Laws.
Such disclosure controls and procedures are designed to ensure that all
material information concerning the Tiger Corporations required to be
disclosed by the Parent in the reports that it is required to file, submit or
furnish under the Exchange Act and/or under Canadian Securities Laws is
recorded, processed, summarized and reported within the time periods specified
in the SEC's rules and forms or under Canadian Securities Laws. The Parent is
in compliance in all material respects with the applicable listing
requirements of the NASDAQ and the TSX, and has not since January 1, 2014
received any notice asserting any non-compliance with the listing requirements
of the NASDAQ or the TSX.

  

  

(e) The financial statements (including any related notes) comprising,
contained or incorporated by reference in the Parent SEC Documents and/or
Parent Canadian Securities Documents: (i) complied as to form and substance in
all material respects with the published rules and regulations of the SEC and
Canadian Securities Laws applicable thereto; (ii) were prepared in accordance
with GAAP applied on a consistent basis throughout the periods covered (except
as may be indicated in the notes to such financial statements or, in the case
of unaudited financial statements, as permitted by Form 10-Q, Form 8-K or any
successor form under the Exchange Act, and except that the unaudited financial
statements may not contain footnotes and are subject to normal and recurring
year-end adjustments, none of which will be material); and (iii) fairly
present, in all material respects, the consolidated financial position of the
Parent and its consolidated Subsidiaries as of the respective dates thereof
and the consolidated results of operations and cash flows of the Parent and
its consolidated Subsidiaries for the periods covered thereby. No financial
statements of any Person other than the Tiger Corporations are required by
GAAP to be included in the consolidated financial statements of the Parent.
There are no comments from the SEC or Canadian securities regulatory
authorities or their respective staff pending with respect to any statements,
reports, schedules, forms or other documents filed by Parent with the SEC or
under Canadian Securities Laws that remain outstanding and unresolved.

  

  

 

 

 

  

 

31  

  

 

 

 

  

(f) The Parent's auditor has at all times since the date of enactment of the
Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined
in Section 2(a)(12) of the Sarbanes-Oxley Act); (ii) "independent" with
respect to the Parent within the meaning of Regulation S-X under the Exchange
Act; and (iii) to the Knowledge of Parent, in compliance with subsections (g)
through (l) of Section 10A of the Exchange Act and the rules and regulations
promulgated by the SEC and the Public Company Accounting Oversight Board
thereunder. All non-audit services performed by the Parent's auditors for the
Tiger Corporations that were required to be approved in accordance with
Section 202 of the Sarbanes-Oxley Act were so approved.

  

  

(g) Parent maintains a system of internal control over financial reporting (as
defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) which is
designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, and includes those policies and procedures
that: (i) pertain to the maintenance of records that in reasonable detail
accurately and fairly reflect the transactions and dispositions of the assets
of the Tiger Corporations; (ii) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in
conformity with GAAP and that receipts and expenditures are being made only in
accordance with authorizations of management and directors of Parent; and
(iii) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the assets of the Tiger
Corporations that could have a material effect on Parent's consolidated
financial statements. Parent's management has completed an assessment of the
effectiveness of the Parent's system of internal controls over financial
reporting in compliance with the requirements of Section 404 of the Sarbanes-
Oxley Act for the fiscal year ended December 31, 2013, and, except as set
forth in the Parent SEC Documents and the Parent Canadian Securities Documents
filed prior to the date of this Agreement, such assessment concluded that such
controls were effective and the Parent's independent registered accountant has
issued (and not subsequently withdrawn or qualified) an attestation report
concluding that the Parent maintained effective internal control over
financial reporting as of December 31, 2013. To the Knowledge of Parent,
except as set forth in the Parent SEC Documents and the Parent Canadian
Securities Documents filed prior to the date of this Agreement, from December
31, 2012 through the date of this Agreement, neither the Parent nor any of its
Subsidiaries nor the Parent's independent registered accountant has identified
or been made aware of: (A) any significant deficiency or material weakness in
the design or operation of internal control over financial reporting utilized
by the Tiger Corporations; (B) any material illegal act or fraud related to
the business of the Tiger Corporations that involves the Parent's management
or other employees; or (C) any material claim or allegation regarding any of
the foregoing.

  

  

(h) Part 3.4(h) of the Parent Disclosure Schedule lists, and the Parent has
delivered or Made Available to the Company accurate and complete copies of the
documentation creating or governing, all securitization transactions and "off-
balance sheet arrangements" (as defined in Item 303(c) of Regulation S-K under
the Exchange Act) currently in effect or effected by any of the Tiger
Corporations since January 1, 2012. None of the Tiger Corporations has any
obligation or other commitment to become a party to any such "off-balance
sheet arrangements" in the future.

  

  

(i) None of the information supplied or to be supplied by or on behalf of
Parent for inclusion or incorporation by reference in the Proxy Statement and
Circular will, at the time the Proxy Statement and Circular is mailed to the
stockholders of Parent or at the time of the Parent Stockholders' Meeting (or
any adjournment or postponement thereof), contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the
circumstances under which they are made, not misleading. The Proxy Statement
and Circular will, at the time the Proxy Statement and Circular is mailed to
the stockholders of Parent, at the time of the Parent Stockholders' Meeting
(or any adjournment or postponement thereof) and at the Effective Time, comply
as to form in all material respects with the provisions of the Securities Act,
the Exchange Act and the rules and regulations promulgated by the SEC
thereunder, the rules and policies of the TSX and Canadian Securities Laws,
except that no representation or warranty is made by Parent with respect to
statements made or incorporated by reference therein based on information
supplied by or on behalf of the Company for inclusion or incorporation by
reference in the Proxy Statement and Circular.

  

  

 

 

 

  

 

32  

  

 

 

 

  

3.5 Absence of Changes. Except as set forth in Part 3.5 of the Parent
Disclosure Schedule, since September 30, 2014 through the date of this
Agreement:

  

  

(a) there has not been any Parent Material Adverse Effect, and no event has
occurred or circumstance has arisen that, in combination with any other events
or circumstances, would reasonably be expected to have or result in a Parent
Material Adverse Effect;

  

  

(b) there has not been any material loss, damage or destruction to, or any
material interruption in the use of, any of the material assets of any of the
Tiger Corporations (whether or not covered by insurance);

  

  

(c) none of the Tiger Corporations has: (i) declared, accrued, set aside or
paid any dividend or made any other distribution in respect of any shares of
capital stock; or (ii) repurchased, redeemed or otherwise reacquired any
shares of capital stock or other securities of the Tiger Corporations (other
than repurchase of restricted Parent Common Stock in connection with
termination of employment of the previous holder of such Parent Common Stock
that were made in the ordinary course of business and consistent with past
practices, or upon the cashless or net exercise of outstanding Parent Options
or Parent Warrants);

  

  

(d) none of the Tiger Corporations has sold, issued or granted, or authorized
the issuance of: (i) any capital stock or other security (except for Parent
Common Stock issued upon the valid exercise of outstanding Parent Options or
Parent Warrants); (ii) any option, warrant or right to acquire any capital
stock or any other security (except for Parent Options and Parent Warrants
identified in Part 3.3(d) of the Parent Disclosure Schedule); or (iii) any
instrument convertible into or exchangeable for any capital stock or other
security;

  

  

(e) the Parent has not amended or waived any of its rights under, or permitted
the acceleration of vesting under: (i) any provision of any of the Parent
Option Plans; (ii) any provision of any Contract evidencing any outstanding
Parent Option; (iii) any restricted stock unit agreement; or (iv) any other
Contract evidencing or relating to any equity award (whether payable in cash
or stock);

  

  

(f) (i) there has been no amendment to the certificate of incorporation,
notice of articles, bylaws or other governing documents of the Parent, (ii)
none of the Tiger Corporations has effected or been a party to any merger,
consolidation, share exchange, business combination, recapitalization,
reclassification of shares, stock split, reverse stock split or similar
transaction and (iii) none of the Tiger Corporations has acquired or disposed
of any business or a material amount of assets;

  

  

(g) the Tiger Corporations have not made any capital expenditures outside the
ordinary course of business that in the aggregate exceed $100,000;

  

  

(h) none of the Tiger Corporations has written off as uncollectible, or
established any extraordinary reserve with respect to, any material account
receivable or other material indebtedness;

  

  

 

 

 

  

 

33  

  

 

 

 

  

(i) none of the Tiger Corporations has: (i) lent money to any Person (other
than routine travel advances made to employees in the ordinary course of
business); or (ii) incurred or guaranteed any indebtedness for borrowed money;

  

  

(j) none of the Tiger Corporations has: (i) adopted, established or entered
into any Parent Employee Plan or Parent Employee Agreement; (ii) caused or
permitted any Parent Employee Plan or Parent Employee Agreement to be amended
in any material respect; or (iii) increased the amount of the wages, salary,
commissions, fringe benefits or other compensation or remuneration payable to
any of its directors, officers or other employees by in excess of $100,000 in
any individual case;

  

  

(k) none of the Tiger Corporations has changed any of its methods of
accounting or accounting practices in any material respect except as required
by concurrent changes in GAAP, SEC rules and regulations or under Canadian
Securities Laws;

  

  

(l) none of the Tiger Corporations has made any material Tax election, made
any material amendments to Tax Returns previously filed or settled or
compromised any material Tax liability or refund;

  

  

(m) none of the Tiger Corporations has commenced or settled any Legal
Proceeding;

  

  

(n) none of the Tiger Corporations has amended, terminated or granted any
waiver under any "standstill" or similar agreement;

  

  

(o) none of the Tiger Corporations has entered into any material transaction
or taken any other material action outside the ordinary course of business or
inconsistent with past practices; and

  

  

(p) none of the Tiger Corporations has agreed or committed to take any of the
actions referred to in clauses "(c)" through "(o)" above.

  

  

3.6 No Collateral Benefits. To the Knowledge of Parent, no related party of
Parent or Merger Sub:

  

  

(a) is a party to any connected transaction to the Merger or the other
Contemplated Transactions; or

  

  

(b) is entitled to receive as a consequence of the Merger or the other
Contemplated Transactions any benefit, other than a benefit described in
paragraph (c) of the definition of collateral benefit where either (A) the
related party, together with its associated entities beneficially owns or
exercises control or direction over less than one percent or more of the
outstanding Parent Common Stock or (B) the requirements of clause
(c)(iv)(B)(I) and (II) of the definition of collateral benefit have been
satisfied with respect to that benefit and Parent will provide the disclosure
contemplated by clause (c)(iv)(B)(III) in the Proxy Statement and Circular.

  

  

The terms "related party", "connected transaction", "associated entity" and
"collateral benefit" are used in this paragraph as defined in Multilateral
Instrument 61-101 "Protection of Minority Security Holders In Special
Transactions" ("MI 61-101") issued by the Canadian Securities Administrators.

  

  

 

 

 

  

 

34  

  

 

 

 

  

3.7 Title to Tangible Assets. The Tiger Corporations own, and have good and
valid title to, all material tangible assets purported to be owned by them,
including: (a) all material assets reflected on the Parent Unaudited Balance
Sheet (except for inventory sold or otherwise disposed of in the ordinary
course of business since the date of the Parent Unaudited Balance Sheet); and
(b) all other material assets reflected in the books and records of the Tiger
Corporations as being owned by the Tiger Corporations. All of said assets are
owned by the Tiger Corporations free and clear of any Encumbrances, except
for: (i) any lien for current Taxes not yet due and payable or for Taxes that
are being contested in good faith and for which adequate reserves have been
established; (ii) minor liens that have arisen in the ordinary course of
business and that do not (in any case or in the aggregate) materially detract
from the value of the assets subject thereto or materially impair the
operations of any of the Tiger Corporations; and (iii) liens described in Part
3.7 of the Parent Disclosure Schedule. The Tiger Corporations are the lessees
of, and hold valid leasehold interests in, all material tangible assets
purported to have been leased by them, including: (A) all material assets
reflected as leased on the Parent Unaudited Balance Sheet; and (B) all other
material assets reflected in the books and records of the Tiger Corporations
as being leased to the Tiger Corporations, and the Tiger Corporations enjoy
undisturbed possession of such leased assets.

  

  

3.8 Equipment; Real Property; Leasehold.

  

  

(a) All material items of equipment and other tangible assets owned by or
leased to the Tiger Corporations are adequate for the uses to which they are
being put, are in good condition and repair (ordinary wear and tear excepted)
and are adequate for the conduct of the businesses of the Tiger Corporations
in the manner in which such businesses are currently being conducted.

  

  

(b) No Tiger Corporation owns any real property.

  

  

(c) Part 3.8(c) of the Parent Disclosure Schedule sets forth an accurate and
complete list of each lease pursuant to which any of the Tiger Corporations
leases real property from any other Person for annual rent payments in excess
of $100,000. (All real property leased to the Tiger Corporations pursuant to
the real property leases identified or required to be identified in Part
3.8(c) of the Parent Disclosure Schedule, including all buildings, structures,
fixtures and other improvements leased to the Tiger Corporations, is referred
to as the "Parent Leased Real Property.") To the Knowledge of Parent, there is
no existing plan or study by any Governmental Body or by any other Person that
challenges or otherwise adversely affects the continuation of the use or
operation of any Parent Leased Real Property. Part 3.8(c) of the Parent
Disclosure Schedule contains an accurate and complete list of all subleases,
occupancy agreements and other Parent Contracts granting to any Person (other
than any Tiger Corporation) a right of use or occupancy of any of the Parent
Leased Real Property. Except as set forth in the leases or subleases
identified in Part 3.8(c) of the Parent Disclosure Schedule, there is no
Person in possession of any Parent Leased Real Property other than a Tiger
Corporation. None of the Tiger Corporations has received any written notice
(or, to the Knowledge of Parent, any other communication, whether written or
otherwise) of a default, alleged failure to perform, or any offset or
counterclaim with respect to any occupancy agreement with respect to any
Parent Leased Real Property which has not been fully remedied and withdrawn.

  

  

3.9 Intellectual Property.

  

  

(a) Part 3.9(a) of the Parent Disclosure Schedule accurately identifies:

  

  

(i) in Part 3.9(a)(i) of the Parent Disclosure Schedule: (A) each item of
Registered IP in which any of the Tiger Corporations has or purports to have
an ownership interest of any nature (whether solely or jointly with another
Person) and that either: (1) relates to any Parent Product; (2) relates to the
manufacture, development, use, administration, delivery, promotion or testing
of any Parent Product or the provision of any service or test using the Parent
Product; or (3) is used or held for use in connection with any Parent Product
(the "Parent Material Registered IP"); (B) the jurisdiction in which such
Parent Material Registered IP has been registered or filed and the applicable
registration or serial number; and (C) any other Person that has an ownership
interest in such item of Parent Material Registered IP and the nature of such
ownership interest; and

  

  

 

 

 

  

 

35  

  

 

 

 

  

(ii) in Part 3.9(a)(ii) of the Parent Disclosure Schedule: (A) each material
item of Registered IP licensed with respect to any field to any of the Tiger
Corporations; (B) each Contract pursuant to which any license or other right
is granted under, to or in any Intellectual Property (x) to any of the Tiger
Corporations (other than commercially available third party software) or (y)
from any of the Tiger Corporations, which Contract is material to the Tiger
Corporations, including any development, collaboration, manufacture, services,
distribution or commercialization agreements relating to any Parent Product;
and (C) whether these licenses or other grant of rights are exclusive or
nonexclusive (for purposes of this Agreement, a covenant not to sue or not to
assert infringement claims shall be deemed to be equivalent to a nonexclusive
license).

  

  

(b) The Parent has Made Available to the Company an accurate and complete copy
of each standard form of the following documents and Contracts used by any
Tiger Corporation at any time: (i) terms and conditions with respect to the
clinical testing, distribution, sale, or provisioning of any Parent Product;
(ii) employee agreement or similar Contract containing any assignment or
license of Intellectual Property or any confidentiality provision; or (iii)
consulting or independent contractor agreement or similar Contract containing
any assignment or license of Intellectual Property or any confidentiality
provision. Part 3.9(b) of the Parent Disclosure Schedule accurately identifies
each Parent Contract concerning the subject matter of (i), (ii) or (iii) that
is material to Parent and that deviates in any material respect from the
corresponding standard form described above.

  

  

(c) The Tiger Corporations exclusively own all right, title and interest to
and in the Parent IP (other than Intellectual Property licensed to the Parent,
as identified in Part 3.9(a)(ii) of the Parent Disclosure Schedule or pursuant
to commercially available third party software and material transfer
agreements entered into in the ordinary course of business) free and clear of
any Encumbrances (other than non-exclusive licenses granted by any Tiger
Corporation in connection with the sale or license of Parent Products in the
ordinary course of business). Without limiting the generality of the
foregoing:

  

  

(i) to the Knowledge of Parent, all documents and instruments necessary to
perfect the rights of the Tiger Corporations in the Parent IP that is Parent
Material Registered IP have been validly executed, delivered and filed in a
timely manner with the appropriate Governmental Body;

  

  

(ii) no Parent Associate, to the Knowledge of Parent, has any claim, right
(whether or not currently exercisable) or interest to or in any Parent IP and
each Parent Associate who is or was involved in the creation or development of
any Intellectual Property for or on behalf of any Tiger Corporation has signed
a valid, enforceable agreement containing an assignment of all rights in and
to such Intellectual Property to the Tiger Corporations and confidentiality
provisions protecting the Parent IP;

  

  

(iii) each Tiger Corporation has taken all reasonable steps to maintain the
confidentiality of and otherwise protect and enforce its rights in all
proprietary information held by any of the Tiger Corporations, or purported to
be held by any of the Tiger Corporations, as a trade secret;

  

  

 

 

 

  

 

36  

  

 

 

 

  

(iv) none of the Tiger Corporations is now or has ever been a member or
promoter of, or a contributor to, any industry standards body or any similar
organization that would reasonably be expected to require or obligate any of
the Tiger Corporations to grant or offer to any other Person any license or
right to any Parent IP; and

  

  

(v) the Tiger Corporations own or otherwise have, and after the Closing the
Surviving Corporation will continue to have, the right, through ownership,
license or otherwise, to all Intellectual Property Rights reasonably necessary
to conduct the business of the Tiger Corporations as conducted as of the date
of this Agreement or as currently proposed to be conducted.

  

  

(d) To the Knowledge of Parent, all Parent IP that is material to the business
of any of the Tiger Corporations is valid, subsisting and enforceable.

  

  

(e) Neither the execution, delivery or performance of this Agreement nor the
consummation of any of the Contemplated Transactions will, or would reasonably
be expected to, with or without notice or the lapse of time, result in or give
any other Person the right or option to cause, create, impose or declare: (i)
a loss of, or Encumbrance on, any Parent IP; or (ii) the grant, assignment or
transfer to any other Person of any license or other right or interest under,
to or in any of the Parent IP.

  

  

(f) Except as disclosed in Part 3.9(f) of the Parent Disclosure Schedule, to
the Knowledge of Parent, no Person has infringed, misappropriated or otherwise
violated, and no Person is infringing, misappropriating or otherwise
violating, any Parent IP. Part 3.9(f) of the Parent Disclosure Schedule: (i)
accurately identifies (and the Parent has Made Available to the Company an
accurate and complete copy of) each letter or other written or electronic
communication or correspondence that has been sent or otherwise delivered by
or to any of the Tiger Corporations or any Representative of any of the Tiger
Corporations as of the date of this Agreement regarding any alleged or
suspected infringement or misappropriation of any Parent IP; (ii) the release,
disclosure or delivery of any Company IP by or to any escrow agent or other
Person and (iii) provides a brief description of the current status of the
matter referred to in such letter, communication or correspondence.

  

  

(g) To the Knowledge of Parent, the conduct of the business of any of the
Tiger Corporations as previously conducted, currently conducted or as
currently proposed to be conducted, including, without limitation, the
development, manufacture, use, import, export, offer for sale, sale or other
commercialization of any of the Parent Products, does not and has not
infringed (directly, contributorily, by inducement or otherwise),
misappropriated or otherwise violated any Intellectual Property of any other
Person. Part 3.9(g) of the Parent Disclosure Schedule: (i) accurately
identifies (and the Parent has Made Available to the Company an accurate and
complete copy of) each letter or other written or electronic communication or
correspondence that has been sent or otherwise delivered by or to any of the
Tiger Corporations or, to the Knowledge of Parent, any Representative of any
of the Tiger Corporations, as of the date of this Agreement regarding any
alleged or suspected infringement or misappropriation of any Intellectual
Property of any other Person by any of the Tiger Corporations or any of the
Parent Products; and (ii) provides a brief description of the current status
of the matter referred to in such letter, communication or correspondence.

  

  

(h) No infringement, misappropriation or similar claim or Legal Proceeding
involving infringement or misappropriation of any Intellectual Property of any
other Person is or has been pending and served or, to the Knowledge of Parent,
pending and not served or threatened against any Tiger Corporation or against
any other Person who is, or has asserted or would reasonably be expected to
assert that it is, entitled to be indemnified, defended, held harmless or
reimbursed by any Tiger Corporation with respect to such claim or Legal
Proceeding (including any claim or Legal Proceeding that has been settled,
dismissed or otherwise concluded).

  

  

 

 

 

  

 

37  

  

 

 

 

  

(i) Except as set forth in Part 3.9(i) of the Parent Disclosure Schedule, none
of the Tiger Corporations has transferred title to, or granted any exclusive
license, or granted an option to acquire title or an exclusive license, with
respect to, any material Parent IP.

  

  

(j) Part 3.9(j) of the Parent Disclosure Schedule lists all inter partes
proceedings or actions known to Parent before any court or tribunal (including
the United States Patent and Trademark Office or equivalent authority anywhere
in the world) related to any Parent IP. No Parent IP is the subject of any
outstanding decree, order, judgment, settlement agreement, or stipulation
restricting in any manner the use, transfer, or licensing thereof by any of
the Tiger Corporations, or that may affect the validity, use or enforceability
of such Parent IP.

  

  

(k) To the Knowledge of Parent, the Tiger Corporations have not taken any
action or failed to take any action that reasonably could be expected to
result in the abandonment, cancellation, forfeiture, relinquishment,
invalidation or unenforceability of any Parent Material Registered IP
(including failure to pay required fees associated with registrations of any
Parent Material Registered IP; failure to disclose any known material prior
art in connection with the prosecution of patent applications included in the
Parent Material Registered IP) nor to Knowledge of Parent, has the owner of
any material items of Registered IP licensed to any of the Tiger Corporations
taken or failed to take any such action in respect to such material items of
Registered IP.

  

  

(l) None of the Tiger Corporations has entered into any services agreements
relating to development, testing, manufacture or formulation of any Parent
Product under which the party performing such services has obtained rights to
Intellectual Property covering such Parent Products or their manufacture,
formulation or use.

  

  

3.10 Contracts.

  

  

(a) Part 3.10(a) of the Parent Disclosure Schedule identifies each Parent
Contract that constitutes a Parent Material Contract as of the date of this
Agreement. For purposes of this Agreement, "Parent Material Contract" shall
mean:

  

  

(i) any Contract which is in effect and which has been filed (or is required
to be filed) by the Parent as an exhibit pursuant to Item 601(b)(10) of
Regulation S-K under the Exchange Act, or that Parent is required to disclose
under Item 404 of Regulation S-K under the Exchange Act or that Parent is
required to file on SEDAR under Canadian Securities Laws;

  

  

(ii) any Contract: (A) constituting a Parent Employee Agreement; (B) pursuant
to which any of the Tiger Corporations is or may become obligated to make any
severance, termination or similar payment to any Parent Associate or any
spouse, heir or Representative of any Parent Associate except for severance,
termination or similar payments required by applicable Legal Requirements that
does not exceed $100,000 per employee; (C) pursuant to which any of the Tiger
Corporations is or may become obligated to make any bonus or similar payment
(other than payments constituting base salary, incentive bonuses or
commissions paid in the ordinary course of business) in excess of $100,000 to
any Parent Associate; or (D) pursuant to which any of the Tiger Corporations
is or may become obligated to grant or accelerate the vesting of, or otherwise
modify, any stock option, restricted stock, stock appreciation right or other
equity interest in any of the Tiger Corporations;

  

  

(iii) any Contract identified or required to be identified in Part 3.9 of the
Parent Disclosure Schedule;

  

  

 

 

 

  

 

38  

  

 

 

 

  

(iv) any Contract with any distributor and any contract with any other
reseller or sales representative, in each case that provides exclusivity
rights to any third party;

  

  

(v) any Contract that is with a supplier of equipment, consumables, products,
reagents, raw materials or any component, or any services used in or with
respect to the Parent's Products, which supplier is the only source of supply
in the market place or only supplier to the Tiger Corporations or that imposes
a minimum purchase order;

  

  

(vi) any Contract pursuant to which a Tiger Corporation (A) is obligated to
pay to any other Person royalties, milestone or other payments with respect to
any Parent Product, (B) is obligated to provide to any other Person a
percentage interest in the sales or revenues of any Parent Product, (C) is
obligated to pay to any Person any royalties, fees, commissions or other
amounts for the use or enforcement of any Parent IP, (D) is obligated to
research, develop, distribute, promote or sell any drug, compound, product or
service, or (E) is required to have an exclusive relationship with any other
Person;

  

  

(vii) each joint venture or partnership agreement or any similar Contract
involving a sharing of profits, losses, costs or liabilities with any other
Person other than another Tiger Corporation (excluding indemnification
obligations entered into in the ordinary course of business, commission, bonus
or similar arrangements with employees and independent contractors);

  

  

(viii) any Contract that provides for: (A) reimbursement of any current
director or officer of a Tiger Corporation for, or advancement to any current
director or officer of a Tiger Corporation of, legal fees or other expenses
associated with any Legal Proceeding or the defense thereof; or (B)
indemnification of any current director or officer of a Tiger Corporation;

  

  

(ix) any Contract imposing any restriction on the right or ability of any
Tiger Corporation: (A) to engage in any line of business, geography or
therapeutic area or compete with any other Person; (B) to acquire any product
or other asset or any services from any other Person; (C) to develop, sell,
supply, distribute, offer, support or service any product or any technology or
other asset to or for any other Person anywhere in the world; (D) to perform
services for any other Person; or (E) to use exploit, assert or enforce any
Parent IP anywhere in the world; or (F) to transact business with any other
Person, in each case which restriction would or would reasonably be expected
to materially and adversely affect: (x) the conduct of the business of the
Tiger Corporations as currently conducted or as currently is proposed to be
conducted; or (y) the design, development, manufacturing, reproduction,
marketing, licensing, sale, offer for sale, importation, distribution,
performance, display, creation of derivative works with respect to and/or use
of any Parent Product or the provision of any service using any Parent
Product;

  

  

(x) any Contract granting to any Person a right of first negotiation, right of
first refusal or option to purchase or acquire any material assets;

  

  

(xi) any Contract incorporating or relating to any material guaranty,
warranty, sharing of liabilities or indemnity (including any indemnity with
respect to Intellectual Property or Intellectual Property Rights) or similar
obligation, other than Contracts entered into in the ordinary course of
business;

  

  

(xii) any Contract relating to any currency hedging;

  

  

 

 

 

  

 

39  

  

 

 

 

  

(xiii) any Contract requiring that any of the Tiger Corporations give any
notice or provide any information to any Person prior to responding to or
prior to accepting any Acquisition Proposal or similar proposal, or prior to
entering into any discussions, agreement, arrangement or understanding
relating to any Acquisition Transaction;

  

  

(xiv) any Contract relating to the lease or sublease of Parent Leased Real
Property or of any real property owned by any Tiger Corporation;

  

  

(xv) any Contract that: (A) involved the payment or delivery of cash or other
consideration in an amount or having a value in excess of $250,000 in the
fiscal year ending December 31, 2014 or the following fiscal years; (B)
requires by its terms the payment or delivery of cash or other consideration
in an amount or having a value in excess of $250,000 in the fiscal year ending
December 31, 2014 or the following fiscal years; (C) involved the performance
of services having a value in excess of $500,000 in the fiscal year ended
December 31, 2014; (D) requires by its terms the performance of services
having a value in excess of $250,000 in the fiscal year ending December 31,
2014 or the following fiscal years; (E) in which the Parent or any Tiger
Corporation has agreed to supply any Parent Product at a specified price or on
specified terms or has granted development rights, "most favored nation"
pricing provisions or marketing or distribution rights relating to any Parent
Product; (F) in which the Parent or any Tiger Corporation has agreed to
purchase a minimum quantity of goods or has agreed to purchase goods
exclusively from a certain party; (G) is material to the Tiger Corporations
and relates to any Parent Product (including any raw materials) or any ongoing
clinical trial; or (H) relates to the lease by a Tiger Corporation of material
tangible personal property;

  

  

(xvi) any Contract, the termination of which would reasonably be expected to
have a Parent Material Adverse Effect.

  

  

The Parent has Made Available to the Company an accurate and complete copy of
each Parent Contract that constitutes a Parent Material Contract, or has
disclosed in the Parent Disclosure Schedule that such Parent Contract exists
but has not been provided to the Company.

  

  

(b) Each Parent Contract that constitutes a Parent Material Contract is valid
and in full force and effect, and is enforceable in accordance with its terms,
subject to: (i) laws of general application relating to bankruptcy, insolvency
and the relief of debtors; and (ii) rules of law governing specific
performance, injunctive relief and other equitable remedies.

  

  

(c) Except as set forth in Part 3.10(c) of the Parent Disclosure Schedule: (i)
none of the Tiger Corporations has violated or breached in any material
respect, or committed any default in any material respect under, any Parent
Material Contract; (ii) to the Knowledge of Parent, no other Person has
violated or breached in any material respect, or committed any default in any
material respect under, any Parent Material Contract; (iii) to the Knowledge
of Parent, no event has occurred, and no circumstance or condition exists,
that (with or without notice or lapse of time) would reasonably be expected
to: (A) result in a violation or breach in any material respect of any of the
provisions of any Parent Material Contract; (B) give any Person the right to
declare a default in any material respect under any Parent Material Contract;
(C) give any Person the right to receive or require a rebate, chargeback,
penalty or change in delivery schedule under any Parent Material Contract; (D)
give any Person the right to accelerate the maturity or performance of any
Parent Material Contract; or (E) give any Person the right to cancel,
terminate or modify any Parent Material Contract; (iv) none of the Tiger
Corporations has received any notice or other communication regarding any
actual or possible violation or breach of, or default under, any Parent
Material Contract; (v) none of the Tiger Corporations has received any notice
or other communication that any of their material suppliers or service
providers intends to cancel, not renew or otherwise terminate their
relationship with any of the Tiger Corporations; (vi) none of the Tiger
Corporations is participating in any active discussions to amend the terms of
any Parent Material Contract other than in the ordinary course of business;
and (vii) none of the Tiger Corporations has received any notice or other
communications from any parties to the Parent Material Contracts set forth in
Part 4.3(b) of the Parent Disclosure Schedule regarding any actual or possible
termination of any such Parent Material Contract or transition of any
exclusive arrangement in any such Parent Material Contract to a non-exclusive
arrangement.

  

  

 

 

 

  

 

40  

  

 

 

 

  

(d) Neither the execution, delivery or performance of this Agreement nor the
consummation of any of the Contemplated Transactions will, or would reasonably
be expected to, with or without notice or the lapse of time, (i) result in a
breach of, default under or termination of any Parent Material Contract; (ii)
by the terms of any Parent Material Contract, result in a loss of any material
rights of any Tiger Corporation under any Parent Material Contract, including
a reduction of any royalties or other payments any Tiger Corporation would
otherwise be entitled to receive; or (iii) by the terms of any Parent Material
Contract, result in a material increase in any obligations of any Tiger
Corporation pursuant to any Parent Material Contract, including causing any
payment by any Tiger Corporation to become due or causing an increase in any
royalty or other payments any Tiger Corporation would otherwise be required to
make under such Parent Material Contract.

  

  

3.11 Liabilities. None of the Tiger Corporations has any accrued, contingent
or other liabilities of the type required to be disclosed, accrued or reserved
in the liabilities column of a balance sheet prepared in accordance with GAAP,
except for: (a) liabilities identified as such, or specifically reserved
against, in the Parent Unaudited Balance Sheet; (b) liabilities that have been
incurred by the Tiger Corporations since the date of the Parent Unaudited
Balance Sheet in the ordinary course of business and consistent with past
practices; (c) liabilities for performance of obligations of the Tiger
Corporations pursuant to the express terms of Parent Contracts; (d)
liabilities under this Agreement or incurred in connection with the
Contemplated Transactions; and (e) liabilities that are not, individually or
in the aggregate, material to the Tiger Corporations, or that are described in
Part 3.11 of the Parent Disclosure Schedule.

  

  

3.12 Compliance with Legal Requirements; Regulatory Matters.

  

  

(a) Except as set forth in Part 3.12(a) of the Parent Disclosure Schedule,
each of the Tiger Corporations is, and at all times has been in compliance in
all material respects with all Legal Requirements (including Health Care
Laws), each to the extent that the same are applicable to the Tiger
Corporations' businesses as they are currently conducted and proposed to be
conducted. None of the Tiger Corporations has received any notice or other
written communication from any Governmental Body or other Person (i) regarding
any violation of, or failure to comply with, any Legal Requirement, (ii) that
it is or has been the subject of any inspection, investigation, survey, audit,
monitoring or other form of review by any Governmental Body, accrediting
organization or certifying agency for the purpose of any alleged improper
activity related to Health Care Laws on the part of such Entity, other than
routine inspections, surveys, audits, monitoring or other forms of review in
the ordinary course of business, or (iii) of any claim, requirement or demand
of any licensing or certifying agency to rework or redesign any Tiger
Corporation's operations or any part thereof, other than rework or design
changes arising from the results of audits or reviews in the ordinary course
of business that are not material to the Tiger Corporations' operations.

  

  

(b) To the Knowledge of Parent, none of the Tiger Corporations nor any of
their employees, officers or directors have been: (i) debarred, disqualified,
suspended or excluded from participation in any state, provincial or Federal
Health Care Program, (ii) listed on the U.S. System for Award Management list
of excluded parties, or (iii) debarred under the FDA Act or any similar state,
provincial or foreign Law. In addition, to the Knowledge of Parent, no Tiger
Corporation has: (A) engaged in any activity: (1) which is cause for the
imposition of mandatory or permissive exclusion from a state, provincial or
Federal Health Care Program, or (2) for which debarment is authorized or
mandated by the FDA Act, the CFDA or any similar state, provincial or foreign
law; nor (B) been made a part to any other action by any Governmental Body
that may prohibit Parent from developing or selling products or providing
services to any governmental or other purchaser pursuant to any Health Care
Laws. To Knowledge of Parent, there is no civil, criminal, administrative or
other legal proceeding, notice or demand pending, received or, to Knowledge of
Parent, threatened against any Tiger Corporation, its employees, officers or
directors, which would reasonably be expected to result in such debarment,
disqualification, suspension or exclusion.

  

  

 

 

 

  

 

41  

  

 

 

 

  

(c) None of the Tiger Corporations or, to the Knowledge of Parent, any
director, officer or employee of any of the Tiger Corporations:

  

  

(i) has been convicted of or has been charged by any Governmental Body or by
any third party on behalf of any Governmental Body with any violation of any
Legal Requirement related to any Federal Health Care Program; or

  

  

(ii) has been convicted of or has been charged by any Governmental Body with
any violation of any Legal Requirement related to fraud, theft, embezzlement,
breach of fiduciary responsibility, financial misconduct, obstruction of an
investigation or controlled substances.

  

  

(d) Other than the partial clinical hold for Tiger Corporation's Ebola
clinical trial with respect to multiple ascending dosing in healthy patients,
there have been no adverse regulatory actions taken (nor, to the Knowledge of
Parent, threatened) by any Governmental Body with respect to any products
being researched or under development by any Tiger Corporation.

  

  

(e) Except as disclosed in Part 3.12(e) of the Parent Disclosure Schedule,
Parent has Made Available prior to the date of this Agreement accurate and
complete copies of (i) all material written surveys, reports, notices,
inquiries, subpoenas and written correspondence from a Governmental Body
related to any certification, licensure or other inspections, and summaries of
all proficiency test results relating to the business of the Tiger
Corporations as of the date of this Agreement; (ii) all material written
inquiries, notices, requests for records, subpoenas and correspondence
received from a Governmental Body by any of the Tiger Corporations related to
utilization, reimbursement or other audits or investigations relating to the
business of the Tiger Corporations as of the date of this Agreement other than
inquiries, notices, requests for records, subpoenas and correspondence
received in the ordinary course of business; and (iii) all current permits of
all of the Tiger Corporations.

  

  

(f) To the Knowledge of Parent, the studies, tests and nonclinical,
preclinical, safety, and clinical studies and testing, if any, conducted by or
on behalf of or sponsored by any Tiger Corporation relating to any product of
any Tiger Corporation were, and, if still pending, are being conducted in all
material respects in accordance with standard and accepted medical and
professional scientific research procedures and all applicable Legal
Requirements; the descriptions of the results of such studies, tests and
trials provided to Parent are accurate in all material respects; and other
than the partial clinical hold for Tiger Corporation's Ebola clinical trial
with respect to multiple ascending dosing in healthy patients, no Tiger
Corporation has received any notices or correspondence from any applicable
Governmental Body or comparable authority requiring the termination,
suspension, material modification or clinical hold of any such studies, tests
or trials conducted by or on behalf of any Tiger Corporation, which
termination, suspension, material modification or clinical hold would
reasonably be expected to result in a Parent Material Adverse Effect. Research
involving human subjects conducted by or on behalf of any Tiger Corporation:
(i) was approved by an institutional review board, if required, (ii) had the
informed consent of the subjects, if required, and (iii) to Knowledge of
Parent, did not involve any investigator who has been disqualified as a
clinical investigator by the FDA or any other Governmental Body or has been
found by any agency with jurisdiction to have engaged in scientific
misconduct.

  

  

 

 

 

  

 

42  

  

 

 

 

  

(g) Except as set forth on Part 3.12(g) of the Parent Disclosure Schedule, to
the Knowledge of Parent, no current manufacturer of a Parent Product has
received a FDA Form 483, notice of adverse finding, notice of violation,
untitled letter, warning letter, or other similar correspondence or notice
from the FDA, Health Canada, state, provincial or any other Governmental Body
(a "Warning Notice") or is currently subject to a Warning Notice impacting any
Parent Product with respect to any facility manufacturing Parent Product (or
any component thereof) that has yet to be corrected or resolved.

  

  

(h) Part 3.12(h) of the Parent Disclosure Schedule contains a true, correct
and complete list of all material manufacturing and supply agreements entered
into by any Tiger Corporation with third parties for the supply of Parent
Products as of the Effective Date (the "Manufacturing Agreements"). Except as
disclosed in Part 3.12(h) of the Parent Disclosure Schedule, Parent has Made
Available to the Company true, correct and complete copies of each
Manufacturing Agreement. Each such Manufacturing Agreement is a valid and
binding obligation of Parent and, to Knowledge of Parent, each other party
thereto, and is in full force and effect, and no Tiger Corporation nor, to the
Knowledge of Parent, any other party thereto, is in breach thereof or default
thereunder. No Tiger Corporation has received any written notice (nor to the
Knowledge of Parent, any oral notice) from any party thereto regarding (i) the
cancellation, termination or invalidation of any such Manufacturing Agreement
or (ii) any written indication by or intent or threat of, such party to reduce
or cease the supply of Parent Products.

  

  

3.13 Certain Business Practices. Neither the Parent, nor, to the Knowledge of
Parent, any of its directors, employees or officers, and to the Knowledge of
Parent, none of the agents, consultants or distributors engaged by the Parent
(a) has used or is using any corporate funds for any illegal contributions,
gifts, entertainment or other unlawful expenses relating to political
activity, (b) has used or is using any corporate funds for any direct or
indirect unlawful payments to any official or employee of a foreign or
domestic Governmental Body, (c) has violated or is violating any provision of
any Anti-Bribery Law, (d) has established or maintained, or is maintaining,
any unlawful fund of corporate monies or other properties, (e) has made any
bribe, unlawful rebate, unlawful payoff, influence payment, kickback or other
unlawful payment of any nature in furtherance of an offer, payment, promise to
pay, authorization, or ratification of the payment, directly or indirectly, of
any gift, money or anything of value to any official or employee of a foreign
or domestic Governmental Body to secure any improper advantage (within the
meaning of such term under any applicable Anti-Bribery Law) or to obtain or
retain business, or (f) has otherwise taken any action that has caused, or
would reasonably be expected to cause the Parent to be in violation of any
applicable Anti-Bribery Law.

  

  

3.14 Governmental Authorizations.

  

  

(a) The Tiger Corporations hold all material Governmental Authorizations
necessary to enable the Tiger Corporations to conduct their respective
businesses in the manner in which such businesses are currently being
conducted, including all Governmental Authorizations required under
Environmental Laws. All such Governmental Authorizations are valid and in full
force and effect. Each Tiger Corporation is, and has at all times been, in
compliance in all material respects with the terms and requirements of such
Governmental Authorizations. None of the Tiger Corporations has received any
notice or other communication from any Governmental Body regarding: (i) any
actual or possible violation of or failure to comply with any term or
requirement of any material Governmental Authorization; or (ii) any actual or
possible revocation, withdrawal, suspension, cancellation, termination or
modification of any material Governmental Authorization.

  

  

 

 

 

  

 

43  

  

 

 

 

  

(b) Part 3.14(b) of the Parent Disclosure Schedule describes the terms of each
material grant, incentive or subsidy provided or Made Available to or for the
benefit of any of the Tiger Corporations by any U.S. federal, state or local
Governmental Body or any foreign Governmental Body. Each of the Tiger
Corporations is in full compliance with all of the material terms and
requirements of each grant, incentive and subsidy identified or required to be
identified in Part 3.14(b) of the Parent Disclosure Schedule. Neither the
execution, delivery or performance of this Agreement, nor the consummation of
the Merger or any of the other Contemplated Transactions, does, will or would
reasonably be expected to (with or without notice or lapse of time) give any
Person the right to revoke, withdraw, suspend, cancel, terminate or modify any
grant, incentive or subsidy identified or required to be identified in Part
3.14(b) of the Parent Disclosure Schedule.

  

  

3.15 Tax Matters.

  

  

(a) Each of the material Tax Returns required to be filed by or on behalf of
the respective Tiger Corporations with any Governmental Body with respect to
any taxable period ending on or before the Closing Date (the "Tiger
Corporation Returns"): (i) has been or will be filed on or before the
applicable due date (including any extensions of such due date); and (ii) has
been, or will be when filed, prepared in all material respects in compliance
with all applicable Legal Requirements. All amounts shown on the Tiger
Corporation Returns to be due on or before the Closing Date have been or will
be paid on or before the Closing Date, except with respect to matters
contested in good faith in appropriate proceedings and for which adequate
reserves have been established in accordance with GAAP.

  

  

(b) To the Knowledge of Parent, the Parent Unaudited Balance Sheet fully
accrues all actual and contingent liabilities for material Taxes with respect
to all periods through the date of the Parent Unaudited Balance Sheet in
accordance with GAAP.

  

  

(c) Except as set forth in Part 3.15(c) of the Parent Disclosure Schedule, to
the Knowledge of Parent, no Tiger Corporation and no Tiger Corporation Return
is subject to (or has been subject to) an audit with respect to Taxes by any
Governmental Body. No extension or waiver of the limitation period applicable
to any of the Tiger Corporation Returns has been granted (by the Parent or any
other Person), and no such extension or waiver has been requested from any
Tiger Corporation.

  

  

(d) No claim or Legal Proceeding is pending or, to the Knowledge of Parent,
has been threatened in writing against or with respect to any Tiger
Corporation in respect of any material Tax. There are no unsatisfied
liabilities for material Taxes with respect to any notice of deficiency or
similar document received by any Tiger Corporation with respect to any
material Tax (other than liabilities for Taxes asserted under any such notice
of deficiency or similar document which are being contested in good faith by
or on behalf of such Tiger Corporation and with respect to which adequate
reserves for payment have been established in accordance with GAAP on the
Parent Unaudited Balance Sheet). There are no liens for material Taxes upon
any of the assets of any of the Tiger Corporations except liens for current
Taxes not yet due and payable or for Taxes which are being contested in good
faith by the Tiger Corporations and with respect to which adequate reserves
for payment have been established in accordance with GAAP on the Parent
Unaudited Balance Sheet. None of the Tiger Corporations has been, and none of
the Tiger Corporations will be, required to include any material adjustment in
taxable income for U.S. federal income Tax purposes for any Tax period (or
portion thereof) pursuant to Section 481 or 263A of the Code as a result of
transactions or events occurring, or accounting methods employed, prior to the
Closing.

  

  

 

 

 

  

 

44  

  

 

 

 

  

(e) To the Knowledge of Parent, no written claim has ever been made by any
Governmental Body in a jurisdiction where a Tiger Corporation does not file a
Tax Return that it is or may be subject to taxation by that jurisdiction which
has resulted or would reasonably be expected to result in an obligation to pay
material Taxes.

  

  

(f) There are no Contracts relating to the allocating, sharing or
indemnification of Taxes to which any Tiger Corporation is a party, other than
Contracts containing customary gross-up or indemnification provisions in
credit agreements, derivatives, leases, and similar agreements entered into in
the ordinary course of business.

  

  

(g) No Tiger Corporation has constituted either a "distributing corporation"
or a "controlled corporation" within the meaning of Section 355(a)(1)(A) of
the Code.

  

  

(h) No Tiger Corporation is or has been a United States real property holding
corporation within the meaning of Section 897(c)(2) of the Code during the
applicable period specified in Section 897(c)(1)(A)(ii)of the Code.

  

  

(i) No Tiger Corporation has been a member of an affiliated group of
corporations within the meaning of Section 1504 of the Code or within the
meaning of any similar Legal Requirement to which a Tiger Corporation may be
subject other than an affiliated group of Persons within the meaning of the
Income Tax Act (Canada) or an affiliated group of which the Parent is the
common parent. No Tiger Corporation has any liability for Taxes of a
predecessor or transferor that became a liability of the successor or
transferee by operation of law.

  

  

(j) The Parent has disclosed on its federal income Tax Returns all positions
that could give rise to a material understatement penalty within the meaning
of Section 6662 of the Code or any similar Legal Requirement.

  

  

(k) No Tiger Corporation has participated in, or is currently participating
in, a "listed transaction" within the meaning of Treasury Regulation Section
1.6011-4(b)(1).

  

  

(l) Each Tiger Corporation has withheld and paid all material Taxes required
to have been withheld and paid in connection with amounts paid or owning by
such Tiger Corporation to any employee, independent contractor, creditor,
shareholder or other Person.

  

  

(m) Based on its current business plans and expectations, Parent does not
believe that it will be classified as a passive foreign investment company
within the meaning of Section 1297 of the Code for its taxable year ending
December 31, 2015.

  

  

(n) No Tiger Corporation has taken any action or knows of any fact that would
reasonably be expected to prevent the Merger from qualifying as a
reorganization within the meaning of Section 368(a) of the Code. No Tiger
Corporation has taken any action or knows of any fact that would reasonably be
expected to cause the Merger to be subject to Section 367(a)(1) of the Code.

  

  

(o) No withholding Taxes will apply to the consideration provided to the
holders of Company Stock Certificates as part of the Merger or otherwise
provided to such holders in connection with this Agreement.

  

  

 

 

 

  

 

45  

  

 

 

 

  

(p) Each Tiger Corporation has filed all Tax Returns which were required to be
filed by with any Tax Authority in Canada prior to the date hereof. All Tax
Returns filed by each such Tiger Corporation are accurate and complete in all
material respects.

  

  

(q) The Tiger Corporations have paid, and will continue until the Closing Date
to pay, all Taxes when due on or before the Closing Date, including
installments or prepayments of Taxes, which are required to have been paid to
any Tax Authority pursuant to applicable law, and no deficiency with respect
to the payment of any Taxes or Tax installments has been asserted against it
by any Tax Authority. To the Knowledge of Parent, the Tiger Corporations have
not incurred any liability, whether actual or contingent, for Taxes or engaged
in any transaction or event that would result in any liability, whether actual
or contingent, for Taxes or realized any income or gain for Tax purposes
otherwise than in the usual and ordinary course of its business. There are no
liens, charges, encumbrances or any rights of others on any of the assets of
the Tiger Corporations that arose in connection with any failure (or alleged
failure) to pay any Tax when due.

  

  

(r) To the Knowledge of the Parent, there are no threatened or potential
assessment or other proceedings, negotiations or investigations in respect of
Taxes against the Tiger Corporations.

  

  

(s) No Tiger Corporation is a party to any agreement, waiver or arrangement
with any Tax Authority that relates to any extension of time with respect to
the filing of any Tax Return, any payment of Taxes or any assessment.

  

  

(t) The Tiger Corporations have not made any elections in respect of Taxes
pursuant to applicable law except those elections which have been disclosed in
Part 3.15(t) of the Parent Disclosure Schedule.

  

  

(u) No facts, circumstances or events exist or have existed that have resulted
in or may result in the application of any of Sections 79 to 80.04 of the
Income Tax Act (Canada) to the Tiger Corporations.

  

  

(v) The Tiger Corporations have not acquired property from any Person in
circumstances where any Tiger Corporation did or could become liable for any
Taxes of such Person. The value of the consideration paid or received by any
Tiger Corporation for the acquisition, sale, transfer or provision of property
(including intangibles) or the provision of services (including financial
transactions) from or to a Person with whom such Tiger Corporation was not
dealing at arm's length within the meaning of the Income Tax Act (Canada) was
equal to the estimated fair market value of such property acquired, provided
or sold or services purchased or provided.

  

  

(w) The Tiger Corporations are not subject to liability for Taxes of any other
Person pursuant to Section 160 of the Income Tax Act (Canada) or any similar
provision of provincial Tax laws. No Tiger Corporation has entered into any
agreement with, or provided any undertaking to, any Person pursuant to which
such Tiger Corporation has assumed liability for the payment of income Taxes
owing by such Person.

  

  

(x) Parent and any other Canadian Tiger Corporation are duly registered with
the Canada Revenue Agency under the Excise Tax Act (Canada) for purposes of
the goods and services tax ("GST"). All input tax credits claimed by any such
company for GST purposes were calculated in accordance with applicable law.
Parent and any other Canadian Tiger Corporation have each complied with all
registration, reporting, payment, collection and remittance requirements
imposed under the Excise Tax Act (Canada) or any similar provincial tax
legislation.

  

  

 

 

 

  

 

46  

  

 

 

 

  

(y) Neither Parent nor any Canadian Subsidiary of Parent have claimed any
reserves for purposes of the Income Tax Act (Canada) or any similar provincial
tax legislation for the most recent taxation year ending prior to the Closing
Date except those elections which have been disclosed in Part 3.15(y) of the
Parent Disclosure Schedule.

  

  

(z) To the Knowledge of Parent, no Tiger Corporation has made any payment, nor
is obligated to make any payment, and is not a party to any agreement under
which it could be obligated to make any payment, that may not be deductible by
virtue of Section 18(1)(a), 67, 69 or 78 of the Income Tax Act (Canada) or any
similar provincial tax legislation.

  

  

(aa) Records or documents that meet the requirements of paragraphs 247(4)(a)
to (c) of the Income Tax Act (Canada) have been made and obtained by the Tiger
Corporations with respect to all material transactions between any Canadian
Tiger Corporation and any Person who is not resident in Canada for purposes of
the Income Tax Act (Canada) and with whom such Canadian Tiger Corporation was
not dealing at arm's length within the meaning of the Income Tax Act (Canada),
during a taxation year commencing after 2009 and ending on or before the
Closing Date.

  

  

3.16 Employee and Labor Matters; Benefit Plans.

  

  

(a) Except as set forth in Part 3.16(a) of the Parent Disclosure Schedule or
as required by applicable Legal Requirements, the employment of each of the
Tiger Corporations' employees based in the United States is terminable by the
applicable Tiger Corporation at will and each of the Tiger Corporations'
employees based in Canada is terminable on provision of the applicable
statutory notice or payment in lieu required by the applicable provincial
employment standards legislation or terminable on reasonable notice as
determined in accordance with the common law without further liability to the
Tiger Corporations. Other than provisions limiting notice or payment in lieu
to the statutory minimums in the provincial employment standards legislation,
Tiger Corporations have not made any commitments or agreements with respect to
the period of notice, the payment of money or otherwise with respect to the
termination of employment of any employees. No current or former independent
contractor of the Tiger Corporations could reasonably be deemed to be a
misclassified employee. No independent contractor (i) has provided services to
any of the Tiger Corporations for a period of six consecutive months or longer
or (ii) is eligible to participate in any Parent Employee Plan. No Tiger
Corporation could be considered a joint or co-employer of any temporary or
leased employees from a third party that worked at any of the Tiger
Corporations.

  

  

(b) Except as set forth in Part 3.16(b) of the Parent Disclosure Schedule,
none of the Tiger Corporations is a party to, or has a duty to bargain for,
any collective bargaining agreement or other Contract with a labor
organization or works council representing any of its employees and there are
no labor organizations or works councils representing, purporting to represent
or, to the Knowledge of Parent, seeking to represent any employees of any of
the Tiger Corporations. There has not been any strike, slowdown, work
stoppage, lockout, job action, picketing, labor dispute, question concerning
representation, union organizing activity, or any threat thereof, or any
similar activity or dispute, affecting any of the Tiger Corporations or any of
their employees. There is not now pending, and, to the Knowledge of Parent, no
Person has threatened to commence, any such strike, slowdown, work stoppage,
lockout, job action, picketing, labor dispute, question regarding
representation or union organizing activity or any similar activity or
dispute. The Tiger Corporations are not and have not engaged in any unfair
labor practices as defined in the NLRA, and there is no claim or grievance
pending or, to the Knowledge of Parent, threatened against any Tiger
Corporation relating to any employment Contract, wages and hours, leave of
absence, plant closing notification, employment statute or regulation, privacy
right, labor dispute, workers' compensation policy or long-term disability
policy, safety, retaliation, immigration or discrimination matters involving
any Parent Associate, including charges of unfair labor practices or
harassment complaints.

  

  

 

 

 

  

 

47  

  

 

 

 

  

(c) For Canadian employees, no trade unions or employee associations are
certified to represent any Tiger Corporation employees, none of the Tiger
Corporations is party to, or has a duty to bargain for, any collective
agreements or other contracts or agreements with any trade unions or employee
associations whether or not the expiry date of such collective agreements or
other contract or agreement has passed, and there are no voluntary
recognitions by trade unions or employee associations relating to employees of
Tiger Corporations and no pending applications for certification by trade
unions or employee associations for employees of Tiger Corporations. There has
not been any strike, slowdown, work stoppage, lockout, job action, picketing,
labor dispute, question concerning representation, union organizing activity,
or any threat thereof, or any similar activity or dispute, affecting any of
the Tiger Corporations or any of their employees. There is not now pending,
and, to the Knowledge of Parent, no Person has threatened to commence, any
such strike, slowdown, work stoppage, lockout, job action, picketing, labor
dispute, question regarding representation or union organizing activity or any
similar activity or dispute. There is no claim or grievance pending or, to the
Knowledge of Parent, threatened against any Tiger Corporation pursuant to any
applicable federal or provincial employment standards, labour, human rights,
workers' compensation or privacy legislation. There are no pending or, to the
Knowledge of the Parent, threatened civil proceedings relating to the
employment or termination of current or former Tiger Corporation employees.

  

  

(d) Parent has delivered or Made Available to the Company an accurate and
complete list, by country and as of the date of this Agreement, of each Parent
Employee Plan and each Parent Employee Agreement. None of the Tiger
Corporations intends, and none of the Tiger Corporations has committed, to
establish or enter into any new Parent Employee Plan or Parent Employee
Agreement, or to modify any Parent Employee Plan or Parent Employee Agreement
(except to conform any such Parent Employee Plan or Parent Employee Agreement
to the requirements of any applicable Legal Requirements, in each case as
previously disclosed to Parent in writing or as required by this Agreement).

  

  

(e) Parent has delivered or Made Available to the Company accurate and
complete copies of: (i) all documents setting forth the terms of each Parent
Employee Plan and each Parent Employee Agreement, including all amendments
thereto and all related trust documents; (ii) the three most recent annual
reports (including Form Series 5500 and all schedules and financial statements
attached thereto), if any, required under applicable Legal Requirements in
connection with each Parent Employee Plan; (iii) if the Parent Employee Plan
is subject to the minimum funding standards of Section 302 of ERISA or to
similar funding standards pursuant to the applicable Legal Requirement, the
most recent annual and periodic accounting or valuation of Parent Employee
Plan assets and liabilities, if any; (iv) the most recent summary plan
description together with the summaries of material modifications thereto, if
any, required under ERISA or any similar Legal Requirement with respect to
each Parent Employee Plan; (v) all material written Contracts relating to each
Parent Employee Plan, including administrative service agreements and group
insurance contracts; (vi) all discrimination tests required under the Code for
each Parent Employee Plan intended to be qualified under Section 401(a) of the
Code for the three most recent plan years; (vii) the most recent IRS
determination or opinion letter issued with respect to each Parent Employee
Plan intended to be qualified under Section 401(a) of the Code; and (viii) all
material correspondence in its possession regarding any Parent Employee Plan
regarding any audit, investigation or proceeding regarding such Parent
Employee Plan or any fiduciary thereof and any correspondence with a
Government Body in respect of the Parent Employee Plan including in respect of
its registration or administration.

  

  

 

 

 

  

 

48  

  

 

 

 

  

(f) Each of the Tiger Corporations and Parent Affiliates has performed in all
material respects all obligations required to be performed by it under each
Parent Employee Plan and Parent Employee Agreement, and each Parent Employee
Plan and Parent Employee Agreement has been established and maintained in all
material respects in accordance with its terms and applicable Legal
Requirements. Any Parent Employee Plan intended to be qualified under Section
401(a) of the Code has obtained a favorable determination letter (or opinion
letter, if applicable) as to its qualified status under the Code. All Parent
Pension Plans required to have been approved by any foreign Governmental Body
have been so approved, no such approval has been revoked (or, to the Knowledge
of Parent, has revocation been threatened) and no event has occurred since the
date of the most recent approval or application therefor relating to any such
Parent Pension Plan that would reasonably be expected to materially affect any
such approval relating thereto or materially increase the costs relating
thereto. Each Parent Employee Plan intended to be tax qualified or to have a
specific tax status under applicable Legal Requirements is so tax qualified or
has maintained that tax status as applicable, and no event has occurred and no
circumstance or condition exists that would reasonably be expected to result
in the disqualification of any such Parent Employee Plan. No "prohibited
transaction," within the meaning of Section 4975 of the Code or Sections 406
and 407 of ERISA, and not otherwise exempt under Section 408 of ERISA, has
occurred with respect to any Parent Employee Plan. Each Parent Employee Plan
(other than any Parent Employee Plan to be terminated prior to the Effective
Time in accordance with this Agreement) can be amended, terminated or
otherwise discontinued after the Closing in accordance with its terms, without
liability to Parent, any of the Tiger Corporations or any Parent Affiliate
(other than any liability for ordinary administration expenses). There are no
audits or inquiries pending or, to the Knowledge of Parent, threatened by the
IRS, the DOL or any other Governmental Body with respect to any Parent
Employee Plan or any fiduciary thereof. There are no actions, suits or claims
pending or, to the Knowledge of Parent, threatened or reasonably anticipated
(other than routine claims for benefits) against any Parent Employee Plan or
against the assets of any Parent Employee Plan. None of the Tiger
Corporations, and no Parent Affiliate, has ever incurred: (i) any material
penalty or tax with respect to any Parent Employee Plan under Section 502(i)
of ERISA or Sections 4975 through 4980 of the Code; or (ii) any material
penalty or Tax under applicable Legal Requirements. Each of the Tiger
Corporations and Parent Affiliates has made all contributions and other
payments required by and due under the terms of each Parent Employee Plan and
each Parent Employee Agreement. Neither the terms nor the performance of any
Parent Employee Agreement or Parent Employee Plan would reasonably be expected
to result in gross income inclusion after the Effective Time pursuant to
Section 409A(a)(1)(A) of the Code.

  

  

(g) None of the Tiger Corporations, and no Parent Affiliate, has ever
maintained, established, sponsored, participated in or contributed to any: (i)
"pension plan" including without limitation a defined benefit or target
benefit pension plan; (ii) Parent Pension Plan subject to Title IV of ERISA;
(iii) "multiemployer plan" within the meaning of Section (3)(37) of ERISA or
within the meaning of the pension standards legislation that would apply to
such a plan; or (iv) plan described in Section 413 of the Code. No Parent
Employee Plan is or has been funded by, associated with or related to a
"voluntary employees' beneficiary association" within the meaning of Section
501(c)(9) of the Code. None of the Tiger Corporations, and no Parent
Affiliate, has ever maintained, established, sponsored, participated in or
contributed to any Parent Pension Plan in which stock of any of the Tiger
Corporations or any Parent Affiliate is or was held as a plan asset. The fair
market value of the assets of each funded Parent Foreign Plan (or other such
method of valuing the assets as is permitted or required by the applicable
Legal Requirements), the liability of each insurer for any Parent Foreign Plan
funded through insurance, or the book reserve established for any Parent
Foreign Plan, together with any accrued contributions, is sufficient to
procure or provide in full for the accrued benefit obligations, with respect
to all current and former participants in such Parent Foreign Plan according
to the reasonable actuarial assumptions and valuations most recently used to
determine employer contributions to and obligations under such Parent Foreign
Plan such that no special payments are required to be made in respect of the
Parent Pension Plan, and no Contemplated Transaction will cause any such
assets or insurance obligations to be less than such benefit obligations.
There are no material liabilities of the Tiger Corporations with respect to
any Parent Employee Plan that are not properly accrued and reflected in the
financial statements of Parent in accordance with GAAP.

  

  

 

 

 

  

 

49  

  

 

 

 

  

(h) None of the Tiger Corporations, and no Parent Affiliate, maintains,
sponsors or contributes to any Parent Employee Plan that is an employee
welfare benefit plan (as such term is defined in Section 3(1) of ERISA), a
"health and welfare trust" or an "employee life and health trust" (as such
terms are used by the Canada Revenue Agency or defined in the Income Tax Act
(Canada)) and that is, in whole or in part, self-funded or self-insured. No
Parent Employee Plan provides (except at no cost to the Tiger Corporations or
any Parent Affiliate), or reflects or represents any liability of any of the
Tiger Corporations or any Parent Affiliate to provide, post-termination or
retiree life insurance, post-termination or retiree health benefits or other
post-termination or retiree employee welfare benefits to any Person for any
reason, except as may be required by COBRA or other applicable Legal
Requirements. None of the Tiger Corporations nor any Parent Affiliate has ever
represented, promised or contracted (whether in oral or written form) to any
Parent Associate (either individually or to Parent Associates as a group) or
any other Person that such Parent Associate(s) or other Person would be
provided with post-termination or retiree life insurance, post-termination or
retiree health benefits or other post-termination or retiree employee welfare
benefits, except to the extent required by applicable Legal Requirements.

  

  

(i) Except as set forth in Part 3.16(i) of the Parent Disclosure Schedule, and
except as expressly required or provided by this Agreement, neither the
execution of this Agreement nor the consummation of the Contemplated
Transactions will or would reasonably be expected to (either alone or in
connection with any other circumstance or event) constitute an event under any
Parent Employee Plan, Parent Employee Agreement, trust or loan that will or
may result (either alone or in connection with any other circumstance or
event) in any payment (whether of severance pay or otherwise), acceleration,
forgiveness of indebtedness, vesting, distribution, increase in benefits or
obligation to fund benefits with respect to any Parent Associate.

  

  

(j) Except as set forth in Part 3.16(j) of the Parent Disclosure Schedule,
each of the Tiger Corporations and Parent Affiliates: (i) is, and has at all
times been, in compliance in all material respects with any Order or
arbitration award of any court, arbitrator or any Governmental Body respecting
employment, employment practices, terms and conditions of employment, wages,
hours, working classification (including the proper classification of workers
as independent contractors and consultants), occupational safety and health
and employment practices, including the Immigration Reform and Control Act, or
other labor related matters; (ii) has, to the Knowledge of Parent, withheld
and reported all amounts required by applicable Legal Requirements or by
Contract to be withheld and reported with respect to wages, salaries and other
payments to Parent Associates; (iii) is not, to the Knowledge of Parent,
liable for any arrears of wages or any taxes or any interest or penalty for
failure to comply with the Legal Requirements applicable to the foregoing;
(iv) is not liable for any payment to any trust or other fund governed by or
maintained by or on behalf of any Governmental Body with respect to workers
compensation assessments and benefits, unemployment compensation benefits,
social security, social charges or other benefits or obligations for Parent
Associates (other than routine payments to be made in the normal course of
business and consistent with past practice); and (v) is not liable for any
unpaid wages, compensation, wage-related penalties, or other sums for failure
to comply with any of the foregoing. There are no controversies pending, or to
the Knowledge of Parent, threatened between any of the Tiger Corporations and
any current or former employee, which controversies would reasonably be
expected to result in an action, suit, proceeding, claim, arbitration or
investigation before any Governmental Body.

  

  

 

 

 

  

 

50  

  

 

 

 

  

(k) There is no agreement, plan, arrangement or other Contract covering any
Parent Associate, and no payments have been made or will be made in connection
with the Merger to any Parent Associate, that, considered individually or
considered collectively with any other such Contracts or payments, will, or
would reasonably be expected to, be characterized as a "parachute payment"
within the meaning of Section 280G(b)(2) of the Code or give rise directly or
indirectly to the payment of any amount that would not be deductible pursuant
to Section 162(m) of the Code (or any comparable provision under state or
foreign Tax laws). No Tiger Corporation is a party to or has any obligation
under any Contract to compensate any Person for excise taxes payable pursuant
to Section 4999 of the Code or for taxes payable pursuant to Section 409A of
the Code.

  

  

(l) Except as set forth in Part 3.16(l) of the Parent Disclosure Schedule or
otherwise Made Available, none of the Tiger Corporations has effectuated a
"plant closing," partial "plant closing," "relocation," "mass layoff," "group
termination" or "termination" (as defined in the WARN Act, or any similar
Legal Requirement) affecting any site of employment or one or more facilities
or operating units within any site of employment or facility of any of the
Tiger Corporations.

  

  

(m) Each Parent Employee Plan and Parent Employee Agreement that is a
"nonqualified deferred compensation plan" (as defined under Section 409A of
the Code) has been operated in compliance in all material respects with
Section 409A of the Code and has complied in all material respects with
applicable documentary requirements of Section 409A of the Code. No stock
right or other equity option or appreciation right granted under any benefit
plan has an exercise price that is less than the fair market value of the
underlying stock or equity units (as the case may be) as of the date such
option or right was granted, or has any feature for the deferral of
compensation other than the deferral of recognition of income until the later
of exercise or disposition of such option or right.

  

  

3.17 Environmental Matters.

  

  

(a) None of the Tiger Corporations has received any notice or other
communication, whether from a Governmental Body, citizens group, or otherwise,
that alleges that any of the Tiger Corporations is not or might not be in
compliance with any Environmental Law, and, to the Knowledge of Parent, there
are no circumstances that may prevent or interfere with the compliance by any
of the Tiger Corporations with any Environmental Law in the future.

  

  

(b) To the Knowledge of Parent: (i) all Parent Leased Real Property and any
other property that is or was leased to or owned, controlled or used by any of
the Tiger Corporations, and all surface water, groundwater and soil associated
with or adjacent to such property, is free of any Materials of Environmental
Concern or material environmental contamination of any nature; (ii) none of
the Parent Leased Real Property or any other property that is or was leased to
or owned, controlled or used by any of the Tiger Corporations contains any
underground storage tanks, asbestos, equipment using PCBs or underground
injection wells; and (iii) none of the Parent Leased Real Property or any
other property that is or was leased to or owned, controlled or used by any of
the Tiger Corporations contains any septic tanks in which process wastewater
or any Materials of Environmental Concern have been Released.

  

  

(c) No Tiger Corporation has ever sent or transported, or arranged to send or
transport, any Materials of Environmental Concern to a site that, pursuant to
any applicable Environmental Law: (i) has been placed on the "National
Priorities List" of hazardous waste sites or any similar state or provincial
list; (ii) is otherwise designated or identified as a potential site for
remediation, cleanup, closure or other environmental remedial activity; or
(iii) is subject to a Legal Requirement to take "removal" or "remedial" action
as detailed in any applicable Environmental Law or to make payment for the
cost of cleaning up any site.

  

  

 

 

 

  

 

51  

  

 

 

 

  

(d) Except with respect to Contracts relating to Parent Leased Real Property,
none of the Tiger Corporations has entered into any Parent Contract that may
require any of them to guarantee, reimburse, defend, hold harmless or
indemnify any other party with respect to liabilities arising out of
Environmental Laws, or the activities of the Tiger Corporations or any other
Person relating to Materials of Environmental Concern.

  

  

3.18 Insurance. Each material insurance policy and self-insurance program and
arrangement relating to the business, assets and operations of the Tiger
Corporations is in full force and effect. None of the Tiger Corporations has
received any notice or other communication regarding any actual or possible:
(a) cancellation or invalidation of any material insurance policy; (b) refusal
of any coverage or rejection of any material claim under any insurance policy;
or (c) material adjustment in the amount of the premiums payable with respect
to any insurance policy. There is no pending workers' compensation or other
claim under or based upon any insurance policy of any of the Tiger
Corporations involving an amount in excess of $100,000 in any individual case
or $500,000 in the aggregate.

  

  

3.19 Transactions with Affiliates. Except as set forth in the Parent SEC
Documents and Parent Canadian Securities Documents filed prior to the date of
this Agreement, during the period commencing on the date of the Parent's last
proxy statement filed with the SEC and on SEDAR through the date of this
Agreement, no event has occurred that would be required to be reported by the
Parent pursuant to Item 404 of Regulation S-K promulgated by the SEC or Item
1.9 of Form 51-102F1.

  

  

3.20 Legal Proceedings; Orders.

  

  

(a) Except as set forth in Part 3.20(a) of the Parent Disclosure Schedule,
there is not as of the date of this Agreement, and there has not at any time
been, any pending and served Legal Proceeding, or (to the Knowledge of Parent)
any pending but not served Legal Proceeding and during such period no Person
has threatened to commence any material Legal Proceeding: (i) that involves
any of the Tiger Corporations, any business of any of the Tiger Corporations,
any of the assets owned, leased or used by any of the Tiger Corporations; or
(ii) that challenges, or that may have the effect of preventing, delaying,
making illegal or otherwise interfering with, the Merger or any of the other
Contemplated Transactions. To the Knowledge of Parent, no event has occurred,
and no claim, dispute or other condition or circumstance exists, that would
reasonably be expected to give rise to or serve as a reasonable basis for the
commencement of any Legal Proceeding of the type described in clause "(i)" or
clause "(ii)" of the first sentence of this Section 3.20(a).

  

  

(b) There is no Order to which any of the Tiger Corporations, or any of the
material assets owned or used by any of the Tiger Corporations, is subject. To
the Knowledge of Parent, no officer or other key employee of any of the Tiger
Corporations is subject to any Order that prohibits such officer or other
employee from engaging in or continuing any conduct, activity or practice
relating to the business of any of the Tiger Corporations.

  

  

3.21 Authority; Binding Nature of Agreement. Parent and Merger Sub have the
corporate right, power and authority to enter into and perform their
respective obligations under this Agreement and, subject to obtaining the
Required Parent Stockholder Vote and the Required Merger Sub Stockholder Vote,
respectively, consummate the transactions contemplated hereby. The Parent
Board (at a meeting duly called and held) has unanimously: (a) determined that
this Agreement and the Merger in the best interests of Parent and fair to its
stockholders; (b) authorized and approved the execution, delivery and
performance of this Agreement by Parent and the issuance of shares of Parent
Common Stock pursuant to this Agreement; and (c) recommended the approval of
the issuance of the Parent Common Stock pursuant to this Agreement for
purposes of NASDAQ Listing Rule 5635 and Part 6 of the TSX Company Manual by
the holders of Parent Common Stock and directed that the proposed issuance of
such shares be submitted for consideration by the Parent's stockholders at the
Parent Stockholders' Meeting. Assuming the due authorization, execution and
delivery of this Agreement by the Company, this Agreement constitutes the
legal, valid and binding obligation of each of Parent and Merger Sub,
enforceable against each of Parent and Merger Sub in accordance with its
terms, subject to: (i) laws of general application relating to bankruptcy,
insolvency, the relief of debtors and creditors' rights generally; and (ii)
rules of law governing specific performance, injunctive relief and other
equitable remedies.

  

  

 

 

 

  

 

52  

  

 

 

 

  

3.22 Inapplicability Anti-takeover Statutes. The Parent Board (at a meeting
duly called and held) has, to the extent necessary, adopted a resolution
having the effect of causing the Parent not to be subject to any takeover law
or similar Legal Requirement that might otherwise apply to the Merger or any
of the other Contemplated Transactions. No takeover statute, including MI
61-101, or similar Legal Requirement applies or purports to apply to the
Merger, this Agreement, the Parent Stockholder Voting Agreements or any of the
Contemplated Transactions.

  

  

3.23 Vote Required. The only vote of Parent's securityholders required to
consummate the transactions contemplated hereby is the affirmative vote of the
holders of a majority of the shares of Parent Common Stock present in person
or by proxy at the Parent Stockholders' Meeting in favor of: (i) the approval
of the issuance of the Parent Common Stock pursuant to this Agreement for the
purpose of approving such issuance under Nasdaq Listing Rule 5635 and under
the TSX Company Manual; (ii) a proposal to approve the Governance Amendments
to Parent Articles as contemplated herein, (iii) if required by the TSX, a
proposal to approve the adoption of the Company Options and Company Option
Plan; and (iv) the shareholder advisory vote contemplated by Rule 14a-21(c)
under the Exchange Act (the "Required Parent Stockholder Vote"). The
affirmative vote of the holders of a majority of the voting power of the
shares of common stock of Merger Sub (the "Required Merger Sub Stockholder
Vote") is the only vote of the holders of any class or series of Merger Sub's
capital stock necessary to adopt this Agreement or consummate the transactions
contemplated hereby. Parent is the sole stockholder of record of Merger Sub.
Parent shall, in its capacity as sole stockholder of Merger Sub, adopt this
Agreement and approve the Merger by written consent as soon as practicable
following execution of this Agreement.

  

  

3.24 Non-Contravention; Consents. Assuming compliance with the applicable
provisions of the BCBCA, DGCL, the HSR Act, Investment Canada Act and the
listing requirements of the NASDAQ and the rules and policies of the TSX, and
assuming the Required Parent Vote is passed, except as set forth in Part 3.24
of the Parent Disclosure Schedule, neither (1) the execution, delivery or
performance of this Agreement, nor (2) the consummation of the Merger or any
of the other Contemplated Transactions, will, directly or indirectly (with or
without notice or lapse of time):

  

  

(a) contravene, conflict with or result in a material violation of: (i) any of
the provisions of the certificate of incorporation, notice of articles,
articles, bylaws, or other charter or organizational documents of any of the
Tiger Corporations; or (ii) any resolution adopted by the stockholders, the
board of directors or any committee of the board of directors of any of the
Tiger Corporations;

  

  

(b) contravene, conflict with or result in a material violation of, any Legal
Requirement or any Order to which any of the Tiger Corporations, or any of the
assets owned or used by any of the Tiger Corporations, is subject;

  

  

(c) contravene, conflict with or result in a material violation of any of the
terms or requirements of, or give any Governmental Body the right to revoke,
withdraw, suspend, cancel, terminate or modify, any Governmental Authorization
that is held by any of the Tiger Corporations or that otherwise relates to the
business of any of the Tiger Corporations or to any of the assets owned or
used by any of the Tiger Corporations;

  

  

 

 

 

  

 

53  

  

 

 

 

  

(d) except as already disclosed in Part 3.10(d) of the Parent Disclosure
Schedule, contravene, conflict with or result in a violation or breach of, or
result in a default under, any provision of any Parent Material Contract, or
give any Person the right to: (i) declare a default or exercise any remedy
under any such Parent Material Contract; (ii) accelerate the maturity or
performance of any such Parent Material Contract; or (iii) cancel, terminate
or modify any right, benefit, obligation or other term of such Parent Material
Contract; or

  

  

(e) result in the imposition or creation of any Encumbrance upon or with
respect to any asset owned or used by any of the Tiger Corporations (except
for minor liens that will not, in any case or in the aggregate, materially
detract from the value of the assets subject thereto or materially impair the
operations of any of the Tiger Corporations).

  

  

Except as may be required by the Securities Act, the Exchange Act, Investment
Canada Act, the HSR Act, Canadian Securities Laws, and the listing
requirements of the NASDAQ and the TSX, none of the Tiger Corporations is or
will be required to make any filing with or give any notice to, or to obtain
any Consent from, any Governmental Body in connection with: (x) the execution,
delivery or performance of this Agreement; or (y) the consummation of the
Merger or any of the other Contemplated Transactions, except where the failure
to make any such filing or give any such notice or to obtain any such Consent
would not, individually or in the aggregate, be material to the Tiger
Corporations.

  

  

3.25 Opinion of Financial Advisor. The Parent Board has received the written
opinion of Lazard (the "Parent's Financial Advisor"), financial advisor to the
Parent, dated as of the date of this Agreement, to the effect that the
issuance by the Parent of the Aggregate Merger Shares to the stockholders of
the Company in connection with the Merger is fair, from a financial point of
view, to the Parent. The Parent will furnish an accurate and complete copy of
said written opinion to the Company for informational purposes.

  

  

3.26 No Broker Fee. Except for the Parent's Financial Advisor, no broker,
finder or investment banker is entitled to any brokerage, finder's or other
fee or commission in connection with the Merger or any of the other
Contemplated Transactions based upon arrangements made by or on behalf of any
of the Tiger Corporations. The Parent has furnished to the Company accurate
and complete copies of all agreements under which any such fees, commissions
or other amounts have been paid or may become payable and all indemnification
and other agreements related to the engagement of the Parent's Financial
Advisor.

  

  

3.27 Valid Issuance. The Parent Common Stock to be issued in the Merger
(including the Parent Common Stock to be issued upon the exercise of assumed
and converted Company Options) has been duly authorized and will, when issued
in accordance with the provisions of this Agreement, be validly issued, fully
paid and nonassessable, free and clear of Encumbrances and will not be subject
to any pre-emptive rights or, subject to the accuracy of the representations
and warranties made by the stockholders of the Company in the Representation
Letters delivered pursuant to Section 6.12, any restriction on resale under
(i) the Securities Act, other than restrictions imposed by Rules 144 and 145
under the Securities Act, (ii) Canadian Securities Laws, other than a
seasoning period under Section 2.6(3) of National Instrument 45-102, or (iii)
the rules and policies of the TSX.

  

  

3.28 Acknowledgement by Parent. Neither Parent nor Merger Sub is relying and
neither Parent nor Merger Sub has relied on any representations or warranties
whatsoever regarding the subject matter of this Agreement, express or implied,
except for the representations and warranties in Section 2 or contained in the
Company Stockholder Voting Agreements. The representations and warranties by
the Company contained in Section 2 constitute the sole and exclusive
representations and warranties of the Company, the other Owl Corporations and
their respective Representatives in connection with the Contemplated
Transactions and each of Parent and Merger Sub understands, acknowledges and
agrees that all other representations and warranties of any kind or nature
whether express, implied or statutory are specifically disclaimed by the
Company.

  

  

 

 

 

  

 

54  

  

 

 

 

  

3.29 Merger Sub. Merger Sub was formed solely for the purpose of engaging in
the Contemplated Transactions and has not engaged in any business activities
or conducted any operations other than in connection with the Contemplated
Transactions.

  

  

Section 4. Certain Covenants of the Parties Regarding Operations during the
Pre-Closing Period.

  

  

4.1 Access and Investigation. During the period commencing on the date of this
Agreement and ending as of the earlier of the termination of this Agreement or
the Effective Time (the "Pre-Closing Period"), subject to applicable Legal
Requirements and the terms of any confidentiality restrictions under Contracts
of a party as of the date of this Agreement, upon reasonable notice the
Company and Parent shall each, and shall cause each of their respective
Subsidiaries to: (a) provide the Representatives of the other party with
reasonable access during normal business hours to its Representatives and
assets and to all existing books, records, Tax Returns, work papers and other
documents and information relating to such Entity or any of its Subsidiaries,
in each case as reasonably requested by Parent or the Company, as the case may
be; and (b) provide the Representatives of the other party with such copies of
the existing books, records, Tax Returns, work papers and other documents and
information relating to such Entity and its Subsidiaries as reasonably
requested by Parent or the Company, as the case may be. During the Pre-Closing
Period, the Company and Parent shall, and shall cause their respective
Representatives to, cause their senior officers to meet, upon reasonable
notice and during normal business hours, with their respective chief financial
officers and other officers responsible for the Company's and Parent's
financial statements and the internal controls, respectively, to discuss such
matters as the Company or Parent may deem necessary or appropriate in order to
enable Parent to comply following the Closing with the Sarbanes-Oxley Act and
the rules and regulations relating thereto and Canadian Securities Laws.
Subject to Section 5.7 and without limiting the generality of any of the
foregoing, during the Pre-Closing Period, the Company and Parent shall provide
the other with copies of any notice, report or other document filed with or
sent to any Governmental Body on behalf of any of the Owl Corporations or the
Tiger Corporations, respectively, in connection with the Merger or any of the
other Contemplated Transactions a reasonable time in advance of the filing or
sending of such document in order to permit a review thereof. Nothing herein
shall require the Company or the Parent to disclose any information if such
disclosure would jeopardize any attorney-client privilege or contravene any
applicable Legal Requirement or binding agreement entered into prior to the
date of this Agreement; provided that the parties shall cooperate to disclose
such information to the extent possible without jeopardizing such privilege or
contravening such Legal Requirements or binding agreements. All information
exchanged pursuant to this Section 4.1 shall be subject to the Confidentiality
Agreement.

  

  

4.2 Operation of the Business of the Owl Corporations.

  

  

(a) During the Pre-Closing Period, except as set forth in Part 4.2(a) of the
Company Disclosure Schedule, as otherwise contemplated by this Agreement, as
required by Legal Requirements or if Parent shall otherwise consent in writing
(which consent shall not be unreasonably withheld or delayed): (i) the Company
shall ensure that each of the Owl Corporations conducts its business and
operations in the ordinary course and consistent with past practices; (ii) the
Company shall use commercially reasonable efforts to attempt to ensure that
each of the Owl Corporations preserves intact the material components of its
current business organization, and maintains its relations and goodwill with
all material suppliers, material customers, material licensors and
Governmental Bodies; and (iii) the Company shall promptly notify Parent of any
claim asserted or Legal Proceeding commenced, or, to the Knowledge of the
Company, threatened in writing by a third-Person, against, relating to,
involving or otherwise affecting any of the Owl Corporations that relates to
any of the Contemplated Transactions.

  

  

 

 

 

  

 

55  

  

 

 

 

  

(b) Except as set forth in Part 4.2(b) of the Company Disclosure Schedule,
during the Pre-Closing Period, the Company shall not (except as otherwise
contemplated by this Agreement, as required by Legal Requirements or with the
prior written consent of Parent, which consent shall not be unreasonably
withheld or delayed), and the Company shall ensure that each of the other Owl
Corporations does not (except as otherwise contemplated by this Agreement, as
required by Legal Requirements or with the prior written consent of Parent,
which consent shall not be unreasonably withheld or delayed):

  

  

(i) declare, accrue, set aside or pay any dividend or make any other
distribution in respect of any shares of capital stock, or repurchase, redeem
or otherwise reacquire any shares of capital stock or other securities, other
than: (A) dividends or distributions between or among any of the Owl
Corporations to the extent consistent with past practices; or (B) pursuant to
the Company's right to purchase restricted shares of Company Common Stock held
by an employee of or other service provider to the Company upon termination of
such Person's services or upon the cashless or net exercise of outstanding
Company Options or to satisfy withholding obligations upon vesting or exercise
of equity awards;

  

  

(ii) sell, issue, grant, authorize the sale, issuance or grant of, or publicly
announce its intention to sell, issue, or grant (including through filing a
registration statement with the SEC): (A) any capital stock or other security;
(B) any option, call, warrant or right to acquire any capital stock or other
security; or (C) any instrument convertible into or exchangeable for any
capital stock or other security (except that: (1) the Company may issue shares
of Company Common Stock upon the valid exercise of Company Options outstanding
as of the date of this Agreement; and (2) Company may, in the ordinary course
of business grant Company Equity Awards to employees) of an Owl Corporation
under the Company Option Plan; provided that such Company Equity Awards may
not exceed 400,000 shares of Company Common Stock in the aggregate under the
Company Option Plan);

  

  

(iii) amend or waive any of its rights under, or accelerate the vesting under,
any provision of any of the Company Option Plan, any provision of any
agreement evidencing any outstanding stock option, restricted stock grant, or
any restricted stock unit purchase agreement, or otherwise modify any of the
terms of any outstanding option, restricted stock agreement, restricted stock
unit, warrant or other security or any related Contract;

  

  

(iv) amend, terminate or grant any waiver under any standstill agreements;

  

  

(v) amend or permit the adoption of any amendment to its certificate of
incorporation or bylaws or other charter or organizational documents;

  

  

(vi) (A) except in the ordinary course of business and consistent with past
practices, acquire any equity interest or other interest in any other Entity;
(B) except in the ordinary course of business and consistent with past
practices, form any Subsidiary; or (C) effect or become a party to any merger,
consolidation, share exchange, business combination, amalgamation,
recapitalization, reclassification of shares, stock split, reverse stock
split, division or subdivision of shares, consolidation of shares or similar
transaction;

  

  

 

 

 

  

 

56  

  

 

 

 

  

(vii) make any capital expenditure (except that the Owl Corporations may make
any capital expenditure that: (A) is provided for in the Company's capital
expense budget delivered or Made Available to Parent prior to the date of this
Agreement; or (B) when added to all other capital expenditures made on behalf
of all of the Owl Corporations since the date of this Agreement but not
provided for in the Company's capital expense budget delivered or Made
Available to Parent prior to the date of this Agreement, does not exceed
$100,000 in the aggregate);

  

  

(viii) other than in the ordinary course of business and consistent with past
practices: (A) enter into or become bound by, or permit any of the assets
owned or used by it to become bound by, any Contract that would be a Company
Material Contract or any other Contract that is material to the Owl
Corporations (taken as a whole); or (B) amend, terminate, or waive any
material right or remedy under, any Company Material Contract or any other
Contract that is material to the Owl Corporations (taken as a whole), other
than termination thereof upon the expiration of any such Contract in
accordance with its terms or upon a material breach thereof by the
counterparty thereto; provided, that, in the case of the foregoing clause
"(B)" an amendment, termination or waiver under any Company Material Contract
listed in Part 4.2(b)(viii) of the Company Disclosure Schedule shall not be
deemed to be in the ordinary course of business and shall not be permitted
without the consent of Parent.

  

  

(ix) acquire, lease or license any right or other asset from any other Person
or sell or otherwise dispose of, or lease or license, any right or other asset
to any other Person (except in each case for: (A) assets acquired, leased,
licensed or disposed of by the Company in the ordinary course of business and
consistent with past practices; (B) assets that are immaterial to the business
of the Owl Corporations; or (C) sales of inventory in the ordinary course of
business);

  

  

(x) make any pledge of any of its material assets or permit any of its
material assets to become subject to any Encumbrances, except for Encumbrances
that do not materially detract from the value of such assets or that do not
materially impair the operations of any of the Owl Corporations;

  

  

(xi) lend money to any Person (other than routine travel and business expense
advances made to directors or employees in the ordinary course of business),
or, except as set forth in Part 4.2(b)(xi) of the Company Disclosure Schedule,
incur or guarantee any indebtedness;

  

  

(xii) establish, adopt, enter into or amend any Company Employee Plan or
Company Employee Agreement, pay any bonus or make any profit-sharing or
similar payment to, pay any severance, retention or change-of-control or
similar benefits, or increase the amount of the wages, salary, commissions,
fringe benefits or other compensation (including equity-based compensation,
whether payable in stock, cash or other property) or remuneration payable to,
any of its directors or any of its officers or other employees (except that
the Company: (A) may amend the Company Employee Plans to the extent required
by applicable Legal Requirements; (B) may make customary bonus payments and
profit sharing payments consistent with past practices in accordance with
bonus and profit sharing plans existing on the date of this Agreement; (C) pay
severance, retention or change-of-control or similar benefits pursuant to any
Company Employee Plan or Company Employee Agreement in effect as of the date
of this Agreement; (D)(1) enter into ordinary course compensation arrangements
with any new employee hired in accordance with clause (xiii), consistent with
past practice or (2) increase the amount of the wages, salary, commissions,
fringe benefits or other compensation (including equity-based compensation,
whether payable in stock, cash or other property) or remuneration payable in
connection with the promotion of any employee in the ordinary course of
business and in accordance with clause (xiii), consistent with past practice;
and (E) may make payments or increase any benefits as required by the terms of
any Company Employee Plan or Company Employee Agreement as in effect as of the
date of this Agreement);

  

  

 

 

 

  

 

57  

  

 

 

 

  

(xiii) hire any employee (except (A) to fill any position set forth in Part
4.2(b) of the Company Disclosure Schedule or (B) in order to fill a position
vacated after the date of this Agreement) or promote any employee to the level
of Vice President or above (except for hiring or promoting an employee to fill
a non-executive officer position vacated after the date of this Agreement);

  

  

(xiv) other than in the ordinary course of business and consistent with past
practices or as required by concurrent changes in GAAP or SEC rules and
regulations or under Canadian Securities Laws, change any of its methods of
accounting or accounting practices in any respect;

  

  

(xv) make any material Tax election, make any material amendments to Tax
Returns previously filed, or settle or compromise any material Tax liability
or refund;

  

  

(xvi) commence any Legal Proceeding, except with respect to: (A) routine
matters in the ordinary course of business and consistent with past practices;
(B) in such cases where the Company reasonably determines in good faith that
the failure to commence suit would result in a material impairment of a
valuable aspect of its business (provided that the Company consults with
Parent and considers the views and comments of Parent with respect to such
Legal Proceedings prior to commencement thereof); or (C) in connection with a
breach of this Agreement or the other agreements listed in the definition of
"Contemplated Transactions;"

  

  

(xvii) except as permitted pursuant to Section 5.16, settle any Legal
Proceeding or other material claim, other than pursuant to a settlement: (A)
that results solely in a monetary obligation involving payment by the Owl
Corporations of the amount specifically reserved in accordance with GAAP with
respect to such Legal Proceedings or claim on the Company Unaudited Balance
Sheet; or (B) that results solely in a monetary obligation involving only the
payment of monies by the Owl Corporations of not more than $100,000 in the
aggregate;

  

  

(xviii) subject to Section 5.9(e), take any action that would reasonably be
expected to cause the Merger to fail to qualify as a "reorganization" under
Section 368(a) of the Code (whether or not otherwise permitted by the
provisions of this Section 4) or fail to take any action reasonably necessary
to cause the Merger to so qualify, or take any action that would reasonably be
expected to cause the Merger to be subject to Section 367(a)(1) of the Code
(whether or not otherwise permitted by the provisions of this Section 4) or
fail to take any action that would reasonably be expected to prevent the
Merger from being subject to Section 367(a)(1) of the Code; or

  

  

(xix) agree or commit to take any of the actions described in clauses "(i)"
through "(xviii)" of this Section 4.2(b).

  

  

(c) During the Pre-Closing Period, the Company shall promptly notify Parent in
writing of any event, condition, fact or circumstance that would reasonably be
expected to make the timely satisfaction of any of the conditions set forth in
Section 6 impossible or unlikely or that has had or would reasonably be
expected to have or result in a Company Material Adverse Effect. Without
limiting the generality of the foregoing, the Company shall promptly: (i)
advise Parent in writing of any material Legal Proceeding or material claim
threatened, commenced or asserted against or with respect to any of the Owl
Corporations and (ii) provide copies to Parent of any material letters,
notices or other written communications from any Governmental Body that it
receives during the Pre-Closing Period. No notification given to Parent
pursuant to this Section 4.2(c) shall limit or otherwise affect any of the
representations, warranties, covenants or obligations of the Company contained
in this Agreement or the conditions to the obligations of the parties under
this Agreement; provided however, that a failure to comply with this Section
4.2(c) will not constitute the failure of any condition set forth in Section 6
to be satisfied unless the underlying event, condition, fact or circumstance
would independently result in the failure of a condition set forth in Section
6 to be satisfied.

  

  

 

 

 

  

 

58  

  

 

 

 

  

4.3 Operation of the Business of the Tiger Corporations.

  

  

(a) During the Pre-Closing Period, except as set forth in Part 4.3(a) of the
Parent Disclosure Schedule, as otherwise contemplated by this Agreement, as
required by Legal Requirements or if the Company shall otherwise consent in
writing (which consent shall not be unreasonably withheld or delayed): (i)
Parent shall ensure that each of the Tiger Corporations conducts its business
and operations in the ordinary course and consistent with past practices; (ii)
Parent shall use commercially reasonable efforts to attempt to ensure that
each of the Tiger Corporations preserves intact the material components of its
current business organization, and maintains its relations and goodwill with
all material suppliers, material customers, material licensors, and
Governmental Bodies; and (iii) Parent shall promptly notify Company of any
claim asserted or Legal Proceeding commenced, or, to the Knowledge of Parent,
threatened in writing by a third-Person, against, relating to, involving or
otherwise affecting any of the Tiger Corporations that relates to any of the
Contemplated Transactions.

  

  

(b) Except as set forth in Part 4.3(b) of the Parent Disclosure Schedule,
during the Pre-Closing Period, Parent shall not (except as otherwise
contemplated by this Agreement, as required by Legal Requirements or with the
prior written consent of Company, which consent shall not be unreasonably
withheld or delayed), and Parent shall ensure that each of the other Tiger
Corporations does not (except as otherwise contemplated by this Agreement, as
required by Legal Requirements or with the prior written consent of the
Company, which consent shall not be unreasonably withheld or delayed):

  

  

(i) declare, accrue, set aside or pay any dividend or make any other
distribution in respect of any shares of capital stock, or repurchase, redeem
or otherwise reacquire any shares of capital stock or other securities, other
than: (A) dividends or distributions between or among any of the Tiger
Corporations to the extent consistent with past practices; or (B) pursuant to
Parent's right to purchase restricted shares of Parent Common Stock held by an
employee of Parent upon termination of such employee's employment or upon the
cashless or net exercise of outstanding Parent Options or to satisfy
withholding obligations upon vesting or exercise of equity awards;

  

  

(ii) sell, issue, grant, authorize the sale, issuance or grant of, or publicly
announce its intention to sell, issue, or grant: (A) any capital stock or
other security; (B) any option, call, warrant or right to acquire any capital
stock or other security; or (C) any instrument convertible into or
exchangeable for any capital stock or other security (except that: (1) the
Parent may issue shares of Parent Common Stock: upon the valid exercise of
Parent Options outstanding as of the date of this Agreement; and (2) Parent
may, in the ordinary course of business grant Parent Equity Awards to
directors, officers and employees of a Tiger Corporation under the Parent
Option Plans; provided that such Parent Equity Awards may not exceed 400,000
shares of Parent Common Stock in the aggregate under the Parent Option Plans);

  

  

(iii) amend or waive any of its rights under, or accelerate the vesting under,
any provision of any of the Parent Option Plans, any provision of any
agreement evidencing any outstanding stock option or any restricted stock unit
purchase agreement, or otherwise modify any of the terms of any outstanding
option, restricted stock agreement, restricted stock unit, warrant or other
security or any related Contract;

  

  

(iv) amend, terminate or grant any waiver under any standstill agreements;

  

  

 

 

 

  

 

59  

  

 

 

 

  

(v) amend or permit the adoption of any amendment to its certificate of
incorporation or bylaws or other charter or organizational documents;

  

  

(vi) (A) except in the ordinary course of business and consistent with past
practices, acquire any equity interest or other interest in any other Entity;
(B) except in the ordinary course of business and consistent with past
practices, form any Subsidiary; or (C) effect or become a party to any merger,
consolidation, share exchange, business combination, amalgamation,
recapitalization, reclassification of shares, stock split, reverse stock
split, division or subdivision of shares, consolidation of shares or similar
transaction;

  

  

(vii) make any capital expenditure (except that the Tiger Corporations may
make any capital expenditure that: (A) is provided for in Parent's capital
expense budget delivered or Made Available to the Company prior to the date of
this Agreement; or (B) when added to all other capital expenditures made on
behalf of all of the Tiger Corporations since the date of this Agreement but
not provided for in Parent's capital expense budget delivered or Made
Available to the Company prior to the date of this Agreement, does not exceed
$100,000 in the aggregate);

  

  

(viii) other than in the ordinary course of business and consistent with past
practices: (A) enter into or become bound by, or permit any of the assets
owned or used by it to become bound by, any Contract that would be a Parent
Material Contract or any other Contract that is material to the Tiger
Corporations (taken as a whole); or (B) amend, terminate, or waive any
material right or remedy under, any Parent Material Contract or any other
Contract that is material to the Tiger Corporations (taken as a whole), other
than termination thereof upon the expiration of any such Contract in
accordance with its terms or upon a material breach thereof by the
counterparty thereto;

  

  

(ix) acquire, lease or license any right or other asset from any other Person
or sell or otherwise dispose of, or lease or license, any right or other asset
to any other Person (except in each case for: (A) assets acquired, leased,
licensed or disposed of by Parent in the ordinary course of business and
consistent with past practices; (B) assets that are immaterial to the business
of the Tiger Corporations; or (C) sales of inventory in the ordinary course of
business);

  

  

(x) make any pledge of any of its material assets or permit any of its
material assets to become subject to any Encumbrances, except for Encumbrances
that do not materially detract from the value of such assets or that do not
materially impair the operations of any of the Tiger Corporations;

  

  

(xi) lend money to any Person (other than routine travel and business expense
advances made to directors or employees in the ordinary course of business),
or, except in the ordinary course of business and consistent with past
practices, incur or guarantee any indebtedness;

  

  

(xii) establish, adopt, enter into or amend any Parent Employee Plan or Parent
Employee Agreement, pay any bonus or make any profit-sharing or similar
payment to, pay any severance, retention or change-of-control or similar
benefits, or increase the amount of the wages, salary, commissions, fringe
benefits or other compensation (including equity-based compensation, whether
payable in stock, cash or other property) or remuneration payable to, any of
its directors or any of its officers or other employees (except that the
Parent: (A) may amend the Parent Employee Plans to the extent required by
applicable Legal Requirements; (B) may make customary bonus payments and
profit sharing payments consistent with past practices in accordance with
bonus and profit sharing plans existing on the date of this Agreement; (C) pay
severance, retention or change-of-control or similar benefits pursuant to any
Parent Employee Plan or Parent Employee Agreement in effect as of the date of
this Agreement; (D)(1) enter into ordinary course compensation arrangements
with any new employee hired in accordance with clause (xiii), consistent with
past practice or (2) increase the amount of the wages, salary, commissions,
fringe benefits or other compensation (including equity-based compensation,
whether payable in stock, cash or other property) or remuneration payable in
connection with the promotion of any employee in the ordinary course of
business and in accordance with clause (xiii), consistent with past practice;
and (E) may make payments or increase any benefits as required by the terms of
any Parent Employee Plan or Parent Employee Agreement as in effect as of the
date of this Agreement);

  

  

 

 

 

  

 

60  

  

 

 

 

  

(xiii) hire any employee (except (A) to fill any position set forth in Part
4.3(b) of the Parent Disclosure Schedule or (B) in order to fill a position
vacated after the date of this Agreement) or promote any employee to the level
of Vice President or above (except for hiring or promoting an employee to fill
a non-executive officer position vacated after the date of this Agreement);

  

  

(xiv) other than in the ordinary course of business and consistent with past
practices or as required by concurrent changes in GAAP or SEC rules and
regulations, change any of its methods of accounting or accounting practices
in any respect;

  

  

(xv) make any material Tax election, make any material amendments to Tax
Returns previously filed, or settle or compromise any material Tax liability
or refund;

  

  

(xvi) commence any Legal Proceeding, except with respect to: (A) routine
matters in the ordinary course of business and consistent with past practices;
(B) in such cases where Parent reasonably determines in good faith that the
failure to commence suit would result in a material impairment of a valuable
aspect of its business (provided that Parent consults with the Company and
considers the views and comments of the Company with respect to such Legal
Proceedings prior to commencement thereof); or (C) in connection with a breach
of this Agreement or the other agreements listed in the definition of
"Contemplated Transactions;"

  

  

(xvii) except as permitted pursuant to Section 5.16, settle any Legal
Proceeding or other material claim, other than pursuant to a settlement: (A)
that results solely in a monetary obligation involving payment by the Tiger
Corporations of the amount specifically reserved in accordance with GAAP with
respect to such Legal Proceedings or claim on the Parent Unaudited Balance
Sheet; or (B) that results solely in a monetary obligation involving only the
payment of monies by the Tiger Corporations of not more than $100,000 in the
aggregate;

  

  

(xviii) subject to Section 5.9(e), take any action that would reasonably be
expected to cause the Merger to fail to qualify as a "reorganization" under
Section 368(a) of the Code (whether or not otherwise permitted by the
provisions of this Section 4) or fail to take any action reasonably necessary
to cause the Merger to so qualify, or take any action that would reasonably be
expected to cause the Merger to be subject to Section 367(a)(1) of the Code
(whether or not otherwise permitted by the provisions of this Section 4) or
fail to take any action that would reasonably be expected to prevent the
Merger from being subject to Section 367(a)(1) of the Code; or

  

  

(xix) agree or commit to take any of the actions described in clauses "(i)"
through "(xviii)" of this Section 4.3(b).

  

  

(c) During the Pre-Closing Period, Parent shall promptly notify the Company in
writing of any event, condition, fact or circumstance that would reasonably be
expected to make the timely satisfaction of any of the conditions set forth in
Section 7 impossible or unlikely or that has had or would reasonably be
expected to have or result in a Parent Material Adverse Effect. Without
limiting the generality of the foregoing, Parent shall promptly: (i) advise
the Company in writing of any material Legal Proceeding or material claim
threatened, commenced or asserted against or with respect to any of the Tiger
Corporations and (ii) provide copies to the Company of any material letters,
notices or other written communications from any Governmental Body that it
receives during the Pre-Closing Period. No notification given to the Company
pursuant to this Section 4.3(c) shall limit or otherwise affect any of the
representations, warranties, covenants or obligations of Parent contained in
this Agreement or the conditions to the obligations of the parties under this
Agreement; provided however, that a failure to comply with this Section 4.3(c)
will not constitute the failure of any condition set forth in Section 7 to be
satisfied unless the underlying event, condition, fact or circumstance would
independently result in the failure of a condition set forth in Section 7 to
be satisfied.

  

  

 

 

 

  

 

61  

  

 

 

 

  

4.4 No Solicitation.

  

  

(a) During the Pre-Closing Period, the Company shall not, directly or
indirectly, and the Company shall cause its Subsidiaries and the respective
directors and officers of the Company and its Subsidiaries not to (and the
Company shall direct the other Representatives of the Owl Corporations not to,
and the Company shall use its reasonable efforts to ensure that the other
Representatives of the Owl Corporations do not), directly or indirectly:

  

  

(i) solicit, initiate, knowingly encourage or knowingly facilitate the making,
submission or announcement of any Acquisition Proposal with respect to an Owl
Corporation or Acquisition Inquiry with respect to an Owl Corporation;

  

  

(ii) knowingly furnish any information regarding any of the Owl Corporations
to any Person in connection with or in response to an Acquisition Proposal
with respect to an Owl Corporation or Acquisition Inquiry with respect to an
Owl Corporation;

  

  

(iii) engage in discussions or negotiations with any Person relating to any
Acquisition Proposal with respect to an Owl Corporation or Acquisition Inquiry
with respect to an Owl Corporation;

  

  

(iv) approve, endorse or recommend any Acquisition Proposal with respect to an
Owl Corporation or Acquisition Inquiry with respect to an Owl Corporation; or

  

  

(v) enter into any letter of intent or similar document or any Contract
contemplating or otherwise relating to any Acquisition Transaction or
Acquisition Inquiry with respect to an Owl Corporation.

  

  

(b) During the Pre-Closing Period, Parent shall not, directly or indirectly,
and Parent shall cause its Subsidiaries and the respective directors and
officers of the Parent and its Subsidiaries not to (and the Parent shall
direct the other Representatives of the Tiger Corporations not to, and the
Parent shall use its reasonable efforts to ensure that the other
Representatives of the Tiger Corporations do not), directly or indirectly:

  

  

(i) solicit, initiate, knowingly encourage or knowingly facilitate the making,
submission or announcement of any Acquisition Proposal with respect to a Tiger
Corporation or Acquisition Inquiry with respect to a Tiger Corporation;

  

  

(ii) knowingly furnish any information regarding any of the Tiger Corporations
to any Person in connection with or in response to an Acquisition Proposal
with respect to a Tiger Corporation or Acquisition Inquiry with respect to a
Tiger Corporation;

  

  

 

 

 

  

 

62  

  

 

 

 

  

(iii) engage in discussions or negotiations with any Person relating to any
Acquisition Proposal with respect to a Tiger Corporation or Acquisition
Inquiry with respect to a Tiger Corporation;

  

  

(iv) approve, endorse or recommend any Acquisition Proposal with respect to a
Tiger Corporation or Acquisition Inquiry with respect to a Tiger Corporation;
or

  

  

(v) enter into any letter of intent or similar document or any Contract
contemplating or otherwise relating to any Acquisition Transaction or
Acquisition Inquiry with respect to a Tiger Corporation;

  

  

provided, however, that prior to the approval of the issuance of shares of
Parent Common Stock in the Merger by the Required Parent Stockholder Vote,
this Section 4.4(b) shall not prohibit Parent from furnishing information
(including non-public information) regarding the Tiger Corporations to, or
entering into discussions and negotiations with, any Person in response to an
Acquisition Proposal that is submitted to Parent by such Person (and not
withdrawn) which after consultation with a financial advisor of nationally
recognized reputation and outside legal counsel, the Parent Board determines
in good faith is, or would reasonably be expected to, result in a Parent
Superior Offer if: (A) such Acquisition Proposal did not result from any
breach of, or any action inconsistent with, any of the provisions set forth in
this Section 4.4; (B) the Parent Board concludes in good faith, after having
consulted with its outside legal counsel, that failure to take such action
would be inconsistent with the fiduciary duties of the Parent Board under
applicable law; (C) at least two Business Days prior to furnishing any such
information to, or entering into discussions or negotiations with, such
Person, Parent gives the Company written notice of the identity of such Person
and of Parent's intention to furnish information to, or enter into discussions
with, such Person, and Parent receives from such Person an executed
confidentiality agreement (which the Parent may discuss with such Person
during the two day period) containing provisions (including nondisclosure
provisions, use restrictions and non-solicitation provisions) at least as
favorable to Parent as the provisions of the Confidentiality Agreement as in
effect immediately prior to the execution of this Agreement (provided that the
non-solicitation provisions shall permit the making of an Acquisition Proposal
and provided further that the requirement to execute a confidentiality
agreement shall not apply if the Person making or proposing to make the
Acquisition Proposal is already party to a confidentiality agreement with the
Parent at least as favorable to Parent as the provisions of the
Confidentiality Agreement as in effect immediately prior to the execution of
this Agreement); and (D) at least two Business Days prior to furnishing any
such information to such Person, Parent furnishes such information to the
Company (to the extent such information has not been previously furnished or
Made Available by Parent to the Company). The Company and Parent agree that
any breach or violation of the restrictions set forth in this Section 4.4 by
(x) any director or officer of a Tiger Corporation will be deemed to be a
breach of this Section 4.4 by Parent or (y) any other Representative of a
Tiger Corporation will be deemed to be a breach of this Section 4.4 by Parent
for purposes of subclause (A) of the preceding sentence and for purposes of
Section 5.3(c).

  

  

(c) Each of Parent and the Company shall promptly (and in no event later than
24 hours after receipt of any Acquisition Proposal with respect to an Owl
Corporation or a Tiger Corporation, as the case may be, or Acquisition Inquiry
with respect to an Owl Corporation or a Tiger Corporation, as the case may be)
advise the other party to this Agreement orally and in writing of any such
Acquisition Proposal or Acquisition Inquiry (including the identity of the
Person making or submitting such Acquisition Proposal or Acquisition Inquiry
and the terms thereof, including a copy of any written Acquisition Proposal or
Acquisition Inquiry) that is made or submitted by any Person during the Pre-
Closing Period. Each party receiving an Acquisition Proposal or Acquisition
Inquiry shall keep the other party informed with respect to: (i) the status of
any such Acquisition Proposal or Acquisition Inquiry; and (ii) the status and
terms of any material modification or proposed material modification thereto.

  

  

 

 

 

  

 

63  

  

 

 

 

  

(d) Each of Parent and the Company shall, and shall cause their respective
Subsidiaries and Representatives to, immediately cease and cause to be
terminated any discussions conducted on or before the date of this Agreement
with any Person that relates to any Acquisition Proposal or Acquisition
Inquiry.

  

  

(e) Each of Parent and the Company agrees not to release or permit the release
of any Person from, or to waive or permit the waiver of any provision of, any
confidentiality, non-solicitation, no hire, "standstill" or similar Contract
to which any such party or any of its Subsidiaries is a party or under which
any such party or any of its Subsidiaries has any rights, and will use its
reasonable efforts to cause each such agreement to be enforced to the extent
requested by the other party to this Agreement except to the extent that the
Parent Board determines in good faith, after having consulted with its outside
legal counsel, that failure to take such action would be inconsistent with the
fiduciary duties of the Parent Board under applicable law.

  

  

Section 5. Additional Covenants of the Parties

  

  

5.1 Proxy Statement; Information Circular. As promptly as practicable after
the date of this Agreement, Parent and the Company shall cooperate to prepare
and Parent shall cause to be filed with the SEC, the TSX and, if applicable,
any other Governmental Authority, the Proxy Statement and Circular. Parent
shall use commercially reasonable efforts: (i) to cause the Proxy Statement
and Circular to comply with the applicable rules and regulations promulgated
by the SEC, Canadian Securities Laws and the rules and policies of the TSX;
(ii) to promptly notify the Company of, cooperate with the Company with
respect to, provide the Company (and its counsel) with a reasonable
opportunity to review and comment on, and respond promptly to any comments of
the SEC, the TSX and if applicable, any other Governmental Authority or their
respective staff with respect to the Proxy Statement or Circular; and (iii) to
provide the Company (and its counsel) with a reasonable opportunity to review
and comment on the Proxy Statement and Circular, and any amendment or
supplement thereto, prior to filing of any such document with the SEC, the TSX
and if applicable, any other Governmental Authority. Parent shall cause to be
filed with the SEC, the TSX and if applicable, any other Governmental
Authority the Proxy Statement and Circular and Parent shall use commercially
reasonable efforts to cause the Proxy Statement and Circular to be mailed to
Parent's stockholders as promptly as practicable. Each of Parent and the
Company shall promptly furnish to the other party all information concerning
such party, its Subsidiaries and stockholders that may be required or
reasonably requested in connection with any action contemplated by this
Section 5.1. If either Parent or the Company becomes aware of any information
that should be disclosed in an amendment or supplement to the Proxy Statement
or Circular, then such party: (i) shall promptly inform the other party
thereof; (ii) shall provide the other party (and its counsel) with a
reasonable opportunity to review and comment on any amendment or supplement to
the Proxy Statement or Circular prior to it being filed with the SEC, the TSX
and if applicable, any other Governmental Authority; (iii) shall provide the
other party with a copy of such amendment or supplement promptly after it is
filed with the SEC, the TSX and if applicable, any other Governmental
Authority; and (iv) shall cooperate, if appropriate, in mailing such amendment
or supplement to the stockholders of Parent.

  

  

5.2 Federal and State Blue Sky Laws. Parent shall take such steps within its
control as may be necessary to comply with the securities and blue sky laws of
all jurisdictions which are applicable to the issuance of shares of Parent
Common Stock pursuant to Section 1.5(a)(ii). The Company shall use its
reasonable best efforts to assist Parent as may be necessary to comply with
the securities and blue sky laws of all jurisdictions which are applicable in
connection with the issuance of Parent Common Stock pursuant to Section
1.5(a)(ii).

  

  

 

 

 

  

 

64  

  

 

 

 

  

5.3 Parent Stockholders' Meeting.

  

  

(a) Parent: (i) shall take all action necessary under all applicable Legal
Requirements to call, give notice of and hold a meeting of the holders of
Parent Common Stock (the "Parent Stockholders' Meeting") to vote on (w) a
proposal to approve the issuance of shares of Parent Common Stock under the
Contemplated Transactions pursuant to Nasdaq Listing Rule 5635 and Part 6 of
the TSX Company Manual, (x) a proposal to approve the Governance Amendments to
Parent Articles as contemplated herein, (y) if required by the TSX, a proposal
to approve the adoption of the Company Options and Company Option Plan; and
(z) the shareholder advisory vote contemplated by Rule 14a-21(c) under the
Exchange Act; and (ii) shall submit such proposals to such holders at the
Parent Stockholders' Meeting and shall not submit any other proposal to such
holders in connection with the Parent Stockholders' Meeting without the prior
written consent of the Company. Parent in consultation with the Company shall
set a record date for Persons entitled to notice of, and to vote at, the
Parent Stockholders' Meeting and shall not change such record date without the
prior written consent of the Company (such consent not to be unreasonably
withheld, conditioned or delayed). Parent shall ensure that all proxies
solicited by the Tiger Corporations and their Representatives in connection
with the Parent Stockholders' Meeting are solicited in compliance with all
applicable Legal Requirements. Notwithstanding anything to the contrary
contained in this Agreement, Parent may after consultation with the Company
adjourn or postpone the Parent Stockholders' Meeting only: (i) to the extent
necessary to ensure that any supplement or amendment to the Proxy Statement or
Circular that is required by applicable Legal Requirement (or in connection
with the settlement of any applicable litigation) is timely provided to
Parent's stockholders; (ii) if as of the time for which the Parent
Stockholders' Meeting is originally scheduled there are insufficient shares of
Parent Common Stock represented (either in person or by proxy) to constitute a
quorum necessary to conduct the business to be conducted at the Parent
Stockholders' Meeting; or (iii) if additional time is reasonably required to
solicit proxies in favor of the approval of the issuance of shares of Parent
Common Stock in the Merger. Nothing contained in this Agreement shall be
deemed to relieve Parent of its obligation to submit the issuance of shares of
Parent Common Stock in the Merger to its stockholders for a vote on the
approval thereof. Parent agrees that, unless this Agreement shall have been
terminated in accordance with Section 8, its obligations to hold the Parent
Stockholders' Meeting pursuant to this Section 5.3(a) shall not be affected by
the commencement, public proposal, public disclosure or communication to
Parent of any Acquisition Proposal with respect to a Tiger Corporation or
Acquisition Inquiry with respect to a Tiger Corporation or by any Parent
Change in Recommendation or the entering into any Alternative Agreement.

  

  

(b) Subject to Section 5.3(c): (i) the Proxy Statement and Circular shall
include a statement to the effect that the Parent Board has determined that
this Agreement and the Merger is in the best interests of Parent and fair to
its stockholders, and recommends that Parent's stockholders vote to approve
the issuance of shares of Parent Common Stock in the Merger at the Parent
Stockholders' Meeting (such determination and recommendation being referred to
as the "Parent Board Recommendation"); (ii) the Parent Board Recommendation
shall not be directly or indirectly withdrawn or modified in a manner adverse
to the Company; (iii) neither the Parent Board nor any committee thereof
shall: (A) fail to publicly reaffirm the Parent Board Recommendation, or fail
to publicly state that this Agreement and the Merger are in the best interests
of Parent and fair to its stockholders, within five Business Days after the
Company requests in writing that such action be taken, provided that the
Company has a reasonable basis for making such request; (B) fail to publicly
announce, within ten Business Days after a tender offer or exchange offer
relating to the securities of Parent shall have been commenced, a statement
disclosing that the Parent Board recommends rejection of such tender or
exchange offer; (C) fail to issue, within five Business Days after an
Acquisition Proposal with respect to a Tiger Corporation is publicly
announced, a press release announcing its opposition to such Acquisition
Proposal; or (D) resolve to take any action described in clauses "(ii)" or
"(iii)" of this sentence (each of the foregoing actions described in clauses
"(ii)" and "(iii)" being referred to as a "Parent Change in Recommendation").

  

  

 

 

 

  

 

65  

  

 

 

 

  

(c) Notwithstanding anything to the contrary contained in Section 5.3(a) or
elsewhere in this Agreement, at any time prior to the approval of the issuance
of shares of Parent Common Stock in the Merger by the Required Parent
Stockholder Vote, the Parent Board may effect, or cause Parent to effect, as
the case may be, a Parent Change in Recommendation:

  

  

(i) if: (A) Parent has not breached its obligations under Section 4.4 in
connection with the offer referred to in the following clause "(B);" (B) after
the date of this Agreement, an unsolicited, bona fide, written Acquisition
Proposal is made to Parent and not withdrawn (provided, however, that for
purposes of this Section 5.3(c)(i), all references to "15%" in the definition
of "Acquisition Transaction" as used in "Acquisition Proposal" shall be deemed
substituted with "90%"); (C) the Parent Board determines in its good faith
judgment, after consulting with a financial advisor of nationally recognized
reputation and outside legal counsel, that such offer constitutes a Parent
Superior Offer; (D) the Parent Board does not effect, or cause Parent to
effect, a Parent Change in Recommendation at any time within five Business
Days after the Company receives written notice from Parent confirming that the
Parent Board has determined that such offer is a Parent Superior Offer
(provided, a new notice shall be required with respect to each material
modification to such offer); (E) during such five Business Day period, if
requested by the Company, Parent engages in good faith negotiations with the
Company to amend this Agreement in such a manner that the offer that was
determined to constitute a Parent Superior Offer no longer constitutes a
Parent Superior Offer; (F) at the end of such five Business Day period, such
offer has not been withdrawn and continues to constitute a Parent Superior
Offer (taking into account any changes to the terms of this Agreement proposed
by the Company as a result of the negotiations required by clause "(E)" or
otherwise); and (G) the Parent Board determines in good faith, after having
consulted with its outside legal counsel, that, in light of such Parent
Superior Offer, a failure to make a Parent Change in Recommendation would be
inconsistent with the fiduciary duties of the Parent Board under applicable
law; or

  

  

(ii) if: (A) other than (1) the development or circumstances contemplated by
clause "(i)" of this Section 5.3(c) or (2) in connection with or as a result
of the making of, or any development or circumstance relating to, an
Acquisition Proposal with respect to a Tiger Corporation or an Acquisition
Inquiry with respect to a Tiger Corporation, a material development or change
in circumstances occurs or arises after the date of this Agreement that was
neither known to the Parent Board or any executive officer nor reasonably
foreseeable to the Parent Board or any executive officer of Parent as of the
date of this Agreement and does not relate to (x) events, changes or
circumstances relating to Company or any of its Affiliates, (y) clearance of
the Merger under the antitrust laws or (z) the mere fact that Parent meets or
exceeds any internal or published projections, forecasts, estimates or
predictions of revenue, earnings or other financial or operating metrics for
any period ending on or after the date of this Agreement, or changes after the
date of this Agreement (however, the underlying reasons for such events may
constitute such material event, development or change in circumstances) (such
material development or change in circumstances being referred to as an
"Intervening Event"); (B) at least five Business Days prior to any meeting of
the Parent Board at which the Parent Board will consider whether such
Intervening Event requires the Parent Board to effect, or cause Parent to
effect, a Parent Change in Recommendation, Parent provides the Company with a
written notice specifying the date and time of such meeting and the reasons
for holding such meeting; (C) during such five Business Day period, if
requested by the Company, Parent engages in good faith negotiations with the
Company to amend this Agreement in such a manner that obviates the need for
the Parent Board to effect, or cause Parent to effect, a Parent Change in
Recommendation as a result of such Intervening Event; and (D) the Parent Board
determines in good faith, after having consulted with its outside legal
counsel, that, in light of such Intervening Event, a failure to make a Parent
Change in Recommendation would be inconsistent with the fiduciary duties of
the Parent Board under applicable law.

  

  

 

 

 

  

 

66  

  

 

 

 

  

(d) (i) Nothing contained in this Section 5.3 will prohibit Parent from taking
and disclosing to its stockholders a position required by Rule 14e-2(a) or
Rule 14d-9 promulgated under the Exchange Act and (ii) no disclosure that the
Parent Board may determine (after consultation with outside counsel) that it
or Parent, as applicable, is required to make under applicable law will
constitute a violation of this Agreement; provided, however, that in any event
the Parent Board shall not make a Parent Change in Recommendation except in
accordance with this Section 5.3. Any public disclosure or statement by a
Tiger Corporation (or any of their respective Representatives) relating to an
Acquisition Proposal or Acquisition Inquiry or Intervening Event with respect
to a Tiger Corporation (other than a 'stop, look and listen' communication)
shall be deemed to be a Parent Change in Recommendation unless the Parent
Board reaffirms the Parent Board Recommendation in such disclosure or
statement.

  

  

(e) Following a Parent Change in Recommendation made or effected pursuant to
Section 5.3(c)(i), Parent may enter into a definitive agreement providing for
the consummation of the transaction contemplated by the Parent Superior Offer
to which such Parent Change in Recommendation relates provided that (i) the
effectiveness of such agreement is conditioned on the termination of this
Agreement, (ii) none of Parent nor any of the other Tiger Corporations has any
obligation or liability of any kind pursuant to such agreement prior to the
termination of this Agreement and the payment of the Parent Termination Fee,
and (iii) such agreement automatically terminates without any further action
by any party thereto and without any payment, penalty or other obligation or
liability of any kind if and when the Required Parent Stockholder Vote is
obtained (an "Alternative Agreement").

  

  

5.4 Company Options and Company Restricted Shares.

  

  

(a) At the Effective Time, Parent shall assume the Company Option Plan and all
awards granted thereunder that are assumed by Parent pursuant to this Section
5.4 (together with all agreements that govern the treatment of such assumed
awards (each, an "Award Agreement")). From and after the Effective Time,
Parent shall be entitled to grant stock awards under the Company Option Plan,
to the extent permissible under applicable Legal Requirements, using the share
reserve of such Company Option Plan as of the Effective Time, except that: (i)
stock covered by such awards shall be shares of Parent Common Stock; (ii) all
references in such Company Option Plan to a number of shares of Company Common
Stock shall be deemed amended to refer instead to a number of shares of Parent
Common Stock determined by multiplying the number of referenced shares of
Company Common Stock by the Exchange Ratio, and rounding the resulting number
down to the nearest whole number of shares of Parent Common Stock; and (iii)
the Parent Board or a committee thereof shall succeed to the authority and
responsibility of the Company Board or any committee thereof with respect to
the administration of such Company Option Plan and Award Agreement.

  

  

(b) At the Effective Time, each outstanding and unexercised Company Option,
whether vested or unvested immediately prior to the Effective Time, shall,
without any further action on the part of any holder of a Company Option, be
assumed by Parent. Each such Company Option so assumed by Parent hereunder
(each, an "Adjusted Option") shall, subject to the requirements of the TSX,
continue to have, and be subject to, substantially the same terms and
conditions as were applicable to the corresponding Company Option under the
Company Option Plan and applicable Award Agreements immediately before the
Effective Time, except that, (i) each Adjusted Option will be exercisable for
that number of shares of Parent Common Stock (rounded down to the nearest
whole share) equal to the product of (x) the number of shares of Company
Common Stock to which the corresponding Company Option related immediately
prior to the Effective Time and (y) the Exchange Ratio, and (ii) the per share
exercise price for the shares of Parent Common Stock issuable upon exercise of
such Assumed Option will be equal to the quotient of (x) the per share
exercise price of the Company Option and (y) the Exchange Ratio, rounded up to
the nearest whole cent. The date of grant of each Adjusted Option will be the
date on which the corresponding Company Option was granted. Notwithstanding
the foregoing, the adjustment described in this Section 5.4(b) shall be made
in a manner consistent with Section 409A of the Code and, with respect to each
Company Option that is an incentive stock option (within the meaning of
Section 422(b) of the Code), no adjustment will be made that would be a
modification (within the meaning of Section 424(h) of the Code) to such
Company Option.

  

  

 

 

 

  

 

67  

  

 

 

 

  

(c) At the Effective Time, each Company Restricted Share outstanding
immediately before the Effective Time, shall, without any further action on
the part of any holder of a Company Restricted Share, be assumed by Parent and
shall be converted into a comparable award in respect of Parent Common Stock
(each, an "Adjusted Restricted Share Award"). Each Adjusted Restricted Share
Award shall continue to have and be subject to the same terms and conditions
as were applicable to the corresponding Company Restricted Share under the
Company Option Plan and applicable Award Agreements immediately before the
Effective Time, except that (A) the number of shares of Parent Common Stock
subject to such Adjusted Restricted Share Award shall be equal to the product
of (i) the number of shares of Company Common Stock that were issuable upon
the lapse of restrictions or conditions on vesting applicable to such Company
Restricted Share immediately prior to the Effective Time, and (ii) the
Exchange Ratio, rounded down to the nearest whole share of Parent Common Stock
subject to an Adjusted Restricted Share Award and (B) the per share purchase
price for the shares of Parent Common Stock purchased pursuant to such Company
Restricted Share will be equal to the quotient of (i) the per share purchase
price, if applicable, of the Company Restricted Share, and (ii) the Exchange
Ratio, rounded up to the nearest whole cent.

  

  

(d) As soon as practicable (but in no event later than five (5) days) after
the Effective Date, Parent shall file a registration statement on Form S-8,
with respect to the shares of Parent Common Stock subject to the Company
Options or Company Restricted Shares assumed by Parent in accordance with
Section 5.4 and Parent shall exercise reasonable best efforts to maintain the
effectiveness of such registration statement until such time as the shares of
Parent Common Stock underlying each such Company Option or Company Restricted
Share assumed by Parent have been issued or such Company Option or Company
Restricted Share has been terminated, expired, cancelled or forfeited.

  

  

(e) Prior to the Effective Time:

  

  

(i) Parent shall take all corporate action necessary, including any action to
be taken under Section 5.3(a)(i)(y) to approve the adoption of the Company
Options and Company Option Plan, to reserve for issuance a sufficient number
of Parent Stock as is equal to the aggregate number of Parent Stock issuable
after the Effective Time (i) upon exercise of the Adjusted Options, and (ii)
in respect of each share of Adjusted Restricted Share Award; and

  

  

(ii) the Company shall use its commercially reasonable efforts to take all
action that may be necessary (under the Company Option Plan, Award Agreements
and otherwise) to effectuate the provisions of this Section 5.4 and to ensure
that, from and after the Effective Time, holders of Company Equity Awards have
no rights with respect thereto other than those specifically provided in this
Section 5.4.

  

  

5.5 Employee Benefits.

  

  

(a) Parent agrees that, subject to any necessary transition period and subject
to any applicable plan provisions, contractual requirements or Legal
Requirements all employees of the Owl Corporations who continue employment
with Parent, the Surviving Corporation or any Subsidiary of the Surviving
Corporation after the Effective Time ("Continuing Employees") shall be
eligible to participate in Parent's health, vacation and 401(k) plans, to
substantially the same extent as similarly situated employees of Parent.

  

  

 

 

 

  

 

68  

  

 

 

 

  

(b) Nothing in this Section 5.5 or elsewhere in this Agreement shall be
construed to create a right in any Company Associate to employment with
Parent, the Surviving Corporation or any other Subsidiary of Parent. Except
for Company Indemnified Persons to the extent of their respective rights
pursuant to Section 5.6, no Company Associate, and no Continuing Employee,
shall be deemed to be a third party beneficiary of this Agreement. Except for
Parent Indemnified Persons to the extent of their respective rights pursuant
to Section 5.6(b), no Parent Associate, shall be deemed to be a third party
beneficiary of this Agreement.

  

  

(c) With respect to each "employee benefit plan" as defined in Section 3(3) of
ERISA and each vacation and severance plan (that is not an "employee benefit
plan" as defined in Section 3(3) of ERISA) maintained by Parent or any
Subsidiary of Parent (collectively, the "Parent Benefit Plans") in which any
Continuing Employee will participate after the Effective Time, Parent shall,
or shall cause the Surviving Corporation to, recognize all service of the
Continuing Employees with the Owl Corporations for purposes of eligibility,
vesting and participation, but not for purposes of benefit accrual, in any
such Parent Benefit Plan to the extent such service was credited under the
applicable Company Benefit Plan. In addition, and subject to the concurrence
of any third-party insurers (which Parent shall use reasonable best efforts to
obtain), Parent shall or shall cause the Surviving Corporation to: (i) waive
all limitations as to preexisting conditions, exclusions and waiting periods
with respect to participation and coverage requirements applicable to the
Continuing Employees under any Parent Benefit Plan that is a welfare benefit
plan in which such Continuing Employees may be eligible to participate after
the Effective Time, other than preexisting condition limitations, exclusions
or waiting periods that are already in effect with respect to such Continuing
Employees and that have not been satisfied or waived as of the Effective Time
under any welfare benefit plan maintained for the Continuing Employees
immediately prior to the Effective Time; and (ii) provide each Continuing
Employee with credit for any co-payments and deductibles paid prior to the
Effective Time in satisfying any applicable deductible or out-of-pocket
requirements under any Parent Benefit Plan that is a welfare benefit plan in
which such Continuing Employees may be eligible to participate after the
Effective Time.

  

  

(d) Nothing contained herein shall be construed as requiring the Owl
Corporations or the Tiger Corporations to continue any specific Company
Employee Plan or Parent Employee Plan. The provisions of this Section 5.5 are
for the sole benefit of Parent and the Company and nothing in this Section
5.5, expressed or implied, is intended or shall be construed to constitute an
amendment of any Company Employee Plan or Parent Employee Plan (or an
undertaking to amend any such plan) or other compensation and benefits plan
maintained for or provided to Company Employees, including Continuing
Employees, prior to, on or following the Effective Time.

  

  

5.6 Indemnification of Officers and Directors.

  

  

(a) Company Indemnified Person.

  

  

(i) All rights to indemnification, advancement of expenses and exculpation
from liabilities by the Company or its Subsidiaries existing in favor of those
Persons who are current or former directors or officers of the Company or its
Subsidiaries at or prior to the Effective Time (the "Company Indemnified
Persons") for their acts and omissions as directors, officers, employees or
agents of the Company or its Subsidiaries occurring prior to the Effective
Time, as provided in the Company's certificate of incorporation or bylaws (as
in effect as of the date of this Agreement) and as provided in any
indemnification agreements between the Company and said Company Indemnified
Persons (as in effect as of the date of this Agreement), shall survive the
Merger and be observed and performed by the Surviving Corporation and any
applicable Subsidiaries to the fullest extent permitted by applicable law for
a period of six years from the date on which the Merger becomes effective.
Parent shall cause the certificate of incorporation and bylaws (or comparable
organizational documents) of the Surviving Corporation and its Subsidiaries to
contain provisions no less favorable with respect to indemnification,
advancement of expenses and exculpation of current and former directors and
officers of the Company and its Subsidiaries than are presently set forth in
the certificate of incorporation and bylaws of the Company and such
Subsidiaries, and such provisions shall not be amended, repealed or otherwise
modified in any manner that would adversely affect any right thereunder of any
Person benefited by such provisions without such Person's prior written
consent. Parent guarantees the full and timely performance of the obligations
of the Surviving Corporation and its Subsidiaries under this Section 5.6(a).

  

  

 

 

 

  

 

69  

  

 

 

 

  

(ii) At or prior to the Effective Time, the Company or the Surviving
Corporation shall purchase a directors' and officers' liability insurance
"tail policy" with a claims period of six years from the Effective Time, and
on terms and conditions no less favorable to the Company Indemnified Parties
than those in effect under the Company Existing DandO Policy in effect on the
date of this Agreement, for the benefit of the Company Indemnified Persons
with respect to their acts and omissions as directors, officers, employees and
agents of the Company or its Subsidiaries occurring prior to the Effective
Time. If such "tail policy" is not obtained then from the Effective Time until
the sixth anniversary of the date on which the Merger becomes effective, the
Surviving Corporation shall maintain in effect, for the benefit of the Company
Indemnified Persons with respect to their acts and omissions as directors,
officers, employees or agents of the Company or any of its Subsidiaries
occurring at or prior to the Effective Time, the existing policy of directors'
and officers' and fiduciary liability insurance maintained by the Company as
of the date of this Agreement in the form delivered or Made Available by the
Company to Parent prior to the date of this Agreement (the "Company Existing
DandO Policy"), to the extent that directors' and officers' liability insurance
coverage is commercially available; provided, however, that: (i) the Surviving
Corporation may substitute for the Company Existing DandO Policy a policy or
policies of comparable coverage; and (ii) the Surviving Corporation shall not
be required to pay annual premiums for the Company Existing DandO Policy (or for
any substitute policies) in excess of 250% of the annual premium paid by the
Company for the Company Existing DandO Policy (the "Company Maximum Premium").
In the event any future annual premiums for the Company Existing DandO Policy
(or any substitute policies) exceed the Company Maximum Premium, the Surviving
Corporation shall be entitled to reduce the amount of coverage of the Company
Existing DandO Policy (or any substitute policies) to the amount of coverage
that can be obtained for a premium equal to the Company Maximum Premium.

  

  

(b) Parent Indemnified Person.

  

  

(i) All rights to indemnification, advancement of expenses and exculpation
from liabilities by the Parent or its Subsidiaries existing in favor of those
Persons who are current or former directors or officers of the Parent or its
Subsidiaries at or prior to the Effective Time (the "Parent Indemnified
Persons") for their acts and omissions as directors, officers, employees or
agents of the Parent or its Subsidiaries occurring prior to the Effective
Time, as provided in the Parent's certificate of incorporation or bylaws (as
in effect as of the date of this Agreement) and as provided in any
indemnification agreements between the Parent and said Parent Indemnified
Persons (as in effect as of the date of this Agreement), shall survive the
Merger and be observed by the Parent and such Subsidiaries to the fullest
extent permitted by applicable law for a period of six years from the date on
which the Merger becomes effective.

  

  

 

 

 

  

 

70  

  

 

 

 

  

(ii) From the Effective Time until the sixth anniversary of the date on which
the Merger becomes effective, the Parent shall maintain in effect, for the
benefit of the Parent Indemnified Persons with respect to their acts and
omissions as directors, officers, employees or agents of the Parent or any of
its Subsidiaries occurring at or prior to the Effective Time, the existing
policy of directors' and officers' liability insurance maintained by the
Parent as of the date of this Agreement in the form delivered or Made
Available by the Parent to Company prior to the date of this Agreement (the
"Parent Existing DandO Policy"), to the extent that directors' and officers'
liability insurance coverage is commercially available; provided, however,
that: (i) the Parent may substitute for the Parent Existing DandO Policy a
policy or policies of comparable coverage; and (ii) the Parent shall not be
required to pay annual premiums for the Parent Existing DandO Policy (or for any
substitute policies) in excess of 250% of the annual premium paid by the
Parent for Parent's Existing DandO Policy (the "Parent Maximum Premium"). In the
event any future annual premiums for the Parent Existing DandO Policy (or any
substitute policies) exceed the Parent Maximum Premium, the Parent shall be
entitled to reduce the amount of coverage of the Parent Existing DandO Policy
(or any substitute policies) to the amount of coverage that can be obtained
for a premium equal to the Parent Maximum Premium.

  

  

(c) Parent shall pay (as incurred) all expenses, including reasonable fees and
expenses of counsel, which any Company Indemnified Person or Parent
Indemnified Person may incur in enforcing the indemnification and other
obligations provided for in this Section 5.6.

  

  

(d) This Section 5.6 is intended to be (i) for the benefit of, and shall be
enforceable by, the Company Indemnified Persons and the Parent Indemnified
Persons, their heirs and personal representatives and shall be binding on the
Parent, the Surviving Corporation and their successors and assigns, (ii) in
addition to, and not in substitution for, any other rights to indemnification
or contribution that any Company Indemnified Person or Parent Indemnified
Person may have by contract or otherwise, including indemnification agreements
that the Company or Parent have entered into with any of their respective
directors or officers and (iii) may not be amended, altered or repealed after
the Effective Time without the prior written consent of the affected Company
Indemnified Person or Parent Indemnified Person (provided that such amendment,
alteration or repeal prior to the Effective Time shall be governed by Section
9.1). In the event that the Parent or the Surviving Corporation or any of
their successors or assigns: (i) consolidates with or merges into any other
Person and shall not be the continuing or surviving corporation or entity in
such consolidation or merger; or (ii) transfers all or substantially all of
its properties and assets to any Person, then, and in each case, Parent (or
its successor, as applicable), shall make proper provision so that the
successors and assigns of the Surviving Corporation or the Parent (as the case
may be) honor the indemnification and other obligations set forth in this
Section 5.6. This Section 5.6 shall survive consummation of the Merger.

  

  

5.7 Regulatory Approvals and Related Matters.

  

  

(a) Each party shall use reasonable best efforts to file, as soon as
practicable after the date of this Agreement (and in all events within 15
Business Days after the date of this Agreement), all notices, reports and
other documents required to be filed by such party with any Governmental Body
with respect to the Merger and the other Contemplated Transactions, and to
submit promptly any additional information requested by any such Governmental
Body. Without limiting the generality of the foregoing, the Company and Parent
shall, promptly (and in any event within 10 Business Days) after the date of
this Agreement, prepare and file the notifications required under the HSR Act
in connection with the Merger. The Company and Parent each shall promptly (i)
supply the other party with any information which may be required in order to
effectuate notices, reports, documents or other filings with any Governmental
Body required to be made pursuant to the HSR Act (the "Antitrust Filings");
and (ii) use reasonable best efforts to supply any additional information
which is required by any Governmental Body in connection with Antitrust
Filings or which the parties may reasonably deem appropriate. Each of the
Company and Parent will notify the other party promptly upon the receipt of
(A) any comments from any Governmental Bodies in connection with any Antitrust
Filings made pursuant hereto; and (B) any request by any Governmental Bodies
for amendments or supplements to any Antitrust Filings made pursuant to, or
information provided to comply in all material respects with, the requirements
of the HSR Act. Whenever any event occurs that is required to be set forth in
an amendment or supplement to any Antitrust Filings, the Company or Parent, as
the case may be, will promptly inform the other party of such occurrence and
cooperate in filing with the applicable Governmental Body such amendment or
supplement. Each of the Company and Parent shall give the other party prompt
notice of the commencement or known threat of commencement of any Legal
Proceeding by or before any Governmental Body with respect to the Merger or
any of the other Contemplated Transactions, keep the other party reasonably
informed as to the status of any such Legal Proceeding or threat, and in
connection with any such Legal Proceeding, each of the Company or Parent will
permit authorized representatives of the other party to be present at each
meeting or conference relating to any such Legal Proceeding, to the extent
permitted by the applicable Governmental Body, and to have access to and be
consulted in connection with any document, opinion or proposal made or
submitted to any Governmental Body in connection with any such Proceeding.

  

  

 

 

 

  

 

71  

  

 

 

 

  

(b) Subject to Section 5.7(c), Parent, Merger Sub and the Company shall use
reasonable best efforts to take, or cause to be taken, all actions necessary
or advisable to satisfy each of the conditions set forth in Section 6 and
Section 7, consummate the Merger and make effective the other Contemplated
Transactions (provided that no party shall be required to waive any of the
conditions set forth in Section 6 or Section 7, as applicable, to its
obligations to consummate the Merger and the other Contemplated Transactions).
Without limiting the generality of the foregoing, but subject to Section
5.7(c), each party to this Agreement: (i) shall make all filings (if any) and
give all notices (if any) required to be made and given by such party in
connection with the Merger and the other Contemplated Transactions; (ii) shall
use reasonable best efforts to obtain each Consent (if any) required to be
obtained (pursuant to any applicable Legal Requirement or Contract, or
otherwise) by such party in connection with the Merger or any of the other
Contemplated Transactions; and (iii) shall use reasonable best efforts to lift
any restraint, injunction or other legal bar to the Merger.

  

  

(c) Notwithstanding anything to the contrary contained in this Section 5.7,
neither Parent, Merger Sub nor the Company shall have any obligation under
this Agreement to divest or agree to divest (or cause any of its Subsidiaries
to divest or agree to divest) any of its respective material businesses,
material product lines or material assets, or to take or agree to take (or
cause any of its Subsidiaries to take or agree to take) any other material
action or agree (or cause any of its Subsidiaries to agree) to any material
limitation or material restriction on any of its respective material
businesses, material product lines or material assets; provided, however, each
of Parent, Merger Sub and the Company shall consider in good faith any
divestiture that would not be reasonably likely to (i) give rise to a Parent
Material Adverse Effect or Company Material Adverse Effect, (ii) materially
impair the benefits or advantages it expects to receive from the Merger and
the transactions contemplated hereby or (iii) give rise to a material adverse
effect on the business plan or business strategy of the combined company.

  

  

5.8 Disclosure. Parent and the Company shall consult with each other before
issuing any press release or otherwise making any public statement regarding
this Agreement or the Contemplated Transactions. The Company shall consult
with Parent and consider the views and comments of Parent before any of the
Owl Corporations or any of their Representatives sends any emails or other
documents to the Company Associates generally or otherwise communicate with
the Company Associates generally, with respect to the Merger or any of the
other Contemplated Transactions. The Parent shall consult with the Company and
consider the views and comments of the Company before any of the Tiger
Corporations or any of their Representatives sends any emails or other
documents to the Parent Associates generally or otherwise communicate with the
Parent Associates generally, with respect to the Merger or any of the other
Contemplated Transactions. Notwithstanding the foregoing: (i) each party may,
without such consultation or consent, make any public statement in response to
questions from the press, analysts, investors or those attending industry
conferences and make internal announcements to employees, so long as such
statements are consistent with previous press releases, public disclosures or
public statements made jointly by the parties (or individually, if approved by
the other party), (ii) a party may, without the prior consent of the other
party hereto, issue any such press release or make any such public
announcement or statement as may be required by Legal Requirement or the rules
and regulations of the NASDAQ and the TSX if it first notifies and consults
with the other party hereto prior to issuing any such press release or making
any such public announcement or statement; and (iii) Parent need not consult
with the Company in connection with any press release, public statement or
filing to be issued or made with respect to any Acquisition Proposal relating
to Parent or any Parent Subsidiaries or any Parent Change in Recommendation.

  

  

 

 

 

  

 

72  

  

 

 

 

  

5.9 Tax Matters.

  

  

(a) Unless otherwise required pursuant to a "determination" within the meaning
of Section 1313(a) of the Code, each of Parent, Merger Sub and Company (i)
shall report the Merger on their Tax Returns as a "reorganization" within the
meaning of Section 368(a) of the Code, (ii) shall, to the extent required,
report the Merger on their Tax Returns as not being subject to Section
367(a)(1) of the Code as a result of the operation of Section 1.367(a)-3(c) of
the Code, (iii) shall not take any inconsistent position with the foregoing on
any Tax Return or in any proceeding before any Tax authority or other
tribunal, and (iv) shall not take any action, cause or permit any action to be
taken or fail to take any action, that would cause the Merger to fail to
qualify as a "reorganization" described in Section 368(a) of the Code or that
would cause the Merger to be subject to Section 367(a)(1) of the Code.

  

  

(b) For so long as the Person listed on Schedule 5.9(b) owns stock of Parent,
Parent shall use its reasonable efforts to avoid, in respect of any taxable
year, being a passive foreign investment company within the meaning of Section
1297 of the Code (a "PFIC"), including, but not limited to, causing a
Subsidiary to file an election pursuant to Treasury Regulation Section
301.7701-3. No later than 75 days after the end of each fiscal year, Parent
shall deliver to the Shareholder an analysis as to whether the Parent believes
that it will be treated as a PFIC in respect of such taxable year. Such
analysis may be prepared by Parent, but in preparing such analysis Parent
shall consult with its internationally recognized tax advisors.

  

  

(c) Parent shall provide, and shall cause each of its Subsidiaries to provide
to the Person listed on Schedule 5.9(b), all information that may be necessary
to allow such Person (or its direct or indirect owners) to evaluate the
analysis referenced in Section 5.9(b) and to fulfill their U.S. tax filing and
reporting obligations. Parent shall provide, and shall cause each of its
Subsidiaries to provide, such information to the Person listed on Schedule
5.9(b) as direct and indirect owners of such Person may reasonably require to
timely file and maintain a "qualified electing fund" ("QEF") election (as
defined in Section 1295(a) of the Code) with respect to any such entity.

  

  

(d) Parent shall cause the Company to comply with the reporting requirements
of United States Treasury Regulations Section 1.367(a)-3(c)(6) applicable to
the transactions contemplated hereunder, and any other reporting requirements
applicable to a tax-free reorganization pursuant to the Code or the Treasury
Regulations promulgated thereunder.

  

  

(e) Notwithstanding anything to the contrary in this Section 5.9 (or in
Sections 4.2(b)(xviii) or Section 4.3(b)(xviii)), none of Parent, its
Subsidiaries, or the Company will be required to comply with the undertakings
set forth in Section 5.9(a) or (d) unless: (i) the shareholders of the Company
immediately prior to the completion of the Merger have provided the Company or
Parent, as applicable, with the information relating to such shareholders that
is necessary for the Company or Parent, as applicable, (A) to establish the
requirements set forth in Treasury Regulation Section 1.367(a)-3(c)(1)(i) and
(B) to comply with Treasury Regulation Section 1.367(a)-3(c)(6), and (ii) with
respect to the application of Sections 5.9(a) and (d) to a shareholder of the
Company immediately prior to the completion of the Merger, if that shareholder
is a "five-percent transferee shareholder" as defined in Treasury Regulation
Section 1.367(a)-3(c)(5)(ii), such shareholder has entered into the five-year
agreement referenced in Treasury Regulation Section 1.367(a)-3(c)(1)(iii)(B).

  

  

 

 

 

  

 

73  

  

 

 

 

  

5.10 Listing. Parent shall use commercially reasonable best efforts obtain TSX
approval of the Contemplated Transactions and to cause the shares of Parent
Common Stock to be issued in the Merger, including the Parent Common Stock to
be issued upon (a) the exercise of assumed and converted Company Options and
(b) the vesting of assumed and converted Company Restricted Shares, to be
approved for listing (subject to notice of issuance) on the NASDAQ and the
TSX, at or prior to the Effective Time.

  

  

5.11 Resignation of Officers and Directors. The Company shall use commercially
reasonable efforts to obtain and deliver to Parent at or prior to the
Effective Time the resignation of each officer and director of each of the Owl
Corporations other than those continuing in office in accordance with Section
5.12 as officers and directors of the surviving entity in the Merger. Parent
shall use commercially reasonable efforts to obtain and deliver to the Company
at or prior to the Effective Time the resignation of each officer and director
of each of the Tiger Corporations other than those continuing in office in
accordance with Section 5.12.

  

  

5.12 Board of Directors of the Combined Company; Management of the Combined
Company.

  

  

(a) The parties shall take all actions necessary to ensure that effective
immediately following the Effective Time, the Parent Board shall consist of
seven seats, to be filled as set forth on Schedule 5.12, and the directors of
which shall remain in office or be appointed as indicated on Schedule 5.12 to
hold office from and after the Effective Time until his or her respective
successor is duly elected.

  

  

(b) The parties shall take all actions necessary to ensure that effective
immediately following the Effective Time, the officers of Parent shall consist
of the persons set forth on Schedule 5.12, each to hold office from and after
the Effective Time until the earliest of appointment of his or her respective
successor, resignation or removal.

  

  

5.13 Section 16 Matters. Subject to the following sentence, prior to the
Effective Time, Parent and the Company shall take all such steps as may be
required (to the extent permitted under applicable Legal Requirements and no-
action letters issued by the SEC) to cause any dispositions of Company Common
Stock (including derivative securities with respect to Company Common Stock)
resulting from the Contemplated Transactions by each individual who is subject
to the reporting requirements of Section 16(a) of the Exchange Act with
respect to the Company, and the acquisition of Parent Common Stock (including
derivative securities with respect to Parent Common Stock) by each individual
who is or will be subject to the reporting requirements of Section 16(a) of
the Exchange Act with respect to Parent, to be exempt under Rule 16b-3 under
the Exchange Act. At least 10 days prior to the Closing Date, the Company
shall furnish the following information to Parent for each Person who,
immediately after the Effective Time, will become subject to the reporting
requirements of Section 16(a) of the Exchange Act with respect to Parent (to
the extent then known): (a) the number of shares of Company Common Stock held
by such Person and expected to be exchanged for shares of Parent Common Stock
pursuant to the Merger; (b) the number of Company Options and Company
Restricted Shares held by such Person and expected to be assumed by Parent and
converted or exercisable into shares of Parent Common Stock in connection with
the Merger; (c) the number of other derivative securities (if any) with
respect to Company Common Stock held by such Person and expected to be
converted into shares of Parent Common Stock or derivative securities with
respect to Parent Common Stock in connection with the Merger; and (d) the
EDGAR codes for each such Person.

  

  

 

 

 

  

 

74  

  

 

 

 

  

5.14 Name of the Combined Corporation and Headquarters. The name of Parent
will not be changed at the Effective Time or as a result of the combination
and the headquarters of Parent shall remain the headquarters of the combined
company at the Effective Time, in each case, except as may otherwise be agreed
by the parties hereto.

  

  

5.15 Obligations of Merger Sub. Parent shall take all action necessary to
cause Merger Sub and, after the Effective Time, the Surviving Corporation to
perform their respective obligations under this Agreement and to consummate
the Contemplated Transactions upon the terms and subject to the conditions set
forth in this Agreement.

  

  

5.16 Securityholder Litigation.

  

  

(a) The Company shall give Parent the right to participate in the defense or
settlement of any securityholder litigation against the Company and/or the
Company Board relating to the Contemplated Transactions. In no event shall the
Company enter into or agree to any settlement with respect to such
securityholder litigation without the Parent's prior written consent (which
consent shall not be unreasonably withheld, conditioned or delayed).

  

  

(b) Parent shall give the Company the right to participate in the defense or
settlement of any securityholder litigation against Parent and/or the Parent
Board relating to the Contemplated Transactions. In no event shall Parent
enter into or agree to any settlement with respect to such securityholder
litigation without the Company's prior written consent (which consent shall
not be unreasonably withheld, conditioned or delayed).

  

  

(c) For purposes of this Section 5.16, "participate" means that the non-
litigating party will be kept apprised of proposed strategy and other
significant decisions with respect to any securityholder litigation by the
litigating party (to the extent the attorney-client privilege between the
litigating party and its counsel is not undermined or otherwise affected), and
the non-litigating party may offer comments or suggestions with respect to the
litigation but will not be afforded any decision making power or authority
over the litigation, except for the right to consent to any settlement as set
forth in this Section 5.16.

  

  

5.17 Company Covenant Regarding Registration Statement. The Company shall not
file any registration statement, or any amendment to a registration statement,
in respect of any of its securities, under the Securities Act.

  

  

5.18 Representation Letters. The Company shall obtain from each Person to whom
Parent Common Stock will be issued pursuant to the Merger a representation
letter in the form of Exhibit G, duly executed and dated the Closing Date.

  

  

5.19 Termination of Agreement. The Company shall cause the Information Sharing
and Cooperation Agreement, dated December 22, 2014, between the Company and
Roivant Sciences Ltd. to be terminated by the parties thereto; provided,
however, that such termination shall not impose any termination or other fee
or payment or other similar obligation on the Company, or result in the grant
of any options or rights to acquire assets or securities of the Company.

  

  

 

 

 

  

 

75  

  

 

 

 

  

5.20 Section 228 Notice Requirements. The Company shall comply with the notice
requirements of Section 228 of the DGCL.

  

  

Section 6. Conditions Precedent to Obligations of Parent and Merger Sub

  

  

The obligations of Parent and Merger Sub to effect the Merger and otherwise
consummate the Contemplated Transactions are subject to the satisfaction, at
or prior to the Closing, of each of the following conditions:

  

  

6.1 Accuracy of Representations.

  

  

(a) Each of the Company Designated Representations shall have been accurate in
all material respects as of the date of this Agreement and shall be accurate
in all material respects as of the Closing Date as if made on and as of the
Closing Date (except for any such representations and warranties made as of a
specific date, which shall have been accurate in all material respects as of
such date); provided, however, that, for purposes of determining the accuracy
of such representations and warranties as of the foregoing dates: (i) all
materiality qualifications limiting the scope of such representations and
warranties shall be disregarded; and (ii) any update of or modification to the
Company Disclosure Schedule made or purported to have been made on or after
the date of this Agreement shall be disregarded.

  

  

(b) Each of the representations and warranties of the Company (other than the
Company Designated Representations) shall have been accurate in all respects
as of the date of this Agreement and shall be accurate in all respects as of
the Closing Date as if made on and as of the Closing Date (except for any such
representations and warranties made as of a specific date, which shall have
been accurate in all respects as of such date); provided, however, that: (i)
for purposes of determining the accuracy of such representations and
warranties as of the foregoing dates: (A) all materiality qualifications
limiting the scope of such representations and warranties shall be
disregarded; and (B) any update of or modification to the Company Disclosure
Schedule made or purported to have been made on or after the date of this
Agreement shall be disregarded; and (ii) any inaccuracies in such
representations and warranties will be disregarded if all such inaccuracies
(considered collectively) do not constitute, and would not reasonably be
expected to have or result in, a Company Material Adverse Effect.

  

  

6.2 Performance of Covenants. The covenants and obligations in this Agreement
that the Company is required to comply with or to perform at or prior to the
Closing shall have been complied with and performed in all material respects.

  

  

6.3 Stockholder Approval.

  

  

(a) This Agreement shall have been duly adopted by the Required Company
Stockholder Vote.

  

  

(b) The issuance of shares of Parent Common Stock in the Merger, the
Governance Amendments to Parent Articles, and, if necessary, the adoption of
the Company Options and Company Option Plan shall each have been duly approved
by the applicable Required Parent Stockholder Vote.

  

  

6.4 Certificate. Parent and Merger Sub shall have received a certificate,
which shall be in full force and effect, executed by the Chief Executive
Officer of the Company confirming that the conditions set forth in 6.1, 6.2,
6.3(a), and 6.5 have been duly satisfied and specifying the number of Fully
Diluted Company Shares (and components thereof).

  

  

 

 

 

  

 

76  

  

 

 

 

  

6.5 No Company Material Adverse Effect. Since the date of this Agreement, no
Company Material Adverse Effect shall have occurred which has not been cured,
and no event shall have occurred or circumstance shall exist that, in
combination with any other events or circumstances, would reasonably be
expected to have or result in a Company Material Adverse Effect.

  

  

6.6 Governmental Approvals.

  

  

(a) Any waiting period applicable to the consummation of the Merger under the
HSR Act and Investment Canada Act, if required, shall have expired or been
terminated.

  

  

(b) Any Governmental Authorization or other Consent required to be obtained
with respect to the Merger under the HSR Act and Investment Canada Act or
other Legal Requirement shall have been obtained and shall remain in full
force and effect (other than any such Governmental Authorization or Consent
under other Legal Requirements, the failure to obtain which would not
reasonably be expected to have a Company Material Adverse Effect or a Parent
Material Adverse Effect).

  

  

6.7 Listing. The shares of Parent Common Stock to be issued in the Merger,
including the Parent Common Stock to be issued upon (a) the exercise of
assumed and converted Company Options and (b) the vesting of assumed and
converted Company Restricted Shares, shall have been approved for listing
(subject to notice of issuance) on the NASDAQ and the TSX. The TSX shall have
approved of the Contemplated Transactions.

  

  

6.8 No Restraints. No temporary restraining order, preliminary or permanent
injunction or other Order preventing the consummation of the Merger shall have
been issued by any court of competent jurisdiction or other Governmental Body
and remain in effect, and there shall not be any Legal Requirement enacted or
deemed applicable to the Merger that makes consummation of the Merger,
including the issuance of Parent Common Stock pursuant to the Merger, illegal.

  

  

6.9 No Governmental Litigation. There shall not be pending any Legal
Proceeding in which a Governmental Body with jurisdiction over the parties is
a party: (a) challenging or seeking to restrain, prohibit, rescind or unwind
the consummation of the Merger or any of the other Contemplated Transactions;
(b) seeking to prohibit or limit in any material respect Parent's ability to
vote, transfer, receive dividends with respect to or otherwise exercise
ownership rights with respect to the stock of the Surviving Corporation; (c)
relating to the Merger or the other Contemplated Transactions and that would
reasonably be expected to materially and adversely affect the right or ability
of Parent to own any of the material assets or materially limit the operation
of the business of any of the Owl Corporations; (d) seeking to compel any of
the Owl Corporations, Parent or any Subsidiary of Parent to dispose of or hold
separate any material assets or material business as a result of the Merger or
any of the other Contemplated Transactions; or (e) relating to the Merger or
the other Contemplated Transactions and seeking to impose (or that would
reasonably be expected to result in the imposition of) any criminal sanctions
or criminal liability on Parent or any of the Owl Corporations.

  

  

6.10 FIRPTA Matters. The Company shall have delivered to Parent a statement
described in Section 1.1445-2(c)(3)(i) of the United States Treasury
Regulations certifying the interests in the Company are not U.S. real property
interests.

  

  

6.11 Issuance of Parent Common Stock. The issuance of the Parent Common Stock
issuable pursuant to the Merger shall be exempt from the registration or
qualification requirements of the Securities Act, applicable state securities
laws, and Canadian Securities Laws.

  

  

 

 

 

  

 

77  

  

 

 

 

  

6.12 Representation Letters. The Company shall have delivered to Parent the
Representation Letters.

  

  

6.13 Termination of Agreement. The Information Sharing and Cooperation
Agreement, dated December 22, 2014, between the Company and Roivant Sciences
Ltd. shall have been terminated by the parties thereto.

  

  

Section 7. Conditions Precedent to Obligation of the Company

  

  

The obligation of the Company to effect the Merger and otherwise consummate
the Contemplated Transactions is subject to the satisfaction, at or prior to
the Closing, of each of the following conditions:

  

  

7.1 Accuracy of Representations.

  

  

(a) Each of the Parent Designated Representations shall have been accurate in
all material respects as of the date of this Agreement and shall be accurate
in all material respects as of the Closing Date as if made on and as of the
Closing Date (except for any such representations and warranties made as of a
specific date, which shall have been accurate in all material respects as of
such date); provided, however, that, for purposes of determining the accuracy
of such representations and warranties as of the foregoing dates: (i) all
materiality qualifications limiting the scope of such representations and
warranties shall be disregarded; and (ii) any update of or modification to the
Parent Disclosure Schedule made or purported to have been made on or after the
date of this Agreement shall be disregarded.

  

  

(b) Each of the representations and warranties of Parent and Merger Sub (other
than the Parent Designated Representations) shall have been accurate in all
respects as of the date of this Agreement and shall be accurate in all
respects as of the Closing Date as if made on and as of the Closing Date
(except for any such representations and warranties made as of a specific
date, which shall have been accurate in all respects as of such date);
provided, however, that: (i) for purposes of determining the accuracy of such
representations and warranties as of the foregoing dates: (A) all materiality
qualifications limiting the scope of such representations and warranties shall
be disregarded; and (B) any update of or modification to the Parent Disclosure
Schedule made or purported to have been made on or after the date of this
Agreement shall be disregarded; and (ii) any inaccuracies in such
representations and warranties will be disregarded if all such inaccuracies
(considered collectively) do not constitute, and would not reasonably be
expected to have or result in, a Parent Material Adverse Effect.

  

  

7.2 Performance of Covenants. The covenants and obligations in this Agreement
that Parent and Merger Sub are required to comply with or to perform at or
prior to the Closing shall have been complied with and performed in all
material respects.

  

  

7.3 Stockholder Approval.

  

  

(a) This Agreement shall have been duly adopted by the Required Company
Stockholder Vote.

  

  

(b) The issuance of shares of Parent Common Stock in the Merger, the
Governance Amendments to Parent Articles, and, if necessary, the adoption of
the Company Options and Company Option Plan shall each have been duly approved
by the applicable Required Parent Stockholder Vote and this Agreement shall
have been duly adopted by Parent as the sole stockholder of Merger Sub.

  

  

 

 

 

  

 

78  

  

 

 

 

  

7.4 Certificate. The Company shall have received a certificate, which shall be
in full force and effect, executed by the Chief Executive Officer of Parent
confirming that the conditions set forth in Sections 7.1, 7.2, 7.3(b) and 7.5
have been duly satisfied and specifying the number of Aggregate Merger Shares
(and components thereof).

  

  

7.5 No Parent Material Adverse Effect. Since the date of this Agreement, no
Parent Material Adverse Effect shall have occurred which has not been cured,
and no event shall have occurred or circumstance shall exist that, in
combination with any other events or circumstances, would reasonably be
expected to have or result in a Parent Material Adverse Effect.

  

  

7.6 Governmental Approvals.

  

  

(a) Any waiting period applicable to the consummation of the Merger under the
HSR Act and Investment Canada Act, if required, shall have expired or been
terminated.

  

  

(b) Any Governmental Authorization or other Consent required to be obtained
with respect to the Merger under the HSR Act and Investment Canada Act or
other Legal Requirement shall have been obtained and shall remain in full
force and effect (other than any such Governmental Authorization or Consent
under other Legal Requirements, the failure to obtain which would not
reasonably be expected to have a Company Material Adverse Effect or a Parent
Material Adverse Effect).

  

  

7.7 Listing. The shares of Parent Common Stock to be issued in the Merger,
including the Parent Common Stock to be issued upon (a) the exercise of
assumed and converted Company Options and (b) the vesting of assumed and
converted Company Restricted Shares, shall have been approved for listing
(subject to notice of issuance) on the NASDAQ and the TSX and shall not be
subject to any resale or escrow restrictions imposed by the TSX. The TSX shall
have approved of the Contemplated Transactions, including the assumption of
the Company Options, Company Option Plan and Company Restricted Shares, and
any amendments thereto required by the TSX shall not economically disadvantage
the holders of the Company Options or Company Restricted Shares.

  

  

7.8 No Restraints. No temporary restraining order, preliminary or permanent
injunction or other Order preventing the consummation of the Merger shall have
been issued by any court of competent jurisdiction or other Governmental Body
and remain in effect, and there shall not be any Legal Requirement enacted or
deemed applicable to the Merger that makes consummation of the Merger illegal.

  

  

7.9 No Governmental Litigation. There shall not be pending any Legal
Proceeding in which a Governmental Body with jurisdiction over the parties is
a party: (a) challenging or seeking to restrain, prohibit, rescind or unwind
the consummation of the Merger or any of the other Contemplated Transactions;
(b) seeking to prohibit or limit in any material respect Parent's ability to
vote, transfer, receive dividends with respect to or otherwise exercise
ownership rights with respect to the stock of the Surviving Corporation; (c)
that would reasonably be expected to materially and adversely affect the right
or ability of Parent or any of the Owl Corporations to own any of the material
assets or materially limit the operation of the business of any of the Owl
Corporations; (d) seeking to compel any of the Owl Corporations, Parent or any
Subsidiary of Parent to dispose of or hold separate any material assets or
material business as a result of the Merger or any of the other Contemplated
Transactions; or (e) relating to the Merger or the other Contemplated
Transactions and seeking to impose (or that would reasonably be expected to
result in the imposition of) any criminal sanctions or criminal liability on
Parent or any of the Owl Corporation.

  

  

 

 

 

  

 

79  

  

 

 

 

  

7.10 Issuance of Parent Common Stock. The issuance of the Parent Common Stock
issuable pursuant to the Merger shall be exempt from the registration or
qualification requirements of the Securities Act, applicable state securities
laws, and the requirement to file a prospectus under Canadian Securities Laws.

  

  

7.11 Registration Rights Agreement. The Registration Rights Agreement shall be
in full force and effect.

  

  

7.12 Directors and Officers. Effective as of the Effective Time, the directors
and officers of Parent shall be as provided in Schedule 5.12.

  

  

7.13 Legal Opinion. The Company shall have received a legal opinion, in a form
satisfactory to the Company, acting reasonably, executed by Farris, Vaughan,
Wills and Murphy LLP, as to the matters set forth in Exhibit I hereto (subject
to customary assumptions and qualifications).

  

  

Section 8. Termination

  

  

8.1 Termination. This Agreement may be terminated prior to the Effective Time
(whether before or after adoption of this Agreement by the Company's
stockholders and whether before or after approval of the issuance of shares of
Parent Common Stock in the Merger by Parent's stockholders):

  

  

(a) by mutual written consent of Parent and the Company;

  

  

(b) by either Parent or the Company if the Merger shall not have been
consummated by the date that is four months after the date of this Agreement
(the "End Date"); provided, however, that a party shall not be permitted to
terminate this Agreement pursuant to this Section 8.1(b) if the failure to
consummate the Merger by the End Date is attributable to a failure on the part
of such party to perform any covenant or obligation in this Agreement required
to be performed by such party at or prior to the Effective Time;

  

  

(c) by either Parent or the Company if a court of competent jurisdiction or
other Governmental Body shall have issued a final and nonappealable Order, or
shall have taken any other action, having the effect of permanently
restraining, enjoining or otherwise prohibiting the Merger;

  

  

(d) by the Company or Parent if: (a) the Parent Stockholders' Meeting
(including any adjournments and postponements thereof) shall have been held
and completed and Parent's stockholders shall have taken a final vote on the
issuance of shares of Parent Common Stock in the Merger; and (b) the issuance
of shares of Parent Common Stock in the Merger shall not have been approved at
the Parent Stockholders' Meeting (and shall not have been approved at any
adjournment or postponement thereof) by the applicable Required Parent
Stockholder Vote; provided, however, that a party shall not be permitted to
terminate this Agreement pursuant to this Section 8.1(d) if the failure to
have the issuance of Parent Common Stock in the Merger approved by the
applicable Required Parent Stockholder Vote is attributable to a failure on
the part of such party to perform any covenant or obligation in this Agreement
required to be performed by such party at or prior to the Effective Time;

  

  

(e) by the Company (at any time prior to the approval of the issuance of
shares of Parent Common Stock in the Merger by the Required Parent Stockholder
Vote) if a Parent Triggering Event shall have occurred;

  

  

 

 

 

  

 

80  

  

 

 

 

  

(f) by Parent if: (i) any of the Company's representations and warranties
contained in this Agreement shall be inaccurate as of the date of this
Agreement such that the condition set forth in Section 6.1(a) or the condition
set forth in Section 6.1(b) would not then be satisfied, or shall have become
inaccurate as of a date subsequent to the date of this Agreement (as if made
on such subsequent date) such that the condition set forth in Section 6.1(a)
or the condition set forth in Section 6.1(b) would not then be satisfied; or
(ii) any of the Company's covenants or obligations contained in this Agreement
shall have been breached such that the condition set forth in Section 6.2
would not be satisfied; provided, however, that, for purposes of clauses "(i)"
and "(ii)" above, if an inaccuracy in any of the Company's representations and
warranties (as of the date of this Agreement or as of a date subsequent to the
date of this Agreement) or a breach of a covenant or obligation by the Company
is curable by the Company by the End Date and the Company is continuing to
exercise its reasonable best efforts to cure such inaccuracy or breach, then
Parent may not terminate this Agreement under this Section 8.1(f) on account
of such inaccuracy or breach unless such inaccuracy or breach shall remain
uncured for a period of 30 days commencing on the date that Parent gives the
Company notice of such inaccuracy or breach;

  

  

(g) by the Company if: (i) any of Parent's representations and warranties
contained in this Agreement shall be inaccurate as of the date of this
Agreement such that the condition set forth in Section 7.1(a) or the condition
set forth in Section 7.1(b) would not then be satisfied, or shall have become
inaccurate as of a date subsequent to the date of this Agreement (as if made
on such subsequent date) such that the condition set forth in Section 7.1(a)
or the condition set forth in Section 7.1(b) would not then be satisfied; or
(ii) any of Parent's covenants or obligations contained in this Agreement
shall have been breached such that the condition set forth in Section 7.2
would not be satisfied; provided, however, that, for purposes of clauses "(i)"
and "(ii)" above, if an inaccuracy in any of Parent's representations and
warranties (as of the date of this Agreement or as of a date subsequent to the
date of this Agreement) or a breach of a covenant or obligation by Parent is
curable by Parent by the End Date and Parent is continuing to exercise its
reasonable best efforts to cure such inaccuracy or breach, then the Company
may not terminate this Agreement under this Section 8.1(g) on account of such
inaccuracy or breach unless such inaccuracy or breach shall remain uncured for
a period of 30 days commencing on the date that the Company gives Parent
notice of such inaccuracy or breach; or

  

  

(h) by the Company if an HBV Material Adverse Event has occurred.

  

  

8.2 Effect of Termination. In the event of the termination of this Agreement
as provided in Section 8.1, this Agreement shall be of no further force or
effect; provided, however, that: (i) this Section 8.2, Section 8.3 and Section
9 shall survive the termination of this Agreement and shall remain in full
force and effect; (ii) the Confidentiality Agreement shall survive the
termination of this Agreement and shall remain in full force and effect in
accordance with its terms; and (iii) the termination of this Agreement shall
not relieve any party from any liability for: (A) any willful inaccuracy in or
breach of any representation or warranty contained in this Agreement to the
extent such inaccuracy or breach: (1) in the case of the Company had (or would
reasonably be expected to have) a Company Material Adverse Effect; and (2) in
the case of Parent or Merger Sub, had (or would reasonably be expected to
have) a Parent Material Adverse Effect; or (B) any breach of any material
covenant or obligation contained in this Agreement.

  

  

8.3 Expenses; Termination Fees.

  

  

(a) Except as set forth in this Section 8.3, all fees and expenses incurred in
connection with this Agreement and the Contemplated Transactions shall be paid
by the party incurring such expenses, whether or not the Merger is
consummated; provided, however, that Parent and the Company shall share
equally all out-of-pocket fees and expenses, other than accountants' and
attorneys' fees, incurred in connection with: (i) the filing, printing and
mailing of the Proxy Statement and Circular and any amendments or supplements
thereto; and (ii) the filing by the parties hereto of any notice or other
document under the HSR Act.

  

  

 

 

 

  

 

81  

  

 

 

 

  

(b) If this Agreement is terminated: (i) by the Company pursuant to Section
8.1(d) or 8.1(e), (ii) by Parent pursuant to Section 8.1(b) or 8.1(d)
following a Parent Change in Recommendation, or (iii) by either Company or
Parent pursuant to Section 8.1(b) if the Parent Stockholders' Meeting has not
been held prior to the End Date and the failure to hold the Parent
Stockholder\'s Meeting is not attributable to a failure on the part of the
Company to perform any covenant or obligation of this Agreement by the time
the Company is required to perform such covenant or obligation, then Parent
shall pay to the Company, in cash at the time specified in the following
sentence, a nonrefundable fee in the amount of $12,000,000 (the "Parent
Termination Fee"); provided, however, that, if there has been (a) no
Acquisition Proposal made or proposed for any of the Tiger Corporations prior
to the time of the Parent Stockholders' Meeting that has become publicly known
and (b) no Parent Change in Recommendation, then in the case of a termination
by the Company pursuant to Section 8.1(d), the Parent Termination Fee shall be
$5,000,000. The Parent Termination Fee shall be paid as follows: in the case
of termination by Parent pursuant to the preceding sentence, simultaneously
with Parent's termination of the Agreement and in the case of termination by
the Company pursuant to the preceding sentence, within two Business Days after
termination of this Agreement.

  

  

(c) In the event that the Company shall receive the Parent Termination Fee,
such fees shall not be penalties but shall be liquidated damages in a
reasonable amount for any and all losses or damages suffered or incurred by
the parties in connection with the matter forming the basis for such
termination. Notwithstanding any other provision of this Agreement to the
contrary, and provided the Company has not (i) notified Parent that it is not
accepting the Parent Termination Fee, which notification shall occur, if at
all, within 5 Business Days following the applicable termination of this
Agreement, and (ii) refunded the Parent Termination Fee in full to Parent
within 5 Business Days following payment thereof, if the Parent Termination
Fee has been previously paid hereunder, the parties agree that the payments
contemplated by this Section 8.3 represent the sole and exclusive remedy of
the parties and that, except for the payments expressly set forth in this
Section 8.3, each of the parties and their respective affiliates shall have no
liability, shall not be entitled to bring or maintain any other claim, action
or proceeding against the other, shall be precluded from any other remedy
against the other, at law or in equity or otherwise, and shall not seek to
obtain any recovery, judgment or damages of any kind against the other (or any
partner, member, stockholder, director, officer, employee, Subsidiary,
affiliate, agent or other representative of such party or parties) in
connection with or arising out of the termination of this Agreement, any
breach of or by any party giving rise to such termination or the failure of
the Merger and the other transactions contemplated by this Agreement to be
consummated.

  

  

(d) If a party fails to pay when due any amount payable by such party under
this Section 8.3, then: (i) such party shall reimburse the other party for all
costs and expenses (including reasonable fees and disbursements of counsel)
incurred in connection with the collection of such overdue amount and the
enforcement by the other party of its rights under this Section 8.3; and (ii)
such party shall pay to the other party interest on such overdue amount (for
the period commencing as of the date such overdue amount was originally
required to be paid through the date such overdue amount is actually paid to
the other party in full) at a rate per annum equal to the lower of: (i) 350
basis points over the "prime rate" (as announced by Bank of America, N.A. or
any successor thereto) in effect on the date such overdue amount was
originally required to be paid; or (ii) the maximum rate permitted by
applicable Legal Requirements.

  

  

 

 

 

  

 

82  

  

 

 

 

  

Section 9. Miscellaneous Provisions

  

  

9.1 Amendment. This Agreement may be amended with the approval of the
respective Company Board and Parent Board at any time (whether before or after
the adoption of this Agreement by the Company's stockholders and whether
before or after approval of the issuance of Parent Common Stock in the Merger
by Parent's stockholders); provided, however, that: (a) after any such
adoption of this Agreement by the Company's stockholders, no amendment shall
be made which by applicable Legal Requirements requires further approval of
the stockholders of the Company without the further approval of such
stockholders; and (b) after any such approval of the issuance of shares of
Parent Common Stock in the Merger by Parent's stockholders, no amendment shall
be made which by law or regulation of the NASDAQ or the TSX requires further
approval of Parent's stockholders without the further approval of such
stockholders. This Agreement may not be amended except by an instrument in
writing signed on behalf of each of the parties hereto.

  

  

9.2 Waiver.

  

  

(a) No failure on the part of any party to exercise any power, right,
privilege or remedy under this Agreement, and no delay on the part of any
party in exercising any power, right, privilege or remedy under this
Agreement, shall operate as a waiver of such power, right, privilege or
remedy; and no single or partial exercise of any such power, right, privilege
or remedy shall preclude any other or further exercise thereof or of any other
power, right, privilege or remedy.

  

  

(b) No party shall be deemed to have waived any claim arising out of this
Agreement, or any power, right, privilege or remedy under this Agreement,
unless the waiver of such claim, power, right, privilege or remedy is
expressly set forth in a written instrument duly executed and delivered on
behalf of such party; and any such waiver shall not be applicable or have any
effect except in the specific instance in which it is given.

  

  

9.3 No Survival of Representations and Warranties. None of the representations
and warranties contained in this Agreement or in any certificate delivered
pursuant to this Agreement shall survive the Merger.

  

  

9.4 Entire Agreement; Counterparts; Exchanges by Facsimile. This Agreement and
the other agreements referred to herein constitute the entire agreement and
supersede all prior agreements and understandings, both written and oral,
among or between any of the parties with respect to the subject matter hereof
and thereof; provided, however, that the Confidentiality Agreement shall not
be superseded and shall remain in full force and effect in accordance with its
terms (it being understood that no provision in the Confidentiality Agreement
shall limit any party's rights or remedies in the case of fraud). This
Agreement may be executed in several counterparts, each of which shall be
deemed an original and all of which shall constitute one and the same
instrument. The exchange of a fully executed Agreement (in counterparts or
otherwise) by facsimile or electronic transmission shall be sufficient to bind
the parties to the terms and conditions of this Agreement.

  

  

9.5 Applicable Law; Jurisdiction; Specific Performance; Remedies. This
Agreement shall be governed by, and construed in accordance with, the laws of
the State of Delaware, regardless of the laws that might otherwise govern
under applicable principles of conflicts of laws thereof. In any action
between any of the parties arising out of or relating to this Agreement or any
of the Contemplated Transactions: (a) each of the parties irrevocably and
unconditionally consents and submits to the exclusive jurisdiction and venue
of the Court of Chancery of the State of Delaware; and (b) each of the parties
irrevocably waives the right to trial by jury. Each of the parties hereto
further agrees that, to the fullest extent permitted by applicable law,
service of any process, summons, notice or document by U.S. registered mail to
such Person's respective address set forth in Section 9.9 will be effective
service of process for any claim, action, suit or other proceeding in the
Court of Chancery of the State of Delaware with respect to any matters to
which it has submitted to jurisdiction as set forth in this paragraph. The
parties hereto hereby agree that a final judgment in any such claim, suit,
action or other proceeding will be conclusive, subject to any appeal, and may
be enforced in other jurisdictions by suit on the judgment or in any other
manner provided by applicable law. The parties agree that irreparable damage
would occur and that the parties would not have any adequate remedy at law in
the event that any of the provisions of this Agreement were not performed in
accordance with their specific terms or were otherwise breached. It is
accordingly agreed that the parties shall be entitled to seek an injunction or
injunctions to prevent breaches of this Agreement and to enforce specifically
the terms and provisions of this Agreement without the requirement for the
posting of any bond, this being in addition to any other remedy to which they
are entitled at law or in equity. All rights and remedies existing under this
Agreement are cumulative to, and not exclusive of, any rights or remedies
otherwise available.

  

  

 

 

 

  

 

83  

  

 

 

 

  

9.6 Disclosure Schedules. The Company Disclosure Schedule shall be arranged in
separate parts corresponding to the numbered and lettered sections contained
in Section 2. The Parent Disclosure Schedule shall be arranged in separate
parts corresponding to the numbered and lettered sections contained in Section
3\. For purposes of this Agreement: (a) each statement or other item of
information set forth in the Company Disclosure Schedule is intended only to
qualify and limit the representations, warranties, covenants and agreements of
the Company contained in this Agreement and shall not be deemed to expand in
any way the scope or effect of any such representations, warranties, covenants
and agreements; and (b) each statement or other item of information set forth
in the Parent Disclosure Schedule is intended only to qualify and limit the
representations, warranties, covenants and agreements of Parent and Merger Sub
contained in this Agreement and shall not be deemed to expand in any way the
scope or effect of any such representations, warranties, covenants and
agreements. The Company Disclosure Schedule and Parent Disclosure Schedule
shall each be delivered as of the date of this Agreement, and no amendments or
modifications thereto shall be made. Any purported update or modification to
the Company Disclosure Schedule or Parent Disclosure Schedule after the date
of this Agreement shall be disregarded.

  

  

9.7 Attorneys' Fees. In any action at law or suit in equity to enforce this
Agreement or the rights of any of the parties hereunder, the prevailing party
in such action or suit shall be entitled to receive a reasonable sum for its
attorneys' fees and all other reasonable costs and expenses incurred in such
action or suit.

  

  

9.8 Assignability; No Third Party Rights. This Agreement shall be binding
upon, and shall be enforceable by and inure solely to the benefit of, the
parties hereto and their respective successors and assigns; provided, however,
that neither this Agreement nor any party's rights or obligations hereunder
may be assigned or delegated by such party without the prior written consent
of the other parties, and any attempted assignment or delegation of this
Agreement or any of such rights or obligations by any party without the prior
written consent of the other parties shall be void and of no effect. Except as
specifically provided in Section 5.6 and, following the Effective Time, except
for the right of holders of Company Common Stock to receive shares of Parent
Common Stock and any cash in lieu of fractional shares of Parent Common Stock
in accordance with Section 1, nothing in this Agreement, express or implied,
is intended to or shall confer upon any Person (other than the parties hereto)
any right, benefit or remedy of any nature whatsoever under or by reason of
this Agreement.

  

  

9.9 Notices. All notices, requests, demands and other communications under
this Agreement shall be in writing and shall be deemed to have been duly given
or made as follows: (a) if sent by registered or certified mail in the United
States return receipt requested, upon receipt; (b) if sent by nationally
recognized overnight air courier (such as Federal Express), two Business Days
after mailing; (c) if sent by facsimile transmission or e-mail before 5:00
p.m. Eastern Time, when transmitted and receipt is confirmed; (d) if sent by
facsimile transmission or e-mail after 5:00 p.m. Eastern Time and receipt is
confirmed, on the following Business Day; and (e) if otherwise actually
personally delivered, when delivered, provided that such notices, requests,
demands and other communications are delivered to the physical address, e-mail
address or facsimile number set forth below, or to such other address as any
party shall provide by like notice to the other parties to this Agreement:

  

  

 

 

 

  

 

84  

  

 

 

 

  

 

if to Parent or Merger Sub:

  

 

  

    

  |  

Tekmira Pharmaceuticals Corporation

   
---|--- 
 

  

    

  |  

100 -8900 Glenlyon Parkway

   
---|--- 
 

  

    

  |  

Glenlyon Business Park

   
---|--- 
 

  

    

  |  

Burnaby, B.C., V5J 5J8

   
---|--- 
 

  

    

  |  

Tel: (604) 419-3200

   
---|--- 
 

  

    

  |  

Attention: Bruce Cousins, Executive Vice President and

   
---|--- 
 

  

     |  

  |  

Chief Financial Officer

   
---|---|--- 
 

  

    

  |  

E-Mail: BCousins@tekmirapharm.com

   
---|--- 
 

  

  

 

with copies (which shall not constitute notice) to:

 

  

  

    

  |  

Farris, Vaughan, Wills and Murphy LLP

   
---|--- 
 

  

    

  |  

700 West Georgia St., 25th Floor

   
---|--- 
 

  

    

  |  

Vancouver, British Columbia V7Y 1B3

   
---|--- 
 

  

    

  |  

Tel: (604) 661-9307

   
---|--- 
 

  

    

  |  

Attention: R. Hector MacKay-Dunn, Q.C.

   
---|--- 
 

  

    

  |  

E-mail: hmackay-dunn@farris.com

   
---|--- 
 

  

  

    

  |  

Dorsey and Whitney LLP

   
---|--- 
 

  

    

  |  

Suite 1605, 777 Dunsmuir Street

   
---|--- 
 

  

    

  |  

Vancouver, British Columbia V7Y 1K4

   
---|--- 
 

  

    

  |  

Tel: (604) 630-5199

   
---|--- 
 

  

    

  |  

Attention: Daniel M. Miller

   
---|--- 
 

  

    

  |  

E-mail: miller.dan@dorsey.com

   
---|--- 
 

  

  

 

if to the Company:

 

  

  

    

  |  

OnCore Biopharma, Inc.

   
---|--- 
 

  

    

  |  

3805 Old Easton Road

   
---|--- 
 

  

    

  |  

Doylestown, Pennsylvania 18902

   
---|--- 
 

  

    

  |  

Attention: Bryce Roberts

   
---|--- 
 

  

 

    

  |  

 

E-Mail: Bryce.roberts@oncorebiopharma.com

 

   
---|--- 
 

  

 

  

 

with a copy (which shall not constitute notice) to:

 

  

  

    

  |  

Cooley LLP

   
---|--- 
 

  

    

  |  

3175 Hanover Street

   
---|--- 
 

  

    

  |  

Palo Alto, California 94304

   
---|--- 
 

  

    

  |  

Tel: (650) 843-5753

   
---|--- 
 

  

    

  |  

Attention: Frank Rahmani

   
---|--- 
 

  

    

  |  

E-mail: rahmaniff@cooley.com

   
---|--- 
 

  

  

 

 

 

  

 

85  

  

 

 

 

  

9.10 Cooperation. The Company and Parent agree to cooperate fully with Parent
and the Company, respectively, and to execute and deliver such further
documents, certificates, agreements and instruments and to take such other
actions as may be reasonably requested by Parent or the Company to evidence or
reflect the Contemplated Transactions and to carry out the intent and purposes
of this Agreement.

  

  

9.11 Severability. Any term or provision of this Agreement that is invalid or
unenforceable in any situation in any jurisdiction shall not affect the
validity or enforceability of the remaining terms and provisions of this
Agreement or the validity or enforceability of the offending term or provision
in any other situation or in any other jurisdiction. If a final judgment of a
court of competent jurisdiction declares that any term or provision of this
Agreement is invalid or unenforceable, the parties hereto agree that the court
making such determination shall have the power to limit such term or
provision, to delete specific words or phrases or to replace such term or
provision with a term or provision that is valid and enforceable and that
comes closest to expressing the intention of the invalid or unenforceable term
or provision, and this Agreement shall be valid and enforceable as so
modified. In the event such court does not exercise the power granted to it in
the prior sentence, the parties hereto agree to replace such invalid or
unenforceable term or provision with a valid and enforceable term or provision
that will achieve, to the extent possible, the economic, business and other
purposes of such invalid or unenforceable term or provision.

  

  

9.12 Construction.

  

  

(a) For purposes of this Agreement, whenever the context requires: the
singular number shall include the plural, and vice versa; the masculine gender
shall include the feminine and neuter genders; the feminine gender shall
include the masculine and neuter genders; and the neuter gender shall include
masculine and feminine genders.

  

  

(b) The parties hereto agree that any rule of construction to the effect that
ambiguities are to be resolved against the drafting party shall not be applied
in the construction or interpretation of this Agreement.

  

  

(c) As used in this Agreement, the words "include" and "including," and
variations thereof, shall not be deemed to be terms of limitation, but rather
shall be deemed to be followed by the words "without limitation."

  

  

(d) Except as otherwise indicated, all references in this Agreement to
"Sections," "Exhibits" and "Schedules" are intended to refer to Sections of
this Agreement and Exhibits or Schedules to this Agreement.

  

  

(e) The bold-faced headings contained in this Agreement are for convenience of
reference only, shall not be deemed to be a part of this Agreement and shall
not be referred to in connection with the construction or interpretation of
this Agreement.

  

  

(f) Any payment to be made pursuant hereto shall be made in U.S. dollars and
by wire transfer of immediately available funds.

  

  

[Remainder of page intentionally left blank]

  

  

 

 

 

  

 

86  

  

 

 

 

  

In Witness Whereof, the parties have caused this Agreement to be executed as
of the date first above written.

  

  

     |  

Tekmira Pharmaceuticals Corporation

   
---|--- 
   |  |   
   |  |   
   |  

By:

  |   
   | Name:  |  

Mark J. Murray

   
   | Title:  |  

President and Chief Executive Officer

   
   |  |   
   |  |   
   |  

By:

  |   
   | Name:  |  

Bruce Cousins

   
   | Title:  |  

Executive Vice President and Chief Financial Officer

   
   |  |   
   |  |   
   |  |   
   |  

TKM Acquisition Corporation

   
   |  |   
   |  |   
   |  

By:

  |   
   | Name:  | Mark J. Murray  
   | Title:  | President   
   |  |   
   |  |   
   |  

By:

  |   
   | Name:  | Bruce Cousins  
   | Title:  | Secretary and Treasurer   
   |  |   
   |  

OnCore Biopharma, Inc.

   
   |  |   
   |  |   
   |  

By:

  |   
   | Name:  | Patrick T Higgins  
   | Title:  | Chief Executive Officer  
 

  

  

 

 

 

  

 

87  

  

 

 

 

  

EXHIBIT A

  

CERTAIN DEFINITIONS

  

  

For purposes of the Agreement (including this Exhibit A):

  

  

Acquisition Inquiry. "Acquisition Inquiry" shall mean an inquiry, indication
of interest or request for information (other than an inquiry, indication of
interest or request for information made or submitted by Parent or the
Company) that could reasonably be expected to lead to an Acquisition Proposal.

  

  

Acquisition Proposal. "Acquisition Proposal" shall mean any offer or proposal
(other than an offer or proposal made or submitted by Parent or the Company)
contemplating or otherwise relating to any Acquisition Transaction.

  

  

Acquisition Transaction. "Acquisition Transaction" with respect to an Entity
shall mean any transaction or series of transactions (other than the
Contemplated Transactions) involving, directly or indirectly:

  

  

(a) any merger, exchange, consolidation, business combination, issuance of
securities, acquisition of securities, reorganization, recapitalization,
takeover offer, tender offer, exchange offer or other similar transaction: (i)
in which such Entity or any of its Subsidiaries is a constituent corporation
and which would result in a third party, or the stockholders of that third
party, beneficially owning 15% or more of any class of equity or voting
securities of such Entity or any of its Subsidiaries, or the Entity resulting
from such transaction or the parent of such Entity; (ii) in which a Person or
"group" (as defined in the Exchange Act and the rules promulgated thereunder)
of Persons directly or indirectly acquires beneficial or record ownership of
securities representing more than 15% of the outstanding securities of any
class of voting securities of such Entity or any of its Subsidiaries; or (iii)
in which such Entity or any of its Subsidiaries issues securities representing
more than 15% of the outstanding securities of any class of voting securities
of such Entity or any of its Subsidiaries;

  

  

(b) any sale, lease, exchange, transfer, exclusive license, acquisition or
disposition of any business or businesses or assets of such Entity or its
Subsidiaries that constitute or account for 15% or more of the consolidated
net revenues, or consolidated net income for the 12 full months immediately
prior to the receipt of the related Acquisition Proposal or 15% or more of the
fair market value of the consolidated assets of such Entity or any of its
Subsidiaries; or

  

  

(c) any liquidation or dissolution of such Entity or any of its Subsidiaries.

  

  

Affiliate. An "affiliate" of any Person means any other Person, that, directly
or indirectly through one or more intermediaries, controls or is controlled
by, or is under common control with, such Person, and, for the purposes of
this definition only, "control" (including the terms "controlling",
"controlled by" and "under common control with") means the possession, direct
or indirect, of the power to direct or cause the direction of the management,
policies or activities of a Person whether through the ownership of
securities, by contract or agency or otherwise.

  

  

Aggregate Merger Shares. "Aggregate Merger Shares" shall mean a number of
shares of Parent Common Stock equal to the sum, without duplication, of the
aggregate number of shares of Parent Common Stock and shares of Parent
Preferred Stock that are issued and outstanding immediately prior to the
Effective Time, or issuable upon the exercise of Parent Options, Parent
Warrants, or other direct or indirect rights to acquire shares of Parent
Common Stock or Parent Preferred Stock that are issued and outstanding
immediately prior to the Effective Time, in each case (a) on an as converted
to common basis, (b) calculated on the treasury stock method and (c) whether
or not then vested, exercisable or subject to repurchase.

  

  

 

 

 

  

 

88  

  

 

 

 

  

Agreement. "Agreement" shall mean the Agreement and Plan of Merger and
Reorganization to which this Exhibit A is attached, as it may be amended from
time to time.

  

  

BCBCA. "BCBCA" means the Business Corporations Act (British Columbia), as
amended, and the regulations thereunder.

  

  

Business Day. "Business day" means any day other than (i) a Saturday or a
Sunday or (ii) a day on which commercial banking institutions are authorized
or required by applicable Legal Requirements to be closed in California or New
York.

  

  

Canadian Securities Laws. "Canadian Securities Laws" means the Securities Act
(BC) and all other applicable Canadian provincial securities laws and Legal
Requirements and, in each case, the rules, regulations and published policies
made thereunder.

  

  

Canadian Tiger Corporation. "Canadian Tiger Corporation" means at a particular
time, any Tiger Corporation that is, or is deemed to be, resident in Canada at
that time for purposes of the Income Tax Act (Canada).

  

  

CFDA. "CFDA" shall mean the Canada Food and Drugs Act, as amended.

  

  

Circular. "Circular" means the notice of meeting and accompanying information
circular (including all schedules, appendices and exhibits thereto) to be sent
to Parent Stockholders in connection with the Parent Stockholders' Meeting,
including any amendments or supplements thereto.

  

  

COBRA. "COBRA" shall mean the Consolidated Omnibus Budget Reconciliation Act
of 1985, as amended.

  

  

Code. "Code" shall mean the United States Internal Revenue Code of 1986, as
amended.

  

  

Company Affiliate. "Company Affiliate" shall mean any Person under common
control with any of the Owl Corporations within the meaning of Section 414(b),
Section 414(c), Section 414(m) or Section 414(o) of the Code, and the
regulations issued thereunder.

  

  

Company Associate. "Company Associate" shall mean any current or former
officer or other employee, or any individual who is a current or former
independent contractor, consultant or director, of or to any of the Owl
Corporations or of or to any Company Affiliate.

  

  

Company Board. "Company Board" shall mean the Company's board of directors.

  

  

Company Capital Stock. "Company Capital Stock" shall mean the Company Common
Stock and Company Preferred Stock and any other capital stock issued by the
Company.

  

  

Company Common Stock. "Company Common Stock" shall mean the Common Stock,
$.001 par value per share, of the Company.

  

  

 

 

 

  

 

89  

  

 

 

 

  

Company Contract. "Company Contract" shall mean any Contract: (a) to which any
of the Owl Corporations is a party; (b) by which any of the Owl Corporations
or any Company IP owned by any of the Owl Corporations or any other asset of
any of the Owl Corporations is or may become bound or under which any of the
Owl Corporations has, or may become subject to, any obligation; or (c) under
which any of the Owl Corporations has or may acquire any right or interest.

  

  

Company Designated Representations. "Company Designated Representations" shall
mean the representations and warranties set forth in Sections 2.3(a), 2.3(c),
2.3(e), 2.20, 2.21, 2.22 and 2.24.

  

  

Company Disclosure Schedule. "Company Disclosure Schedule" shall mean the
Company Disclosure Schedule that has been prepared by the Company in
accordance with the requirements of Section 9.6 of the Agreement and that has
been delivered by the Company to Parent on the date of the Agreement.

  

  

Company Employee. "Company Employee" shall mean any director or any officer or
other employee of any of the Owl Corporations.

  

  

Company Employee Agreement. "Company Employee Agreement" shall mean each
management, employment, severance, retention, transaction bonus, change in
control, consulting, relocation, repatriation or expatriation agreement or
other Contract between: (a) any of the Owl Corporations; and (b) any Company
Associate, other than any such Contract that is terminable "at will" (or
following a notice period imposed by applicable law) without any obligation on
the part of any Owl Corporation to make any severance, termination, change in
control or similar payment or to provide any benefit.

  

  

Company Employee Plan. "Company Employee Plan" shall mean each plan, program,
policy, practice or Contract providing for compensation, severance,
termination pay, deferred compensation, performance awards, stock or stock-
related awards, fringe benefits, change in control payments, sick pay, paid
time off, vacation pay, retirement benefits or other benefits or remuneration
of any kind, whether or not in writing and whether or not funded, including
each "employee benefit plan," within the meaning of Section 3(3) of ERISA
(whether or not ERISA is applicable to such plan): (a) that is or has been
maintained or contributed to, or required to be maintained or contributed to,
by any of the Owl Corporations for the benefit of any Company Associate; or
(b) with respect to which any of the Owl Corporations has or may incur or
become subject to any liability or obligation; provided, however, that a
Company Employee Agreement shall not be considered a Company Employee Plan.

  

  

Company Equity Award. "Company Equity Award" shall mean any form of
compensation (including deferred compensation) that is or may be paid or
settled in Company Common Stock.

  

  

Company Foreign Plan. "Company Foreign Plan" shall mean: (a) any plan,
program, policy, practice, Contract or other arrangement mandated by a
Governmental Body outside of the United States to which any of the Owl
Corporations is required to contribute or under which any of the Owl
Corporations has or may have any liability; (b) any Company Employee Plan that
is subject to any of the Legal Requirements of any jurisdiction outside of the
United States; or (c) any Company Employee Plan that covers or has covered any
Company Employee whose services are or have been performed primarily outside
of the United States.

  

  

Company IP. "Company IP" shall mean: (a) all Intellectual Property relating to
the Company Products in which any of the Owl Corporations has an ownership
interest; and (b) all other Intellectual Property with respect to which any of
the Owl Corporations has (or purports to have) an ownership interest or an
exclusive license or similar exclusive right.

  

  

 

 

 

  

 

90  

  

 

 

 

  

Company Material Adverse Effect. "Company Material Adverse Effect" shall mean
any effect, change, event, circumstance or occurrence (collectively, "Effect")
that, considered together with all other Effects, is or would reasonably be
expected to be materially adverse to, or has or would reasonably be expected
to have or result in a material adverse effect on the assets, liabilities
(whether matured or unmatured, absolute or contingent), condition (financial
or otherwise) or results of operations of the Owl Corporations taken as a
whole; provided, however, that, in no event shall any Effect resulting from
any of the following, alone or in combination, be deemed to constitute, or be
taken into account in determining whether there has occurred, a Company
Material Adverse Effect: (i) conditions generally affecting the
biopharmaceutical industry or the U.S., Canada or global economy as a whole,
to the extent that such conditions do not have a disproportionate impact on
the Owl Corporations taken as a whole; (ii) general conditions in the
financial or currency markets, and any changes therein; (iii) changes in GAAP
(or any interpretations of GAAP) or Legal Requirements (or any interpretations
thereof) applicable to the Company or any of its Subsidiaries; (iv) the
announcement of the transactions contemplated by the Agreement; (v) any
natural disaster, adverse weather conditions or other force majeure events or
any acts of terrorism, sabotage, military action or war (whether or not
declared) or any escalation or worsening thereof; and (vi) the failure to meet
internal projections, forecasts or budgets of revenues, earnings or other
financial metrics.

  

  

Company Option Plan. "Company Option Plan" shall mean the Company's 2014
Equity Incentive Plan.

  

  

Company Options. "Company Options" shall mean options to purchase shares of
Company Common Stock from the Company (whether granted by the Company pursuant
to the Company Option Plan, assumed by the Company or otherwise).

  

  

Company Pension Plan. "Company Pension Plan" shall mean each: (a) Company
Employee Plan that is an "employee pension benefit plan," within the meaning
of Section 3(2) of ERISA; or (b) other occupational pension plan, including
any final salary or money purchase plan.

  

  

Company Preferred Stock. "Company Preferred Stock" shall mean the Series R
Preferred Stock, $0.001 par value per share, of the Company.

  

  

Company Product. "Company Product" shall mean product candidates based on the
Company's drug development programs targeting hepatitis B virus, as currently
under development.

  

  

Company Restricted Shares. "Company Restricted Shares" shall mean each share
of restricted Company Common Stock issued by the Company, which is subject to
vesting conditions and/or rights to repurchase or reacquire by the Company,
whether granted, assumed, or issued by the Company pursuant to a Company
Option Plan or otherwise.

  

  

Company Unaudited Balance Sheet. "Company Unaudited Balance Sheet" shall mean
the unaudited balance sheet of the Company as of September 30, 2014.

  

  

Confidentiality Agreement. "Confidentiality Agreement" shall mean that certain
Confidentiality Agreement, as amended, dated as of November 14, 2014, between
the Company and Parent.

  

  

Consent. "Consent" shall mean any approval, consent, ratification, permission,
waiver or authorization (including any Governmental Authorization).

  

  

 

 

 

  

 

91  

  

 

 

 

  

Contemplated Transactions. "Contemplated Transactions" shall mean the Merger
and the other transactions contemplated by the Agreement, including the
matters contemplated in the Company Stockholder Voting Agreements, the Parent
Stockholder Voting Agreements, the Lock-up Agreements, the Registration Rights
Agreement, the Governance Agreement, the Standstill Agreement, the
Representation Letter, the Subscription Agreement and the Governance Amendment
to Parent Articles.

  

  

Contract. "Contract" shall mean any written, oral or other agreement,
contract, subcontract, lease, understanding, arrangement, instrument, note,
option, warranty, purchase order, license, sublicense, insurance policy,
benefit plan or legally binding commitment or undertaking of any nature.

  

  

DGCL. "DGCL" shall mean the Delaware General Corporation Law.

  

  

DOL. "DOL" shall mean the United States Department of Labor.

  

  

Encumbrance. "Encumbrance" shall mean any lien, pledge, hypothecation, charge,
mortgage, easement, encroachment, imperfection of title, title exception,
title defect, right of possession, lease, tenancy license, security interest,
encumbrance, claim, infringement, interference, option, right of first
refusal, preemptive right, community property interest or restriction of any
nature (including any restriction on the voting of any security, any
restriction on the transfer of any security or other asset, any restriction on
the receipt of any income derived from any asset, any restriction on the use
of any asset and any restriction on the possession, exercise or transfer of
any other attribute of ownership of any asset).

  

  

Environmental Law. "Environmental Law" means any federal, state, provincial,
local or foreign Legal Requirement relating to pollution worker safety,
exposure of any individual to Materials of Environmental Concern or protection
of human health or the environment (including ambient air, surface water,
ground water, land surface or subsurface strata), including any Legal
Requirement relating to emissions, discharges, releases or threatened releases
of Materials of Environmental Concern, or otherwise relating to the
manufacture, processing, distribution, use, treatment, storage, disposal,
transport or handling of Materials of Environmental Concern.

  

  

Entity. "Entity" shall mean any corporation (including any non-profit
corporation), general partnership, limited partnership, limited liability
partnership, joint venture, estate, trust, company (including any company
limited by shares, limited liability company or joint stock company), firm,
society or other enterprise, association, organization or entity.

  

  

ERISA. "ERISA" shall mean the Employee Retirement Income Security Act of 1974,
as amended.

  

  

Exchange Act. "Exchange Act" shall mean the Securities Exchange Act of 1934,
as amended.

  

  

Exchange Ratio. "Exchange Ratio" shall mean the number equal to the Aggregate
Merger Shares divided by the Fully Diluted Company Shares.

  

  

FDA. "FDA" shall mean the U.S. Food and Drug Administration or any successor
Governmental Body thereto.

  

  

FDA Act. "FDA Act" shall mean the U.S. Federal Food, Drug, and Cosmetic Act,
as amended.

  

  

Federal Health Care Program. "Federal Health Care Program" shall mean any plan
or program that provides health care benefits, whether directly, through
insurance, or otherwise, that is funded directly, in whole or in part, by the
federal government of Canada, by the government of the United States of
America (other than the Federal Employees Health Benefits Program), including
the Medicare, Medicaid and TRICARE programs (described in Title XVIII of the
Social Security Act, Title XIX of the Social Security Act, and Title 10,
Chapter 55 of the United States Code, respectively), or any state health care
program (as defined in Section 1128(h) of the Social Security Act).

  

  

 

 

 

  

 

92  

  

 

 

 

  

Fully Diluted Company Shares. "Fully Diluted Company Shares" shall mean the
sum, without duplication, of the aggregate number of shares of Company Capital
Stock that are issued and outstanding immediately prior to the Effective Time,
or issuable upon the exercise of Company Options or other direct or indirect
rights to acquire shares of Company Capital Stock that are issued and
outstanding immediately prior to the Effective Time, in each case (a) on an as
converted to common basis, (b) calculated on the treasury stock method and (c)
whether or not then vested, exercisable or subject to repurchase.

  

  

GAAP. "GAAP" shall mean generally accepted accounting principles in the United
States.

  

  

Governmental Authorization. "Governmental Authorization" shall mean any: (a)
permit, license, certificate, franchise, permission, variance, clearance,
registration, qualification or authorization issued, granted, given or
otherwise made available by or under the authority of any Governmental Body or
pursuant to any Legal Requirement; or (b) right under any Contract with any
Governmental Body.

  

  

Governmental Body. "Governmental Body" shall mean any: (a) nation, state,
commonwealth, province, territory, county, municipality, district or other
jurisdiction of any nature; (b) federal, state, provincial, local, municipal,
foreign or other government; (c) governmental or quasi-governmental authority
of any nature (including any governmental division, department, agency,
commission, instrumentality, official, ministry, fund, foundation, center,
organization, unit, body or Entity and any court or other tribunal); or (d)
self-regulatory organization (including the NASDAQ and the TSX).

  

  

Governance Amendment to Parent Articles. "Governance Amendment to Parent
Articles" shall mean the amendment to the articles of the Parent, in the form
attached hereto as Exhibit H, proposed to be adopted by Parent as at the
Effective Time to (i) remove the right of the chair to a second or casting
vote at a meeting of the Parent Board and (ii) to implement certain
transitional governance matters as set out in Exhibit E.

  

  

HBV Material Adverse Event. "HBV Material Adverse Event" shall mean (i) the
occurrence of any event or condition which would be expected to delay the
first human subject from receiving TKM-HBV in Canada until after June 30,
2015, or (ii) the TKM-HBV Clinical Trial Authorization is cancelled in its
entirety by Health Canada, or the TKM-HBV phase 1 clinical trial is otherwise
terminated.

  

  

Health Canada. "Health Canada" shall mean Health Canada or any successor
Governmental Body thereto.

  

  

Health Care Laws. "Health Care Laws" shall mean (a) the FDA Act and the
regulations promulgated thereunder, (b) the Public Health Service Act (42
U.S.C. 201 et seq.), and the regulations promulgated thereunder, (c) all
federal and state fraud and abuse laws, including the federal Anti-Kickback
Statute (42 U.S.C. 1320a-7b(b)), the civil False Claims Act (31 U.S.C. 3729
et seq.), the administrative false claims law (42 U.S.C. 1320a-7b(a)), the
anti-inducement law (42 U.S.C. 1320a-7a(a)(5)), the exclusion laws (42 U.S.C.
1320a-7), and the regulations promulgated pursuant to such statutes, (d) all
laws and regulations governing the confidentiality of patient information,
including the Health Insurance Portability and Accountability Act of 1996 (42
U.S.C. 1320d et seq.), as amended by the Health Information, Technology for
Economic and Clinical Health Act of 2009, the regulations promulgated
thereunder and comparable state laws, (e) the Controlled Substances Act (21
U.S.C. 801 et seq.), (f) the CFDA and the regulations promulgated thereunder,
(g) the PMPRB, and (h) all applicable laws, rules and regulations, ordinances,
judgments, decrees, orders, writs and injunctions administered by the FDA,
Health Canada and other Governmental Bodies that regulate the research,
design, development, evaluation, testing, studying, manufacturing, processing,
storing, importing or exporting, licensing, labeling or packaging, promotion,
sale, distributing or marketing, recall and reporting of prescription drugs
and biologics (in any stage of development), or related to kickbacks, patient
or program charges, recordkeeping, documentation requirements, referrals, the
hiring of employees or acquisition of services or supplies from those who have
been debarred by the FDA or Health Canada or excluded from Federal Health Care
Programs, quality, safety, privacy, security, licensure, or any other aspect
of developing health care products and services.

  

  

 

 

 

  

 

93  

  

 

 

 

  

HSR Act. "HSR Act" shall mean the Hart-Scott-Rodino Antitrust Improvements Act
of 1976, as amended.

  

  

Intellectual Property. "Intellectual Property" shall mean United States and
Canadian, foreign and international patents, patent applications, including
provisional applications, statutory invention registrations, invention
disclosures, inventions, trademarks, service marks, trade names, domain names,
URLs, trade dress, logos and other source identifiers, including registrations
and applications for registration thereof, together with the goodwill
symbolized by any of the foregoing, copyrights, including registrations and
applications for registration thereof, software, formulae, trade secrets,
know-how, methods, processes, protocols, specifications, techniques, and other
forms of technology (whether or not embodied in any tangible form and
including all tangible embodiments of the foregoing, such as laboratory
notebooks, samples, studies and summaries), and all rights under, in or to any
of the foregoing that may exist or be created under the laws of any
jurisdiction in the world.

  

  

IRS. "IRS" shall mean the United States Internal Revenue Service.

  

  

Knowledge of the Company. "Knowledge of the Company" or a similar phrase shall
mean the actual knowledge of the Company's executive officers after reasonable
inquiry.

  

  

Knowledge of Parent. "Knowledge of Parent" or a similar phrase shall mean the
actual knowledge of Parent's executive officers after reasonable inquiry.

  

  

Legal Proceeding. "Legal Proceeding" shall mean any action, suit, litigation,
arbitration, proceeding (including any civil, criminal, administrative,
investigative or appellate proceeding), hearing, inquiry, audit, examination
or investigation commenced, brought, conducted or heard by or before, or
otherwise involving, any court or other Governmental Body or any arbitrator or
arbitration panel.

  

  

Legal Requirement. "Legal Requirement" shall mean any federal, state,
provincial, local, municipal, foreign or other law, statute, constitution,
principle of common law or equity, resolution, ordinance, code, edict, decree,
rule, regulation, order, award, ruling or requirement issued, enacted,
adopted, promulgated, implemented or otherwise put into effect by or under the
authority of any Governmental Body (or under the authority of the NASDAQ and
the TSX).

  

  

Made Available. Any statement in the Agreement to the effect that any
information, document or other material has been "Made Available" shall mean
that: (a) with respect to information, document or other material to which the
Company has given Parent access: (i) such information, document or material
was made available by the Company for review by Parent or Parent's
Representatives for a reasonable period of time prior to the execution of the
Agreement in the virtual data room maintained by the Company with Merrill
Corporation in connection with the transactions contemplated by the Agreement
(it being understood that a document that was only made available for review
in the virtual data room in the two days prior to the execution of the
Agreement shall only be deemed to have been made available for a reasonable
period of time if the Company shall have promptly notified Parent or its
outside legal counsel that such document was uploaded into the virtual data
room); and (ii) Parent and Parent's Representatives had access to such
information, document or material throughout such period of time; and (b) with
respect to information, document or other material to which Parent has given
the Company access: either (x) (i) such information, document or material was
made available by Parent for review by the Company or the Company's
Representatives for a reasonable period of time prior to the execution of the
Agreement in the virtual data room maintained by Parent with Data Site with
Firmex Inc. in connection with the transactions contemplated by the Agreement
(it being understood that a document that was only made available for review
in the virtual data room in the two days prior to the execution of the
Agreement shall only be deemed to have been made available for a reasonable
period of time if Parent shall have promptly notified the Company or its
outside legal counsel that such document was uploaded into the virtual data
room); and (ii) the Company and the Company's Representatives had access to
such information, document or material throughout such period of time or (y)
that such information was filed by the Parent, with the SEC and Canadian
securities regulatory authorities prior to the date of this Agreement and was,
as of the date of this Agreement, publicly available on the SEC's EDGAR
database or on SEDAR. As used in this definition of "Made Available", the term
"file" and variations thereof shall be broadly construed to include any manner
in which a document or information is filed, furnished, submitted, supplied or
otherwise made available to the SEC or Canadian securities regulatory
authorities or any member of their respective staff.

  

  

 

 

 

  

 

94  

  

 

 

 

  

Materials of Environmental Concern. "Materials of Environmental Concern"
include chemicals, pollutants, contaminants, wastes, toxic substances,
petroleum and petroleum products and any other substance that is now or
hereafter regulated by any Environmental Law or that is otherwise a danger to
health, reproduction or the environment.

  

  

NASDAQ. "NASDAQ" shall mean the NASDAQ Global Market.

  

  

Order. "Order" shall mean any order, writ, injunction, judgment or decree of a
Governmental Body of competent jurisdiction.

  

  

Owl Corporations. "Owl Corporations" shall mean: (a) the Company; and (b) the
Company's Subsidiary.

  

  

Parent Affiliate. "Parent Affiliate" shall mean any Person under common
control with any of the Tiger Corporations within the meaning of Section
414(b), Section 414(c), Section 414(m) or Section 414(o) of the Code, and the
regulations issued thereunder.

  

  

Parent Associate. "Parent Associate" shall mean any current or former officer
or other employee, or any individual who is a current or former independent
contractor, consultant or director, of or to any of the Tiger Corporations or
of or to any Parent Affiliate.

  

  

Parent Board. "Parent Board" shall mean the Parent's board of directors.

  

  

Parent Common Stock. "Parent Common Stock" shall mean the common shares
without par value in the capital of Parent.

  

  

Parent Contract. "Parent Contract" shall mean any Contract: (a) to which any
of the Tiger Corporations is a party; (b) by which any of the Tiger
Corporations or any Parent IP owned by any of the Tiger Corporations or any
other asset of any of the Tiger Corporations is or may become bound or under
which any of the Tiger Corporations has, or may become subject to, any
obligation; or (c) under which any of the Tiger Corporations has or may
acquire any right or interest.

  

  

 

 

 

  

 

95  

  

 

 

 

  

Parent Designated Representations. "Parent Designated Representations" shall
mean the representations and warranties set forth in Sections 3.2, 3.3(a),
3.3(c), 3.3(f), 3.21, 3.22, 3.23, 3.25 and 3.26.

  

  

Parent Disclosure Schedule. "Parent Disclosure Schedule" shall mean the Parent
Disclosure Schedule that has been prepared by Parent in accordance with the
requirements of Section 9.6 of the Agreement and that has been delivered by
Parent to the Company on the date of the Agreement.

  

  

Parent Employee. "Parent Employee" shall mean any director or any officer or
any other employee of any of the Tiger Corporations.

  

  

Parent Employee Agreement. "Parent Employee Agreement" shall mean any
management, employment, severance, retention, transaction bonus, change in
control, consulting, relocation, repatriation or expatriation agreement or
other Contract between: (a) any of the Tiger Corporations; and (b) any Parent
Employee, other than any such Contract that is terminable "at will" (or
following a notice period imposed by applicable law) without any obligation on
the part of any Tiger Corporation to make any severance, termination, change
in control or similar payment or to provide any benefit.

  

  

Parent Employee Plan. "Parent Employee Plan" shall mean any plan, program,
policy, practice or Contract providing for compensation, severance,
termination pay, deferred compensation, performance awards, stock or stock-
related awards, fringe benefits, change in control payments, disability
benefits, sick pay, paid time off, vacation pay, retirement benefits, retiree
health benefits or other benefits or remuneration of any kind, whether or not
in writing and whether or not funded, including each "employee benefit plan,"
within the meaning of Section 3(3) of ERISA (whether or not ERISA is
applicable to such plan) and any "health and welfare trust" or "employee life
and health trust" within the meaning of the Income Tax Act (Canada): (a) that
is maintained or contributed to, or required to be maintained or contributed
to, by any of the Tiger Corporations for the benefit of any Parent Employee;
or (b) with respect to which any of the Tiger Corporations has or may incur or
become subject to any liability or obligation; provided, however, that a
Parent Employee Agreement shall not be considered a Parent Employee Plan. For
greater certainty, "Parent Employee Plan" includes any Parent Foreign Plan.

  

  

Parent Equity Award. "Parent Equity Award" shall mean any form of compensation
(including deferred compensation) that is or may be paid or settled in Parent
Common Stock.

  

  

Parent Foreign Plan. "Parent Foreign Plan" shall mean: (a) any plan, program,
policy, practice, Contract or other arrangement mandated by a Governmental
Body outside of the United States to which any of the Tiger Corporations is
required to contribute or under which any of the Tiger Corporations has or may
have any liability; (b) any Parent Employee Plan that is subject to any of the
Legal Requirements of any jurisdiction outside of the United States; or (c)
any Parent Employee Plan that covers or has covered any Parent Employee whose
services are or have been performed primarily outside of the United States.

  

  

Parent IP. "Parent IP" shall mean: (a) all Intellectual Property relating to
the Parent Products in which any of the Tiger Corporations has an ownership
interest; and (b) all other Intellectual Property with respect to which any of
the Tiger Corporations has (or purports to have) an ownership interest or an
exclusive license or similar exclusive right.

  

  

 

 

 

  

 

96  

  

 

 

 

  

Parent Material Adverse Effect. "Parent Material Adverse Effect" shall mean
any effect, change, event, circumstance or occurrence (collectively, "Effect")
that, considered together with all other Effects, is or would reasonably be
expected to be materially adverse to, or has or would reasonably be expected
to have or result in a material adverse effect on the assets, liabilities
(whether matured or unmatured, absolute or contingent), condition (financial
or otherwise) or results of operations of the Tiger Corporations taken as a
whole; provided, however, that, in no event shall any Effect resulting from
any of the following, alone or in combination, be deemed to constitute, or be
taken into account in determining whether there has occurred, a Parent
Material Adverse Effect: (i) conditions generally affecting the
biopharmaceutical industry or the U.S., Canada or global economy as a whole,
to the extent that such conditions do not have a disproportionate impact on
the Tiger Corporations taken as a whole; (ii) general conditions in the
financial or currency markets, and any changes therein; (iii) any change in
the market price or trading volume of Parent Common Stock; (iv) changes in
GAAP (or any interpretations of GAAP) or Legal Requirements (or any
interpretations thereof) applicable to Parent or any of its Subsidiaries; (v)
the announcement of the transactions contemplated by the Agreement; (vi) any
natural disaster, adverse weather conditions or other force majeure events or
any acts of terrorism, sabotage, military action or war (whether or not
declared) or any escalation or worsening thereof; and (vii) the failure to
meet internal projections, forecasts or budgets of revenues, earnings or other
financial metrics.

  

  

Parent Option Plans. "Parent Option Plans" shall mean Parent's: (a) 2007 Plan,
(b) 2011 Plan, (c) two Designated Plans and (d) Protiva Option Plan, each as
have been amended.

  

  

Parent Options. "Parent Options" shall mean options to purchase shares of
Parent Common Stock from Parent (whether granted by Parent pursuant to the
Parent Option Plans, assumed by Parent or otherwise).

  

  

Parent Pension Plan. "Parent Pension Plan" shall mean each: (a) Parent
Employee Plan that is an "employee pension benefit plan," within the meaning
of Section 3(2) of ERISA; or (b) other occupational pension plan, including
any final salary or money purchase plan.

  

  

Parent Preferred Stock. "Parent Preferred Stock" shall mean the Preferred
Stock, $.001 par value per share, of Parent.

  

  

Parent Products. "Parent Products" shall mean product candidates based on RNA
interference therapeutics and/or lipid nanoparticle (LNP) delivery technology
or any other programs that any Tiger Corporation is currently preclinically or
clinically developing, marketing, selling, distributing or manufacturing for
clinical or commercial use (whether or not in collaboration with another
Person).

  

  

Parent Superior Offer. "Parent Superior Offer" shall mean an unsolicited bona
fide written offer by a third party (or any subsequent written offer by such
third party that results from the negotiations with such third party, in
accordance with the terms of the Agreement, of such third party's initial
unsolicited Acquisition Proposal) to purchase all or substantially all of the
outstanding assets of the Parent or all of the shares of Parent Common Stock
(whether through a tender offer, merger or otherwise), that is determined by
the Parent Board, in its good faith judgment, after consulting with a
financial advisor of nationally recognized reputation and outside legal
counsel, and after taking into account the terms and conditions of the offer,
including the likelihood and anticipated timing of consummation and all other
financial, regulatory, legal and other aspects of such offer, including any
financing condition, to be more favorable to Parent or the Parent's
stockholders from a financial point of view, to the combination with the
Company, taking into account long-term value of the combined company rather
than short term value.

  

  

 

 

 

  

 

97  

  

 

 

 

  

Parent Triggering Event. A "Parent Triggering Event" shall be deemed to have
occurred if: (a) the Parent Board shall have failed to recommend that Parent's
stockholders vote to approve the issuance of shares of Parent Common Stock in
the Merger, or shall have directly or indirectly withdrawn or modified in a
manner adverse to the Company the Parent Board Recommendation, including a
Parent Change in Recommendation; (b) Parent shall have failed to include in
the Proxy Statement or Circular the Parent Board Recommendation and a
statement to the effect that the Parent Board has determined that this
Agreement and the Merger are in the best interests of the Parent and fair to
its stockholders; (c) the Parent Board fails to publicly reaffirm the Parent
Board Recommendation, or fails to publicly reaffirm its determination that
this Agreement and the Merger are in the best interests of Parent and fair to
its stockholders, within five Business Days after the Company requests in
writing that such recommendation or determination be reaffirmed, provided that
the Company has a reasonable basis for making such request; (d) the Parent
Board shall have approved, endorsed or recommended any Acquisition Proposal
(other than any confidentiality agreement contemplated by Section 4.4(b)); (e)
Parent shall have entered into any letter of intent or similar document or any
Contract relating to any Acquisition Proposal including any Alternative
Agreement; (f) a tender or exchange offer relating to securities of Parent
shall have been commenced and Parent shall not have publicly announced, within
10 Business Days after the commencement of such tender or exchange offer, a
statement disclosing that Parent recommends rejection of such tender or
exchange offer; (g) an Acquisition Proposal with respect to a Tiger
Corporation is publicly announced, and Parent fails to issue a press release
announcing its opposition to such Acquisition Proposal within five Business
Days after such Acquisition Proposal is announced; or (h) Parent shall have
breached, or shall have been deemed to have breached pursuant to the last
sentence of Section 4.4(b), in any material respect Section 4.4 or Section 5.3
of the Agreement.

  

  

Parent Unaudited Balance Sheet. "Parent Unaudited Balance Sheet" shall mean
the unaudited consolidated balance sheet of Parent and its consolidated
Subsidiaries as of September 30, 2014.

  

  

Parent Warrants. "Parent Warrants" shall mean (i) the outstanding Warrants
dated June 16, 2011 to purchase 185,500 shares of Parent Common Stock and (ii)
the Warrants dated February 29, 2012 to purchase 212,750 shares of Parent
Common Stock.

  

  

Person. "Person" shall mean any individual, Entity or Governmental Body.

  

  

PMPRB. "PMPRB" shall mean the Canada Patent Act and Patented Medicines
Regulations and the guidelines of the Patent Medicines Pricing Review Board.

  

  

Proxy Statement. "Proxy Statement" shall mean the Proxy Statement to be sent
to Parent's stockholders in connection with the Parent Stockholders' Meeting.

  

  

Registered IP. "Registered IP" shall mean all Intellectual Property that is
registered, filed or issued with, by or under the authority of any
Governmental Body, including all patents, registered copyrights, registered
mask works and registered trademarks and all applications for any of the
foregoing.

  

  

Release. "Release" means any spilling, leaking, emitting, discharging,
depositing, escaping, leaching, dumping or other releasing into the
environment, whether intentional or unintentional.

  

  

Representatives. "Representatives" shall mean with respect to an Entity, the
directors, officers, other employees, agents, attorneys, accountants,
investment bankers, other advisors and representatives of such Entity.

  

  

Sarbanes-Oxley Act. "Sarbanes-Oxley Act" shall mean the Sarbanes-Oxley Act of
2002, as it may be amended from time to time.

  

  

 

 

 

  

 

98  

  

 

 

 

  

SEC. "SEC" shall mean the United States Securities and Exchange Commission.

  

  

Securities Act. "Securities Act" shall mean the Securities Act of 1933, as
amended.

  

  

Securities Act (BC). "Securities Act (BC)" means the Securities Act (British
Columbia).

  

  

SEDAR. "SEDAR" means the System for Electronic Document Analysis Retrieval.

  

  

Subsidiary. An Entity shall be deemed to be a "Subsidiary" of another Person
if such Person directly or indirectly owns, beneficially or of record: (a) an
amount of voting securities of or other interests in such Entity that is
sufficient to enable such Person to elect at least a majority of the members
of such Entity's board of directors or other governing body; or (b) at least
50% of the outstanding equity, voting or financial interests in such Entity.

  

  

Tax. "Tax" shall mean any federal, state, provincial, local, foreign or other
tax (including any income tax, franchise tax, capital gains tax, gross
receipts tax, value-added tax, surtax, estimated tax, unemployment tax,
premium tax, national health insurance tax, excise tax, ad valorem tax,
transfer tax, stamp tax, sales tax, use tax, property tax, business tax,
license tax, alternative or add-on minimum tax, withholding tax or payroll
tax), and any charge, fine, penalty or interest related to a tax, imposed,
assessed or collected by or under the authority of any Governmental Body.

  

  

Tax Return. "Tax Return" shall mean any return (including any information
return), report, statement, declaration, estimate, schedule, notice,
notification, form, election, certificate or other document or information,
and any amendment or supplement to any of the foregoing, filed with or
submitted to, or required to be filed with or submitted to, any Governmental
Body in connection with the determination, assessment, collection or payment
of any Tax or in connection with the administration, implementation or
enforcement of or compliance with any Legal Requirement relating to any Tax.

  

  

Tiger Corporations. "Tiger Corporations" shall mean: (a) Parent; and (b) each
of Parent's Subsidiaries, including Merger Sub.

  

  

TSX. "TSX" shall mean the Toronto Stock Exchange.

  

  

Warning Notice. "Warning Notice" shall have the meaning set forth in Section
3.12(g).

  

  

  

 

 

 

  

 

99  

  

 

 

 

  

EXHIBIT B

  

FORM OF PARENT STOCKHOLDER VOTING AGREEMENT

  

  

  

  

  

  

  

  


 

  

 

 

 

  

   

  

 

 

 

  

FORM OF VOTING AGREEMENT

  

  

This Voting Agreement ("Agreement") is entered into as of January 11 , 2015,
by and between OnCore Biopharma, Inc., a Delaware corporation ("Company") and
____________________________ (the "Shareholder").

  


 

  

Recitals

  


 

  

A. Shareholder is a holder of record and beneficially owns (whether directly
or indirectly, or over which Shareholder has control or direction of) certain
common shares without par value ("Common Shares') in the capital of Tekmira
Pharmaceuticals Corporation, a British Columbia corporation ("Parent").

  


 

  

B. Company, Parent, and TKM Acquisition Corporation, a Delaware corporation
and wholly-owned subsidiary of Parent ("Merger Sub"), are entering into an
Agreement and Plan of Merger and Reorganization of even date herewith (the
"Merger Agreement") which provides (subject to the conditions set forth
therein) for the merger of Merger Sub with and into the Company (the "Merger")
with the Company surviving the Merger as a wholly-owned subsidiary of Parent.
Capitalized terms used but not otherwise defined herein shall have the
respective meanings ascribed to them in the Merger Agreement.

  

  

C. In order to induce Company to enter into the Merger Agreement, Shareholder
is entering into this Agreement.

  

  

Agreement

  


 

  

The parties to this Agreement, intending to be legally bound, agree as
follows:

  


 

  

Section 1\. Certain Definitions

  


 

  

For purposes of this Agreement:

  


 

  

(a) "Acquisition Proposal" shall mean any offer or proposal (other than an
offer or proposal made or submitted by the Company) contemplating or otherwise
relating to any Acquisition Transaction.

  


 

  

(b) The term "Acquisition Transaction" shall have the meaning assigned to that
term in the Merger Agreement.

  


 

  

(c) Shareholder shall be deemed to "Own" or to have acquired "Ownership" of a
security if Shareholder: (i) is the record owner of such security; or (ii)
beneficially owns (whether directly or indirectly, or over which Shareholder
has control or direction of) such security, regardless of whether Shareholder
Owns such security on the date hereof or has acquired Ownership of such
security at any time after the date hereof and regardless of the manner in
which Shareholder has acquired Ownership of such security, including, without
limitation, as a result of the exercise of stock options, conversion of
convertible securities, exchange of any securities or otherwise.

  


 

  

 

 

 

  

   

  

 

 

 

  

(d) "Parent Triggering Event" shall have the meaning assigned to that term in
the Merger Agreement.

  


 

  

(e) "Person" shall mean any (i) individual, (ii) corporation, limited
liability company, partnership or other entity, or (iii) governmental
authority.

  


 

  

(g) "Subject Securities" shall mean: (i) all Common Shares of Parent Owned by
Shareholder as of the date of this Agreement; and (ii) all additional
securities of the Parent (including all additional Common Shares and all
additional options, warrants and other rights to acquire Common Shares) of
which Shareholder acquires Ownership during the period from the date of this
Agreement through and including the Voting Covenant Expiration Date.

  


 

  

(h) A Person shall be deemed to have effected a "Transfer" of a security if
such Person directly or indirectly sell, transfer or assign or agree to sell,
transfer or assign or grant to any person any right or option to buy any of
the Subject Securities or the voting rights attached thereto, without the
prior written consent of the Company.

  


 

  

(i) "Voting Covenant Expiration Date" shall mean the earlier of the date upon
which: (a) a Parent Triggering Event occurs; (b) the Merger Agreement is
validly terminated, or (c) the date upon which the Merger is consummated.

  


 

  

Section 2. Transfer of Subject Securities and Voting Rights

  


 

  

2.1 Restriction on Transfer of Subject Securities. Subject to Section 2.3,
during the period from the date of this Agreement through and including the
Voting Covenant Expiration Date, Shareholder shall not, directly or
indirectly, cause or permit any Transfer of any of the Subject Securities to
be effected.

  


 

  

2.2 Restriction on Transfer of Voting Rights. During the period from the date
of this Agreement through and including the Voting Covenant Expiration Date,
Shareholder shall ensure that: (a) none of the Subject Securities is deposited
into a voting trust; and (b) no proxy or power of attorney is granted (other
than in connection with Shareholder's compliance with Section 2.3 of this
Agreement), and no voting agreement or similar agreement is entered into, with
respect to any of the Subject Securities. During the period from the date of
this Agreement through and including the Voting Covenant Expiration Date,
Shareholder shall not enter into any agreement or understanding with any
person that is inconsistent with, violates, contravenes, or results in a
violation, breach or contravention of, any of the provisions of this
Agreement.

  


 

  

2.3 Permitted Transfers. Section 2.1 shall not prohibit a transfer of any
Subject Securities by Shareholder (i) to Company or to any wholly-owned
subsidiary of Company, (ii) to any member of Shareholder's immediate family,
or to a trust for the benefit of Shareholder or any member of Shareholder's
immediate family, (iii) upon the death of Shareholder, (iv) if Shareholder is
a partnership or limited liability company, to one or more partners or members
of Shareholder or to an affiliated corporation under common control with
Shareholder, or (v) the transfer is to any nominee or custodian (including a
trust) where there is no change in beneficial ownership (other than a change
in beneficial ownership resulting from a transfer to a trust for the direct or
indirect benefit of the immediate family members of the Shareholder);
provided, however, in the case of each of clauses (ii), (iii) and (iv) above,
that a transfer referred to in this sentence shall be permitted only if, as a
precondition to such transfer, the transferee agrees in a writing,
satisfactory in form and substance to Parent, to be bound by the terms of this
Agreement.

  


 

  

 

 

 

  

   

  

 

 

 

  

Section 3. Voting of Shares

  


 

  

3.1 Voting Covenant Prior to Voting Covenant Expiration Date. Shareholder
hereby agrees that prior to the Voting Covenant Expiration Date, at any
meeting of the Shareholders of the Parent, however called, and in any written
action by consent of Shareholders of the Parent, unless otherwise directed in
writing by Company, Shareholder shall cause the Subject Securities to be
voted:

  


 

  

(a) in favor of all matters comprising the Required Parent Stockholder Vote,
in favor of each of the other actions contemplated by the Merger Agreement and
in favor of any action in furtherance of any of the foregoing;

  


 

  

(b) against any action or agreement that would result in a breach of any
representation, warranty, covenant or obligation of the Parent or any
subsidiary of the Parent in the Merger Agreement; and

  


 

  

(c) against the following actions (other than the Merger and the transactions
contemplated by the Merger Agreement): (A) any extraordinary corporate
transaction, such as a merger, consolidation or other business combination
involving the Parent or any subsidiary of the Parent; (B) any sale, lease or
transfer of a material amount of assets of the Parent or any subsidiary of the
Parent; (C) any reorganization, recapitalization, dissolution or liquidation
of the Parent or any subsidiary of the Parent; (D) any change in a majority of
the board of directors of the Parent; (E) any amendment to the Parent's
constating documents; (F) any material change in the capitalization of the
Parent or the Parent's corporate structure; and (G) any other action which is
intended, or could reasonably be expected, to impede, interfere with, delay,
postpone, discourage or adversely affect the Merger or any of the other
transactions contemplated by the Merger Agreement or this Agreement.

  


 

  

During the period from the date of this Agreement through and including the
Voting Covenant Expiration Date, Shareholder shall not enter into any
agreement or understanding with any Person to vote or give instructions in any
manner inconsistent with clause "(a)" to "(c)" of the preceding sentence.

  


 

  


 

  


 

  

 

 

 

  

   

  

 

 

 

  

Section 4. No Solicitation

  


 

  

Shareholder agrees that, during the period from the date of this Agreement
through and including the Voting Covenant Expiration Date, Shareholder shall
not directly or indirectly: (i) solicit, initiate, encourage, induce or
facilitate the making, submission or announcement of any Acquisition Proposal
or take any action that could reasonably be expected to lead to an Acquisition
Proposal; (ii) furnish any information regarding the Parent or any subsidiary
of the Parent to any Person in connection with or in response to an
Acquisition Proposal or an inquiry or indication of interest that could lead
to an Acquisition Proposal; (iii) engage in discussions or negotiations with
any Person with respect to any Acquisition Proposal; (iv) approve, endorse or
recommend any Acquisition Proposal; or (v) enter into any letter of intent or
similar document or any agreement or understanding contemplating or otherwise
relating to any Acquisition Transaction. Shareholder shall immediately cease
and discontinue any existing discussions with any Person that relate to any
Acquisition Proposal.

  


 

  

Section 5. Representations and Warranties of Shareholder

  


 

  

Shareholder hereby represents and warrants to Company as follows:

  


 

  

5.1 Authorization, etc. Shareholder has the absolute and unrestricted right,
power, authority and capacity to execute and deliver this Agreement and to
perform Shareholder's obligations hereunder and thereunder. Shareholder has
sole power to vote or otherwise agree to all of the matters set forth in this
Agreement, in each case with respect to the Subject Securities Owned by such
Shareholder on the date of this Agreement. This Agreement has been duly
executed and delivered by Shareholder and constitute legal, valid and binding
obligations of Shareholder, enforceable against Shareholder in accordance with
their terms, subject to (i) laws of general application relating to
bankruptcy, insolvency and the relief of debtors, and (ii) rules of law
governing specific performance, injunctive relief and other equitable
remedies. If Shareholder is a general or limited partnership, then Shareholder
is a partnership duly organized, validly existing and in good standing under
the laws of the jurisdiction in which it was organized. If Shareholder is a
limited liability company, then Shareholder is a limited liability company
duly organized, validly existing and in good standing under the laws of the
jurisdiction in which it was organized.

  


 

  

5.2 No Conflicts or Consents.

  


 

  

(a) The execution and delivery of this Agreement by Shareholder does not, and
the performance of this Agreement by Shareholder will not: (i) conflict with
or violate any law, rule, regulation, order, decree or judgment applicable to
Shareholder or by which Shareholder or any of Shareholder's properties is or
may be bound or affected; or (ii) result in or constitute (with or without
notice or lapse of time) any breach of or default under, or give to any other
Person (with or without notice or lapse of time) any right of termination,
amendment, acceleration or cancellation of, or result (with or without notice
or lapse of time) in the creation of any encumbrance or restriction on any of
the Subject Securities pursuant to, any contract to which Shareholder is a
party or by which Shareholder or any of Shareholder's affiliates or properties
is or may be bound or affected.

  


 

  

 

 

 

  

   

  

 

 

 

  

(b) Any proxies heretofore given in respect of any Subject Securities are not
irrevocable and all such proxies have been or are hereby revoked.

  


 

  

(c) The execution and delivery of this Agreement by Shareholder does not, and
the performance of this Agreement by Shareholder will not, require any consent
or approval of any Person.

  


 

  

5.3 Title to Securities. As of the date of this Agreement: (a) Shareholder
holds of record (free and clear of any encumbrances or restrictions) the
number of outstanding Common Shares set forth under the heading "Shares Held
of Record" on the signature page hereof; (b) Shareholder holds (free and clear
of any encumbrances or restrictions) the options, warrants and other rights to
acquire shares of Common Stock set forth under the heading "Options, Warrants
and Other Rights" on the signature page hereof; (c) Shareholder Owns the
additional securities of the Company set forth under the heading "Additional
Securities Beneficially Owned" on the signature page hereof; (d) Shareholder
does not directly or indirectly Own any other Common Shares or any other
securities of the Company, or any option, warrant or other right to acquire
(by purchase, conversion or otherwise) any Common Shares or other securities
of the Company, other than the Common Shares and options, warrants and other
rights set forth on the signature page hereof; and (e) Shareholder has not
entered into any voting agreement or given any person any proxy with respect
to the Subject Securities other than as set forth in this Agreement.

  


 

  

5.4 Accuracy of Representations. The representations and warranties contained
in this Agreement are accurate in all respects as of the date of this
Agreement, will be accurate in all respects at all times through and including
the Voting Covenant Expiration Date and will be accurate in all respects as of
the date of the consummation of the Merger as if made on that date.

  

  

Section 6. Additional Covenants of Shareholder

  


 

  

6.1 Further Assurances. From time to time and without additional
consideration, Shareholder shall (at Company's sole expense) execute and
deliver, or cause to be executed and delivered, such additional transfers,
assignments, endorsements, proxies, consents and other instruments, and shall
(at Company's sole expense) take such further actions, as Company may
reasonably request for the purpose of carrying out and furthering the intent
of this Agreement.

  


 

  

Section 7. Miscellaneous

  


 

  

7.1 Survival of Representations, Warranties and Agreements. All claims for
breaches of representations, warranties, covenants and agreements made by
Shareholder in this Agreement shall survive (i) the consummation of the
Merger, (ii) any termination of the Merger Agreement, and (iii) the Voting
Covenant Expiration Date.

  


 

  

7.2 Expenses. Except as set forth in this Agreement, all costs and expenses
incurred in connection with the transactions contemplated by this Agreement
shall be paid by the party incurring such costs and expenses.

  


 

  

 

 

 

  

   

  

 

 

 

  

7.3 Notices. Any notice or other communication required or permitted to be
delivered to either party under this Agreement shall be in writing and shall
be deemed properly delivered, given and received when delivered (by hand, by
registered mail, by courier or express delivery service, by facsimile or by
electronic mail) to the address, facsimile telephone number or electronic mail
address set forth beneath the name of such party below (or to such other
address, facsimile telephone number or electronic mail address as such party
shall have specified in a written notice given to the other party):

  


 

  

if to Shareholder:

  


 

  

________________________________

  

________________________________

  

________________________________

  

________________________________

  


 

  

if to Company:

  


 

  

OnCore Biopharma, Inc.

  

3805 Old Easton Road

  

Doylestown, Pennsylvania 18902

  

Attention: Bryce Roberts

  

E-Mail: Bryce.roberts@oncorebiopharma.com

  

  

with a required copy to (which alone shall not constitute notice):

  


 

  

Cooley LLP

  

3175 Hanover Street

  

Palo Alto, California 94304

  

Attn: Frank Rahmani

  

Fax: (650) 843-5753

  

Email: frahmani@cooley.com

  


 

  

7.4 Severability. Any term or provision of this Agreement that is invalid or
unenforceable in any situation in any jurisdiction shall not affect the
validity or enforceability of the remaining terms and provisions hereof or the
validity or enforceability of the offending term or provision in any other
situation or in any other jurisdiction. If the final judgment of a court of
competent jurisdiction declares that any term or provision hereof is invalid
or unenforceable, the parties hereto agree that the court making such
determination shall have the power to limit the term or provision, to delete
specific words or phrases, or to replace any invalid or unenforceable term or
provision with a term or provision that is valid and enforceable and that
comes closest to expressing the intention of the invalid or unenforceable term
or provision, and this Agreement shall be enforceable as so modified. In the
event such court does not exercise the power granted to it in the prior
sentence, the parties hereto agree to replace such invalid or unenforceable
term or provision with a valid and enforceable term or provision that will
achieve, to the extent possible, the economic, business and other purposes of
such invalid or unenforceable term.

  


 

  

 

 

 

  

   

  

 

 

 

  

7.5 Entire Agreement. This Agreement and any other documents delivered by the
parties in connection herewith or in connection with the Merger Agreement
constitute the entire agreement between the parties with respect to the
subject matter hereof and thereof and supersede all prior agreements and
understandings between the parties with respect thereto. No addition to or
modification of any provision of this Agreement shall be binding upon either
party unless made in writing and signed by both parties.

  


 

  

7.6 Assignment; Binding Effect. Except as provided herein, neither this
Agreement nor any of the interests or obligations hereunder may be assigned or
delegated by Shareholder, by operation of law or otherwise, and any attempted
or purported assignment or delegation of any of such interests or obligations
shall be void. Subject to the preceding sentence, this Agreement shall be
binding upon Shareholder and Shareholder's heirs, estate, executors and
personal representatives and Shareholder's successors and assigns, and shall
inure to the benefit of Company and its successors and assigns. Without
limiting any of the restrictions set forth in Section 2 or elsewhere in this
Agreement, this Agreement shall be binding upon any Person to whom any Subject
Securities are transferred. Nothing in this Agreement is intended to confer on
any Person (other than Parent and its successors and assigns) any rights or
remedies of any nature.

  


 

  

7.7 Specific Performance. The parties agree that irreparable damage would
occur in the event that any of the provisions of this Agreement were not
performed in accordance with its specific terms or were otherwise breached.
Shareholder agrees that, in the event of any breach or threatened breach by
Shareholder of any covenant or obligation contained in this Agreement, Company
shall be entitled (in addition to any other remedy that may be available to
it, including monetary damages) to seek and obtain (a) a decree or order of
specific performance to enforce the observance and performance of such
covenant or obligation, and (b) an injunction restraining such breach or
threatened breach. Shareholder further agrees that neither Company nor any
other Person shall be required to obtain, furnish or post any bond or similar
instrument in connection with or as a condition to obtaining any remedy
referred to in this Section 7.7, and Shareholder irrevocably waives any right
he or it may have to require the obtaining, furnishing or posting of any such
bond or similar instrument.

  


 

  

7.8 Non-Exclusivity. The rights and remedies of Company under this Agreement
are not exclusive of or limited by any other rights or remedies which it may
have, whether at law, in equity, by contract or otherwise, all of which shall
be cumulative (and not alternative). Without limiting the generality of the
foregoing, the rights and remedies of Company under this Agreement, and the
obligations and liabilities of Shareholder under this Agreement, are in
addition to their respective rights, remedies, obligations and liabilities
under common law requirements and under all applicable statutes, rules and
regulations. Nothing in this Agreement shall limit any of Shareholder's
obligations, or the rights or remedies of Company, under any other agreement
between Company and Shareholder; and nothing in any such other agreement shall
limit any of Shareholder's obligations, or any of the rights or remedies of
Company, under this Agreement.

  


 

  

7.9 Governing Law; Venue. This Agreement shall be governed by and construed in
accordance with the laws of the Province of British Columbia and the federal
laws of Canada applicable therein and each of the parties attorns to the non-
exclusive jurisdiction of the Province of British Columbia for all purposes
hereof. Nothing contained in this Section 7.9 shall be deemed to limit or
otherwise affect the right of Shareholder or Company to commence any legal
proceeding or otherwise proceed against the other in any other forum or
jurisdiction.

  


 

  

 

 

 

  

   

  

 

 

 

  

7.10 Counterparts. This Agreement may be executed in separate counterparts,
each of which when so executed and delivered shall be an original, but all
such counterparts shall together constitute one and the same instrument.

  


 

  

7.11 Captions. The captions contained in this Agreement are for convenience of
reference only, shall not be deemed to be a part of this Agreement and shall
not be referred to in connection with the construction or interpretation of
this Agreement.

  


 

  

7.12 Attorneys' Fees. If any legal action or other legal proceeding relating
to this Agreement or the enforcement of any provision of this Agreement is
brought by or against any party to this Agreement, the prevailing party shall
be entitled to recover reasonable attorneys' fees, costs and disbursements (in
addition to any other relief to which the prevailing party may be entitled).

  


 

  

7.13 Amendment; Waiver. This Agreement may not be amended, changed,
supplemented, or otherwise modified or terminated, except upon the execution
and delivery of a written agreement executed by the parties hereto. No failure
on the part of Company to exercise any power, right, privilege or remedy under
this Agreement, and no delay on the part of Company in exercising any power,
right, privilege or remedy under this Agreement, shall operate as a waiver of
such power, right, privilege or remedy; and no single or partial exercise of
any such power, right, privilege or remedy shall preclude any other or further
exercise thereof or of any other power, right, privilege or remedy. Company
shall not be deemed to have waived any claim available to such party arising
out of this Agreement, or any power, right, privilege or remedy of such party
under this Agreement, unless the waiver of such claim, power, right, privilege
or remedy is expressly set forth in a written instrument duly executed and
delivered by or on behalf of Company; and any such waiver shall not be
applicable or have any effect except in the specific instance in which it is
given.

  


 

  

7.14 Construction.

  


 

  

(a) For purposes of this Agreement, whenever the context requires: the
singular number shall include the plural, and vice versa; the masculine gender
shall include the feminine and neuter genders; the feminine gender shall
include the masculine and neuter genders; and the neuter gender shall include
masculine and feminine genders.

  

  

(b) The parties agree that any rule of construction to the effect that
ambiguities are to be resolved against the drafting party shall not be applied
in the construction or interpretation of this Agreement.

  


 

  

(c) As used in this Agreement, the words "include" and "including," and
variations thereof, shall not be deemed to be terms of limitation, but rather
shall be deemed to be followed by the words "without limitation."

  


 

  

 

 

 

  

   

  

 

 

 

  

(d) Except as otherwise indicated, all references in this Agreement to
"Sections" and "Exhibits" are intended to refer to Sections of this Agreement
and Exhibits to this Agreement.

  


 

  

[Signature Page Follows]

  

  

  

  

  

  

  

  

  

  

 

 

 

  

   

  

 

 

 

  

In Witness Whereof, Company and Shareholder have caused this Agreement to be
executed as of the date first written above.

  

  

  

     |  

OnCore Biopharma, Inc.

   
---|--- 
   |  |   
   |  

By:

  |   
   |  

Name:

  |   
   |  

Title:

  |   
   |  |   
   |  |   
   |  

Shareholder

  |   
   |  |   
   |  

By:

  |   
   |  

Name:

  |   
   |  

Title:

  |   
 

  

  

     | Address:  |   
---|---|--- 
   |  |   
   | Facsimile:  |   
   |  

Email:

  |   
  

 

  


 

  


 

  

No. of Parent Common Shares beneficially owned, directly or indirectly, by
Shareholder:

  

______________________ 
 

  

  

No. of Parent Common Shares over which control or direction is exercised by
Shareholder:

  

______________________ 
 

  

  

No. of Parent Options held by Shareholder:

  

______________________

  

  

 

 

 

  

 

 

SIGNATURE PAGE TO VOTING AGREEMENT

   

  

 

 

 

  

EXHIBIT C

  

FORMS OF LOCK-UP AGREEMENT

  

  


 

  

  

There are three forms of Lock-Up Agreement, attached hereto as Exhibit C-1,
C-2 and C-3.

  

  

C-1 is being signed by Roivant

  

  

C-2 is being signed by certain Company stockholders other than Roivant

  

  

C-3 is being signed by certain Parent stockholders

  

  

 

 

 

  

   

  

 

 

 

  

EXHIBIT C-1

  

FORM OF LOCK-UP AGREEMENT

  

  

January 11, 2015

  

TEKMIRA PHARMACEUTICALS CORPORATION

  

8900 Glenlyon Parkway

  

Burnaby, British Columbia V5J 5J8

  

Canada

  


 

  


 

  

Ladies and Gentlemen:

  

  

This Lock-Up Agreement is being delivered to Tekmira Pharmaceuticals
Corporation, a British Columbia corporation (the "Company"), in connection
with the transactions contemplated by that certain Agreement and Plan of
Merger and Reorganization, dated January 11, 2015, by and among the Company,
OnCore Biopharma, Inc., a Delaware corporation, and TKM Acquisition
Corporation, a Delaware corporation (the "Merger Agreement").

  


 

  

In order to induce the Company to complete the transactions contemplated by
the Merger Agreement, the undersigned irrevocably agrees that for the Lock-Up
Period (as defined below) and solely with respect to the applicable amount of
the Lock-Up Securities (as defined below) as specified in the immediately
following paragraph, other than as set forth below or with the prior written
consent of the Company, the undersigned will not, directly or indirectly by
itself or through others: (1) offer, pledge, announce the intention to sell,
sell, contract to sell, sell any option, purchase any option or contract to
sell, grant any option, right or warrant to purchase, or otherwise transfer or
dispose of, directly or indirectly, any shares of common stock of the Company
("Common Stock"), or any securities of the Company that are substantially
similar to the Common Stock, or any securities convertible into or exercisable
or exchangeable for Common Stock (including, but not limited to, Common Stock
which may be deemed to be beneficially owned by the undersigned in accordance
with the rules and regulations of the Securities and Exchange Commission and
securities which may be issued upon exercise of a stock option or warrant), in
each case, which are issued in connection with the Merger (as defined in the
Merger Agreement) (collectively, the "Lock-Up Securities"); or (2) enter into,
sell or otherwise dispose of any swap, option, future, forward or other
agreement that transfers, in whole or in part, any of the economic
consequences of ownership of the Lock-Up Securities, whether any such
transaction described in clause (1) or (2) above is to be settled by delivery
of Common Stock or such other securities, in cash or otherwise.

  


 

  

For the purpose of this Lock-Up Agreement, the "Lock-Up Period" shall mean
such period commencing on the date hereof and ending as follows: (i) with
respect to an aggregate of 25% of the Lock-Up Securities, 9 months after the
date hereof; (ii) with respect to an aggregate of 35% of the Lock-Up
Securities, 12 months after the date hereof; (iii) with respect to an
aggregate of 45% of the Lock-Up Securities, 15 months after the date hereof;
(iv) with respect to an aggregate of 55% of the Lock-Up Securities, 18 months
after the date hereof; (v) with respect to an aggregate of 65% of the Lock-Up
Securities, 21 months after the date hereof; (vi) with respect to an aggregate
of 75% of the Lock-Up Securities, 24 months after the date hereof; and (vii)
with respect to all of the Lock-Up Securities, 27 months after the date
hereof.

  

  

 

 

 

  

   

  

 

 

 

  

The restrictions contained in this Lock-Up Agreement shall not apply to the
following:

  


 

  

    

a.

  |  

the establishment of a 10b5-1 trading plan under the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), by a security holder for the sale of
shares of Common Stock, provided that such plan shall only provide for the
transfer of such number of shares of Common Stock for which the Lock-Up Period
has terminated pursuant to the immediately preceding paragraph;

   
---|--- 
 

  

    

b.

  |  

transfers by security holders of shares of Common Stock or other securities as
a bona fide gift or charitable contribution or by will or intestacy;

   
---|--- 
 

  

    

c.

  |  

transfers by distribution by security holders of shares of Common Stock or
other securities to partners, members, stockholders or holders of similar
equity interests of the security holder;

   
---|--- 
 

  

    

d.

  |  

transfers by security holders of shares of Common Stock or other securities to
any trust or other entity for the direct or indirect benefit of the security
holder or the "immediate family" of the security holder;

   
---|--- 
 

  

    

e.

  |  

transfers of shares of Common Stock pursuant to a domestic order or negotiated
divorce settlement;

   
---|--- 
 

  

    

f.

  |  

the exercise by the undersigned of a stock option granted under a stock
incentive plan or stock purchase plan authorized by the Board of Directors of
the Company, and the receipt by the undersigned from the Company of shares of
Common Stock upon such exercise, provided that the underlying shares shall
continue to be subject to the restrictions on transfer set forth in this Lock-
Up Agreement;

   
---|--- 
 

  

    

g.

  |  

transfers by securityholders to the Company in connection with the repurchase
of shares of Common Stock in connection with the termination of the
undersigned's employment with the Company pursuant to contractual agreements
with the Company;

   
---|--- 
 

  

    

h.

  |  

pursuant to any tender offer, takeover bid, merger, consolidation, acquisition
of the Company or its voting securities or other similar transaction relating
to the Company or its voting securities that occurs after the Merger and that
is approved by the Board of Directors of the Company;

   
---|--- 
 

  

    

i.

  |  

the disposition of such number of shares of Common Stock with a fair market
value (determined as of such time) equal to the aggregate amount of any
applicable U.S. federal, state, local and non-U.S. taxes (including any
applicable penalties and additions to tax) (i) imposed by a taxing authority
on such holder or (ii) determined by such holder upon advice of counsel or
other qualified tax advisor to be due, in either case, as a result of and in
connection with the Merger;

   
---|--- 
 

  

    

j.

  |  

granting of a security interest in (whether by way of pledge or otherwise)
shares of Common Stock or other securities by the undersigned in connection
with a loan made in good faith on bona fide, arm's length terms, and any
subsequent transfer of such securities to such lender or collateral agent in
connection with the exercise of remedies in connection with such loan in the
event of default; and

   
---|--- 
 

  

    

k.

  |  

sales of shares of Common Stock not to exceed 0.5% of the issued and
outstanding shares of Common Stock of the Company as of the date of such sale
if the undersigned's employment with the Company is terminated without Cause
(as defined in the employment agreement between the undersigned and the
Company).

   
---|--- 
 

  

  

 

 

 

  

   

  

 

 

 

  

provided however, that in the case of any transfer, disposition, distribution
or pledge pursuant to clause (b), (c), (d) or (e) hereunder, such transfer
shall not involve a disposition for value and provided further, in the case of
any transfer, disposition, distribution or pledge pursuant to clause (b), (c),
(d), (e) or (j) hereunder, that each transferee, donee distributee or pledgee
shall execute and deliver to the Company a lock-up agreement in the form of
this Lock-Up Agreement; and (ii) that no filing by any party (donor, donee,
transferor, transferee, pledger or pledgee) under the Exchange Act, or other
public announcement shall be made (including voluntarily) in connection with
such transfer, disposition, distribution or pledge, except as otherwise
compelled to do so or is required to do so to comply with applicable law or
legal process or any request by or from a governmental authority or the rules
of any securities exchange or the rules and regulations of any "self
regulatory organization" as defined in Section 3(a)(26) of the Securities
Exchange Act of 1934, as amended, or any other United States or foreign
securities exchange, futures exchange, commodities exchange or contract
market.

  


 

  

For the avoidance of doubt, this Lock-Up Agreement shall not apply to shares
of Common Stock or other securities acquired in open market transactions after
the completion of the Merger (as defined in the Merger Agreement).

  


 

  

For the purposes of this Lock-Up Agreement, "immediate family" shall mean
spouse, domestic partner, parent, sibling, child, grandchild or first cousin
of the undersigned.

  


 

  

The undersigned represents and warrants that it is not a party to any
agreement or understanding that would cause a breach of this Lock-Up Agreement
if it were entered into during the period in which the restrictions set forth
herein are effective.

  


 

  

The undersigned acknowledges that the execution, delivery and performance of
this Lock-Up Agreement is a material inducement to the Company to enter into
the transactions contemplated by the Merger Agreement, and the Company shall
be entitled to specific performance of the undersigned's obligations
hereunder. The parties agree that any breach or threatened breach of this
Lock-Up Agreement by the undersigned may cause immediate and irreparable harm
to the Company for which monetary damages will not be adequate and that, in
the event of a breach or threatened breach of this Lock-Up Agreement, the
Company shall be entitled to seek and obtain immediate injunctive and other
equitable relief without proof of actual damages in addition to any other
remedies as may be available at law or in equity. The undersigned further
agrees to waive any requirement for the securing or posting of any bond in
connection with such remedy. All rights under this Lock-Up Agreement are
cumulative, not exclusive, and will be in addition to all rights and remedies
available to the Company at law or in equity.

  


 

  

The undersigned and the Company agree that this Lock-Up Agreement shall
automatically terminate and be of no further force or effect if (a) the
Company is in material breach of its obligations under Articles 2 or 4 of the
Governance Agreement dated the date hereof between the undersigned and the
Company or Part 27 or Part 28 of the Company's Articles and (b) such breach
remains uncured for at least thirty (30) days after notice to the Company
thereof.

  


 

  

 

 

 

  

   

  

 

 

 

  

The undersigned agrees and consents to the entry of stop transfer instructions
with the Company's transfer agent and registrar against the transfer of the
Lock-Up Securities except in compliance with the foregoing restrictions. In
furtherance of the foregoing, the Company and any duly appointed transfer
agent for the registration or transfer of the securities described herein are
hereby authorized to decline to make any transfer of securities if such
transfer would constitute a violation or breach of this Lock-Up Agreement.

  


 

  

The undersigned hereby represents and warrants that the undersigned has full
power and authority to execute, deliver and perform this Lock-Up Agreement.
All authority herein conferred or agreed to be conferred and any obligations
of the undersigned shall be binding upon the successors, assigns, heirs or
personal representatives of the undersigned. This Lock-Up Agreement may not be
amended or otherwise modified in any respect without the written consent of
the Company and the undersigned.

  


 

  

This Lock-Up Agreement shall become effective only upon the closing of the
Merger.

  

  

THIS LOCK-UP AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR
RELATED TO THIS LOCK-UP AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO THE
CONFLICT OF LAWS PRINCIPLES THEREOF.

  


 

  

The undersigned hereby irrevocably submits to the exclusive jurisdiction and
venue of the Court of Chancery of the State of Delaware, for the purposes of
any suit, action or proceeding arising out of or relating to this Lock-Up
Agreement, and hereby waives, and agrees not to assert in any such suit,
action or proceeding, any claim that (i) it is not personally subject to the
jurisdiction of such court, (ii) the suit, action or proceeding is brought in
an inconvenient forum, or (iii) the venue of the suit, action or proceeding is
improper. The undersigned hereby irrevocably waives personal service of
process and consents to process being served in any such suit, action or
proceeding by receiving a copy thereof sent to the undersigned at the address
on the signature page below, and such service shall constitute good and
sufficient service of process and notice thereof. The undersigned hereby
waives any right to a trial by jury. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.

  


 

  

[Signature page follows]

  


 

  

 

 

 

  

   

  

 

 

 

  

     |  

Very truly yours,

   
---|--- 
   |  |   
   |  

IF AN INDIVIDUAL:

   
   |  |   
   |  

By:

  |   
   |  |  

(duly authorized signature)

   
   |  |   
   |  

Name:

  |   
   |  |  

(please print full name)

   
   |  |   
   | Address:   
   |  |   
   |  |   
   |  |   
   |  

Date:

  |   
   |  |   
   |  |   
   |  

IF AN ENTITY:

   
   |  |   
   |  |   
   |  

(please print complete name of entity)

   
   |  |   
   |  

By:

  |   
   |  |  

(duly authorized signature)

   
   |  |   
   |  

Name:

  |   
   |  |  

(please print full name and title)

   
   |  |   
   | Address:  |   
   |  |   
   |  |   
   |  |   
   |  

Date:

  |   
 

  

  

[Signature page to Lock-Up Agreement]

  

  

 

 

 

  

   

  

 

 

 

  

Accepted as of the date first set forth above:

  

  

TEKMIRA PHARMACEUTICALS CORPORATION

  

  

    

By:

  |  |   
---|---|--- 
   |  

Name:

  |   
   |  

Title:

  |   
 

  

  


 

  

  


 

  

[Signature page to Lock-Up Agreement]

  

  

  

  


 

  

 

 

 

  

   

  

 

 

 

  

EXHIBIT C-2

  

FORM OF LOCK-UP AGREEMENT

  

  

January 11, 2015

  

TEKMIRA PHARMACEUTICALS CORPORATION

  

8900 Glenlyon Parkway

  

Burnaby, British Columbia V5J 5J8

  

Canada

  


 

  


 

  

Ladies and Gentlemen:

  

  

This Lock-Up Agreement is being delivered to Tekmira Pharmaceuticals
Corporation, a British Columbia corporation (the "Company"), in connection
with the transactions contemplated by that certain Agreement and Plan of
Merger and Reorganization, dated January 11, 2015, by and among the Company,
OnCore Biopharma, Inc., a Delaware corporation, and TKM Acquisition
Corporation, a Delaware corporation (the "Merger Agreement").

  


 

  

In order to induce the Company to complete the transactions contemplated by
the Merger Agreement, the undersigned irrevocably agrees that for the Lock-Up
Period (as defined below) and solely with respect to the applicable amount of
the Lock-Up Securities (as defined below) as specified in the immediately
following paragraph, other than as set forth below or with the prior written
consent of the Company, the undersigned will not, directly or indirectly by
itself or through others: (1) offer, pledge, announce the intention to sell,
sell, contract to sell, sell any option, purchase any option or contract to
sell, grant any option, right or warrant to purchase, or otherwise transfer or
dispose of, directly or indirectly, any shares of common stock of the Company
("Common Stock"), or any securities of the Company that are substantially
similar to the Common Stock, or any securities convertible into or exercisable
or exchangeable for Common Stock (including, but not limited to, Common Stock
which may be deemed to be beneficially owned by the undersigned in accordance
with the rules and regulations of the Securities and Exchange Commission and
securities which may be issued upon exercise of a stock option or warrant), in
each case, which are issued in connection with the Merger (as defined in the
Merger Agreement) (collectively, the "Lock-Up Securities"); or (2) enter into,
sell or otherwise dispose of any swap, option, future, forward or other
agreement that transfers, in whole or in part, any of the economic
consequences of ownership of the Lock-Up Securities, whether any such
transaction described in clause (1) or (2) above is to be settled by delivery
of Common Stock or such other securities, in cash or otherwise.

  


 

  

For the purpose of this Lock-Up Agreement, the "Lock-Up Period" shall mean
such period commencing on the date hereof and ending as follows: (i) with
respect to an aggregate of 25% of the Lock-Up Securities, 9 months after the
date hereof; (ii) with respect to an aggregate of 35% of the Lock-Up
Securities, 12 months after the date hereof; (iii) with respect to an
aggregate of 45% of the Lock-Up Securities, 15 months after the date hereof;
(iv) with respect to an aggregate of 55% of the Lock-Up Securities, 18 months
after the date hereof; (v) with respect to an aggregate of 65% of the Lock-Up
Securities, 21 months after the date hereof; (vi) with respect to an aggregate
of 75% of the Lock-Up Securities, 24 months after the date hereof; and (vii)
with respect to all of the Lock-Up Securities, 27 months after the date
hereof.

  


 

  

 

 

 

  

   

  

 

 

 

  

The restrictions contained in this Lock-Up Agreement shall not apply to the
following:

  


 

  

    

l.

  |  

the establishment of a 10b5-1 trading plan under the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), by a security holder for the sale of
shares of Common Stock, provided that such plan shall only provide for the
transfer of such number of shares of Common Stock for which the Lock-Up Period
has terminated pursuant to the immediately preceding paragraph;

   
---|--- 
 

  

    

m.

  |  

transfers by security holders of shares of Common Stock or other securities as
a bona fide gift or charitable contribution or by will or intestacy;

   
---|--- 
 

  

    

n.

  |  

transfers by distribution by security holders of shares of Common Stock or
other securities to partners, members, stockholders or holders of similar
equity interests of the security holder;

   
---|--- 
 

  

    

o.

  |  

transfers by security holders of shares of Common Stock or other securities to
any trust or other entity for the direct or indirect benefit of the security
holder or the "immediate family" of the security holder;

   
---|--- 
 

  

    

p.

  |  

transfers of shares of Common Stock pursuant to a domestic order or negotiated
divorce settlement;

   
---|--- 
 

  

    

q.

  |  

the exercise by the undersigned of a stock option granted under a stock
incentive plan or stock purchase plan authorized by the Board of Directors of
the Company, and the receipt by the undersigned from the Company of shares of
Common Stock upon such exercise, provided that the underlying shares shall
continue to be subject to the restrictions on transfer set forth in this Lock-
Up Agreement;

   
---|--- 
 

  

    

r.

  |  

transfers by securityholders to the Company in connection with the repurchase
of shares of Common Stock in connection with the termination of the
undersigned's employment with the Company pursuant to contractual agreements
with the Company;

   
---|--- 
 

  

    

s.

  |  

pursuant to any tender offer, takeover bid, merger, consolidation, acquisition
of the Company or its voting securities or other similar transaction relating
to the Company or its voting securities that occurs after the Merger and that
is approved by the Board of Directors of the Company;

   
---|--- 
 

  

    

t.

  |  

the disposition of such number of shares of Common Stock with a fair market
value (determined as of such time) equal to the aggregate amount of any
applicable U.S. federal, state, local and non-U.S. taxes (including any
applicable penalties and additions to tax) (i) imposed by a taxing authority
on such holder or (ii) determined by such holder upon advice of counsel or
other qualified tax advisor to be due, in either case, as a result of and in
connection with the Merger;

   
---|--- 
 

  

    

u.

  |  

granting of a security interest in (whether by way of pledge or otherwise)
shares of Common Stock or other securities by the undersigned in connection
with a loan made in good faith on bona fide, arm's length terms, and any
subsequent transfer of such securities to such lender or collateral agent in
connection with the exercise of remedies in connection with such loan in the
event of default; and

   
---|--- 
 

  

    

v.

  |  

sales of shares of Common Stock not to exceed 0.5% of the issued and
outstanding shares of Common Stock of the Company as of the date of such sale
if the undersigned's employment with the Company is terminated without Cause
(as defined in the employment agreement between the undersigned and the
Company).

   
---|--- 
 

  

  

 

 

 

  

   

  

 

 

 

  

provided however, that in the case of any transfer, disposition, distribution
or pledge pursuant to clause (b), (c), (d) or (e) hereunder, such transfer
shall not involve a disposition for value and provided further, in the case of
any transfer, disposition, distribution or pledge pursuant to clause (b), (c),
(d), (e) or (j) hereunder, that each transferee, donee distributee or pledgee
shall execute and deliver to the Company a lock-up agreement in the form of
this Lock-Up Agreement; and (ii) that no filing by any party (donor, donee,
transferor, transferee, pledger or pledgee) under the Exchange Act, or other
public announcement shall be made (including voluntarily) in connection with
such transfer, disposition, distribution or pledge, except as otherwise
compelled to do so or is required to do so to comply with applicable law or
legal process or any request by or from a governmental authority or the rules
of any securities exchange or the rules and regulations of any "self
regulatory organization" as defined in Section 3(a)(26) of the Securities
Exchange Act of 1934, as amended, or any other United States or foreign
securities exchange, futures exchange, commodities exchange or contract
market.

  


 

  

For the avoidance of doubt, this Lock-Up Agreement shall not apply to shares
of Common Stock or other securities acquired in open market transactions after
the completion of the Merger (as defined in the Merger Agreement).

  


 

  

For the purposes of this Lock-Up Agreement, "immediate family" shall mean
spouse, domestic partner, parent, sibling, child, grandchild or first cousin
of the undersigned.

  


 

  

The undersigned represents and warrants that it is not a party to any
agreement or understanding that would cause a breach of this Lock-Up Agreement
if it were entered into during the period in which the restrictions set forth
herein are effective.

  


 

  

The undersigned acknowledges that the execution, delivery and performance of
this Lock-Up Agreement is a material inducement to the Company to enter into
the transactions contemplated by the Merger Agreement, and the Company shall
be entitled to specific performance of the undersigned's obligations
hereunder. The parties agree that any breach or threatened breach of this
Lock-Up Agreement by the undersigned may cause immediate and irreparable harm
to the Company for which monetary damages will not be adequate and that, in
the event of a breach or threatened breach of this Lock-Up Agreement, the
Company shall be entitled to seek and obtain immediate injunctive and other
equitable relief without proof of actual damages in addition to any other
remedies as may be available at law or in equity. The undersigned further
agrees to waive any requirement for the securing or posting of any bond in
connection with such remedy. All rights under this Lock-Up Agreement are
cumulative, not exclusive, and will be in addition to all rights and remedies
available to the Company at law or in equity.

  


 

  

The undersigned agrees and consents to the entry of stop transfer instructions
with the Company's transfer agent and registrar against the transfer of the
Lock-Up Securities except in compliance with the foregoing restrictions. In
furtherance of the foregoing, the Company and any duly appointed transfer
agent for the registration or transfer of the securities described herein are
hereby authorized to decline to make any transfer of securities if such
transfer would constitute a violation or breach of this Lock-Up Agreement.

  


 

  

 

 

 

  

   

  

 

 

 

  

The undersigned hereby represents and warrants that the undersigned has full
power and authority to execute, deliver and perform this Lock-Up Agreement.
All authority herein conferred or agreed to be conferred and any obligations
of the undersigned shall be binding upon the successors, assigns, heirs or
personal representatives of the undersigned. This Lock-Up Agreement may not be
amended or otherwise modified in any respect without the written consent of
the Company and the undersigned.

  


 

  

This Lock-Up Agreement shall become effective only upon the closing of the
Merger.

  

  

THIS LOCK-UP AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR
RELATED TO THIS LOCK-UP AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO THE
CONFLICT OF LAWS PRINCIPLES THEREOF.

  


 

  

The undersigned hereby irrevocably submits to the exclusive jurisdiction and
venue of the Court of Chancery of the State of Delaware, for the purposes of
any suit, action or proceeding arising out of or relating to this Lock-Up
Agreement, and hereby waives, and agrees not to assert in any such suit,
action or proceeding, any claim that (i) it is not personally subject to the
jurisdiction of such court, (ii) the suit, action or proceeding is brought in
an inconvenient forum, or (iii) the venue of the suit, action or proceeding is
improper. The undersigned hereby irrevocably waives personal service of
process and consents to process being served in any such suit, action or
proceeding by receiving a copy thereof sent to the undersigned at the address
on the signature page below, and such service shall constitute good and
sufficient service of process and notice thereof. The undersigned hereby
waives any right to a trial by jury. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.

  


 

  

[Signature page follows]

  


 

  

 

 

 

  

   

  

 

 

 

  

     |  

Very truly yours,

   
---|--- 
   |  |   
   |  

IF AN INDIVIDUAL:

   
   |  |   
   |  

By:

  |   
   |  |  

(duly authorized signature)

   
   |  |   
   |  

Name:

  |   
   |  |  

(please print full name)

   
   |  |   
   | Address:   
   |  |   
   |  |   
   |  |   
   |  

Date:

  |   
   |  |   
   |  |   
   |  

IF AN ENTITY:

   
   |  |   
   |  |   
   |  

(please print complete name of entity)

   
   |  |   
   |  

By:

  |   
   |  |  

(duly authorized signature)

   
   |  |   
   |  

Name:

  |   
   |  |  

(please print full name and title)

   
   |  |   
   | Address:  |   
   |  |   
   |  |   
   |  |   
   |  

Date:

  |   
 

  

  

[Signature page to Lock-Up Agreement]

  

  

 

 

 

  

   

  

 

 

 

  

Accepted as of the date first set forth above:

  

  

TEKMIRA PHARMACEUTICALS CORPORATION

  


 

  

 

    

By:

  |  |   
---|---|--- 
   |  

Name:

  |   
   |  

Title:

  |   
 

 

  


 

  


 

  

[Signature page to Lock-Up Agreement]

  

  

  


 

  

 

 

 

  

   

  

 

 

 

  

EXHIBIT C-3

  

LOCK-UP AGREEMENT

  

  

____________ ____, 2015

  

TEKMIRA PHARMACEUTICALS CORPORATION

  

8900 Glenlyon Parkway

  

Burnaby, British Columbia V5J 5J8

  

Canada

  


 

  

Ladies and Gentlemen:

  

  

This Lock-Up Agreement is being delivered to Tekmira Pharmaceuticals
Corporation, a British Columbia corporation (the "Company"), in connection
with the transactions contemplated by that certain Agreement and Plan of
Merger and Reorganization, dated __________, 2015, by and among the Company,
OnCore Biopharma, Inc., a Delaware corporation ("OnCore"), and TKM Acquisition
Corporation, a Delaware corporation (the "Merger Agreement").

  


 

  

In order to induce the Company and OnCore to complete the transactions
contemplated by the Merger Agreement, the undersigned irrevocably agrees that
for the Lock-Up Period (as defined below) and solely with respect to the
applicable amount of the Lock-Up Securities (as defined below) as specified in
the immediately following paragraph, other than as set forth below or with the
prior written consent of the Company, the undersigned will not, directly or
indirectly by itself or through others: (1) offer, pledge, announce the
intention to sell, sell, contract to sell, sell any option, purchase any
option or contract to sell, grant any option, right or warrant to purchase, or
otherwise transfer or dispose of, directly or indirectly, any common shares of
the Company ("Common Stock"), or any securities of the Company that are
substantially similar to the Common Stock, or any securities convertible into
or exercisable or exchangeable for Common Stock (including, but not limited
to, Common Stock which may be deemed to be beneficially owned by the
undersigned in accordance with the rules and regulations of the Securities and
Exchange Commission and securities which may be issued upon exercise of a
stock option or warrant) as of the date of the Merger (as defined in the
Merger Agreement) (collectively, the "Lock-Up Securities"); or (2) enter into,
sell or otherwise dispose of any swap, option, future, forward or other
agreement that transfers, in whole or in part, any of the economic
consequences of ownership of the Lock-Up Securities, whether any such
transaction described in clause (1) or (2) above is to be settled by delivery
of Common Stock or such other securities, in cash or otherwise.

  


 

  

For the purpose of this Lock-Up Agreement, the "Lock-Up Period" shall mean
such period commencing on the date hereof and ending as follows: (i) with
respect to an aggregate of 25% of the Lock-Up Securities, 9 months after the
date hereof; (ii) with respect to an aggregate of 35% of the Lock-Up
Securities, 12 months after the date hereof; (iii) with respect to an
aggregate of 45% of the Lock-Up Securities, 15 months after the date hereof;
(iv) with respect to an aggregate of 55% of the Lock-Up Securities, 18 months
after the date hereof; (v) with respect to an aggregate of 65% of the Lock-Up
Securities, 21 months after the date hereof; (vi) with respect to an aggregate
of 75% of the Lock-Up Securities, 24 months after the date hereof; and (vii)
with respect to all of the Lock-Up Securities, 27 months after the date
hereof.

  

  

 

 

 

  

   

  

 

 

 

  

The restrictions contained in this Lock-Up Agreement shall not apply to the
following:

  


 

  

    

w.

  |  

the establishment of a 10b5-1 trading plan under the Securities Exchange Act
of 1934, as amended (the "Exchange Act") or similar provisions under
applicable securities laws in Canada, by a security holder for the sale of
shares of Common Stock, provided that such plan shall only provide for the
transfer of such number of shares of Common Stock for which the Lock-Up Period
has terminated pursuant to the immediately preceding paragraph;

   
---|--- 
 

  

    

x.

  |  

transfers by security holders of shares of Common Stock or other securities as
a bona fide gift or charitable contribution or by will or intestacy;

   
---|--- 
 

  

    

y.

  |  

transfers by distribution by security holders of shares of Common Stock or
other securities to partners, members, stockholders or holders of similar
equity interests of the security holder;

   
---|--- 
 

  

    

z.

  |  

transfers by security holders of shares of Common Stock or other securities to
any trust or other entity for the direct or indirect benefit of the security
holder or the "immediate family" of the security holder;

   
---|--- 
 

  

    

aa.

  |  

transfers of shares of Common Stock pursuant to a domestic order or negotiated
divorce settlement;

   
---|--- 
 

  

    

bb.

  |  

the exercise by the undersigned of a stock option granted under a stock
incentive plan or stock purchase plan authorized by the board of directors of
the Company, and the receipt by the undersigned from the Company of shares of
Common Stock upon such exercise, provided that the underlying shares shall
continue to be subject to the restrictions on transfer set forth in this Lock-
Up Agreement;

   
---|--- 
 

  

    

cc.

  |  

transfers by securityholders to the Company in connection with the repurchase
of shares of Common Stock in connection with the termination of the
undersigned's employment with the Company pursuant to contractual agreements
with the Company;

   
---|--- 
 

  

    

dd.

  |  

pursuant to any tender offer, takeover bid, merger, consolidation, acquisition
of the Company or its voting securities or other similar transaction relating
to the Company or its voting securities that occurs after the Merger and that
is approved by the board of directors of the Company;

   
---|--- 
 

  

    

ee.

  |  

granting of a security interest in (whether by way of pledge or otherwise) of
shares of Common Stock or other securities by the undersigned in connection
with a loan made in good faith on bona fide, arm's length terms, and any
subsequent transfer of such securities to such lender or collateral agent in
connection with the exercise of remedies in connection with such loan in the
event of default; and

   
---|--- 
 

  

    

ff.

  |  

sales of shares of Common Stock not to exceed 0.5% of the issued and
outstanding shares of the Company as of the date of such sale if the
undersigned's employment with the Company is terminated without "Cause" (as
defined in the employment agreement between the undersigned and the Company).

   
---|--- 
 

  

  

provided however, that in the case of any transfer, disposition, distribution
or pledge pursuant to clause (b), (c), (d) or (e) hereunder, such transfer
shall not involve a disposition for value and provided further that in the
case of any transfer, disposition, distribution or pledge pursuant to clause
(b), (c), (d), (e) or (i), each transferee, donee, distributee or pledgee
shall execute and deliver to the Company a lock-up agreement in the form of
this Lock-Up Agreement; and (ii) that no filing by any party (donor, donee,
transferor, transferee, pledger or pledgee) under the Exchange Act, or other
public announcement shall be made (including voluntarily) in connection with
such transfer, disposition, distribution or pledge, except as otherwise
compelled to do so or is required to do so to comply with applicable law or
legal process or any request by or from a governmental authority or the rules
of any securities exchange or the rules and regulations of any "self
regulatory organization" as defined in Section 3(a)(26) of the Securities
Exchange Act of 1934, as amended, or any other United States or foreign
securities exchange, futures exchange, commodities exchange or contract
market.

  


 

  

 

 

 

  

   

  

 

 

 

  

For the avoidance of doubt, this Lock-Up Agreement shall not apply to shares
of Common Stock or other securities acquired in open market transactions after
the completion of the Merger (as defined in the Merger Agreement). 
 

  

For the purposes of this Lock-Up Agreement, "immediate family" shall mean
spouse, domestic partner, parent, sibling, child, grandchild or first cousin
of the undersigned.

  


 

  

The undersigned represents and warrants that it is not a party to any
agreement or understanding that would cause a breach of this Lock-Up Agreement
if it were entered into during the period in which the restrictions set forth
herein are effective.

  


 

  

The undersigned acknowledges that the execution, delivery and performance of
this Lock-Up Agreement is a material inducement to the Company and OnCore to
enter into the transactions contemplated by the Merger Agreement, and the
Company shall be entitled to specific performance of the undersigned's
obligations hereunder. The parties agree that any breach or threatened breach
of this Lock-Up Agreement by the undersigned may cause immediate and
irreparable harm to the Company for which monetary damages will not be
adequate and that, in the event of a breach or threatened breach of this Lock-
Up Agreement, the Company shall be entitled to seek and obtain immediate
injunctive and other equitable relief without proof of actual damages in
addition to any other remedies as may be available at law or in equity. The
undersigned further agrees to waive any requirement for the securing or
posting of any bond in connection with such remedy. All rights under this
Lock-Up Agreement are cumulative, not exclusive, and will be in addition to
all rights and remedies available to the Company at law or in equity.

  


 

  

The undersigned agrees and consents to the entry of stop transfer instructions
with the Company's transfer agent and registrar against the transfer of the
Lock-Up Securities except in compliance with the foregoing restrictions. In
furtherance of the foregoing, the Company and any duly appointed transfer
agent for the registration or transfer of the securities described herein are
hereby authorized to decline to make any transfer of securities if such
transfer would constitute a violation or breach of this Lock-Up Agreement.

  


 

  

The undersigned hereby represents and warrants that the undersigned has full
power and authority to execute, deliver and perform this Lock-Up Agreement.
All authority herein conferred or agreed to be conferred and any obligations
of the undersigned shall be binding upon the successors, assigns, heirs or
personal representatives of the undersigned. This Lock-Up Agreement may not be
amended or otherwise modified in any respect without the written consent of
the Company and the undersigned.

  


 

  

 

 

 

  

   

  

 

 

 

  

This Lock-Up Agreement shall become effective only upon the closing of the
Merger.

  


 

  

This Agreement shall be governed by and construed in accordance with the laws
of the Province of British Columbia and the federal laws of Canada applicable
therein and each of the parties attorns to the exclusive jurisdiction of the
Province of British Columbia for all purposes hereof.

  


 

  

  

  

  

  

  

 

 

 

  

   

  

 

 

 

  

 

     |  

Very truly yours,

   
---|--- 
   |  |   
   |  

IF AN INDIVIDUAL:

   
   |  |   
   |  

By:

  |   
   |  |  

(duly authorized signature)

   
   |  |   
   |  

Name:

  |   
   |  |  

(please print full name)

   
   |  |   
   | Address:   
   |  |   
   |  |   
   |  |   
   |  

Date:

  |   
   |  |   
   |  |   
   |  

IF AN ENTITY:

   
   |  |   
   |  |   
   |  

(please print complete name of entity)

   
   |  |   
   |  

By:

  |   
   |  |  

(duly authorized signature)

   
   |  |   
   |  

Name:

  |   
   |  |  

(please print full name and title)

   
   |  |   
   | Address:  |   
   |  |   
   |  |   
   |  |   
   |  

Date:

  |   
 

 

  

  

 

 

 

  

   

  

 

 

 

  

Accepted as of the date first set forth above:

  

  

TEKMIRA PHARMACEUTICALS CORPORATION

  


 

  

 

    

By:

  |  |   
---|---|--- 
   |  

Name:

  |   
   |  

Title:

  |   
 

 

  


 

  


 

  


 

  

[Signature page to Lock-Up Agreement]

  


 

  


 

  

 

 

 

  

   

  

 

 

 

  

EXHIBIT D

  

FORM OF REGISTRATION RIGHTS AGREEMENT

  

  

  

  

  

  

 

 

 

  

   

  

 

 

  

  

  

  

  

  

 

  

TEKMIRA PHARMACEUTICALS CORPORATION

  


 

  

FORM OF REGISTRATION RIGHTS AGREEMENT

  


 

  


 

  


 

  

January 11, 2015

  

  

  

  

  

 

 

 

  

   

  

 

 

 

  

TABLE OF CONTENTS

  

  

 

     |  |  |  |  |  

Page

   
---|---|---|---|---|--- 
  

1

  |  |  |  |  

Registration Rights

  |  

1

   
   |  |  |  |  |   
   |  |  

1.1

  |  |  

Definitions

  |  

1

   
   |  |  

1.2

  |  |  

Form S-3 Shelf Registration

  |  

2

   
   |  |  

1.3

  |  |  

Request for Registration

  |  

4

   
   |  |  

1.4

  |  |  

Company Registration

  |  

5

   
   |  |  

1.5

  |  |  

Suspension of Offers, Sales and Dispositions of Registrable Securities Under
Registration Statement.

  |  

7

   
   |  |  

1.6

  |  |  

Obligations of the Company

  |  

8

   
   |  |  

1.7

  |  |  

Information from Holder

  |  

11

   
   |  |  

1.8

  |  |  

Expenses of Registration

  |  

11

   
   |  |  

1.9

  |  |  

Delay of Registration

  |  

12

   
   |  |  

1.10

  |  |  

Indemnification

  |  

12

   
   |  |  

1.11

  |  |  

Reports Under the 1934 Act

  |  

14

   
   |  |  

1.12

  |  |  

Assignment of Registration Rights

  |  

15

   
   |  |  

1.13

  |  |  

Limitations on Subsequent Registration Rights

  |  

15

   
   |  |  

1.14

  |  |  

"Market Stand-Off" Agreement

  |  

16

   
   |  |  |  |  |   
  

2

  |  |  |  |  

Miscellaneous

  |  

17

   
   |  |  |  |  |   
   |  |  

2.1

  |  |  

Successors and Assigns

  |  

17

   
   |  |  

2.2

  |  |  

Governing Law

  |  

17

   
   |  |  

2.3

  |  |  

Counterparts

  |  

17

   
   |  |  

2.4

  |  |  

Titles and Subtitles

  |  

17

   
   |  |  

2.5

  |  |  

Notices

  |  

17

   
   |  |  

2.6

  |  |  

Expenses

  |  

17

   
   |  |  

2.7

  |  |  

Entire Agreement; Amendments and Waivers

  |  

18

   
   |  |  

2.8

  |  |  

Severability

  |  

18

   
   |  |  

2.9

  |  |  

Aggregation of Stock

  |  

18

   
   |  |  

2.10

  |  |  

Specific Performance

  |  

18

   
 

 

  

  

 

 

 

  

 

i  

  

 

 

 

  

FORM OF REGISTRATION RIGHTS AGREEMENT

  

  

THIS REGISTRATION RIGHTS AGREEMENT (the "Agreement") is entered into as of
January 11, 2015, by and among Tekmira Pharmaceuticals Corporation, a British
Columbia corporation (the "Company") and the OnCore Holders (as defined below)
and shall become effective upon closing of the Merger (as defined below).

  

  

RECITALS

  

  

WHEREAS, concurrently with the execution and delivery hereof, the Company, TKM
Acquisition Corporation, a Delaware corporation and a wholly-owned direct
subsidiary of the Company ("Merger Sub"), and OnCore Biopharma, Inc., a
Delaware corporation ("OnCore"), are entering into that certain Agreement and
Plan of Merger and Reorganization (the "Merger Agreement"), which provides for
the business combination of OnCore and the Company through the merger of
Merger Sub with and into OnCore, pursuant to which OnCore will become a
wholly-owned subsidiary of the Company (the "Merger"); and

  


 

  

WHEREAS, in order to induce OnCore to enter into the Merger Agreement, the
OnCore Holders and the Company have agreed to enter into this Agreement
providing for certain rights related to the registration of the shares of the
Company to be received by the OnCore Holders pursuant to the Merger.

  

  

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

  

  

1. REGISTRATION RIGHTS. The Company covenants and agrees as follows:

  

  

1.1 Definitions. For purposes of this Agreement:

  

  

(a) The term "1934 Act" means the Securities Exchange Act of 1934, as amended.

  

  

(b) The term "Act" means the Securities Act of 1933, as amended.

  

  

(c) The term "Board" means the board of directors of the Company.

  

  

(d) The term "Business Day" means any day on which banks in the State of New
York or the Province of British Columbia are required or authorized to close.

  

  

(e) The term "Common Stock" means the Company's common shares, no par value
per share.

  

  

(f) The term "Excluded Registration" means any registration statement relating
solely to the sale of securities to participants in a Company stock plan, a
registration statement relating to a corporate reorganization or other
transaction of the nature covered by Rule 145 under the Act, a registration
statement on any form that does not include substantially the same information
as would be required to be included in a registration statement covering the
sale of the Registrable Securities, or a registration statement in which the
only Common Stock being registered is Common Stock issuable upon conversion of
debt securities that are also being registered.

  

  

 

 

 

  

   

  

 

 

 

  

(g) The term "Form S-3" means such form under the Act as in effect on the date
hereof or any registration form under the Act subsequently adopted by the SEC
that permits inclusion or incorporation of substantial information by
reference to other documents filed by the Company with the SEC.

  

  

(h) The term "Free Writing Prospectus" means a free writing prospectus, as
defined in Rule 405 under the Act.

  

  

(i) The term "Holder" means an OnCore Holder or any assignee thereof in
accordance with Section 1.12 hereof.

  

  

(j) The term "Lock-Up Agreement" means one or more Lock-Up Agreements, dated
the date hereof, between each of the OnCore Holders and Company.

  

  

(k) The term "OnCore Holder" means each former security holder of OnCore
listed on Schedule A hereto who has executed and delivered to the Company a
counterpart signature page to this Agreement.

  

  

(l) The terms "register," "registered" and "registration" refer to a
registration effected by preparing and filing a registration statement or
similar document in compliance with the Act, and the declaration or ordering
of effectiveness of such registration statement or document under the Act.

  

  

(m) The term "Registrable Securities" means (A) the shares of Common Stock
issued to the OnCore Holders pursuant to the Merger Agreement and any assignee
or transferee thereof in accordance with Section 1.12 hereof, and (B) any
shares of Common Stock issued as (or issuable upon the conversion or exercise
of any warrant, right or other security that is issued as) a dividend or other
distribution with respect to, or in exchange for, or in replacement of, the
shares referenced in (A) above. Notwithstanding the foregoing, Registrable
Securities shall not include any securities (x) sold by a person to the public
pursuant to a registration statement (on Form S-8 or otherwise) or pursuant to
Rule 144, (y) sold in a private transaction in which the transferor's rights
under Section 1 of this Agreement are not assigned or (z) held by a Holder
(together with its affiliates and other Holders that share a common investment
advisor with such Holder) if such Holder (together with its affiliates and
other Holders that share a common investment advisor with such Holder)
beneficially owns less than 3% of the Company's outstanding shares of Common
Stock, if such securities may then be sold pursuant to Rule 144(b)(1).

  

  

(n) The "number of Registrable Securities" outstanding shall be determined by
the number of shares of Common Stock outstanding that are, and the number of
shares of Common Stock issuable pursuant to then exercisable or convertible
securities that are, Registrable Securities.

  

  

 

 

 

  

 

2  

  

 

 

 

  

(o) The term "Rule 144" means Rule 144 under the Act.

  

  

(p) The term "SEC" means the Securities and Exchange Commission.

  

  

1.2 Form S-3 Shelf Registration.

  

  

(a) After the closing of the Merger, the Company shall file a resale
registration statement on Form S-3 (the "Resale Registration Statement") in
accordance with and pursuant to Rule 415 promulgated under the Securities Act
(or any successor rule then in effect) and shall effect any related
qualification or compliance as would permit or facilitate the sale and
distribution of all or any portion of the Registrable Securities owned by the
Holders, including by naming such Holders as selling securityholders, and
shall use its commercially reasonable efforts to cause such Resale
Registration Statement to become effective under the Act no later than the
first date Registrable Securities may be sold by any OnCore Holder under its
Lock-Up Agreement.

  

  

(b) The Company shall use its reasonable best efforts to keep such Resale
Registration Statement continuously effective under the Act in order to permit
the prospectus forming a part thereof to be usable by the Holders until the
date as of which there are no Registrable Securities outstanding and in no
event prior to the applicable period referred to in Section 4(3) of the Act
and Rule 174 thereunder. During the period that the Resale Registration
Statement is effective, the Company shall supplement the prospectus contained
in the Resale Registration Statement or make amendments to the Resale
Registration Statement (whether or not required by the form on which the
Registrable Securities are being registered), if required by the Act or if
requested by any Holder, including to reflect any specific plan of
distribution or method of sale, and shall use its reasonable best efforts to
have any such amendments declared effective as soon as practicable after
filing.

  

  

(c) At any time and from time to time after the Resale Registration Statement
has been declared effective by the Commission, any one or more Holders of
Registrable Securities that in the aggregate hold at least 40% of the then
total outstanding Registrable Securities may request to sell all or any
portion of their Registrable Securities in an underwritten offering (including
an "at-the-market offering" or a "registered direct offering") that is
registered pursuant to the Resale Registration Statement (each, an
"Underwritten Shelf Takedown"); provided that in the case of any such
Underwritten Shelf Takedown such Holder or Holders will be entitled to make
such demand only if the total offering price to the public of the Registrable
Securities to be sold in such offering is reasonably expected to exceed
$20,000,000 in the aggregate. The Company shall, within five (5) days of the
receipt of such demand, give written notice thereof to all other Holders, and
shall include in such Underwritten Shelf Takedown all Registrable Securities
with respect to which the Company has received written requests for inclusion
therein within ten (10) Business Days after sending such written notice.

  

  

 

 

 

  

 

3  

  

 

 

 

  

(d) The Company shall not be obligated to effect, or take any action to
effect, an Underwritten Shelf Takedown pursuant to this Section 1.2:

  

  

(i) if Form S-3 is not available for such offering by the Holders;

  

  

(ii) if such Underwritten Shelf Takedown would be priced within less than
ninety (90) days after the pricing of a previous Underwritten Shelf Takedown
or a Piggy-Back Underwritten Offering; and

  

  

(iii) if the Company has already effected two (2) Underwritten Shelf Takedowns
in the preceding twelve (12) months.

  

  

(e) All Holders proposing to distribute their securities through an
Underwritten Shelf Takedown shall enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for such
underwriting by a majority in interest of participating Holders (which
underwriter or underwriters shall be reasonably acceptable to the Company).
Notwithstanding any other provision of this Section 1.2, if the underwriter
advises the Company that marketing factors require a limitation on the number
of securities to be underwritten, then the Company shall so advise all Holders
participating in the Underwritten Shelf Takedown, and the number of shares
that may be included therein shall be allocated to the Holders pro rata based
on the number of Registrable Securities held by all such Holders. In no event
shall any Registrable Securities held by Holders be excluded from such
underwriting unless all other securities are first excluded.

  

  

1.3 Request for Registration.

  

  

(a) Subject to the conditions of this Section 1.3, if the Company shall
receive at any time a written request from the Holders (for purposes of this
Section 1.3, the "Initiating Holders") holding forty percent percent (40%) or
more of the Registrable Securities then outstanding that the Company file a
registration statement under the Act covering the registration of Registrable
Securities with an aggregate offering price to the public that is reasonably
expected to exceed $25,000,000 in the aggregate or (ii) holding seventy-five
percent (75%) or more of the Registrable Securities then outstanding that the
Company file a registration statement under the Act covering the registration
of Registrable Securities with an aggregate offering price to the public that
is reasonably expected to exceed $20,000,000 in the aggregate, then the
Company shall, within five (5) days of the receipt thereof, give written
notice of such request to all Holders, and subject to the limitations of this
Section 1.3, use all reasonable best efforts to effect, as soon as
practicable, the registration under the Act of all Registrable Securities that
the Holders request to be registered in a written request received by the
Company within ten (10) Business Days of the mailing of the Company's notice
pursuant to this Section 1.3(a).

  

  

 

 

 

  

 

4  

  

 

 

 

  

(b) If the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the
Company as a part of their request made pursuant to this Section 1.3, and the
Company shall include such information in the written notice referred to in
Section 1.3(a). In such event, the right of any Holder to include its
Registrable Securities in such registration shall be conditioned upon such
Holder's participation in such underwriting and the inclusion of such Holder's
Registrable Securities in the underwriting (unless otherwise mutually agreed
by a majority in interest of the Initiating Holders and such Holder) to the
extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for such
underwriting by a majority in interest of the Initiating Holders (which
underwriter or underwriters shall be reasonably acceptable to the Company).
Notwithstanding any other provision of this Section 1.3, if the underwriter
advises the Company that marketing factors require a limitation on the number
of securities underwritten (including Registrable Securities), then the
Company shall so advise all Holders holding Registrable Securities that would
otherwise be underwritten pursuant hereto, and the number of shares that may
be included in the underwriting shall be allocated to the Holders holding such
Registrable Securities pro rata based on the number of Registrable Securities
held by all such Holders (including the Initiating Holders). In no event shall
any Registrable Securities held by Holders be excluded from such underwriting
unless all other securities are first excluded. Any Registrable Securities
excluded or withdrawn from such underwriting shall be withdrawn from the
registration.

  

  

(c) Notwithstanding the foregoing, the Company shall not be required to effect
a registration pursuant to this Section 1.3:

  

  

(i) after the Company has effected three (3) registrations pursuant to this
Section 1.3, and such registrations have been declared or ordered effective;

  

  

(ii) if the Registration Statement would become effective prior to the first
date Registrable Securities may be sold by any OnCore Holder under the Lock-Up
Agreement;

  

  

(iii) if the Registration Statement would be filed less than ninety (90) days
after the pricing of an Underwritten Shelf Takedown or a Piggy-Back
Underwritten Offering; or

  

  

(iv) if the Initiating Holders propose to dispose of Registrable Securities
that are registered on the Resale Registration Statement and such Resale
Registration Statement is effective and available for such proposed offering
by the Holders.

  

  

 

 

 

  

 

5  

  

 

 

 

  

1.4 Company Registration.

  

  

(a) Other than in connection with a request for registration pursuant to
Section 1.2 or 1.3 of this Agreement and other than in the case of an Excluded
Registration, if at any time the Company proposes to file (i) a prospectus
supplement to an effective shelf registration statement (a "Shelf Registration
Statement"), or (ii) a registration statement other than a Shelf Registration
Statement for a delayed or continuous offering pursuant to Rule 415 under the
Securities Act, in either case, for the sale of Common Stock for its own
account, or for the benefit of the holders of any of its securities other than
the Holders, to an underwriter on a firm commitment basis for reoffering to
the public or in a "bought deal" or "registered direct offering" with one or
more investment banks (collectively, a "Piggy-Back Underwritten Offering"),
then as soon as practicable but not less than fifteen (15) days prior to the
filing of (a) any preliminary prospectus supplement relating to such Piggy-
Back Underwritten Offering pursuant to Rule 424(b) under the Securities Act,
(b) any prospectus supplement relating to such Piggy-Back Underwritten
Offering pursuant to Rule 424(b) under the Securities Act (if no preliminary
prospectus supplement is used) or (c) such Shelf Registration Statement, as
the case may be, the Company shall give notice of such proposed Piggy-Back
Underwritten Offering to the Holders and such notice (a "Piggyback Notice")
shall offer the Holders the opportunity to include in such Piggy-Back
Underwritten Offering such number of Registrable Securities as each such
Holder may request in writing. Each such Holder shall then have ten (10)
Business Days after receiving such notice to request in writing to the Company
inclusion of Registrable Securities in the Piggy-Back Underwritten Offering,
except that such Holder shall have three (3) days after such Holder confirms
receipt of the notice to request inclusion of Registrable Securities in the
Piggy Back Underwritten Offering in the case of a "bought deal," "registered
direct offering" or "overnight transaction" where no preliminary prospectus is
used. Upon receipt of any such request for inclusion from a Holder received
within the specified time, the Company shall include in the Piggy Back
Underwritten Offering any of the Holders' Registrable Securities requested to
be included on the terms set forth in this Agreement. Prior to the
commencement of any "road show," any Holder shall have the right to withdraw
its request for inclusion of its Registrable Securities in any registration by
giving written notice to the Company of its request to withdraw and such
withdrawal shall be irrevocable and, after making such withdrawal, such Holder
shall no longer have any right to include Registrable Securities in the Piggy-
Back Underwritten Offering as to which such withdrawal was made.

  

  

(b) If the Company does not qualify as a well-known seasoned issuer (within
the meaning of Rule 405 under the Securities Act) (a "WKSI"), (i) the Company
shall give each Holder fifteen (15) days' notice prior to filing a Shelf
Registration Statement and, upon the written request of any Holder, received
by the Company within ten (10) days of such notice to the Holder, the Company
shall include in such Shelf Registration Statement a number of shares of
Common Stock equal to the aggregate number of Registrable Securities requested
to be included without naming any requesting Holder as a selling shareholder
and including only a generic description of the holder of such securities (the
"Undesignated Registrable Securities"), (ii) the Company shall not be required
to give notice to any Holder in connection with a filing pursuant to Section
1.4(a) unless such Holder provided such notice to the Company pursuant to this
Section 1.4(b) and included Undesignated Registrable Securities in the Shelf
Registration Statement related to such filing, and (iii) at the written
request of a Holder given to the Company more than seven (7) days before the
date specified in writing by the Company as the Company's good faith estimate
of a launch of a Piggy-Back Underwritten Offering (or such shorter period to
which the Company in its sole discretion consents), the Company shall use its
reasonable best efforts to effect the registration of any of the Holders'
Undesignated Registrable Securities so requested to be included and shall file
a post-effective amendment or, if available, a prospectus supplement to a
Shelf Registration Statement to include such Undesignated Registrable
Securities as any Holder may request.

  

  

 

 

 

  

 

6  

  

 

 

 

  

(c) Right to Terminate Registration. The Company shall have the right to
terminate or withdraw any registration or offering initiated by it under this
Section 1.4 before the effective date of such registration or the completion
of such offering, whether or not any Holder has elected to include Registrable
Securities in such registration or offering. The expenses of such withdrawn
registration or offering shall be borne by the Company in accordance with
Section 1.8.

  

  

(d) Underwriting Requirements. All Holders proposing to include their
securities in any Piggyback Underwritten Offering shall enter into an
underwriting agreement in customary form. Notwithstanding any other provision
of this Section 1.4, if the underwriter advises the Company that marketing
factors require a limitation on the number of securities to be underwritten,
then the Company shall so advise all Holders participating in the Piggyback
Underwritten Offering, and the number of securities that may be included
therein shall be allocated to the Holders pro rata based on the number of
Registrable Securities held by all such Holders, provided that, in no event
shall any Registrable Securities held by Holders be excluded from such
underwriting unless all other securities are first excluded other than
securities proposed to be included by the Company and, provided further, that
in no event shall the amount of securities of the selling Holders included in
the offering be reduced below twenty percent (20%) of the total amount of
securities included in such offering.

  

  

1.5 Suspension of Offers, Sales and Dispositions of Registrable Securities
Under Registration Statement.

  

  

 

 

 

  

 

7  

  

 

 

 

  

If the Company shall furnish at any time to Holders of Registrable Securities
seeking to effect and Underwritten Shelf Takedown pursuant to Section 1.2 or
seeking the filing of a registration statement or offering pursuant to Section
1.3, a certificate signed by the Company's Chief Executive Officer or Chairman
of the Board stating that in the good faith judgment of the Board, it would be
seriously detrimental to the Company and its stockholders for a registration
statement to be filed or for offers and sales or other dispositions of
Registrable Securities to continue under any registration statement, the
Company may delay such filing or restrict such offers and sales or other
dispositions of Registrable Securities for a reasonable period of time not to
exceed ninety (90) days, and a Holder will not be permitted to offer or sell
or otherwise dispose of Registrable Securities, by delivering a written notice
(a "Suspension Notice") to all such Holders (such delivery shall be made to
such Holders' address set forth opposite each such Holders' name on Schedule
A) stating that a delay in the offer and sale or other disposition of
Registrable Securities is necessary due to such a finding by the Board,
provided that (1) such right may not be exercised with respect to the filing
of the Resale Registration Statement, (2) such right shall be exercised by the
Company not more than once in any twelve (12) month period, (3) all executive
officers and directors of the Company shall also be prohibited from selling
securities of the Company during any such period other than pursuant to Rule
10b5-1 trading plans previously adopted by such individuals prior to such
suspension in the offer, sale or other disposition of such Registrable
Securities, and (4) the Company shall not register or sell any securities for
the account of itself or any other stockholder during such period (other than
a registration relating solely to the sale of securities of participants in a
Company stock plan (including any stock plan assumed by the Company in
connection with a merger or similar transaction), or a registration in which
the only Common Stock being registered is Common Stock issuable upon
conversion of debt securities that are also being registered). Promptly
following the cessation or discontinuance of the facts and circumstances
forming the basis for any Suspension Notice, the Company shall use its
reasonable best efforts to amend such registration statement and/or amend or
supplement the related prospectus included therein to the extent necessary,
and take all other actions reasonably necessary, to allow the offer and sale
or other disposition of Registrable Securities to recommence as promptly as
possible, and promptly notify all Holders in writing when such offers and
sales or other dispositions of Registrable Securities under such registration
statement may recommence. Upon receipt of a Suspension Notice, Holders shall
immediately suspend their use of such registration statement and any
prospectus included therein or forming a part thereof to offer and sell or
otherwise dispose of Registrable Securities, and shall not offer or sell or
otherwise dispose of Registrable Securities under such registration statement
or any prospectus included therein or forming a part thereof until receipt of
a notice from the Company pursuant to the preceding sentence that offers and
sales or other dispositions of Registrable Securities may recommence. Holders
shall keep the fact that the Company has delivered a Suspension Notice and any
non-public information provided by the Company in connection therewith
strictly confidential, shall not disclose or reveal the Suspension Notice or
any such information to any person or entity and shall not use such
information for securities trading or any other purpose.

  

  

 

 

 

  

 

8  

  

 

 

 

  

1.6 Obligations of the Company. Whenever required under this Section 1 to
effect the registration of any Registrable Securities, the Company shall, as
expeditiously as reasonably possible:

  

  

(a) prepare and file with the SEC a registration statement with respect to
such Registrable Securities and use its reasonable best efforts to cause such
registration statement to become effective, and keep such registration
statement effective until the distribution contemplated in the registration
statement has been completed and prepare and file with the SEC such amendments
and supplements to such registration statement and the prospectus used in
connection with such registration statement as may be necessary to comply with
the provisions of the Act with respect to the disposition of all securities
covered by such registration statement; provided that before filing a
registration statement or prospectus or any amendments or supplements thereto
or any Free Writing Prospectuses related thereto, the Company will furnish to
one counsel selected by the holders of a majority of the Registrable
Securities included in such registration statement or offering copies of all
such documents proposed to be filed which documents shall be subject to the
review and comment of such counsel, and include in any registration statement
such additional information reasonably requested by the holders of a majority
of the Registrable Securities registered under the applicable registration
statement, or the underwriters, if any, for marketing purposes, whether or not
required by applicable securities laws;

  

  

(b) if requested by the managing underwriters (if any) or the holders of a
majority of the then outstanding Registrable Securities included in such
registration statement or offering, as applicable, promptly include in a
prospectus supplement or post-effective amendment such information as the
managing underwriters (if any) or such holders may reasonably request in order
to permit the intended method of distribution of such securities and make all
required filings of such prospectus supplement or such post-effective
amendment as soon as practicable after the Company has received such request;

  

  

(c) furnish without charge to the Holders of Registrable Securities included
in such registration such number of copies of a prospectus, including a
preliminary prospectus and any Free Writing Prospectus, in conformity with the
requirements of the Act, and such other documents as they may reasonably
request in order to facilitate the disposition of Registrable Securities owned
by them;

  

  

(d) use commercially reasonable efforts to register and qualify the securities
covered by such registration statement under such other securities or blue sky
laws of such jurisdictions as shall be reasonably requested by the Holders
included in such registration, provided that the Company shall not be required
in connection therewith or as a condition thereto to qualify to do business or
to file a general consent to service of process in any such states or
jurisdictions unless the Company is already subject to service in such
jurisdiction;

  

  

(e) in the event of any underwritten public offering, enter into and perform
its obligations under an underwriting agreement, in usual and customary form,
with the managing underwriter of such offering, provided that the Holders
selling Registrable Securities in such underwritten public offering are
entering into the same underwriting agreement;

  

  

 

 

 

  

 

9  

  

 

 

 

  

(f) notify each seller of such Registrable Securities, (i) promptly after it
receives notice thereof, of the date and time when such registration statement
and each post-effective amendment thereto has become effective or a prospectus
or supplement to any prospectus relating to a registration statement has been
filed and when any registration or qualification has become effective under a
state securities or blue sky law or any exemption thereunder has been
obtained, (ii) promptly after receipt thereof, of any request by the SEC or
any state securities authority for the amendment or supplementing of such
registration statement or prospectus or for additional information, (iii)
promptly after it receives notice thereof, of the issuance by the SEC or any
state securities authority of any stop order suspending such registration
statement or the initiation of any proceedings for that purpose, (iv) promptly
after receipt thereof, of any notification with respect to the suspension of
qualification of the Registrable Securities for sale in any jurisdiction or
the initiation of any proceeding for such purpose and (v) promptly at any time
when a prospectus relating thereto is required to be delivered under the Act
that includes the happening of any event the result of which the prospectus
included in such registration statement contains an untrue statement of a
material fact or omits any fact necessary to make the statements therein not
misleading, and, at the request of any such seller, the Company will promptly
prepare a supplement or amendment to such prospectus so that, as thereafter
delivered to the purchasers of such Registrable Securities, such prospectus
will not contain an untrue statement of a material fact or omit to state any
fact necessary to make the statements therein not misleading in light of the
circumstances under which they were made;

  

  

(g) cause all Registrable Securities registered pursuant to this Section 1 to
be listed on a national exchange or trading system and on each securities
exchange and trading system on which similar securities issued by the Company
are then listed;

  

  

(h) enter into and perform such customary agreements (including underwriting
agreements in customary form, which agreements include customary limitations
on the liability of the holders of Registrable Securities) and take all such
other actions as holders of a majority of the Registrable Securities being
sold, or the underwriters, if any, reasonably request in order to expedite or
facilitate the disposition of such Registrable Securities (including, without
limitation, using reasonable best efforts to have officers and senior
management of the Company and its subsidiaries, participate in "road shows,"
analyst and investor presentations and marketing events);

  

  

(i) promptly make available at reasonable times for inspection by any seller
of Registrable Securities, any underwriter participating in any disposition
pursuant to such registration statement and any attorney, accountant or other
agent retained by any such seller or underwriter, all financial and other
records, pertinent corporate documents and properties of the Company, and
cause the Company's officers, directors, employees and independent accountants
to supply all information reasonably requested by any such seller,
underwriter, attorney, accountant or agent in connection with such
registration statement subject to the applicable person(s) executing a
nondisclosure agreement in reasonable form and substance if reasonably
required by the Company;

  

  

 

 

 

  

 

10  

  

 

 

 

  

(j) permit any holder of Registrable Securities who, in its sole and exclusive
judgment, might be deemed to be an underwriter or a person who controls the
Company within the meaning of the Act (a "controlling Person") of the Company,
to participate in the preparation of such registration or comparable statement
and to require the insertion therein of material, furnished to the Company in
writing, which in the reasonable judgment of such holder and its counsel
should be included;

  

  

(k) use commercially reasonable efforts to prevent the issuance of any stop
order suspending the effectiveness of a registration statement, or of any
order suspending or preventing the use of any related prospectus or suspending
the qualification of any Registrable Securities included in such registration
statement for sale in any jurisdiction, and in the event of the issuance of
any such stop order or other such order the Company shall advise such holders
of Registrable Securities of such stop order or other such order promptly
after it shall receive notice or obtain knowledge thereof and shall use
reasonable best efforts to promptly obtain the withdrawal of such order;

  

  

(l) use commercially reasonable efforts to cause such Registrable Securities
covered by such registration statement to be registered with or approved by
such other governmental agencies or authorities as may be necessary to enable
the sellers thereof to consummate the disposition of such Registrable
Securities;

  

  

(m) use commercially reasonable efforts to obtain a "comfort" letter from the
Company's independent public accountants in customary form, addressed to each
of the underwriters, as applicable, and covering such matters of the type
customarily covered by "comfort" letters as the holders of a majority of the
Registrable Securities being sold, or managing underwriters reasonably
request;

  

  

(n) provide a legal opinion of the Company's outside counsel addressed to the
Company and the holders of Registrable Securities, dated the effective date of
such registration statement (and, if such registration includes an
underwritten public offering, dated the date of the closing under the
underwriting agreement), with respect to the registration statement, each
amendment and supplement thereto, the prospectus included therein (including
the preliminary prospectus) and such other documents relating thereto in
customary form, and reasonably acceptable to the managing underwriters, and
covering such matters of the type customarily covered by legal opinions of
such nature;

  

  

(o) use commercially reasonable efforts to cooperate and assist in any filings
required to be made with the Financial Industry Regulatory Authority
("FINRA"); and

  

  

 

 

 

  

 

11  

  

 

 

 

  

(p) take such other actions and deliver such other documents and instruments
as may be reasonably necessary to facilitate the registration and disposition
of Registrable Securities as contemplated hereby.

  

  

If any such registration or comparable statement refers to any Holder by name
or otherwise as the Holder of any securities of the Company and if, in its
sole and exclusive judgment, such Holder is or might be deemed to be a
controlling Person of the Company, such Holder shall have the right to require
(i) the insertion therein of language, in form and substance reasonably
satisfactory to such Holder and presented to the Company in writing, to the
effect that the holding by such Holder of such securities is not to be
construed as a recommendation by such Holder of the investment quality of the
Company's securities covered thereby and that such holding does not imply that
such Holder will assist in meeting any future financial requirements of the
Company or (ii) in the event that such reference to such Holder by name or
otherwise is not required by the Act or any similar federal statute then in
force, the deletion of the reference to such Holder.

  

  

1.7 Information from Holder. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 1 with
respect to the Registrable Securities of any selling Holder that such Holder
shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of
such securities as shall be reasonably required to effect the registration of
such Holder's Registrable Securities.

  

  

1.8 Expenses of Registration. All expenses (other than underwriting discounts
and commissions and stock transfer taxes applicable to the securities
registered by the Holders) incurred in connection with registrations, filings
or qualifications pursuant to Sections 1.2, 1.3 and 1.4, including (without
limitation) all registration, filing and qualification fees, printers' and
accounting fees, fees and disbursements of counsel for the Company and the
reasonable and customary fees and disbursements of one counsel for the selling
Holders not to exceed $50,000 for each registration or underwritten offering
shall be borne by the Company. Notwithstanding the foregoing, the Company
shall not be required to pay for any expenses of any registration proceeding
or offering begun pursuant to Section 1.2 or Section 1.3 if the registration
or offering request is subsequently withdrawn at the request of the Holders of
a majority of the Registrable Securities to be registered or sold in such
offering (in which case all participating Holders shall bear such expenses pro
rata based upon the number of Registrable Securities that were to be included
in the withdrawn registration), unless, in the case of a registration
requested under Section 1.3, the Holders of a majority of the Registrable
Securities agree to forfeit their right to one demand registration pursuant to
Section 1.3; provided, however, that if at the time of such withdrawal, the
Holders have learned of a material adverse change in the condition, business
or prospects of the Company from that known to the Holders at the time of
their request and have withdrawn the request with reasonable promptness
following disclosure by the Company of such material adverse change, then the
Holders shall not be required to pay any of such expenses and shall retain
their rights pursuant to Sections 1.2 and 1.3 without any such forfeiture.

  

  

 

 

 

  

 

12  

  

 

 

 

  

1.9 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any such registration as the
result of any controversy that might arise with respect to the interpretation
or implementation of this Section 1.

  

  

1.10 Indemnification. In the event any Registrable Securities are included in
a registration statement under this Section 1:

  

  

(a) To the extent permitted by law, the Company agrees to indemnify and hold
harmless each Holder, the partners, members, managers, officers, directors and
stockholders of each Holder, legal counsel, accountants and investment
advisors for each Holder, any underwriter (as defined in the Act) for such
Holder and each person, if any, who controls such Holder or underwriter within
the meaning of the Act or the 1934 Act, against any losses, claims, damages or
liabilities (joint or several) to which they may become subject under the Act,
the 1934 Act, any state securities laws or any rule or regulation promulgated
under the Act, insofar as such losses, claims, damages, liabilities or
expenses (or actions in respect thereof) arise out of or are based upon any of
the following statements, omissions or violations (collectively a "Violation")
(i) any untrue statement or alleged untrue statement of a material fact
contained or incorporated by reference in such registration statement,
including any preliminary prospectus, final prospectus, or Free Writing
Prospectus contained therein or any amendments or supplements thereto, any
issuer information (as defined in Rule 433 of the Act) incident to such
registration prepared by or on behalf of the Company or used or referred to by
the Company, (ii) the omission or alleged omission to state in such
registration statement a material fact required to be stated therein, or
necessary to make the statements therein not misleading or (iii) any violation
or alleged violation by the Company of the Act, the 1934 Act, any state
securities laws or any rule or regulation promulgated under the Act, the 1934
Act or any state securities laws, and the Company will reimburse each such
Holder, underwriter, controlling Person or other aforementioned person for any
legal or other expenses reasonably incurred by them in connection with
investigating or defending any such loss, claim, damage, liability or action
as such expenses are incurred; provided, however, that the indemnity agreement
contained in this subsection 1.10(a) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Company, nor shall the
Company be liable in any such case for any such loss, claim, damage, liability
or action to the extent that it arises out of or is based upon a Violation
that occurs in reliance upon and in conformity with written information
furnished expressly for use in connection with such registration by any such
Holder or underwriter. The Company shall reimburse such holder, partners,
members, director, officer or controlling Person for any legal or other
expenses reasonably incurred by such Holder, partner, member, manager,
officer, director and stockholder of such Holder, legal counsel, accountant
and investment advisor in connection with the investigation or defense of such
loss, claim, damage, liability or expense.

  

  

(b) To the extent permitted by law, each selling Holder, severally and not
jointly, will indemnify and hold harmless the Company, each of its directors,
each of its officers who has signed the registration statement, each
controlling Person, legal counsel and accountants for the Company, any
underwriter, any other Holder selling securities in such registration
statement and any controlling Person of any such underwriter or other Holder,
against any losses, claims, damages or liabilities (joint or several) to which
any of the foregoing persons may become subject, under the Act, the 1934 Act,
any state securities laws or any rule or regulation promulgated under the Act,
the 1934 Act or any state securities laws, insofar as such losses, claims,
damages or liabilities (or actions in respect thereto) arise out of or are
based upon any Violation, in each case to the extent (and only to the extent)
that such Violation occurs in reliance upon and in conformity with written
information furnished by such Holder expressly for use in connection with such
registration; and each such Holder will reimburse any person intended to be
indemnified pursuant to this subsection 1.10(b) for any legal or other
expenses reasonably incurred by such person in connection with investigating
or defending any such loss, claim, damage, liability or action as such
expenses are incurred; provided, however, that the indemnity agreement
contained in this subsection 1.10(b) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Holder, and provided that in
no event shall any indemnity under this subsection 1.10(b) when taken together
with any contribution under subsection 1.10(d) exceed the net proceeds from
the offering received by such Holder.

  

  

 

 

 

  

 

13  

  

 

 

 

  

(c) Promptly after receipt by an indemnified party under this Section 1.10 of
notice of the commencement of any action (including any governmental action)
for which a party may be entitled to indemnification, such indemnified party
will, if a claim in respect thereof is to be made against any indemnifying
party under this Section 1.10, deliver to the indemnifying party a written
notice of the commencement thereof and the indemnifying party but the failure
so to notify the indemnifying party (i) will not relieve it from liability
under paragraph (a) or (b) above unless and to the extent such action and such
failure results in material prejudice to the indemnifying party and forfeiture
by the indemnifying party of substantial rights and defenses; and (ii) will
not, in any event, relieve the indemnifying party from any obligations to any
indemnified party other than the indemnification obligation provided in
paragraph (a) or (b) above. The indemnifying party shall have the right to
participate in and, to the extent the indemnifying party so desires, jointly
with any other indemnifying party similarly noticed, to assume the defense
thereof with counsel mutually satisfactory to the parties; provided, however,
that an indemnified party (together with all other indemnified parties that
may be represented without conflict by one counsel) shall have the right to
retain one separate counsel, with the fees and expenses to be paid by the
indemnifying party, if (i) the use of counsel chosen by the indemnifying party
to represent the indemnified party would present such counsel with a conflict
of interest; (ii) the actual or potential defendants in, or targets of, any
such action include both the indemnified party and the indemnifying party and
the indemnified party shall have reasonably concluded that there may be legal
defenses available to it and/or other indemnified parties which are different
from or additional to those available to the indemnifying party; (iii) the
indemnifying party shall not have employed counsel satisfactory to the
indemnified party to represent the indemnified party within a reasonable time
after notice of the institution of such action; or (iv) the indemnifying party
shall authorize the indemnified party to employ separate counsel at the
expense of the indemnifying party.

  

  

 

 

 

  

 

14  

  

 

 

 

  

(d) If the indemnification provided for in this Section 1.10 is held by a
court of competent jurisdiction to be unavailable to an indemnified party with
respect to any loss, liability, claim, damage or expense referred to herein,
then the indemnifying party, in lieu of indemnifying such indemnified party
hereunder, shall contribute to the amount paid or payable by such indemnified
party as a result of such loss, liability, claim, damage or expense in such
proportion as is appropriate to reflect the relative fault of the indemnifying
party on the one hand and the indemnified party on the other hand in
connection with the statements or omissions that resulted in such loss,
liability, claim, damage or expense, as well as any other relevant equitable
considerations; provided, however, that (i) no contribution by any Holder,
when combined with any amounts paid by such Holder pursuant to Section
1.10(b), shall exceed the net proceeds from the offering received by such
Holder and (ii) no person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Act) will be entitled to contribution from any
person who was not guilty of such fraudulent misrepresentation. The relative
fault of the indemnifying party and the indemnified party shall be determined
by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the indemnifying party or by
the indemnified party and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.

  

  

(e) No indemnifying party shall, except with the consent of the indemnified
party, consent to the entry of any judgment or enter into any settlement
unless such judgment or settlement (i) includes as an unconditional term
thereof the giving by the claimant or plaintiff to such indemnified party of a
release from all liability in respect to such claim or litigation, and (ii)
does not include any statement as to or any admission of fault, culpability or
a failure to act by or on behalf of any indemnified party.

  

  

(f) The indemnification and contribution provided for under this Agreement
shall be in addition to any other rights to indemnification and contribution
that any indemnified party may have pursuant to law or contract and shall
remain in full force and effect regardless of any investigation made by or on
behalf of the indemnified party or any officer, director or controlling Person
of such indemnified party and shall survive the transfer of securities.

  

  

(g) The obligations of the Company and Holders under this Section 1.10 shall
survive the completion of any offering of Registrable Securities in a
registration statement under this Section 1 and otherwise.

  

  

1.11 Reports Under the 1934 Act. With a view to making available to the
Holders the benefits of Rule 144 and any other rule or regulation of the SEC
that may at any time permit a Holder to sell securities of the Company to the
public without registration or pursuant to a registration on Form S-3, the
Company agrees to:

  

  

(a) make and keep current public information available, as those terms are
understood and defined in Rule 144, at all times after the date of this
Agreement;

  

  

 

 

 

  

 

15  

  

 

 

 

  

(b) file with the SEC in a timely manner all reports and other documents
required of the Company under the Act and the 1934 Act; and

  

  

(c) furnish to any Holder, so long as the Holder owns any Registrable
Securities, forthwith upon request (i) a written statement by the Company that
it has complied with the reporting requirements of Rule 144, the Act and the
1934 Act, or that it qualifies as a registrant whose securities may be resold
pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the
most recent annual or quarterly report of the Company and such other reports
and documents so filed by the Company and (iii) such other information as may
be reasonably requested to avail any Holder of any rule or regulation of the
SEC that permits the selling of any such securities without registration or
pursuant to such form.

  

  

The Company shall take such further action as any holder of Registrable
Securities may reasonably request, all to the extent required from time to
time to enable such holder of Registrable Securities to sell Registrable
Securities without registration under the Act within the limitation of the
exemptions provided by (A) Rule 144 or (B) any similar rule or regulation
hereafter adopted by the SEC.

  

  

1.12 Assignment of Registration Rights. The rights to cause the Company to
register Registrable Securities pursuant to this Section 1 may be assigned
(but only with all related obligations) by a Holder to a transferee or
assignee of such securities that (i) is a subsidiary, parent, partner, former
partner, limited partner, retired partner, member, former member, stockholder,
former stockholder or affiliate of a Holder (including, in the case of a
venture capital, private equity or similar investment fund, another fund
affiliated with or under common investment management with such fund), (ii) is
a Holder's family member or trust for the benefit of an individual Holder or
(iii) after such assignment or transfer, holds (together with its affiliates
and other entities that share a common investment advisor with such transferee
or assignee) at least 3% of the Company's outstanding shares of Common Stock,
provided: (a) the Company is, within a reasonable time after such transfer,
furnished with written notice of the name and address of such transferee or
assignee and the securities with respect to which such registration rights are
being assigned; (b) such transferee or assignee agrees in writing to be bound
by and subject to the terms and conditions of this Agreement, including,
without limitation, the provisions of Section 1.14 below; and (c) such
assignment shall be effective only if immediately following such transfer the
further disposition of such securities by the transferee or assignee is
restricted under the Act.

  

  

1.13 Limitations on Subsequent Registration Rights. From and after the date of
this Agreement, the Company shall not, without the prior written consent of
the Holders holding a majority of the then outstanding Registrable Securities,
enter into any agreement with any holder or prospective holder of any
securities of the Company that would allow such holder or prospective holder
(a) to include any of such securities in any registration statement filed
under Section 1.2, Section 1.3 or Section 1.4 hereof, unless under the terms
of such agreement, such holder or prospective holder may include such
securities in any such registration only to the extent that the inclusion of
such securities will not reduce the amount of the Registrable Securities of
the Holders that are included or (b) to demand registration of their
securities.

  

  

 

 

 

  

 

16  

  

 

 

 

  

1.14 "Market Stand-Off" Agreement.

  

  

(a) In connection with any underwritten offering pursuant to Sections 1.2, 1.3
or 1.4 hereof, upon the request of the Company or the managing underwriters of
such public offering (a "Public Offering"), no Holder of Registrable
Securities shall effect any sale of the Company's equity securities during the
period beginning on the most recent effective date of the registration
statement relating to such underwritten registration and through the date that
is no longer than ninety (90) days after the effective date of such public
offering (each, a "Follow-on Holdback Period"), except as part of such Public
Offering provided that nothing herein shall prevent a Holder from transferring
Registrable Securities to pursuant to and in accordance with Section 1.12(i)
hereof. Each Holder's agreement to not sell any of the Company's equity
securities during the Follow-on Holdback Period in connection with a Public
Offering shall be subject to and conditioned upon the executive officers and
directors of the Company entering into an agreement on substantially the same
terms relating to such Public Offering. The Follow-on Holdback Period may be
extended for no longer than thirty-five (35) days as requested by the Company
or the managing underwriters to accommodate regulatory restrictions on (A) the
publication or other distribution of research reports and (B) analyst
recommendations and opinions, including, but not limited to, the restrictions
contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor
provisions or amendments thereto (such period referred to herein as the
"Holdback Extension"). The Company may impose stop-transfer instructions with
respect to the Company's equity securities (or other securities) subject to
the foregoing restriction until the end of such period, including any period
of Holdback Extension.

  

  

(b) The Company (i) shall not effect any public sale or distribution of its
equity securities, or any securities convertible into or exchangeable or
exercisable for such securities, during the seven (7) days prior to and during
such period of time as in either case may be determined by the underwriters
managing the underwritten registration following the most recent effective
date of any underwritten registration pursuant to Sections 1.2, 1.3 or 1.4
hereof (not to exceed ninety (90) days, except as extended during the period
of any Holdback Extension), except as part of such underwritten registration
or pursuant to registrations on Form S-8, Form S-4 or in either case any
successor form and unless the underwriters managing the registered public
offering otherwise agree in writing, and (ii) shall use reasonable best
efforts to cause each director and executive officer to agree not to effect
any public sale or distribution (including sales pursuant to Rule 144) of any
such securities during such period (as extended by any Holdback Extension),
except as part of such underwritten registration, if otherwise permitted,
unless the underwriters managing the registered public offering otherwise
agree in writing.

  

  

(c) Except as provided below in this Section 1.14(c), any discretionary waiver
or termination of the restrictions of any or all of the agreements referenced
in Section 1.14(a) or Section 1.14(b) above by the Company or the managing
underwriters shall apply to all Holders subject to such restrictions pro rata
based on the number of shares subject to such restrictions, except that the
managing underwriters may, in their sole discretion, release up to an
aggregate of 100,000 shares (subject to appropriate adjustment for stock
splits, stock dividends, combinations or the like) subject to the restrictions
in Section 1.14(a) or Section 1.14(b), as applicable.

  

  

 

 

 

  

 

17  

  

 

 

 

  

2. MISCELLANEOUS.

  

  

2.1 Successors and Assigns. Except as otherwise provided herein, the terms and
conditions of this Agreement shall inure to the benefit of and be binding upon
the respective successors and assigns of the parties (including transferees
and assignees of any Registrable Securities pursuant to Section 1.12). Nothing
in this Agreement, express or implied, is intended to confer upon any party
other than the parties hereto or their respective successors and assigns any
rights, remedies, obligations or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement.

  

  

2.2 Governing Law. This Agreement shall be governed by and construed under the
laws of the State of New York as applied to agreements among New York
residents entered into and to be performed entirely within New York without
giving effect to principles of conflicts of laws.

  

  

2.3 Counterparts. This Agreement may be executed and delivered in two or more
counterparts (including facsimile, PDF, or other electronic counterparts),
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

  

  

2.4 Titles and Subtitles. The titles and subtitles used in this Agreement are
used for convenience only and are not to be considered in construing or
interpreting this Agreement.

  

  

2.5 Notices. All notices and other communications given or made pursuant
hereto shall be in writing and shall be deemed effectively given: (a) upon
personal delivery to the party to be notified; (b) when sent by confirmed
electronic mail or facsimile if sent during normal business hours of the
recipient; if not, then on the next business day; (c) five (5) days after
having been sent by registered or certified mail, return receipt requested,
postage prepaid; or (d) one (1) business day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the respective
parties at the addresses set forth on the signature pages attached hereto (or
at such other addresses as shall be specified by notice given in accordance
with this Section 2.5).

  

  

2.6 Expenses. If any action at law or in equity is necessary to enforce or
interpret the terms of this Agreement, the prevailing party shall be entitled
to reasonable attorneys' fees, costs and necessary disbursements in addition
to any other relief to which such party may be entitled.

  

  

 

 

 

  

 

18  

  

 

 

 

  

2.7 Entire Agreement; Amendments and Waivers. This Agreement (including the
Schedules and Exhibits hereto, if any) constitutes the full and entire
understanding and agreement among the parties with regard to the subjects
hereof and thereof. Subject to Section 1.13, any term of this Agreement may be
amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or
prospectively) only with the written consent of the Company and the holders of
a majority of the Registrable Securities. Any amendment or waiver effected in
accordance with this paragraph shall be binding upon each holder of any
Registrable Securities, each future holder of all such Registrable Securities,
and the Company.

  

  

2.8 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, such provision(s) shall be excluded from
this Agreement and the balance of the Agreement shall be interpreted as if
such provision(s) were so excluded and shall be enforceable in accordance with
its terms.

  

  

2.9 Aggregation of Stock. All Registrable Securities held or acquired by
affiliated entities (including affiliated investment funds or other entities
under common investment management) or persons sharing a common investment
advisor shall be aggregated together for the purpose of determining the
availability of any rights under this Agreement.

  

  

2.10 Specific Performance. The parties hereto recognize and agree that money
damages may be insufficient to compensate the holders of any Registrable
Securities for breaches by the Company of the terms hereof and, consequently,
that the equitable remedy of specific performance of the terms hereof will be
available in the event of any such breach.

  

  

[Remainder of page left intentionally blank. Signature page follows.]

  


 

  

 

 

 

  

 

19  

  

 

 

 

  

IN WITNESS WHEREOF, the parties have executed this Registration Rights
Agreement as of the date first above written.

  

  

     |  

TEKMIRA PHARMACEUTICALS CORPORATION

   
---|--- 
   |  

a British Columbia corporation

   
   |  |   
   |  |   
   |  

By:

  |   
   |  |  

Name:

   
   |  |  

Title:

   
  

  

 

  

     |  

Address:

  |   
---|---|--- 
   |  |   
   |  |   
 

  


 

  

  


 

  

  


 

  

  

 

 

 

  

 

1  

  

 

 

 

  

IN WITNESS WHEREOF, the parties have executed this Registration Rights
Agreement as of the date first above written.

  

  

     |  

ROIVANT SCIENCES LTD.

   
---|--- 
   |  |   
   |  |   
   |  

By:

  |   
   |  |  

Name:

   
   |  |  

Title:

   
 

  

  

  

  


 

  


 

  

  

  

 

 

 

  

 

2  

  

 

 

 

  

IN WITNESS WHEREOF, the parties have executed this Registration Rights
Agreement as of the date first above written.

  

  

     |  

By:

  |   
---|---|--- 
   |  |  

Name: Patrick T. Higgins

   
   |  |   
 

  

  

  


 

  

  

  


 

  


 

  


 

  

 

 

 

  

 

3  

  

 

 

 

  

IN WITNESS WHEREOF, the parties have executed this Registration Rights
Agreement as of the date first above written.

  

  

 

     |  

By:

  |   
---|---|--- 
   |  |  

 

Name: Michael J. McElhaugh

 

   
   |  |   
 

 

  

  

  


 

  

  

  

  


 

  

 

 

 

  

 

4  

  

 

 

 

  

IN WITNESS WHEREOF, the parties have executed this Registration Rights
Agreement as of the date first above written.

  

  

 

     |  

By:

  |   
---|---|--- 
   |  |  

 

 

Name: Michael J. Sofia

 

 

   
   |  |   
 

 

  

  

  

  

  

  

  

 

 

  

 

 

 

  

 

5  

  

 

 

 

  

IN WITNESS WHEREOF, the parties have executed this Registration Rights
Agreement as of the date first above written.

  

  

 

     |  

By:

  |   
---|---|--- 
   |  |  

 

 

 

Name: Bryce A. Roberts

 

 

 

   
   |  |   
 

 

  

  


 

  


 

  

  


 

  

  


 

  

 

 

 

  

 

6  

  

 

 

 

  

SCHEDULE A

  


 

  

Schedule of OnCore Holders

  

  


 

  

Roivant Sciences Ltd.

  

  

Patrick T. Higgins

  

Michael J. McElhaugh

  

Michael J. Sofia

  

Bryce A. Roberts

  

  

 

 

 

  

 

7  

  

 

 

 

  

EXHIBIT E

  

FORM OF GOVERNANCE AGREEMENT

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

 

 

 

  

 

8  

  

 

 

 

  

FORM OF GOVERNANCE AGREEMENT

  

  

THIS AGREEMENT is made as of this 11th day of January, 2015.

  

  

BETWEEN:

  

  

  

Tekmira Pharmaceuticals Corporation, a corporation incorporated under the laws
of British Columbia

  

  

(the "Company");

  

  

\- and -

  

  

Roivant Sciences Ltd., a Bermuda exempted company

  

  

(the "Shareholder")

  

WHEREAS:

  

  

    

A.

  |  

On January 11, 2015 the Company and a wholly-owned subsidiary of the Company
entered into an Agreement and Plan of Merger and Reorganization with OnCore
Biopharma, Inc. ("Owl"), a Delaware corporation (the "Merger Agreement");

   
---|--- 
 

  

  

    

B.

  |  

Pursuant to the Merger Agreement, Owl will become a wholly owned subsidiary of
the Company (the "Merger") and the Shareholder will receive Common Shares of
the Company; and

   
---|--- 
 

  

  

    

C.

  |  

As a condition of completing the Merger, the Company shall amend its Articles,
which amendment (the "Amendment") is attached as Schedule 1 to this Agreement.

   
---|--- 
 

  

NOW THEREFORE in consideration of the mutual covenants and agreements
contained in this Agreement and other good and valuable consideration (the
receipt and sufficiency of which are hereby acknowledged), the Parties agree
as follows:

  

  

I.

  

INTERPRETATION AND GENERAL MATTERS

  

  

A. Definitions

  

In this Agreement, including the recitals, unless otherwise stated,
capitalized terms used will have the meanings specified below:

  

  

"Affiliate" means with respect to any Person, any other Person that, directly
or indirectly: (i) Controls, (ii) is Controlled by or (iii) is under common
Control with, such Person;

  

  

"Agreement" means this document, together with any schedules attached hereto
and made a part hereof, all as amended, supplemented or modified from time to
time in accordance with the provisions hereof;

  

  

 

 

 

  

 

1  

  

 

 

 

  

"Amendment" has the meaning ascribed thereto in Recital C;

  

  

"Articles" means the articles of the Company as amended by the Amendment;

  

  

"Board" means the board of directors of the Company;

  

  

"Business Day" means any day other than (i) a Saturday or a Sunday or (ii) a
day on which commercial banking institutions are authorized or required by
applicable law to be closed in California, New York or British Columbia;

  

  

"Common Shares" means the common shares in the capital of the Company;

  

  

"Company" has the meaning given to it in the Preamble;

  

  

"Control" means, (i) when applied to the relationship between any Person(s)
and a corporation, the beneficial ownership by such Person(s) at the relevant
time of shares of that corporation carrying the lesser of (A) a majority of
the voting rights ordinarily exercisable at meetings of shareholders of that
corporation and (B) the percentage of voting rights ordinarily exercisable at
meetings of shareholders of that corporation that are sufficient to elect a
majority of the directors, (ii) when applied to the relationship between any
Person(s) and a limited liability company, partnership, trust or joint
venture, means the beneficial ownership by such Person(s) at the relevant time
of more than 50% of the ownership interests of the limited liability company,
partnership, trust or joint venture or the contractual right to direct the
affairs of the limited liability company, partnership, trust or joint venture,
and (iii) when applied to the relationship between any Person and a limited
partnership, means that such Person is the general partner of the limited
partnership; and the words "Controlled by", "Controlling" and similar words
have corresponding meanings; provided that any Person(s) who Controls a
corporation, limited liability company, partnership, limited partnership,
trust or joint venture will be deemed to Control a corporation, limited
liability company, partnership, limited partnership, trust or joint venture
that is Controlled by such corporation, limited liability company,
partnership, limited partnership, trust or joint venture, and so on;

  

  

"Convertible Securities" means any debt or equity securities convertible into,
or exchangeable or exercisable for, equity or voting shares in the capital of
the subject Person;

  

  

"Owl" has the meaning given to it in Recital A;

  

  

"Parties" means the Company, the Shareholder and their respective successors
and permitted assigns, and "Party" means any one of them;

  

  

"Person" includes an individual, a limited liability company, a partnership, a
limited partnership, a corporation with or without share capital, a trust, a
joint venture, a syndicate, an unincorporated organization, a union, a
government or any department or agency thereof and the heirs, executors,
administrators or other legal representatives of an individual;

  

  

"Merger" has the meaning given to it in the Merger Agreement;

  

  

"Merger Agreement" has the meaning given to it in Recital A;

  

  

"Shareholder" has the meaning given to it in the Preamble;

  

  

 

 

 

  

 

2  

  

 

 

 

  

"Shareholder Designees" has the meaning given to it in Section 2.1(a); and

  

  

"Shares" means any Common Shares beneficially owned by the Shareholder and any
Common Shares issuable upon the conversion of Convertible Securities
beneficially owned by the Shareholder.

  

  

B. Effectiveness

  

Notwithstanding any other provision contained herein or in any other agreement
between the Parties, this Agreement will come into full force and effect, upon
completion of the Merger in accordance with the terms of the Merger Agreement
and terminating upon the earlier of (i) thirty-six (36) months following the
effective date of the Merger and (ii) when Shareholder no longer has a right
to nominate one or more directors under Section 1 of this Part 28. For greater
certainty, this Agreement will not be effective, and the provisions hereof
will have no force or effect, if the Merger is not completed.

  

  

C. References, Headings and Schedule

  

The references "hereunder", "herein" and "hereof" refer to the provisions of
this Agreement, and references to Articles and Sections herein refer to
articles, sections, or subsections of this Agreement. The headings of the
Articles and Sections and any other headings, captions or indices herein are
inserted for convenience of reference only and shall not be used in any way in
construing or interpreting any provision hereof. Schedule 1 - Amendment to
Articles attached hereto forms a part of this Agreement.

  

  

D. Singular/Plural; Derivatives

  

Whenever the singular or masculine or neuter is used in this Agreement, it
shall be interpreted as meaning the plural or feminine or body politic or
corporate, and vice versa, as the context requires. Where a term is defined
herein, a capitalized derivative of such term shall have a corresponding
meaning unless the context otherwise requires.

  

  

E. Statutory References

  

Unless stated otherwise, any reference to a statute shall include and shall be
deemed to be a reference to such statute and to the regulations made pursuant
thereto, and all amendments made thereto and enforced from time to time, and
to any statute or regulation that may be passed which has the effect of
supplementing the statute so referred to or the regulations made pursuant
thereto.

  

  

F. Business Days

  

Whenever any action to be taken pursuant to this Agreement would otherwise be
required to be taken or made on a day that is not a Business Day, such action
shall be taken on the first Business Day following such day.

  

  

G. Calculation of Equity Interests

  

References to the shareholding percentage of the Shareholder in the Company in
this Agreement shall be calculated based upon the number of Shares held by the
Shareholder and its Affiliates as a percentage of the total number of issued
and outstanding Common Shares (on a non-diluted basis) of the Company at the
relevant time. The Company shall be entitled to rely on the public filings of
the Shareholder and its Affiliates with respect to the number of Shares held
by them unless and until such time as the Shareholder provides evidence
satisfactory to the Company, acting reasonably, as to the number of Shares
held by them.

  

  

 

 

 

  

 

3  

  

 

 

 

  

II.

  

GOVERNANCE MATTERS

  

  

A. Board

  

  

    

1.

  |  

In compliance with the Articles and concurrently with the completion of the
Merger, the Company has caused two (2) individuals designated by the
Shareholder (the "Shareholder Designees") to be appointed to the Board.

   
---|--- 
 

  

  

    

2.

  |  

At the annual general or special meeting of the Company's shareholders held
immediately following the effective date hereof at which directors of the
Company are elected, the Company will put forward for nomination for election
to the Board the Shareholder Designees. At each subsequent annual general or
special meeting of the Company's shareholders thereafter the Company will put
forward for nomination those Shareholder Designees that the Shareholder is
entitled to nominate pursuant to the Articles (who need not be the same
individuals as the Shareholder Designees appointed to the Board pursuant to
Section 2.1(a) but shall be those individuals set out as RS Nominated
Directors pursuant to a Nomination Notice as those terms are defined in the
Articles), and shall use commercially reasonable efforts to obtain shareholder
approval for the election of the Shareholder Designees at such meetings
(including by soliciting proxies in favour of the Shareholder Designees) and
to that end will support the Shareholder Designees for election in a manner no
less rigorous or favourable than the manner in which the Company supports any
of its other nominees.

   
---|--- 
 

  

  

    

3.

  |  

The Company shall provide advance notice to the Shareholder of any upcoming
shareholders' meetings in accordance with Part 28 of the Articles.

   
---|--- 
 

  

  

    

4.

  |  

In the event that any Shareholder Designee resigns, dies, becomes
incapacitated or otherwise ceases to be a director prior to the expiration of
his or her term as a director, such vacancy shall be filled in accordance with
the provisions of section 5 of Part 28 of the Articles. The Company shall use
all commercially reasonable steps, promptly upon receipt by it of a written
notice from the Shareholder identifying a Shareholder Designee to fill such
vacancy and in any event no later than five (5) Business Days following
receipt of such written notice, as are necessary to call a meeting of the
board of directors to vote on the appointment of such Shareholder Designee to
fill such vacancy (or to obtain a vote of the directors by way of unanimous
written resolution) and take all such other steps as are required by the
Articles and the Act with respect to such appointment.

   
---|--- 
 

  

  

 

 

 

  

 

4  

  

 

 

 

  

B. Voting

  

Unless and until the Shareholder no longer has the right to appoint a
Shareholder Designee pursuant to the Articles and provided that the Company is
in material compliance with the terms of this Agreement and the Articles, the
Shareholder will vote, and will cause its Affiliates to vote, all of the
Shares then owned by the Shareholder and its Affiliates:

  

  

    

1.

  |  

in favour of:

   
---|--- 
 

  

  

    

a.

  |  

the election of any person or persons nominated for election to the Board by
the Board from time to time in accordance with the Articles, and

   
---|--- 
 

  

  

    

2.

  |  

against:

   
---|--- 
 

  

  

    

a.

  |  

the election of any person nominated by anyone other than the Board.

   
---|--- 
 

  

  

III.

  

REPRESENTATIONS

  

Each Party represents and warrants to the other Party that it has all
requisite corporate power and authority to enter into this Agreement and the
execution and delivery of, and the performance of, and compliance with, the
terms of this Agreement does not and will not result in any breach of, or
constitute a default under, and do not and will not create a state of facts
which, after notice or lapse of time or both, would result in a breach of or
constitute a default under any term or provision of the articles, or
resolutions of that Party, any applicable laws, mortgage, note, contract,
agreement (written or oral), instrument, lease or other document to which that
Party is bound, or any judgment, decree, order, statute, rule or regulation
applicable to that Party.

  

  

IV.

  

INFORMATION RIGHTS

  

  

A. Shareholder Designee

  

[Intentionally deleted]

  

  

B. Shareholder Requirements

  

If the Shareholder (i) notifies the Company that it is actively engaging in
the preparation of a registration statement to be filed under the Securities
Act of 1933, as amended, for an initial public offering of its securities or
(ii) has a class of securities registered under Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended, and, in each case, the
Shareholder is required to either account for its investment in the Company
under the equity method of accounting or include separate financial statements
of the Company in any filing with the Securities Exchange Commission by the
Shareholder, then the Company agrees to timely provide such information that
the Shareholder reasonably requests in connection the Shareholder\'s
preparation and filing of any registration statement or other filing with
Securities and Exchange Commission, or as is otherwise reasonably necessary
for Shareholder to comply with obligations imposed on it under applicable
securities laws or any stock exchange.

  

  

 

 

 

  

 

5  

  

 

 

 

  

C. Confidentiality

  

The Shareholder agrees that, unless the written consent of the Company is
obtained, the Shareholder will not at any time use, disclose or make
available, to any Person, any information (herein "Confidential Information")
concerning the business or affairs of the Company acquired pursuant to the
provisions of Section 4.2 and Section 5.2 of this Agreement; provided,
however, that notwithstanding the foregoing, the Shareholder may make use of,
reveal or disclose Confidential Information:

  

  

    

1.

  |  

as may be expressly permitted by this Agreement;

   
---|--- 
 

  

  

    

2.

  |  

where it is already in the public domain when disclosed to the Shareholder or
becomes, after having been disclosed to the Shareholder, generally available
to the public through publication or otherwise unless the publication or other
disclosure was made directly or indirectly by the Shareholder in breach of
this Agreement;

   
---|--- 
 

  

  

    

3.

  |  

as required in order to comply with applicable laws, the orders or directions
of any governmental authority, the requirements of any stock exchange or
clearing house, or the requirements of any other regulatory authority having
jurisdiction; and

   
---|--- 
 

  

  

    

4.

  |  

to Affiliates of the Shareholder, provided such Persons have agreed to
maintain such Confidential Information in confidence on terms substantially
similar to those in this Section 4.3.

   
---|--- 
 

  

  

V.

  

TAX MATTERS

  

  

A. PFIC Status

  

For so long as the Shareholder owns stock of the Company, the Company will use
its reasonable efforts to avoid, in respect of any taxable year, being treated
as a passive foreign investment company ("PFIC") within the meaning of Section
1297 of the Code, including, but not limited to, causing a Subsidiary to file
an election pursuant to Treasury Regulation Section 301.7701-3. No later than
75 days after the end of each taxable year, the Company shall deliver to the
Shareholder an analysis as to whether the Company believes that it will be
treated as a PFIC in respect of such taxable year. Such analysis may be
prepared by the Company, but in preparing such analysis the Company shall
consult with its internationally recognized tax advisors.

  

  

B. Classification of the Merger

  

  

    

1.

  |  

Unless otherwise required pursuant to a "determination" within the meaning of
Section 1313(a) of the Code, each of the Company and Owl (i) shall report the
Merger on their Tax Returns as a "reorganization" within the meaning of
Section 368(a) of the Code, (ii) shall, to the extent required, report the
Merger on their Tax Returns as not being subject to Section 367(a)(1) of the
Code as a result of the operation of Treasury Regulation Section
1.367(a)-3(c), (iii) shall not take any inconsistent position with the
foregoing on any Tax Return or in any proceeding before any Tax authority or
other tribunal, and (iv) shall not take any action, cause or permit any action
to be taken or fail to take any action, that would cause the Merger to fail to
qualify as a "reorganization" described in Section 368(a) of the Code or that
would cause the Merger to be subject to Section 367(a)(1) of the Code.

   
---|--- 
 

  

  

 

 

 

  

 

6  

  

 

 

 

  

    

2.

  |  

The Company shall cause Owl to comply with the reporting requirements of
Treasury Regulations Section 1.367(a)-3(c)(6) applicable to the transactions
contemplated hereunder, and any other reporting requirements applicable to a
tax-free reorganization pursuant to the Code or the Treasury Regulations
promulgated thereunder.

   
---|--- 
 

  

  

    

3.

  |  

Notwithstanding anything to the contrary in this Section 5.2, neither the
Company nor Owl will be required to comply with the undertakings set forth in
Section 5.2(a) or (b) unless: (i) the shareholders of Owl immediately prior to
the completion of the Merger have provided the Company or Owl, as applicable,
with the information relating to such shareholders that is necessary for the
Company or Owl, as applicable, (A) to establish the requirements set forth in
Treasury Regulation Section 1.367(a)-3(c)(1)(i) and (B) to comply with
Treasury Regulation Section 1.367(a)-3(c)(6), and (ii) with respect to the
application of Sections 5.2(a) and (b) to a shareholder of Owl immediately
prior to the completion of the Merger, if that shareholder is a "five-percent
transferee shareholder" as defined in Treasury Regulation Section
1.367(a)-3(c)(5)(ii), such shareholder has entered into the five-year
agreement referenced in Treasury Regulation Section 1.367(a)-3(c)(1)(iii)(B).

   
---|--- 
 

  

  

C. QEF Information

  

The Company shall use its commercially reasonable efforts to provide, and
shall cause each of its subsidiaries to use its commercially reasonably
efforts to provide, to the Shareholder all information that may be necessary
to allow the Shareholder, and direct or indirect owners of the Shareholder, to
evaluate the analysis referenced in Section 5.1 and to fulfill their U.S. tax
filing and reporting obligations. The Company shall provide, and shall cause
each of its subsidiaries to provide, such information to the Shareholder as
direct and indirect owners of the Shareholder may reasonably require to timely
file and maintain a "qualified electing fund" election (as defined in Section
1295(a) of the Code) with respect to any such entity.

  

  

VI.

  

MISCELLANEOUS PROVISIONS

  

  

A. Waiver Must be in Writing

  

No waiver by any Party of any breach (whether actual or anticipated) of any of
the terms, conditions, representations or warranties contained herein shall
take effect or be binding upon that Party unless the waiver is expressed in
writing under the authority of that Party. Any waiver so given shall extend
only to the particular breach so waived and shall not limit or affect any
rights with respect to any other or future breach.

  

  

 

 

 

  

 

7  

  

 

 

 

  

B. No Amendment Except in Writing

  

This Agreement may be amended only by written instrument executed by the
Company and the Shareholder.

  

  

C. Service of Notice

  

Notwithstanding anything to the contrary contained herein, any notices,
consents, waivers or other communications required or permitted to be given
under the terms of this Agreement must be in writing and will be deemed to
have been delivered: (i) upon receipt, when delivered personally; (ii) upon
delivery, when sent by facsimile (provided that confirmation of transmission
is generated and kept on file by the sending party); or (iii) one (1) Business
Day after deposit with an overnight courier service with next day delivery
specified, in each case, properly addressed to the party to receive the same.

  

  

D. Addresses for Notice

  

The address for service of notices hereunder of each of the Parties shall be
as follows:

  

  

To the Company:

  


 

  

Tekmira Pharmaceuticals Corporation

  

100-8900 Glenlyon Parkway

  

Burnaby, British Columbia

  

Canada V5J 5J8

  

Attention:

  

Facsimile:

  

Email:

  


 

  

With a copy sent concurrently to:

  


 

  

Farris, Vaughan, Wills and Murphy LLP

  

700 West Georgia St., 25th Floor

  

Vancouver, British Columbia V7Y 1B3

  

Tel: (604) 661-9307

  

Attention: R. Hector MacKay-Dunn, Q.C.

  

E-mail: hmackay-dunn@farris.com

  

  

 

 

 

  

 

8  

  

 

 

 

  

and

  


 

  

Dorsey and Whitney LLP

  

 

Pacific Centre

  

777 Dunsmuir Street

  

Suite 1605

  

P.O. Box 10444

  

Vancouver V7Y 1K4 Canada

 

  

 

Tel: (604) 687-5151

  

Attention: Daniel Miller

 

  

Email: miller.dan@dorsey.com

  

  

To the Shareholder:

  


 

  

Roivant Sciences Ltd.

  

Clarendon House

  

2 Church Street

  

Hamilton HM11

  

Bermuda

  

Attention: Corporate Secretary

  

Facsimile: +1 (441) 292 4720

  

Email: info@roivant.com

  


 

  

and

  


 

  

Roivant Sciences, Inc.

  

1441 Broadway, 3rd Floor

  

New York, NY 10018

  

Attention: Alan S. Roemer, SVP, Finance and Operations

  

Facsimile: +1 (212) 202-4650

  

Email: alan.roemer@roivant.commailto:info@roivant.com

  

  

With a copy sent concurrently to:

  


 

  

White and Case LLP

  

1155 Avenue of the Americas

  

New York, New York 10036

  

Attention: Sang I. Ji and Chang-Do Gong

  

Facsimile: (212) 354-8113

  

E-mail: sji@whitecase.com; cgong@whitecase.com

  

  

 

 

 

  

 

9  

  

 

 

 

  

and

  

  

Cooley LLP

  

3175 Hanover Street

  

Palo Alto, California 94304-1130

  

Attention: Frank Rahmani

  

Facsimile: (650) 849-7400

  

Email: rahmaniff@cooley.com

  

  

A Party may change its address for service by notice to the other Party, and
such changed address for service thereafter shall be effective for all
purposes of this Agreement.

  

  

E. Further Assurances

  

Each Party shall provide such further documents or instruments required by any
other Party as may be reasonably necessary or desirable to effect the purpose
of this Agreement and carry out its provisions.

  

  

F. Governing Law

  

This Agreement shall be governed by and construed in accordance with the laws
of the Province of British Columbia and the laws of Canada applicable therein.
Each of the Company and the Shareholder hereby attorn to the exclusive
jurisdiction of the courts of competent jurisdiction in the Province of
British Columbia located in Vancouver, British Columbia.

  

  

G. Time

  

Time shall be of the essence in this Agreement.

  

  

H. Entire Agreement

  

This Agreement and any agreement or document delivered pursuant to this
Agreement constitute the entire agreement between the Company and the
Shareholder relating to the subject matter hereof and thereof. There are no
collateral or other statements, understandings, covenants, agreements,
representations or warranties, written or oral, relating to the subject matter
hereof. This Agreement supersedes all prior agreements, understandings,
negotiations and discussions, whether oral or written, between the Parties or
their predecessors relating to the subject matter of this Agreement.

  

  

I. Assignment and Enurement

  

Neither this Agreement nor any benefits or obligations accruing under this
Agreement shall be assignable by any Party other than by the Shareholder to an
Affiliate with the prior written consent of the Company not to be unreasonably
withheld. Subject to the foregoing, this Agreement shall enure to the benefit
of and be binding upon the Parties and their respective successors and
permitted assigns.

  

  

 

 

 

  

 

10  

  

 

 

 

  

J. Counterpart Execution

  

A Party will be entitled to rely on delivery by facsimile or by e-mail in PDF
format of an executed copy of this Agreement by the other Party, including the
completed attachments hereto, and acceptance by the receiving party of such
facsimile or PDF copy will be legally effective to create a valid and binding
agreement between the Company and the Shareholder in accordance with the terms
hereof. This Agreement may be executed in counterparts, each of which shall be
deemed to be an original and all of which shall constitute one and the same
document.

  

  

[The remainder of this page is left blank intentionally]

  

  

  

  

  

 

 

 

  

 

11  

  

 

 

 

  

IN WITNESS WHEREOF the Parties have duly executed this Agreement as of the
date first written above.

  

  

     |  

TEKMIRA PHARMACEUTICALS CORPORATION

   
---|--- 
   |  |   
   |  

Per:

  |   
   |  |  

Name:

   
   |  |  

Title:

   
   |  |   
   |  |   
   |  

ROIVANT SCIENCES LTD.

   
   |  |   
   |  

Per:

  |   
   |  |  

Name:

   
   |  |  

Title:

   
  

 

  

  

  

[Signature Page to Governance Agreement]

  

  


 

  

  

 

 

 

  

 

12  

  

 

 

 

  

EXHIBIT F

  

  

FORM OF STANDSTILL AGREEMENT

  

  


 

  

  

  

  


 

  

 

 

 

  

 

13  

  

 

 

 

  

FORM OF STANDSTILL AGREEMENT

  


 

  

This Standstill Agreement (this "Agreement") is made as of January 11, 2015 by
and between Tekmira Pharmaceuticals Corporation, a British Columbia
corporation ("Tekmira" or the "Company"), and Roivant Sciences Ltd., a Bermuda
exempted Company, for and on behalf of itself and entities and accounts that
it controls directly or indirectly, or with respect to which it exercises
voting discretion, whether such entities or accounts now exist or are
organized in the future (collectively, the "Shareholder"). This Agreement
shall become effective as of the closing of the Merger (as defined below)

  


 

  

WHEREAS, on January 11, 2015, the Company entered into an Agreement and Plan
of Merger and Reorganization by and among OnCore Biopharma, Inc., a Delaware
Corporation ("OnCore"), TKM Acquisition Corporation, a Delaware corporation
("Merger Sub"), and the Company (the "Merger Agreement");

  


 

  

WHEREAS, pursuant to the Merger Agreement, OnCore will become a wholly-owned
subsidiary of the Company (the "Merger"), and the Shareholder will receive
shares of common stock of the Company (the "Common Stock") in the Merger
pursuant to the terms of the Merger Agreement (the "Shareholder Shares"); and

  


 

  

WHEREAS, as an inducement for the Company and Merger Sub to enter into the
Merger Agreement and consummate the Merger, and for the Company to enter into
a governance agreement dated as of the date hereof with the Shareholder (the
"Governance Agreement"), the Shareholder has agreed to execute and deliver
this Agreement.

  


 

  

NOW, THEREFORE, in consideration of the mutual promises and covenants
contained in this Agreement, and for other good and valuable consideration
that the parties hereby acknowledge, the parties agree as follows:

  


 

  

    

1.

  |  

Definitions. In this Agreement, the following terms shall have the meaning
assigned to them below:

   
---|--- 
 

  


 

  

"Total Shares" means all outstanding voting common stock of the company;

  


 

  

"Shareholder Maximum Ownership Percentage" means the percentage equal to (i)
the Shareholder Shares issued at closing of Merger, divided by (ii) Total
Shares immediately following the closing of the Merger.

  


 

  

    

2.

  |  

Standstill. For a period commencing on the date hereof and ending on the
earlier of (i) thirty-six (36) months following the effective date of the
Merger and (ii) the date upon which the Shareholder no longer has the right to
nominate at least one (1) director to the Company's board of directors (the
"Board") pursuant to the Governance Agreement, the Shareholder shall not,
without the prior written consent of the Company, directly or indirectly:

   
---|--- 
 

  


 

  

 

 

 

  

 

1  

  

 

 

 

  

    

a.

  |  

acquire, offer to acquire, or agree to acquire ownership (including, but not
limited to, beneficial ownership as defined in Rule 13d-3 under the Securities
Exchange Act of 1934, as amended ("Exchange Act")), by purchase or otherwise,
any additional shares of Common Stock, or any rights or options to acquire any
such securities or any securities convertible into such securities; provided
that, in the event that at any time, whether due to an increase in the total
outstanding shares of Common Stock, a sale of shares of Common Stock by the
Shareholder or otherwise (made in compliance with the provisions of the lock-
up agreement dated as of the date hereof with the Shareholder, as same may be
amended from time to time (the "Lock-Up Agreement"), the Shareholder
beneficially owns, directly or indirectly, Common Stock representing less than
the Shareholder Maximum Ownership Percentage, the Shareholder may acquire
additional shares of Common Stock or rights or options to acquire any such
securities or any securities convertible into such securities; provided,
further, that the Shareholder's ownership percentage will not exceed the
Shareholder Maximum Ownership Percentage;

   
---|--- 
 

  


 

  

    

b.

  |  

call or seek to call any meeting of the stockholders of the Company;

   
---|--- 
 

  


 

  

    

c.

  |  

submit, or participate with others that submit, any stockholder proposals for
the vote or consent (collectively, "vote") of stockholders (whether pursuant
to Rule 14a-8 under the Exchange Act, or otherwise) of the Company or any
proposal for consideration by the Board;

   
---|--- 
 

  


 

  

    

d.

  |  

solicit "proxies" or make, participate in or encourage any "solicitation" (as
such terms are used in the proxy rules of the Securities Exchange Commission)
for proxies for any stockholder proposals of the Company or nominations of
candidates for election as directors or trustees of the Company;

   
---|--- 
 

  


 

  

    

e.

  |  

form or join in a partnership, syndicate or other group, including, without
limitations, a "group" as defined under Section 13(d) of the Exchange Act,
with respect to the Shareholder Shares, or deposit any Shareholder Shares in a
voting trust, arrangement or agreement, except for such actions that may be
permitted under the Lock-Up Agreement;

   
---|--- 
 

  


 

  

    

f.

  |  

explicitly or implicitly, publicly or privately: (i) encourage, recommend,
advise, finance or urge others to put forward stockholder proposals of the
Company or nominations with respect to directors/trustees of the Company or
enter into any arrangements with any other person in connection with any of
the foregoing as they relate to the Company; (ii) indicate support or approval
for any stockholder proposals or nominations relating to the Company that are
not otherwise approved by the Board in accordance with the Articles; (iii)
solicit or encourage others to vote against any matter recommended by the
Board in accordance with the Articles; or (iv) act alone or in concert with
others to seek control of, or otherwise effect a change to, the management or
policies of the Company, unless otherwise approved by the Board in accordance
with the Articles; or

   
---|--- 
 

  


 

  

 

 

 

  

 

2  

  

 

 

 

  

    

g.

  |  

take or seek to take, or cause or seek to cause or solicit others to take any
action inconsistent with any of the foregoing as they relate to the Company.

   
---|--- 
 

  


 

  

Notwithstanding the foregoing, this Agreement will not be construed to
preclude, prohibit, restrict or otherwise require the Shareholder to take any
actions that are permitted or contemplated by the Governance Agreement or the
Company's Articles.

  


 

  

    

3.

  |  

Termination. The Shareholder may terminate this Agreement if the Company is
in material breach of Articles 2 or 4.2 of the Governance Agreement or Part 27
or Part 28 of the Company's Articles and such breach remains uncured for at
least fifteen (15) days after notice to the Company thereof.

   
---|--- 
 

  


 

  

    

4.

  |  

Remedies. The parties agree that any breach or threatened breach of this
Agreement may cause immediate and irreparable harm to the Company for which
monetary damages will not be adequate and that, in the event of a breach or
threatened breach of this Agreement, the Company shall be entitled to seek and
obtain immediate injunctive and other equitable relief without proof of actual
damages in addition to any other remedies as may be available at law or in
equity. The Shareholder further agrees to waive any requirement for the
securing or posting of any bond in connection with such remedy. All rights
under this Agreement are cumulative, not exclusive, and will be in addition to
all rights and remedies available to the Company at law or in equity.

   
---|--- 
 

  


 

  

    

5.

  |  

No Assignment. This Agreement shall be binding upon and inure to the benefit
of the parties and their respective agents, executors, heirs, successors and
permitted assigns. Neither this Agreement nor any of the benefits of this
Agreement shall be assigned by a party without prior written consent of the
other parties hereto. No person not a party to this Agreement shall have
rights, benefits, or obligations hereunder.

   
---|--- 
 

  


 

  

    

6.

  |  

Amendments. No amendments, changes, or modifications may be made to this
Agreement without the express prior written consent of each of the parties
hereto.

   
---|--- 
 

  


 

  

    

7.

  |  

Notices. All notices or communications hereunder shall be in writing,
addressed as follows:

   
---|--- 
 

  


 

  

 

 

 

  

 

3  

  

 

 

 

  

To the Company:

  


 

  

Tekmira Pharmaceuticals Corporation

  

100-8900 Glenlyon Parkway

  

Burnaby, British Columbia

  

Canada V5J 5J8

  

Attention:

  

Facsimile:

  

Email:

  


 

  

With a copy sent concurrently to:

  


 

  

Farris, Vaughan, Wills and Murphy LLP

  

700 West Georgia St., 25th Floor

  

Vancouver, British Columbia V7Y 1B3

  

Tel: (604) 661-9307

  

Attention: R. Hector MacKay-Dunn, Q.C.

  

E-mail: hmackay-dunn@farris.com

  


 

  

and

  


 

  

Dorsey and Whitney LLP

  

Pacific Centre

  

 

777 Dunsmuir Street

  

Suite 1605

  

P.O. Box 10444

  

Vancouver V7Y 1K4 Canada

 

  

 

Tel: (604) 687-5151

  

Attention: Daniel Miller

  

Email: miller.dan@dorsey.com

 

  


 

  


 

  

To the Shareholder:

  


 

  

Roivant Sciences Ltd.

  

Clarendon House

  

2 Church Street

  

Hamilton HM11

  

Bermuda

  

Attention: Corporate Secretary

  

Facsimile: +1 (441) 292 4720

  

Email: info@roivant.com

  


 

  

and

  


 

  

 

 

 

  

 

4  

  

 

 

 

  

Roivant Sciences, Inc.

  

1441 Broadway, 3rd Floor

  

New York, NY 10018

  

Attention: Alan S. Roemer, SVP, Finance and Operations

  

Facsimile: +1 (212) 202-4650

  

Email: alan.roemer@roivant.commailto:info@roivant.com

  

  

With a copy sent concurrently to:

  


 

  

White and Case LLP

  

1155 Avenue of the Americas

  

New York, New York 10036

  

Attention: Sang I. Ji and Chang-Do Gong

  

Facsimile: (212) 354-8113

  

E-mail: sji@whitecase.com; cgong@whitecase.com

  

  

and

  

  

Cooley LLP

  

3175 Hanover Street

  

Palo Alto, California 94304-1130

  

Attention: Frank Rahmani

  

Facsimile: (650) 849-7400

  

Email: rahmaniff@cooley.com

  

  

Any such notice or communication shall be delivered by hand or by courier or
sent certified or registered mail, return receipt requested, postage prepaid,
addressed as above (or to such other address as such party may designate in a
notice duly delivered as described above), and the third business day after
the actual date of mailing shall constitute the time at which notice was
given.

  

  

    

8.

  |  

Invalidity. If any term or provision of this Agreement is held by a court of
competent jurisdiction to be invalid, void or unenforceable, the remainder of
the terms and provisions of this Agreement shall remain in full force and
effect and shall in no way be affected, impaired or invalidated.

   
---|--- 
 

  

  

    

9.

  |  

No Waiver. No failure or delay by a party in exercising any right hereunder or
any partial exercise thereof shall operate as a waiver thereof or preclude any
other or further exercise of any right hereunder. No waiver, express or
implied, by any party of any breach of default by any other party in the
performance by the other party of its obligations under this Agreement shall
be deemed or construed to be a waiver of any other breach or default, whether
prior, subsequent, or contemporaneous, under this Agreement. Any waiver must
be in writing and executed by the party against whom the waiver is sought to
be charged.

   
---|--- 
 

  

  

 

 

 

  

 

5  

  

 

 

 

  

    

10.

  |  

Counterparts. This Agreement may be executed in two counterparts, which may be
delivered by facsimile or by portable document format (PDF) attachment to
email transmission, each of which shall be deemed an original, and when taken
together all such counterparts shall be deemed to constitute one and the same
document.

   
---|--- 
 

  

  

    

11.

  |  

Applicable Law This Agreement shall be construed, interpreted and governed in
accordance with the laws of the State of Delaware, without reference to rules
relating to conflicts of law.

   
---|--- 
 

  

  

    

12.

  |  

Entire Agreement. This Agreement contains the entire understanding between the
parties and is intended to be the complete and exclusive statement of the
terms and conditions of the agreement between the parties and supersedes in
all respects any prior agreement or understanding between the Company and the
Shareholder.

   
---|--- 
 

  

  

{REMAINDER INTENTIONALLY LEFT BLANK}

  

  


 

  

  


 

  

  


 

  

  

 

 

 

  

 

6  

  

 

 

 

  

IN WITNESS THEREOF, the parties hereto have executed this Agreement on the
date first written above.

  

  

     |  

COMPANY:

   
---|--- 
   |  |  |   
   |  

TEKMIRA PHARMACEUTICALS CORPORATION

   
   |  |  |   
   | By: |  |   
   |  | Name:  |   
   |  | Title:  |   
   |  | Date:  |   
   |  |  |   
   |  |  |   
   |  

SHAREHOLDER:

   
   |  |  |   
   |  

ROIVANT SCIENCES LTD.

   
   |  |  |   
   | By: |  |   
   |  | Name:  |   
   |  | Title:  |   
   |  | Date:  |   
 

  

  

  

  

  

[Signature Page to Standstill Agreement]

  


 

  

  

  

 

 

 

  

 

7  

  

 

 

 

  

EXHIBIT G

  

FORM OF REPRESENTATION LETTER

  

REPRESENTATION LETTER

  

  

This Representation Letter, dated as of _______________, 2015, is being
delivered to Tekmira Pharmaceuticals Corporation, a British Columbia
corporation (the "Company"), by __________________________________ (the
"Stockholder") in connection with that certain Agreement and Plan of Merger
dated as of _________________, 2015 (the "Merger Agreement") by and among the
Company, OnCore Biopharma, Inc., a Delaware corporation ("OnCore"), and TKM
Acquisition Corporation, a Delaware corporation ("Merger Sub"), pursuant to
which Merger Sub will be merged with and into OnCore, with OnCore surviving as
a wholly owned subsidiary of the Company (the "Merger"). In connection with
the Merger, the Stockholder will receive shares of the Company's common stock
(the "Company Securities") at the Closing (as defined in the Merger Agreement)
pursuant to the terms and conditions of the Merger Agreement, and such
Stockholder hereby represents and warrants to the Company as of the date
hereof and as of the Closing as follows:

  


 

  

I. AUTHORITY AND RELIANCE. I REPRESENT THAT I HAVE FULL POWER AND AUTHORITY TO
EXECUTE THIS LETTER AND MAKE THE REPRESENTATIONS CONTAINED HEREIN, WITHOUT
OBTAINING THE APPROVAL OR CONSENT OF ANY OTHER PERSON. I UNDERSTAND THAT THE
COMPANY IS RELYING ON THIS STATEMENT IN ISSUING ME THE COMPANY SECURITIES IN
CONNECTION WITH THE MERGER. THIS AGREEMENT HAS BEEN DULY AND VALIDLY EXECUTED
AND DELIVERED BY ME AND CONSTITUTES A LEGAL, VALID AND BINDING OBLIGATION OF
SUCH MINE, ENFORCEABLE AGAINST ME IN ACCORDANCE WITH ITS TERMS.

  

  

II. ACQUIRED ENTIRELY FOR OWN ACCOUNT. I AM ACQUIRING THE COMPANY SECURITIES
FOR INVESTMENT FOR AN INDEFINITE PERIOD FOR MY OWN ACCOUNT, NOT AS A NOMINEE
OR AGENT, AND NOT WITH A VIEW TO THE SALE OR DISTRIBUTION OF ANY PART THEREOF,
AND I HAVE NO PRESENT INTENTION OF SELLING, GRANTING PARTICIPATION IN, OR
OTHERWISE DISTRIBUTING THE SAME. I FURTHER REPRESENT THAT I DO NOT HAVE ANY
CONTRACT, UNDERTAKING OR ARRANGEMENT WITH ANY PERSON TO SELL, TRANSFER OR
GRANT PARTICIPATION TO SUCH PERSON OR TO ANY THIRD PERSON, WITH RESPECT TO ANY
OF THE COMPANY SECURITIES.

  

  

III. DISCLOSURE OF INFORMATION. I HAVE HAD AN OPPORTUNITY TO REVIEW THE MERGER
AGREEMENT AND THE PARENT DISCLOSURE SCHEDULE (AS DEFINED IN THE MERGER
AGREEMENT) IN CONNECTION WITH THE MERGER. I HAVE ALSO HAD AN OPPORTUNITY TO
ASK QUESTIONS OF AND RECEIVE ANSWERS FROM THE COMPANY REGARDING THE COMPANY,
ITS BUSINESS AND THE TERMS AND CONDITIONS OF THE MERGER AGREEMENT AND THE
COMPANY SECURITIES. I BELIEVE I HAVE RECEIVED ALL THE INFORMATION I CONSIDER
NECESSARY OR APPROPRIATE FOR DECIDING WHETHER TO APPROVE THE MERGER AND
ACQUIRE THE COMPANY SECURITIES.

  

  

IV. SECURITIES LAWS. I UNDERSTAND THE COMPANY SECURITIES ARE "RESTRICTED
SECURITIES" WITHIN THE MEANING OF RULE 144 UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE "ACT"), AND WILL BE FURTHER SUBJECT TO THE FEDERAL SECURITIES
LAWS AND APPLICABLE REGULATIONS, AND THAT SUCH COMPANY SECURITIES MAY NOT BE
RESOLD WITHOUT REGISTRATION UNDER THE ACT, EXCEPT IN CERTAIN LIMITED
CIRCUMSTANCES. IN THIS CONNECTION, I REPRESENT THAT I AM FAMILIAR WITH RULE
144 AS PRESENTLY IN EFFECT, AND I UNDERSTAND THE RESALE LIMITATIONS IMPOSED
THEREBY AND BY THE ACT.

  

  

 

 

 

  

   

  

 

 

 

  

V. ACCREDITED INVESTOR. I AM AN "ACCREDITED INVESTOR" (AS DEFINED IN RULE
501(A) OF REGULATION D PROMULGATED UNDER THE ACT).

  

  

VI. TRANSFERS. I WILL NOT SELL, TRANSFER, PLEDGE OR OTHERWISE DISPOSE OF OR
ENCUMBER ANY OF THE COMPANY SECURITIES I RECEIVES UNLESS AND UNTIL (A) SUCH
SHARES ARE SUBSEQUENTLY REGISTERED UNDER THE ACT AND EACH APPLICABLE STATE
SECURITIES LAW; OR (B) (I) AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE
THEREUNDER, AND (II) I HAVE NOTIFIED THE COMPANY OF THE PROPOSED TRANSFER AND
HAVE FURNISHED THE COMPANY WITH AN OPINION OF COUNSEL, REASONABLY SATISFACTORY
TO THE COMPANY THAT SUCH TRANSFER WILL NOT REQUIRE REGISTRATION OF SUCH SHARES
UNDER THE ACT.

  

  

VII. INVESTMENT EXPERIENCE. I AM ABLE TO FEND FOR MYSELF, CAN BEAR THE
ECONOMIC RISK OF AN INVESTMENT IN THE COMPANY AND HAVE SUCH KNOWLEDGE AND
EXPERIENCE IN FINANCIAL OR BUSINESS MATTERS THAT I AM CAPABLE OF EVALUATING
THE MERITS AND RISKS OF ACQUIRING THE COMPANY SECURITIES.

  

  

VIII. NO GENERAL SOLICITATION OR ADVERTISING. I ACKNOWLEDGE THAT I AM NOT
ACQUIRING THE COMPANY SECURITIES AS A RESULT OF ANY "GENERAL SOLICITATION" OR
"GENERAL ADVERTISING," AS SUCH TERMS ARE USED IN REGULATION D UNDER THE ACT,
INCLUDING THE COMPANY'S REGISTRATION STATEMENTS OR OTHER FILINGS WITH THE SEC
OR SEDAR, ADVERTISEMENTS, ARTICLES, NOTICES OR OTHER COMMUNICATIONS PUBLISHED
IN ANY NEWSPAPER, MAGAZINE OR SIMILAR MEDIA OR BROADCAST OVER RADIO OR
TELEVISION, OR ANY SEMINAR OR MEETING WHOSE ATTENDEES HAVE BEEN INVITED BY
GENERAL SOLICITATION OR GENERAL ADVERTISING.

  

  

IX. LEGENDS. I AUTHORIZE THE COMPANY AND ITS AGENTS TO PLACE ON THE
CERTIFICATES FOR THE COMPANY SECURITIES LEGENDS STATING THAT SUCH COMPANY
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE ACT OR ANY STATE SECURITIES LAW
AND SETTING FORTH THE AFOREMENTIONED RESTRICTIONS ON TRANSFER, INCLUDING ONE
OR ALL OF THE FOLLOWING LEGENDS:

  

  

"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933 (THE "ACT"), OR ANY STATE SECURITIES LAWS. THE
SECURITIES MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, OR OTHERWISE
TRANSFERRED UNLESS REGISTERED OR QUALIFIED PURSUANT TO THE PROVISIONS OF THE
ACT AND APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO BUYER IS OBTAINED BY THE HOLDER OF THIS CERTIFICATE STATING
THAT SUCH OFFER, SALE, ASSIGNMENT, PLEDGE OR TRANSFER IS EXEMPT FROM SUCH
REGISTRATION OR QUALIFICATION."

  

  

 

 

 

  

   

  

 

 

 

  

IN WITNESS WHEREOF, the undersigned has executed this Representation Letter as
of the date set forth below.

  

  


 

  


 

  

DATED: ____________________

  


 

  

  

     |  

STOCKHOLDER

   
---|--- 
   |  |   
   |  

[ENTITY NAME]

   
   |  |   
   |  

By:

  |   
   |  

Name:

  |   
   |  

 

Title:

 

  |   
   |  |   
   |  

OR

   
   |  |   
   |  |   
   |  

[Name], and individual

   
  

  

 

   
 

 

  

  

 

 

 

  

   

  

 

 

 

  

EXHIBIT H

  

FORM OF GOVERNANCE AMENDMENT TO PARENT ARTICLES

  

  

  

  

  

  

  

  

  

  

  

  

 

 

 

  

   

  

 

 

 

  

AMENDMENT TO TEKMIRA PHARMACEUTICALS CORPORATION ARTICLES OF INCORPORATION

  

  

Part 18.2

  

  

Questions arising at any meeting of directors are to be decided by a majority
of votes (subject to Part 27), and, in the case of an equality of votes, the
chair of the meeting shall not have a second (or casting) vote.

  

  

Part 27 - Transitional Governance Matters

  

  

Notwithstanding any other provision of these Articles, for a period commencing
upon the effective date of the merger (the "Merger") between TKM Acquisition
Corporation, a wholly-owned subsidiary of the Company, and OnCore Biopharma,
Inc., a Delaware corporation, undertaken pursuant to an Agreement and Plan of
Merger and Reorganization dated January 11, 2015, and ending upon the earlier
of (i) thirty-six (36) months following the effective date of the Merger and
(ii) when RS no longer has a right to nominate one or more directors under
Section 1 of this Part 28, the following provisions shall apply:

  

  

Supermajority Matters

  

  

    

1.

  |  

Any one of the following matters shall require the approval of at least
seventy percent (70%) of the number of directors then in office, whether such
approval is given by way of a vote at a meeting of directors or by written
consent:

   
---|--- 
 

  

  

    

(a)

  |  

the removal or replacement of the chair of the board of directors of the
Company;

   
---|--- 
 

  

  

    

(b)

  |  

the removal or replacement of the chief executive officer of the Company,

   
---|--- 
 

  

  

    

(c)

  |  

subject to Part 28, the nomination of a director for election to the board of
directors of the Company;

   
---|--- 
 

  

  

    

(d)

  |  

subject to Part 28, the appointment of a director to the board of directors of
the Company to fill a vacancy created by the resignation or death of a
director;

   
---|--- 
 

  

  

    

(e)

  |  

subject to Part 28, the appointment of an additional director to the board of
directors of the Company;

   
---|--- 
 

  

  

    

(f)

  |  

any take-over bid, issuer bid, amalgamation, plan of arrangement, business
combination, merger, tender offer, exchange offer, consolidation,
recapitalization, reorganization, liquidation, dissolution or winding-up in
respect of, or involving, the Company or any subsidiary of the Company;

   
---|--- 
 

  

  

    

(g)

  |  

any sale or issuance of shares of the Company or other equity interests in the
Company (or rights, interests or securities convertible into or exercisable
for such shares or other equity interests), in one or more connected
transactions, which would be greater than 5% of the outstanding shares of
stock of the company, other than the grant or issuance of such equity
interests in connection with any stock-based compensation plan or plans
approved by the board of directors of the Company;

   
---|--- 
 

  

  

    

(h)

  |  

any sale of assets (or any strategic alliance, joint venture, license or other
arrangement having the same economic effect as a sale) of the Company or any
subsidiary of the Company representing a transaction value and/or payments
greater than $10 million;

   
---|--- 
 

  

  

    

(i)

  |  

ceasing or abandoning any research, development or commercialization efforts
that were publicly disclosed by the Company as having been underway as at the
effective date of the Merger, or declining to advance the development or
commercialization of such programs, whether by failing to continue to fund
such programs or otherwise;

   
---|--- 
 

  

  

 

 

 

  

   

  

 

 

 

  

    

(j)

  |  

incurring any indebtedness or third party guarantees in excess of $5,000,000
individually or $10,000,000 in the aggregate; or

   
---|--- 
 

  

  

    

(k)

  |  

any amendment or proposed amendment to the Articles or Notice of Articles of
the Company,

   
---|--- 
 

  

  

(collectively referred to as "Supermajority Matters").

  

  

Inconsistencies

  

  

    

2.

  |  

In the event of an inconsistency between a provision of this Part 27 and any
other provision of these Articles, the provision of this Part 27 shall
prevail.

   
---|--- 
 

  

  

Alterations of Part 27 and Section 18.2

  

  

    

3.

  |  

This Part 27 and Section 18.2 may only be amended by special resolution.

   
---|--- 
 

  

  

Part 28 - Director Election Matters

  

  

Definitions

  

  

 

In this Part, the following terms shall have the meaning assigned to them
below:

 

  

  

"Calculated on an Undiluted Basis" means calculated before giving effect to
the exercise, conversion or exchange of any securities exercisable for,
convertible into, or exchangeable for, Company Shares;

  

  

"Company Shares" means the common shares in the capital of the Company as
constituted on the date hereof;

  

  

"Record Date Notice" means the date of the letter filed on SEDAR by the
Company's registrar and transfer agent giving notice of the record date for
determination of the shareholders entitled to notice of and to vote at any
Shareholder Meeting; and

  

  

"Shareholder Meeting" means an annual general meeting of shareholders or
special meeting of shareholders of the Company called for the purpose of
electing directors to the board of directors of the Company.

  

  

 

 

 

  

   

  

 

 

 

  

Election of Directors

  

  

1. For so long as Roivant Sciences Ltd. ((the "Nominating Shareholder" or "RS") has "beneficial ownership" (as defined pursuant Rule 13d-3 under the United States, Securities Exchange Act of 1934, as amended) ("Beneficial Ownership") owns or exercises control or direction over not less than:

  

  

(a) twenty- percent (20%) of the issued and outstanding Company Shares
Calculated on an Undiluted Basis as at the Record Date Notice, RS has the
right to nominate two (2) individuals for election to the board of directors
of the Company at each Shareholder Meeting; and

  

  

(b ) ten percent (10%) of the issued and outstanding Company Shares Calculated
on an Undiluted Basis as at the Record Date Notice, RS has the right to
nominate one (1) individual for election to the board of directors of the
Company at each Shareholder Meeting,

  

  

    

  |  

(where such designee directors are referred to as the "RS Nominated
Directors").

   
---|--- 
 

  

  

2. Upon the Nominating Shareholder having Beneficial Ownership or exercising control or direction over less than ten percent (10%) of the outstanding Company Shares Calculated on an Undiluted Basis as at the Record Date Notice, the nomination rights provided under Section 1 will be of no further force and effect.

  

  

Number of Directors

  

  

3. For so long as the Nominating Shareholder has a right to nominate one or more directors under Section 1 of this Part 28, the number of directors of the Company shall not exceed seven (7) directors without the prior written consent of the Nominating Shareholder.

  

  

Nomination Procedure

  

  

    

4.

  |  

For so long as the Nominating Shareholder has a right to nominate one or more
directors under Section 1 of this Part 28:

   
---|--- 
 

  

  

    

(a)

  |  

No earlier than ninety (90) days and no later than sixty (60) days prior to
the date of each Shareholder Meeting, the Company shall notify RS in writing
of the date of the Shareholder Meeting (the "Company Notice"). The Company
Notice shall specify the total number of Company Shares issued and outstanding
Calculated on an Undiluted Basis as at the Record Date Notice.

   
---|--- 
 

  

  

    

(b)

  |  

RS shall have the right and option, exercisable within fifteen (15) days from
receipt of the Company Notice (the "Nomination Right Notice Period") by
written notice to the Company (the "Nomination Notice") to exercise the
Nomination Right. If RS wishes to exercise the Nomination Right, RS must
specify in the Nomination Notice (i) the number of Company Shares beneficially
owned by the Nominating Shareholder as at the date of the Nomination Notice,
(ii) the name of the individual(s) RS wishes to nominate for election to the
board of directors of the Company, and (iii) confirm that the nominee(s) are
eligible to act as director(s) under the Act or, if the Company is otherwise
governed by another statue or regime, that the nominee(s) are eligible to act
as a director under such statute or regime. As soon as reasonably possible
after the request by the Company, duly completed forms and any other
information in respect of the RS Nominated Directors, as required by the
relevant stock exchange, shall be provided by the RS Nominated Directors.

   
---|--- 
 

  

  

 

 

 

  

   

  

 

 

 

  

    

(c)

  |  

If RS fails to deliver a Nomination Notice in response to a Company Notice
within the Nomination Right Notice Period, then the Company will not be
required to nominate individuals identified by RS for election to the board of
directors of the Company at the Shareholder Meeting with respect to which RS
failed to deliver the Nomination Notice, and RS shall have the right to
nominate person(s) for election to the board of directors of the Company at
the next Shareholder Meeting in accordance with this Part 28.

   
---|--- 
 

  

  

    

(d)

  |  

If RS delivers a Nomination Notice in response to a Company Notice within the
Nomination Right Notice Period then, subject only to the nominee(s) identified
in the Nomination Notice being eligible to act as director(s) of the Company,
the Company shall (i) nominate the RS nominee(s) to stand for election to the
board of directors of the Company at the Shareholder Meeting, and (ii) solicit
proxies from the holders of Company Shares in respect thereof which will be
satisfied by delivery of a form of proxy to the holders of Company Shares
following standard procedures consistent with past practice. For greater
certainty, the Company (x) shall not be required to retain a third party
solicitation agent, and (y) shall include the name of the RS nominee(s) to
stand for election to the board of directors of the Company in the proxy to be
delivered to each holder of Company Shares in respect of the Shareholder
Meeting. The Nominating Shareholder shall also provide to the Company such
other information regarding the RS nominee(s) as may be reasonably requested
by the Company so as to comply with applicable proxy disclosure requirements
under applicable securities laws, together with such other information,
including a biography of the RS Nominated Directors, that is consistent with
the information the Company intends to publish about management nominees as
directors of the Company in the information circular to be prepared by the
Company in connection with the election of directors at a Shareholder Meeting.

   
---|--- 
 

  

  

Casual Vacancies

  

  

    

5.

  |  

In the event that an RS Nominated Director resigns, dies, becomes
incapacitated or otherwise ceases to be a director prior to the expiration of
his or her term as a director, such vacancy on the board of directors shall be
filled by the remaining directors with the nominee identified by RS promptly.
The Company shall use all commercially reasonable steps, promptly upon receipt
by it of a written notice from RS to fill such vacancy, as are necessary to
call (no later than five (5) days following notice of such identified nominee
by RS) a meeting of the board of directors to vote on the appointment of such
Shareholder Designee to fill such vacancy (or to obtain a vote of the
directors by way of unanimous written resolution) and take all such other
steps as are required by the Act with respect to such appointment.

   
---|--- 
 

  

  

Transitional Period

  

  

    

6.

  |  

This Part 28 shall remain in effect until the date that is the earlier of (i)
thirty-six (36) months following the effective date of the Merger and (ii)
when RS no longer has a right to nominate one or more directors under Section
1 of this Part 28.

   
---|--- 
 

  

  

Inconsistencies

  

  

    

7.

  |  

In the event of an inconsistency between a provision of this Part 28 and any
other provision of these Articles, the provision of this Part 28 shall
prevail.

   
---|--- 
 

  

  

 

 

 

  

   

  

 

 

 

  

EXHIBIT I

  

  

FORM OF LEGAL OPINION

  

  

To the Company and the recipients of securities of Parent ("Recipients")
pursuant to the Merger:

  

  

    

1.

  |  

The Parent Common Stock to be issued pursuant to the Merger, including Parent
Common Stock issued in respect of Company Restricted Stock, ("Issued Shares")
have been validly authorized and issued as fully paid and non-assessable
common shares of Parent to the holders thereof.

   
---|--- 
 

  

  

    

2.

  |  

The Company Options assumed by Parent pursuant to the Merger ("Assumed
Options") have been validly authorized by Parent.

   
---|--- 
 

  

  

    

3.

  |  

The Parent Common Stock to be issued on the exercise of Assumed Options
("Option Shares") have been allotted and reserved for issuance to the holders
of the Assumed Options and, upon the due and proper exercise of the Assumed
Options in accordance with the terms thereof (including payment of the
exercise price therefor), the Option Shares will be validly issued as fully-
paid and non-assessable shares of Parent.

   
---|--- 
 

  

  

    

4.

  |  

The issue of the Issued Shares and Assumed Options by Parent to the Recipients
in the manner contemplated in the Merger Agreement has been effected in such
manner as to be exempt from the prospectus requirements of Canadian Securities
Laws and no prospectus or other document is required to be filed, no
proceeding is required to be taken and no approval, permit, consent or
authorization is required to be obtained by Parent under Canadian Securities
Laws to permit the issue of the Issued Shares and Assumed Options to the
holders thereof; however, Parent is required to, within ten days after the
date the Issued Shares are issued file a report on Form 45-106F6 with the
British Columbia Securities Commission, and pay the prescribed fees,
accompanied by the fee checklist, if any, to the British Columbia Securities
Commission.

   
---|--- 
 

  

  

    

5.

  |  

The issue of the Option Shares upon the due exercise of the Assumed Options in
accordance with their terms will be exempt from the prospectus requirements of
Canadian Securities Laws and no prospectus or other document will be required
to be filed, no proceeding is required to be taken and no approval, permit,
consent or authorization is required to be obtained by Parent under Canadian
Securities Laws to permit the issue of the Option Shares to the holders
thereof.

   
---|--- 
 

  

  

    

6.

  |  

No prospectus or other document will be required to be filed, no proceeding is
required to be taken and no approval, permit, consent or authorization is
required to be obtained by Parent under Canadian Securities Laws in connection
with the first trade of Issued Shares or Option Shares in British Columbia by
the holders thereof through registrants duly registered under Canadian
Securities Laws who have complied with the relevant provisions of such
Canadian Securities Laws and the terms of such registrations, provided that:

   
---|--- 
 

  

  

    

(a)

  |  

Parent is and has been a "reporting issuer" in a jurisdiction of Canada for
the four months immediately preceding the trade;

   
---|--- 
 

  

  

    

(b)

  |  

such trade is not a "control distribution" as defined in NI 45-102;

   
---|--- 
 

  

  

    

(c)

  |  

no unusual effort is made to prepare the market or create a demand for the
Issued Shares or Option Shares that are the subject of the trade;

   
---|--- 
 

  

  

    

(d)

  |  

no extraordinary commission or other consideration is paid to a person or
company in respect of the trade; and

   
---|--- 
 

  

  

 

 

 

  

   

  

 

 

 

  

    

(e)

  |  

if the selling security holder is an "insider" or "officer" of Parent as those
terms are defined under Canadian Securities Laws, the selling security holder
has no reasonable grounds to believe that Parent is in default of "securities
legislation", as defined in National Instrument 14-101 Definitions ("NI
14-101").

   
---|--- 
 

  

  

  

  

  

  

  

  

  

 

 

 

  

   

  

 

 

 

  

SCHEDULE 5.9(b)

  

  

PERSON

  

  

Roivant Sciences Ltd.

  

  

  

  

 

 

 

  

   

  

 

 

 

  

SCHEDULE 5.12

  

  

DIRECTORS AND OFFICERS

  

  

Tiger Designated Directors:

  

1\. Mark Murray

  

2\. Daniel Kisner, Vice Chairman

  


 

  

Owl Designated Directors:

  

1\. Vivek Ramaswamy, Chairman

  

2\. Keith Manchester

  


 

  

Of the three remaining directors to be designated by Parent to be effective
immediately following the Effective Time, one director will be designated by
the Company and one director will be designated by Parent, each of whom will
be designated no later than the date that is five Business Days prior to the
mailing of the Proxy Statement and Circular, and the designation of one
director will be agreed upon by Parent and Company no later than the date that
is five Business Days prior to the mailing of the Proxy Statement and
Circular, if possible.

  


 

  

The appointment and designation of each director is subject to such individual
delivering to the Parent consents to act as required by the BCBCA.

  


 

  

Should any of the foregoing individuals be unable or unwilling to serve as a
director (or fail to deliver the consent to act as required by the BCBCA),
then such open director position shall be filled by an individual designated
by the party who originally designated the individual for such director
position.

  


 

  

The parties shall work together to ensure that the proposed collective board
of directors of Parent will satisfy any applicable Nasdaq and TSX requirements
relating to number of directors who are independent, financially literate
and/or financial experts, as defined by such applicable requirements.

  


 

  

Officers and other Senior Advisors:

  

Mark J. Murray - Chief Executive Officer

  


 

  

The parties shall work together to agree to additional officers that are to be
appointed as at the Effective Time of the Merger.

  


 

  

Should the foregoing individual be unable or unwilling to serve as an officer,
then such open officer position shall be filled by mutual agreement by the
parties before the Closing.

  

  

 

 

 

  

   

  

 

 

 

  

 

  

  

      
--- 
 

  

  

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION

 

  


 

  

  

among:

  

  

Tekmira Pharmaceuticals Corporation,

  

a British Columbia corporation;

  

  

TKM Acquisition Corporation,

  

a Delaware corporation; and

  

  

OnCore Biopharma, Inc.,

  

a Delaware corporation

  

  


 

  

  

___________________________

  

  

Dated as of January 11, 2015

  

  

___________________________

  

  

      
--- 
 

  


 

  

  


 

  

 

 

 

  

   

  

 

 

 

  

TABLE OF CONTENTS

  


 

  

 

 

    

Section 1.

  |  |  

 

DESCRIPTION OF TRANSACTION

 

  |  

2

   
---|---|---|--- 
   |  |  |   
   |  |  

1.1

  |  |  

Merger of Merger Sub into the Company

  |  

2

   
   |  |  

1.2

  |  |  

Effects of the Merger

  |  

2

   
   |  |  

1.3

  |  |  

Closing; Effective Time

  |  

2

   
   |  |  

1.4

  |  |  

Certificate of Incorporation and Bylaws; Directors and Officers

  |  

2

   
   |  |  

1.5

  |  |  

Conversion of Shares

  |  

2

   
   |  |  

1.6

  |  |  

Closing of the Company's Transfer Books

  |  

3

   
   |  |  

1.7

  |  |  

Exchange of Certificates

  |  

4

   
   |  |  

1.8

  |  |  

Issuance of Shares of Surviving Corporation

  |  

5

   
   |  |  

1.9

  |  |  

Tax Consequences

  |  

5

   
   |  |  

1.10

  |  |  

Further Action

  |  

6

   
   |  |  

1.11

  |  |  

Dissenting Shares

  |  

6

   
   |  |  |  |  |   
  

Section 2.

  |  |  

 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

  |  

6

   
   |  |  |   
   |  |  

2.1

  |  |  

Subsidiaries; Due Organization; Etc.

  |  

6

   
   |  |  

2.2

  |  |  

Certificate of Incorporation and Bylaws

  |  

7

   
   |  |  

2.3

  |  |  

Capitalization; Ownership of Subsidiary

  |  

7

   
   |  |  

2.4

  |  |  

Financial Statements

  |  

9

   
   |  |  

2.5

  |  |  

Absence of Changes

  |  

10

   
   |  |  

2.6

  |  |  

Title to Tangible Assets

  |  

11

   
   |  |  

2.7

  |  |  

Equipment; Real Property; Leasehold

  |  

12

   
   |  |  

2.8

  |  |  

Intellectual Property

  |  

12

   
   |  |  

2.9

  |  |  

Contracts

  |  

15

   
   |  |  

2.10

  |  |  

Liabilities

  |  

18

   
   |  |  

2.11

  |  |  

Compliance with Legal Requirements; Regulatory Matters

  |  

18

   
   |  |  

2.12

  |  |  

Certain Business Practices

  |  

19

   
   |  |  

2.13

  |  |  

Governmental Authorizations

  |  

19

   
   |  |  

2.14

  |  |  

Tax Matters

  |  

20

   
   |  |  

2.15

  |  |  

Employee and Labor Matters; Benefit Plans

  |  

21

   
   |  |  

2.16

  |  |  

Environmental Matters

  |  

24

   
   |  |  

2.17

  |  |  

Insurance

  |  

25

   
   |  |  

2.18

  |  |  

Transactions with Affiliates

  |  

25

   
   |  |  

2.19

  |  |  

Legal Proceedings; Orders

  |  

25

   
   |  |  

2.20

  |  |  

Authority; Binding Nature of Agreement

  |  

25

   
   |  |  

2.21

  |  |  

Inapplicability of Section 203 of the DGCL and other Anti-takeover Statute

  |  

26

   
   |  |  

2.22

  |  |  

Vote Required

  |  

26

   
   |  |  

2.23

  |  |  

Non-Contravention; Consents

  |  

26

   
   |  |  

2.24

  |  |  

No Broker Fee

  |  

27

   
   |  |  

2.25

  |  |  

Acknowledgement by the Company

  |  

27

   
   |  |  

2.26

  |  |  

Private Placement

  |  

27

   
   |  |  |  |  |   
  

Section 3.

  |  |  

 

REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

 

  |  

27

   
   |  |  |   
   |  |  

3.1

  |  |  

Subsidiaries; Due Organization; Etc.

  |  

28

   
   |  |  

3.2

  |  |  

Certificate of Incorporation and Articles

  |  

28

   
 

  

  

 

 

 

  

   

  

 

 

 

  

     |  |  

3.3

  |  |  

Capitalization, Etc.

  |  

29

   
---|---|---|---|---|--- 
   |  |  

3.4

  |  |  

SEC Filings; Canadian Securities Regulatory Filings; Financial Statements

  |  

30

   
   |  |  

3.5

  |  |  

Absence of Changes

  |  

33

   
   |  |  

3.6

  |  |  

No Collateral Benefits

  |  

34

   
   |  |  

3.7

  |  |  

Title to Tangible Assets

  |  

35

   
   |  |  

3.8

  |  |  

Equipment; Real Property; Leasehold

  |  

35

   
   |  |  

3.9

  |  |  

Intellectual Property

  |  

35

   
   |  |  

3.10

  |  |  

Contracts

  |  

38

   
   |  |  

3.11

  |  |  

Liabilities

  |  

41

   
   |  |  

3.12

  |  |  

Compliance with Legal Requirements; Regulatory Matters

  |  

41

   
   |  |  

3.13

  |  |  

Certain Business Practices

  |  

43

   
   |  |  

3.14

  |  |  

Governmental Authorizations

  |  

43

   
   |  |  

3.15

  |  |  

Tax Matters

  |  

44

   
   |  |  

3.16

  |  |  

Employee and Labor Matters; Benefit Plans

  |  

47

   
   |  |  

3.17

  |  |  

Environmental Matters

  |  

51

   
   |  |  

3.18

  |  |  

Insurance

  |  

52

   
   |  |  

3.19

  |  |  

Transactions with Affiliates

  |  

52

   
   |  |  

3.20

  |  |  

Legal Proceedings; Orders

  |  

52

   
   |  |  

3.21

  |  |  

Authority; Binding Nature of Agreement

  |  

52

   
   |  |  

3.22

  |  |  

Inapplicability Anti-takeover Statutes

  |  

53

   
   |  |  

3.23

  |  |  

Vote Required

  |  

53

   
   |  |  

3.24

  |  |  

Non-Contravention; Consents

  |  

53

   
   |  |  

3.25

  |  |  

Opinion of Financial Advisor

  |  

54

   
   |  |  

3.26

  |  |  

No Broker Fee

  |  

54

   
   |  |  

3.27

  |  |  

Valid Issuance

  |  

54

   
   |  |  

3.28

  |  |  

Acknowledgement by Parent

  |  

54

   
   |  |  

3.29

  |  |  

Merger Sub

  |  

55

   
   |  |  |  |  |   
  

Section 4.

  |  |  

 

CERTAIN COVENANTS OF THE PARTIES REGARDING OPERATIONS DURING THE PRE-CLOSING
PERIOD

 

  |  

55

   
   |  |  |   
   |  |  

4.1

  |  |  

Access and Investigation

  |  

55

   
   |  |  

4.2

  |  |  

Operation of the Business of the Owl Corporations

  |  

55

   
   |  |  

4.3

  |  |  

Operation of the Business of the Tiger Corporations

  |  

59

   
   |  |  

4.4

  |  |  

No Solicitation

  |  

62

   
   |  |  |  |  |   
  

Section 5.

  |  |  

 

ADDITIONAL COVENANTS OF THE PARTIES

 

  |  

64

   
   |  |  |   
   |  |  

5.1

  |  |  

Proxy Statement; Information Circular

  |  

64

   
   |  |  

5.2

  |  |  

Federal and State Blue Sky Laws

  |  

64

   
   |  |  

5.3

  |  |  

Parent Stockholders' Meeting

  |  

65

   
   |  |  

5.4

  |  |  

Company Options and Company Restricted Shares

  |  

67

   
   |  |  

5.5

  |  |  

Employee Benefits

  |  

68

   
   |  |  

5.6

  |  |  

Indemnification of Officers and Directors

  |  

69

   
   |  |  

5.7

  |  |  

Regulatory Approvals and Related Matters

  |  

71

   
   |  |  

5.8

  |  |  

Disclosure

  |  

72

   
   |  |  

5.9

  |  |  

Tax Matters

  |  

73

   
   |  |  

5.10

  |  |  

Listing

  |  

74

   
   |  |  

5.11

  |  |  

Resignation of Officers and Directors

  |  

74

   
   |  |  

5.12

  |  |  

Board of Directors of the Combined Company; Management of the Combined Company

  |  

74

   
 

  

  

 

 

 

  

   

  

 

 

 

  

     |  |  

5.13

  |  |  

Section 16 Matters

  |  

74

   
---|---|---|---|---|--- 
   |  |  

5.14

  |  |  

Name of the Combined Corporation and Headquarters

  |  

75

   
   |  |  

5.15

  |  |  

Obligations of Merger Sub

  |  

75

   
   |  |  

5.17

  |  |  

Company Covenant Regarding Registration Statement

  |  

75

   
   |  |  

5.18

  |  |  

Representation Letters

  |  

75

   
   |  |  

5.19

  |  |  

Termination of Agreement

  |  

75

   
   |  |  

5.20

  |  |  

Section 228 Notice Requirements

  |  

76

   
   |  |  |  |  |   
  

Section 6.

  |  |  

 

CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB

 

  |  

76

   
   |  |  |   
   |  |  

6.1

  |  |  

Accuracy of Representations

  |  

76

   
   |  |  

6.2

  |  |  

Performance of Covenants

  |  

76

   
   |  |  

6.3

  |  |  

Stockholder Approval

  |  

76

   
   |  |  

6.4

  |  |  

Certificate

  |  

76

   
   |  |  

6.5

  |  |  

No Company Material Adverse Effect

  |  

77

   
   |  |  

6.6

  |  |  

Governmental Approvals

  |  

77

   
   |  |  

6.7

  |  |  

Listing

  |  

77

   
   |  |  

6.8

  |  |  

No Restraints

  |  

77

   
   |  |  

6.9

  |  |  

No Governmental Litigation

  |  

77

   
   |  |  

6.10

  |  |  

FIRPTA Matters

  |  

77

   
   |  |  

6.11

  |  |  

Issuance of Parent Common Stock

  |  

77

   
   |  |  

6.12

  |  |  

Representation Letters

  |  

78

   
   |  |  

6.13

  |  |  

Termination of Agreement

  |  

78

   
   |  |  |  |  |   
  

Section 7.

  |  |  

 

CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY

 

  |  

78

   
   |  |  |   
   |  |  

7.1

  |  |  

Accuracy of Representations

  |  

78

   
   |  |  

7.2

  |  |  

Performance of Covenants

  |  

78

   
   |  |  

7.3

  |  |  

Stockholder Approval

  |  

78

   
   |  |  

7.4

  |  |  

Certificate

  |  

79

   
   |  |  

7.5

  |  |  

No Parent Material Adverse Effect

  |  

79

   
   |  |  

7.6

  |  |  

Governmental Approvals

  |  

79

   
   |  |  

7.7

  |  |  

Listing

  |  

79

   
   |  |  

7.8

  |  |  

No Restraints

  |  

79

   
   |  |  

7.9

  |  |  

No Governmental Litigation

  |  

79

   
   |  |  

7.10

  |  |  

Issuance of Parent Common Stock

  |  

80

   
   |  |  

7.11

  |  |  

Registration Rights Agreement

  |  

80

   
   |  |  

7.12

  |  |  

Directors and Officers

  |  

80

   
   |  |  

7.13

  |  |  

Legal Opinion

  |  

80

   
   |  |  |  |  |   
  

Section 8.

  |  |  

 

TERMINATION

 

  |  

80

   
   |  |  |   
   |  |  

8.1

  |  |  

Termination

  |  

80

   
   |  |  

8.2

  |  |  

Effect of Termination

  |  

81

   
   |  |  

8.3

  |  |  

Expenses; Termination Fees

  |  

81

   
   |  |  |  |  |   
  

Section 9.

  |  |  

 

MISCELLANEOUS PROVISIONS

 

  |  

83

   
   |  |  

9.1

  |  |  

Amendment

  |  

83

   
   |  |  

9.2

  |  |  

Waiver

  |  

83

   
 

  

  

 

 

 

  

   

  

 

 

 

      |  |  

9.3

  |  |  

No Survival of Representations and Warranties

  |  

83

   
---|---|---|---|---|--- 
   |  |  

9.4

  |  |  

Entire Agreement; Counterparts; Exchanges by Facsimile

  |  

83

   
   |  |  

9.5

  |  |  

Applicable Law; Jurisdiction; Specific Performance; Remedies

  |  

83

   
   |  |  

9.6

  |  |  

Disclosure Schedules

  |  

84

   
   |  |  

9.7

  |  |  

Attorneys' Fees

  |  

84

   
   |  |  

9.8

  |  |  

Assignability; No Third Party Rights

  |  

84

   
   |  |  

9.9

  |  |  

Notices

  |  

84

   
   |  |  

9.10

  |  |  

Cooperation

  |  

86

   
   |  |  

9.11

  |  |  

Severability

  |  

86

   
   |  |  

9.12

  |  |  

Construction

  |  

86

   
 

 

  

  

  

 

    

EXHIBIT A

  |  |  

CERTAIN DEFINITIONS

   
---|---|--- 
  

EXHIBIT B

  |  |  

FORM OF PARENT STOCKHOLDER VOTING AGREEMENT

   
  

EXHIBIT C

  |  |  

FORMS OF LOCK-UP AGREEMENT

   
  

EXHIBIT D

  |  |  

FORM OF REGISTRATION RIGHTS AGREEMENT

   
  

EXHIBIT E

  |  |  

FORM OF GOVERNANCE AGREEMENT

   
  

EXHIBIT F

  |  |  

FORM OF STANDSTILL AGREEMENT

   
  

EXHIBIT G

  |  |  

FORM OF REPRESENTATION LETTER

   
  

EXHIBIT H

  |  |  

FORM OF GOVERNANCE AMENDMENT TO PARENT ARTICLES

   
  

EXHIBIT I

  |  |  

FORM OF LEGAL OPINION

   
  

SCHEDULE 5.9(b)

  |  |  

PERSON

   
  

SCHEDULE 5.12

  |  |  

DIRECTORS AND OFFICERS

   
   |  |   
 

 

  

    

 

     '

